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Summary 
Antibiotic resistance of bacterial pathogens is an emerging problem worldwide.  
As multidrug resistant organisms fail to respond to antimicrobial therapy, infections 
become more severe and cause more complications which in turn leads to longer illnesses 
(Gould, 2006; Haecker, 2009; Hübner et al., 2012). The aerobic Gram-negative bacterium 
Pseudomonas aeruginosa is one of the most important and dangerous microbes inhabiting 
the hospital environment. It has the ability to adapt to and thrive in many ecological niches, 
from water and soil environments to plant and animal tissues. P. aeruginosa also possesses 
a wide array of virulence factors, that do not only cause extensive tissue damage, but also 
interfere with the human immune system (Dzierżanowska, 2008). As an opportunistic 
pathogen it is particularly known for causing endogenous infections in immune-deficient 
individuals (AIDS, cystic fibrosis, cancer) and presents resistance to many antibiotics 
(Cornelis et al., 2008).  
During chronic infections populations of P. aeruginosa undergo characteristics 
evolutionary adaptations, including reduction of virulence factors production and transition 
from planktonic form to biofilm-associated lifestyle. The biofilm play an important role  
in evolution of high-level antibiotic resistance and protects the embedded bacteria from 
antimicrobial agents applied from without. Moreover, during prolonged infections 
coexistence of divergent phenotypic lineages of Pseudomonas within patients was 
observed, which makes accurate diagnosis and treatment even more challenging 
(Winstanley et al., 2016). 
For these reason, new antibacterial therapies are urgently needed. With hurdles  
in the antibiotic research and development pipelines, especially against Gram-negative 
pathogens, the scientific community is exploring the development of alternative forms  
of antimicrobial therapies. The idea of using bacteriophages as natural parasites  
of bacteria is well known. Bacteriophages have co-evolved intimately with their host for 
three billion years, and therefore highly efficient antibacterial mechanisms have emerged, 
granting them unique advantages over classical antibiotics to kill bacteria. Indeed, phage 
cocktails are commonly applied as alternative or as supportive treatments simultaneously 
with antibiotics in Eastern Europe, as part of standard care. Positive results are routinely 
obtained with the eradication of Escherichia, Pseudomonas, Proteus, Klebsiella and 
Staphylococcus clinical strains from various kinds of purulent wounds (Slopek et al., 1981; 
Wright et al., 2009; Maura and Debarbieux, 2011). These viruses developed also the ability 
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to tunnel through bacterial biofilms by employment of specific enzymes, which degrade 
the bacterial exopolysaccharides (EPS), one of the main component of the biofilm matrix. 
Such phages can be identified by the appearance of a halo zone around the phage plaques, 
which results from the enzymatic degradation of bacterial EPS without phage infection 
(Azeredo et al., 2008). Furthermore, bacteriophages can kill bacteria with peptidoglycan 
degrading enzymes, endolysins and virion-associated peptidoglycan hydrolases (VAPGH), 
that disrupt specific bonds in the peptidoglycan, a major component of bacterial cell wall. 
The use of bacteriophages and their recombinantly manufactured proteins offers a great 
opportunity to bypass antibiotic therapy hurdles. This dissertation specifically focuses  
on bacteriophages and their two types of enzymes: the polysaccharide depolymerases and 
peptidoglycan degrading enzymes, endolysins and VAPGHs, active against P. aeruginosa. 
In first part of this study we focused on characterization of four newly isolated 
bacteriophages KT28, KTN6, KTN4 and PA5oct, lytic towards P. aeruginosa. Their basic 
biology was evaluated, including morphology, host surface receptors, host range, stability 
and infection process. All phages were stable in a range of temperatures, pH and in presence 
of chloroform. KT28, KTN6 and KTN4 had relatively broad host range, in contrast  
to PA5oct. Host cell receptors were different for each type of phage, and included LPS, 
type IV pili and flagella. Furthermore, the phage genomes were sequenced and analyzed  
in depth. Unwanted genes or mobile elements were not found, which supports obligatory 
lytic nature of these bacteriophages. Functional genome analysis was supported with  
ESI-MS/MS analysis of phage proteome and RNA seq. With the use of comparative 
genomics, the protein-sharing network was constructed, that revealed phage evolution and 
homology. KTN6 and KT28 belong to Pbunavirus, KTN4 is a Phikzvirus and PA5oct  
is a unique giant virus. Finally phage antibacterial activity was evaluated in vitro using  
a novel Airway Surface Liquid model on non-CF and CF epithelial cells lines, in an effort 
to mimic in vivo conditions of the respiratory tract, developed at the laboratory  
of Prof. B. Harvey (Department of Molecular Medicine, Royal College of Surgeons  
in Ireland, Education and Research Centre, Beaumont Hospital, Dublin, Ireland). Phages 
KTN4 and PA5oct presented substantial antibacterial activity, reducing bacterial load from 
2.5 to 7 logs, depending on the P. aeruginosa strain used.  
Second part of this dissertation focuses on phage-encoded PG degrading enzymes 
(KT28 gp49, KT28 gp41 and its domain, KTN6 gp46, PA5oct gp214, PA5oct gp250, 
KTN4 gp48) and polysaccharide depolymerases (LKA1 gp49, LUZ7 gp56 and their 
domains). Their secondary and tertiary structure was analyzed in depth based  
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on available homology and crystal structures. The corresponding recombinant proteins 
have been produced and their bactericidal activity and biofilm eradication potential was 
evaluated. Among the PG degrading enzymes included in this study, the strongest 
antibacterial activity presented KTN6 gp46, a globular endolysin. Research  
of polysaccharide depolymerases was complicated, time consuming and required  
the greatest effort to obtain bioactive, recombinant and purified protein. LKA1 gp49 and 
its domain reduced EPS slime surrounding bacterial cell. In the future, their biofilm 
degradation activity should be further evaluated with more specific and quantitative biofilm 
assays. 
This research presents the potential of bacteriophages and their enzymes, which can 
be considered for therapy or industrial purposes. However, further research is required  
to analyze e.g. antibacterial activity in details, stability, dose, toxicity or structure. 
Furthermore, in vivo animal studies would show the true power of this alternative therapy.  
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Streszczenie 
Wzrost oporności na antybiotyki pośród bakterii chorobotwórczych stanowi 
poważny problem terapeutyczny na całym świecie. Coraz częściej pojawiają się 
wielolekooporne infekcje bakteryjne, które prowadzą do nasilonych i przedłużających się 
objawów oraz powikłań (Gould, 2006; Haecker, 2009;. Hübner i wsp., 2012). Tlenowa 
Gram-ujemna bakteria z gatunku Pseudomonas aeruginosa jest jednym z najważniejszych 
i najgroźniejszych drobnoustrojów, zasiedlających środowisko szpitalne. Wykazuje ona 
zdolność do przystosowania się i zasiedlania różnorodnych nisz ekologicznych,  
od środowisk wodnych i gleby po tkanki roślinne i zwierzęce. Dodatkowo posiada szeroki 
wachlarz czynników wirulencji, których efektem działania są nie tylko rozległe 
uszkodzenia tkanek, ale również zaburzenie funkcjonowania układu odpornościowego 
(Dzierżanowska, 2008). P. aeruginosa jest oportunistycznym patogenem, który powoduje 
endogenne infekcje u osób z niedoborami odporności (AIDS, mukowiscydoza, nowotwór), 
a jego eradykacja jest trudna ze względu na dużą oporność na antybiotyki (Cornelis i wsp., 
2008). 
 W trakcie przedłużającej się infekcji populacja P. aeruginosa ulega szybkim 
zmianom zarówno o podłożu genetycznym, jak i fenotypowym, takim jak redukcja 
produkcji czynników wirulencji oraz zmiana formy życia z planktonicznej  
na wielokomórkowe populacje, zwane biofilmem. Biofilm odgrywa ważną rolę w ewolucji 
odporności na antybiotyki i chroni bakterie przed niekorzystnymi warunkami środowiska, 
w tym mechanizmami obronnymi gospodarza. Hiperzmienność fenotypowa szczepów 
Pseudomonas izolowanych od pacjentów z mukowiscydozą, dodatkowo wpływa  
na trudności w diagnostyce i leczeniu (Winstanley i wsp., 2016). 
W związku z tym zapotrzebowanie na alternatywne metody leczenia jest duże. 
Pomysł wykorzystania bakteriofagów, naturalnych drapieżników bakterii, jest dobrze 
znany. Wirusy te wspólnie ewoluowały ze swoim gospodarzem bakteryjnym, w związku  
z tym wytworzyły bardzo wydajne mechanizmy przeciwbakteryjne, które stanowią 
ciekawą alternatywę w stosunku do klasycznych antybiotyków. Koktajle fagowe  
są stosowane jako zastępcza lub wspomagająca leczenie antybiotykowe terapia w krajach 
Europy Wschodniej. Pozytywne rezultaty uzyskano przy zwalczaniu infekcji ran, 
wywołanych przez bakterie z rodzaju Escherichia, Pseudomonas, Proteus, Klebsiella  
i Staphylococcus (Ślopek i wsp, 1981;. Wright i wsp., 2009, Maura i Debarbieux 2011). 
Dodatkowo wirusy te posiadają zdolność rozprzestrzeniania się w strukturze biofilmu 
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poprzez zastosowanie specyficznych enzymów, które degradują egzopolisacharydy 
bakteryjne (EPS), główny składnik macierzy biofilmu. Tego typu fagi można 
zidentyfikować poprzez obecność strefy halo wokół łysinki fagowej, utworzonej  
na murawie bakteryjnej, które to halo jest wynikiem degradacji enzymatycznej 
bakteryjnego EPS (Azeredo i wsp., 2008). Bakteriofagi wykorzystują jeszcze inne enzymy 
zwane endolizynami oraz hydrolazami peptydoglikanu związanych z wirionem (VAPGH). 
Białka te degradują specyficzne wiązania w peptydoglikanie, głównym składniku ściany 
komórkowej bakterii. Fagi i ich rekombinowane białka dają wiele możliwości 
zastosowania ich jako preparatów praciwbakteryjnych wspomagających klasyczną 
antybiotykoterapię. Niniejsza rozprawa doktorska skupia się na charakterystyce 
bakteriofagów oraz kodowanych przez nie dwóch typach enzymów, depolimerazach 
polisacharydów oraz endolizynach i VAPGH, aktywnych wobec P. aeruginosa. 
Pierwsza część prezentowanej pracy badawczej skupia się na charakterystyce 
czterech nowo izolowanych bakteriofagów KT28, KTN6, KTN4 i PA5oct, litycznych 
wobec P. aeruginosa. Przebadano ich podstawową biologię, ze szczególnym 
uwzględnieniem morfologii cząsteczki wirusowej, identyfikacji receptorów  
na powierzchni komórki gospodarza, zakresu litycznego, stabilności wirionów oraz 
procesu infekcji. Wszystkie fagi wykazały się stabilnością w szerokim zakresie 
temperatury, pH oraz w obecności chloroformu. Wszystkie, za wyjątkiem PA5oct, miały 
stosunkowo szeroki zakres lityczny. Pośród receptorów powierzchniowych gospodarza 
bakteryjnego, zidentyfikowano LPS oraz fimbrie typu IV. W dalszej części genomy 
czterech bakteriofagów zostały zsekwencjonowane i poddane szczegółowej analizie. 
Ruchome elementy genetyczne oraz integrazy nie zostały zidentyfikowane, co wskazuje  
na lityczny charakter badanych wirusów. Analiza funkcjonalna genomu została również 
wsparta sekwencjonowaniem RNA oraz analizą zestawu białek strukturalnych przy użyciu 
metody ESI-MS/MS. Dzięki zastosowaniu genomiki porównawczej, została również 
skonstruowana sieć powiązań, która pozwoliła domniemać proces ewolucji fagów oraz  
ich homologię. Fagi KTN6 i KT28 należą do rodzaju Pbunavirus, KTN4 do Phikzvirus, 
natomiast PA5oct należy do nowej grupy wirusów typu gigant. Oceniono również  
ich zdolność antybakteryjną in vitro przy użyciu nowego modelu infekcji dróg 
oddechowych z zastosowaniem linii komórkowych nabłonka płuc, izolowanych od osób 
zdrowych oraz chorych na mukowiscydozę. Model ten został opracowany w laboratorium 
Prof. B. Harvey (Department of Molecular Medicine, Royal College of Surgeons in Ireland, 
Education and Research Centre, Beaumont Hospital, Dublin, Irlandia) i imituje środowisko 
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oraz warunki panujące w drogach oddechowych in vivo. Fagi KTN4 i PA5oct wykazały się 
znaczącą aktywnością przeciwbakteryjną, redukując liczbę komórek bakteryjnych  
w zakresie 2,5 - 7 rzędów cfu/ml, w zależności od badanego szczepu P. aeruginosa. 
Druga część prezentowanej rozprawy koncentruje się na enzymach degradujących 
bakteryjny peptydoglikan (KT28 gp49, KT28 gp41 i jego domenie, KTN6 gp46, PA5oct 
gp214, PA5oct gp250, KTN4 gp48) oraz depolimerazach polisacharydów (LKA1 gp49  
LUZ7 gp56 i ich domenach). Druga i czwartorzędowa struktura białkowa została 
szczegółowo omówiona w oparciu o dostępną homologię sekwencji aminokwasowej oraz 
dostępne struktury krystaliczne białka. Czyste białka rekombinacyjne zostały 
wyprodukowane i oceniono ich potencjał bakteriobójczy oraz zdolność do degradacji 
biofilmu. Pośród enzymów degradujących peptydoglikan najsilniejsze działanie 
przeciwbakteryjne wykazało białko KTN6 gp46 o globularnej strukturze. Badania 
depolimeraz polisacharydów okazały się skomplikowane, czasochłonne i wymagały 
najwięcej nakładu pracy, w celu uzyskania czystych bioaktywnych białek 
rekombinacyjnych. Wykazano, że LKA1 gp49 i jego domena były zdolne do redukcji 
zewnątrzkomórkowego śluzu EPS. Aczkolwiek dalsza analiza jest wymagana, w celu 
dokładnego zbadania ich aktywność wobec biofilmu, przy zastosowaniu bardziej 
specyficznych metod. 
Przedstawione badania obrazują potencjał bakteriofagów i ich enzymów  
w leczeniu oraz w przemyśle. Niemniej jednak dalsze badania są wymagane, w celu 
szczegółowej analizy aktywności przeciwbakteryjnej, stabilności cząsteczek wirusowych  
i ich białek, potencjalnej toksyczności oraz struktury białkowej. Dodatkowo, badania  
in vivo na modelach zwierzęcych pozwolą zweryfikować prawdziwy potencjał tej 
alternatywnej terapii. 
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Samenvatting 
De verspreiding van antibioticumresistentie bij bacteriële infecties is een opkomend 
wereldwijd probleem. Aangezien antibioticumresistente bacteriën niet reageren  
op de bestaande antimicrobiële therapieën, zijn deze infecties ook zwaarder en veroorzaken 
ze meer complicaties, hetgeen leidt tot langere ziektebeelden en een hogere 
behandelingskost (Gould, 2006; Haecker, 2009; Hübner et al., 2012). De aerobe Gram-
negatieve bacterie Pseudomonas aeruginosa is één van de belangrijkste en meest 
gevaarlijke pathogenen in de ziekenhuisomgeving. Deze bacterie heft de capaciteit om tal 
van verschillende niches te koloniseren en past zich aan tal van ecologische niches aan,  
van water en grond omgevingen tot plant- en dierweefsels. P. aeruginosa bezit ook  
een uitgebreid arsenaal aan virulentiefactoren die niet alleen uitgebreide weefselschade 
geven, maar ook interfereren met het menselijk immuunsysteem (Dzierżanowska, 2008). 
Als opportunistisch pathogeen staat deze bacterie ook bekend voor het induceren  
van endogene infecties bij immune-deficiënte patiënten (AIDS, mucoviscidose, kanker)  
en is bovendien resistent tegen tal van antibiotica (Cornelis et al., 2008).  
‘Cystic fibrosis’ of mucoviscidose is een veelvoorkomende genetische ziekte die 
wordt veroorzaakt door mutaties in het ‘Cystic Fibrosis Transmembrane Conductance 
Regulator’ gen. De meeste mucoviscidose patiënten sterven rond de gemiddelde leeftijd 
van 40 jaar, als gevolg van longfibrose, veroorzaakt door de continue aanvallen op het 
immuunsysteem, veroorzaakt door de chronische pulmonaire infecties door bacteriën 
(Carmody et al., 2010). Opportunistische pathogenen zoals P. aeruginosa, Staphylococcus 
aureus, Haemophilus influenze en het Burholderia cepacia complex, kunnen slechts zeer 
moeilijk uitgeroeid worden in de longomgeving, door hun natuurlijke capaciteit om zich 
zeer snel aan te passen. (Hogardt et al., 2010). Een belangrijk probleem bij de behandeling 
van deze infecties is de klonale heterogeniteit van isolaten, alsook hun capaciteit  
om extracellulaire polysacharide matrices (zoals biofilms) te vormen (Campodonico et al., 
2008). Deze biofilmmatrix beschermt de ingebedde bacteriën tegen de externe toediening 
van antibiotica.  
Uit dit alles blijkt dat er een dringende nood is voor nieuwe antibacteriële 
behandelingsmethodes. Ondanks de moeilijkheden in het antibioticumonderzoek  
en de ontwikkelingspijplijnen (in het bijzonder bij gramnegatieve bacteriën), onderzoekt 
de wetenschappelijke gemeenschap alternatieve vormen van antimicrobiële therapieën.  
Het idee om bacteriofagen, de natuurlijke parasieten van bacteriën, te gebruiken als 
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hiervoor te gebruiken is bekend. Bacteriofagen hebben gedurende drie miljard jaar  
co-evolutie ondergaan met hun gastheer. Op die manier hebben er zich zeer efficiënte 
antibacteriële mechanismen ontwikkeld, die een uniek voordeel kunnen bieden ten opzichte 
van klassieke antibiotica om bacteriën af te doden. Bacteriofaagcocktails worden in Oost-
Europa frequent gebruikt in standaardbereidingen als een alternatief of ondersteunende 
therapie voor antibiotica. Positieve resultaten worden regelmatig bekomen voor het 
afdoden van Escherichia, Pseudomonas, Proteus, Klebsiella en Staphylococcus klinische 
stammen in verschillende vormen van geïnfecteerde wonden (Slopek et al., 1981a,b; 
Wright et al., 2009, Maura and Debarbieux, 2011). Deze virussen hebben ook 
eigenschappen ontwikkeld die hen toelaat bacteriële biofilms te degraderen door middel 
van specifieke enzymen die de bacteriële exopolysachariden (EPS) afbreken, één van  
de belangrijkste componenten in de biofilmmatrix. Deze fagen kunnen geïdentificeerd 
worden door het verschijnen van een halo zone rond de plaques van de faag. Deze halo 
zone is het resultaat van de enzymatische afbraak van het EPS (Azeredo et al., 2008).  
Daarnaast beschikken bacteriofagen ook nog over peptidoglycaan-hydrolyserende 
enzymen (endolysines en virion-geassocieerde enzymen) die specifieke bindingen  
in de peptidoglycaan, de belangrijkste component van de bacteriële celwand, hydrolyseren. 
Het gebruik van bacteriofagen en afgeleide enzymen die recombinant worden aangemaakt 
bieden een belangrijk potentieel om de bestaande barrières in de ontwikkeling van nieuwe 
antibacteriële therapieën te overbruggen. In dit eindwerk wordt specifiek de nadruk gelegd 
op Pseudomonas aeruginosa en haar bacteriofagen & afgeleide enzymen: de polysacharide 
depolymerasen en de peptidoglycaan-degraderende enzymen. 
In het eerste luik van deze studie wordt er gefocust op de karakterisering van vier 
nieuw-geïsoleerde fagen KT28, KTN6, KTN4 en PA5oct, die alle op een strikt lytische 
manier inwerken op P. aeruginosa. De basis microbiologische eigenschappen worden 
hierbij bestudeerd, waaronder de morfologie, gastheerreceptoren, gastheerspectrum en hun 
infectieproces. Alle fagen bleken stabiel in een breed spectrum van temperaturen,  
pH en bij aanwezigheid van chloroform. KT28, KTN6 en KTN4 hebben een relatief breed 
gastheerspectrum, in tegenstelling tot faag PA5oct. De gastheerreceptoren, waaronder  
de LPS, type IV pili en flagellen, verschilden van faag tot faag. Daarnaast werd het genoom 
van deze fagen bepaald en geanalyseerd. Ongewenste genen of mobiele elementen worden 
niet gevonden, hetgeen het strikt lytische karakter van deze fagen ondersteund.  
De experimentele functionele genoomanalyse gebeurde met behulp van een ESI-MS/MS 
analyse en RNAseq. Aan de hand van vergelijkende genomica en het opbouwen van een 
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proteïn-familie netwerk, kon de faagevolutie en homologie bestudeerd worden. KTN6  
en KT28 zijn leden van het genus Pbunavirus, KTN4 is een lid van de Phikzvirus terwijl 
faag PA5oct een uniek nieuw virus is. In een laatste stap werd de antibacteriële activiteit 
van deze fagen in vitro geëvalueerd door middel van een nieuw “Airway Surface Liquid 
model” op niet-CF en CF epitheliale cellijnen, een model ontwikkeld aan het lab van  
Prof. B. Harvey, als een poging om de in vivo condities van de luchtwegen na te bootsen. 
Fagen KTN4 en PA5oct vertoonden een aanzienlijke antibacteriële activiteit: een reductie 
van 2.5 tot 7 log eenheden, afhankelijk van de gebruikte P. aeruginosa stam.  
Het tweede luik van dit doctoraat focust zich op de faag-gecodeerde  
PG degraderende enzymes (KT28 gp49, KT28 gp41 en een afgeleid domein, KTN6 gp46, 
PA5oct gp214, PA5oct gp250, KTN4 gp48) en op de polysacharide depolymerasen  
(LKA1 gp49, LUZ7 gp56 en hun subdomeinen). De secundaire en tertiaire structuur van 
deze enzymen werd bestudeerd op basis van homologie en beschikbare kristalstructuren. 
De overeenkomstige recombinante eiwitten werden aangemaakt en hun antibacteriële  
en antibiofilm activiteit werd geëvalueerd. Van de geanalyseerde PG hydrolasen vertoonde 
KTN6 gp46 (een globulair eiwit) de sterkste antibacteriële activiteit. Het onderzoek naar 
de polysacharide depolymerases bleek ingewikkeld, tijdrovend en vereiste specifieke 
optimalisaties om recombinant, opgezuiverd en bioactief enzyme te bekomen. LKA1 gp49 
en een domein van dit eiwit konden het viskeuze EPS en LPS rond de bacteriële cel.  
In de toekomst moet deze biofilm degradatieactiviteit verder bestudeerd worden en zijn 
meer kwantitatieve assays nodig om dit te bereiken. 
Dit onderzoek toont het potentieel van bacteriofagen en hun enzymen voor 
therapeutische en industriële doeleinden. Er is echter nog verder onderzoek nodig,  
bv. om de antibacteriële activiteit verder te bestuderen, de stabiliteit, dosering, toxiciteit  
en structuur. Een verdere focus op in vivo dierproeven zijn nu aan de orde om de kracht 
van deze alternatieve therapie te tonen. 
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1.1. Pseudomonas aeruginosa, an opportunistic pathogen 
1.1.1. Taxonomy and general characteristics 
In 1872 two German scientists, Joseph Schröter (1872) and Ferdinand Cohn (1872), 
isolated a blue pigmented microorganism, calling it “Bacterium aeruginosum”  
or “Bacillus aeruginosus”. In 1900, Polish botanist Emil Friedrich August Walter Migula 
for the first time coined the name Pseudomonas aeruginosa in his “System der Bakterien” 
(1900).  
The word Pseudomonas means "false unit", from Greek pseudo, ψευδο (false) and 
Latin monas, Greek: μονος (a single unit). Aeruginosa is from Latin meaning verdigris, 
“copper rust” or from the Greek prefix ae-meaning "old or aged", and the suffix ruginosa 
means wrinkled or bumpy.  
The current classification of P. aeruginosa is presented in Table 1.1.  
Table 1.1: P. aeruginosa taxonomy according Uniprot Database (2015).  
 
 
 
 
 
 
 
 
P. aeruginosa is a motile Gram-negative rod-shaped bacterium, that can be found 
in a wide range of environmental niches, such as terrestrial and marine environments,  
as well as associated with plants and animals, including humans (Fig.1.1). This 
opportunistic pathogen causes chronic and acute infections of burn wounds, as well  
as respiratory and urinary tracts (Kobayashi et al., 2009). Particularly vulnerable are 
patients in intensive care units (ICUs) and the immunocompromised (e.g. cancer, AIDS, 
cystic fibrosis) (Murray et al., 2007; Kobayashi et al., 2009; Trautmann et al., 2005).  
P. aeruginosa possesses a wide array of virulence factors that do not only cause extensive 
tissue damage, but also directly interfere with the human immune system (Dzierżanowska, 
2008).  
 
 
Kingdom Bacteria 
Phylum Proteobacteria  
Class γ-Proteobacteria 
Order Pseudomonadales 
Family Pseudomonadaceae 
Genus Pseudomonas 
Species Pseudomonas aeruginosa 
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Figure 1.1: P. aeruginosa SEM image (© Dennis Kunkel/ Microbiology, Inc.). A rod-shaped bacterium 
with flagella, dimensions of 0.5 to 0.8 µm by 1.5 to 3.0 µm (Lederberg et al., 2000). 
A major advantage to this pathogen is its diverse metabolic competence, that 
enables it to employ small molecules or complex organic compounds as a carbon source 
and aerobic as well as anaerobic growth in the presence of NO3
- as electron acceptor.  
P. aeruginosa has broad growth temperature range (6 - 45°C, with an optimum growth  
at 37°C) (Slonczewski et al., 2011; Szewczyk, 2005). Furthermore, it lives as planktonic 
cells, colonies or biofilms, reversibly regulates gene expression and changes its phenotype 
and genotype in response to the environmental signals during infection (Essoh et al., 2013; 
Bragonzi et al., 2009). This provides a protective mode that allows survival in hostile 
environments and disperses seeding cells to colonize new niches with desirable conditions 
(Wei et al., 2013). 
P. aeruginosa cultures can create three different morphological types of colonies: 
1) colonies with a diameter ~ 2 mm, rough, gray color, the slightly dull surface with 
irregular edges (the environmental isolates from soil/water); 2) large colonies, smooth, 
shiny and flattened at the edges (mostly clinical isolates); 3) mucous with alginate 
overproduction (clinical isolates, mainly from respiratory and urinary tracks) (Szewczyk, 
2005). 
Another diagnostic significant characteristic is the P. aeruginosa pigment 
production capacity. These pigments can diffuse through the medium, giving rise  
to colonies with variable colors (Fig. 1.2). Depending on the strain, these pigments include 
pyocyanin (blue-green, nonfluorescent), pyorubin (red-brown), pyomelanin (brown-black, 
rather uncommon) and pyoverdine (yellow-green, fluorescent under UV light) (Khalifa  
et al., 2011; Jayaseelan et al., 2014).  
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Figure 1.2: Different pigmentation of P. aeruginosa. A) P. aeruginosa E1 isolated from refinery soil, 
pyocyanin overproduction B) P. aeruginosa C6 isolated from burn wound, pyorubrin overproduction.  
C) P. aeruginosa C10 isolated from burn wound, pyoverdine overproduction. D) P. aeruginosa PA1111, 
clinical isolate, pyomelanine overproduction. The cetrimide medium (Yu et al., 2002; Nowroozi et al., 2012; 
Ketelboeter et al., 2014). 
1.1.2. Pathogenesis of Pseudomonas aeruginosa 
1.1.2.1. Pseudomonas aeruginosa infections, a public health crisis brews 
P. aeruginosa belongs to infamous ESKAPE group of pathogens (Enterococcus 
faecium, Staphylococcus aureus, Klebsiella pneumoniae, Acinetobacter baumannii, 
Pseudomonas aeruginosa, and Enterobacter species), that effectively “escape”  
the conventional antimicrobial therapies and is considered to be one of the major threats  
to public health (Rice, 2010; Boucher et al., 2009). This opportunistic pathogen  
is a leading Gram-negative organism associated with nosocomial infections (11 - 13.8%  
of total), that can spread e.g. during intubation, tracheotomy, colostomy, operations, cross-
contaminations between patients and water fittings (Dzierżanowska, 2008; Driscoll et al., 
2007). Infections are associated with a disrupted epithelial layer (e.g. burn wounds)  
or mucosal barrier (e.g. lung infections), malfunctioning of the immune system (e.g. AIDS) 
or when bacteria are introduced into the eye (e.g. by contact lenses).  
P. aeruginosa can also form biofilms on the medical devices surface, such as catheters, 
intubation tubes or implants (Ballok et al., 2013). The mortality range is 15 - 78% in ICUs. 
Among hospital-acquired P. aeruginosa infections, we may distinguish: 1) ventilator-
associated pneumonia with ~20% prevalence and dramatically high mortality (Fujitani  
et al., 2011, Kollef et al., 2014); 2) chronic obstructive pulmonary disease; 3) pneumonia 
in cystic fibrosis (CF) patients; 4) burn and postoperative/surgical wound infections;  
5) urinary tract infections (Table 1.2). During their lifetime, all CF patients experience  
P. aeruginosa lung infections and more than 80% of them become chronically infected  
in their adult years (Döring et al., 2011). Such a lifelong infection decreases lung function 
and ultimately results in death (Minandri et al., 2016). 
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Table 1.2: Most frequent diseases correlated with P. aeruginosa infections (Rehm, 2009).  
Organ Infection Symptoms Acute/ 
Chronic 
Origin Prevention 
eye contact lens, 
keratitis 
 inflammation 
 pain 
 swelling 
 redness 
 impaired vision 
acute water hygiene 
ear external otitis  swelling 
 ear pain 
 itching inside the ear 
 discharge from the ear 
 difficulty hearing 
acute/ 
chronic 
possibly 
water 
hygiene 
nasal 
sinuses 
sinusitis  swelling 
 pain 
 difficulty breathing 
chronic possibly 
water 
unknown 
skin folliculitis, 
wound/ ulcer 
infection, burn 
infections 
 redness of the skin 
 abscess formation in the 
skin 
 draining wounds 
acute water, soil hygiene 
urine 
bladder  
urinary tract 
infection 
 persistent urge to urinate 
 burning sensation when 
urinating 
 cloudy and smelling 
urine 
acute/ 
chronic 
nosocomial early 
aggressive 
antibiotic 
eradication 
therapy 
bones diabetic 
osteomyelitis  
in feet 
 swelling 
 pain in the affected joint 
chronic possibly 
water 
hygiene 
blood sepsis, 
neutropenic 
patients 
 fever and chills 
 fatigue 
 muscle and joint pain 
 hemodynamic shock 
acute unknown antibiotic 
prophylaxis 
lungs/ 
bronchi  
ventilator-
associated 
pneumonia 
 chills 
 fever 
 cough with or without 
sputum production 
 difficulty breathing 
acute nosocomial 
humidifiers 
hygiene 
endobroncholitis, 
cystic fibrosis, 
bronchiectasis 
chronic nosocomial, 
environment 
hygiene, 
early 
aggressive 
antibiotic 
therapy  
of 
intermittent 
colonization 
Infection in CF environment  
The best known genetically inherited diseases with increased prevalence  
of P. aeruginosa infections is CF, correlated with defects in a transport protein,  
the CF transmembrane conductance regulator (CFTR) (Winstanley et al., 2016). CFTR  
is a chloride ion channel of the ABC transporter family and its mutation result  
in misfolding, a lack of proper localization, and/or a complete lack of the protein (Chambers 
et al., 2007). In cooperation with the epithelial sodium channel (ENaC), this protein  
is responsible for controlling the level of airway surface liquid (ASL) layer, that covers  
the lung surface and consists of a mucus and a periciliary liquid layer. The former traps and 
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removes inhaled pathogens, while the latter keeps the mucus at an optimal distance from 
the underlying epithelia to maximize ciliary mobility, provides a low viscosity solution and 
acts as a lubricant layer for mucus transport (Danis-Wlodarczyk et al., 2015). Together, 
they play a critical role in effective mucociliary clearance of the airway (Matsui et al., 
1998;. Zabner et al., 2003). In the absence of CFTR, ENaC is hyperactive leading to loss 
of a chloride secretion and increase in a sodium import. This results in the decreased ASL 
volume or altered mucus impede phagocyte function, making bacterial elimination 
defective. Moreover, inflammatory response is abnormal (Danis-Wlodarczyk et al., 2015). 
The CF airways sticky mucus provides the perfect milieu, microaerophilic to anaerobic 
environment, enabling the colonization and propagation of P. aeruginosa (Worlitzsch  
et al., 2002; Danis-Wlodarczyk et al., 2015). The resident microbial community  
of CF lungs is known to be complex and it has considerably changed, mainly due  
to alterations in antibiotic regimens. Nevertheless, P. aeruginosa is still the most prevalent 
pathogen isolated from CF sputum, occurring more frequently in adults (Folkesson et al., 
2012; Sousa et al., 2014). Once entering in CF airways, P. aeruginosa is practically 
impossible to eradicate due to its remarkable genome plasticity, that allows it to rapidly 
adapt to the specific CF environment (Hogardt et al., 2010). 
Establishing an infection 
Most CF patients acquired pathogens mainly from environment, especially  
in clinical settings where CF patients remain for long periods of time. P. aeruginosa has  
to properly regulate its gene expression to quickly adapt to a hostile CF lung environment, 
where it is exposed to host immune defenses, antibiotics, and oxidative stress. The bacterial 
features among CF acute isolates fluctuate significantly. However, there is a trend towards 
high virulence potential and cytotoxicity as well as lower frequency of mutator strains.  
The expression of virulence factors, including cell-associated and secreted virulence 
factors, is considered to be fundamental at early stage for the success of infection 
establishment (Sousa et al., 2014). A first group of virulence factors includes the flagellum, 
type IV pili, lipopolysaccharide (LPS) and alginate. A second group includes e.g. elastases 
(LasB and LasA), alkaline protease, pyocyanin, and the effector molecules of the type III 
secretion system (T3SS) (Qaisar et al., 2016). Flagella, pili, and LPS are important for 
motility and adhesion by binding to respiratory mucin and the glycolipid, asialoGM1,  
as well as for activations of Toll-like receptors (TLR5, TLR2, TLR4), which leads  
to immune activation (McIsaac et al., 2012; Amiel et al., 2010; Lau et al., 2005).  
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The secretion of protein ExoA gives P. aeruginosa the ability to stop epithelial cell protein 
expression and kill host cells (Wolf et al., 2009; Deng et al., 2008; Liu, 1973). The T3SS 
plays a major role in establishing infection (Bleves et al., 2010; Engel et al., 2009).  
The T3SS effectors ExoS, ExoT, ExoY, ExoU inhibit actin polymerization, prevent 
phagocytosis and cell migration, and promote apoptosis (Barbieri et al., 2004). They also 
modulate the inflammatory response, increase membrane permeability (Ochoa et al., 2012), 
leading to membrane damage, and cell lysis (Deng et al., 2008; Anderson et al., 2012).  
At an early stage of infection, eradication is still possible when a suitable antibiotic 
treatment has been started in a timely manner. Otherwise, 20% of those first P. aeruginosa 
colonization could become directly chronic infections and may persist up to the end  
of the patient’s life (Bragonzi et al., 2009; Montanari et al., 2007; Sousa et al., 2014). 
Internalization in lung epithelia cells 
Although P. aeruginosa was generally thought to be an extracellular pathogen,  
a number of different groups have found that it can be internalized into a range of different 
cell types, including epithelial cells (Darling et al. 2004; Fleiszig et al., 1996 and 1995; 
Evans et al., 1998; Plotkowski et al., 1999; Burns et al., 1996; Danis-Wlodarczyk et al., 
2015). Fleiszig et al. (1996) results suggested, that the determination as to whether a strain 
of P. aeruginosa is invasive in epithelial cells is related to its ability to kill eukaryotic cells. 
Strains with low cytotoxicity showing high levels of invasion and vice versa. Schroeder  
et al. (2001) presented that the highest attachment of PAO1 was after 3 h of infection and 
the maximum percentage of internalized bacteria was found after 6 h of incubation. 
However, it is not clear how the different mechanisms resulting in Pseudomonas 
internalization are switched on, how such a decision is established at the level of bacteria 
and host cells, and which structures govern this process (Byfield et al., 2011). 
To start the invasion of the lung epithelial cells, Pseudomonas first has to find  
its receptor and adhere to the cell surface. In healthy epithelum the CFTR protein serves  
as a cell surface receptor for non-mucoid smooth strains of P. aeruginosa with an intact 
LPS core (Pier et al., 1997; 1996a, b). However, Darling et al. (2004) stated that CFTR 
does not exert a direct stoichiometric effect on P. aeruginosa uptake in a specific cell, but 
rather alters the properties of the whole apical epithelial surface to inhibit bacterial 
invasion. The CFTR does not occur with mucoid rough P. aeruginosa strains that emerge 
during lung colonization in CF patients (Pier et al., 1996b). A study by Kato et al. (2010) 
showed that also MUC1 mucin serves as a binding site for P. aeruginosa. The adhesion 
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process is supported by type IV pili, Psl exopolysaccharide (EPS) and flagella FliD protein 
that binds to mucins (Arora et al.,1998; Häussler, 2003; Merritt et al., 2007).  
In CF P. aeruginosa internalize without epithelial cell apoptosis, resulting in intracellular 
bacterial survival, division, and escape from the host immune system (Grassme et al., 2000; 
Byfield et al. ,2011).  
Infection maintenance 
Once P. aeruginosa has succeeded in lung invasion and inhibited clearance, it must 
induce changes in order to reduce immune activation and obstruct clearance mechanisms 
to persist in the lung (Ballok et al., 2013). To facilitate mucus penetration, the pathogen 
employs a suite of secreted enzymes (exoproteins) to impair host immune system (Bleves 
et al., 2010; Lau et al., 2005; Ballok et al., 2013). These immunosuppressing factors 
comprise the elastases LasA and LasB, and phospholipases PlcB, PlcH and PlcN, which 
target the mucus layer and cell membrane, facilitating bacterial transit through the mucus 
layer and liberating nutrients exploited by the bacteria (Ochsner et al., 2002; Schmiel et al., 
1999; Barker et al., 2004). Furthermore, the neutrophil respiratory burst is suppress by PlcH 
(Terada et al., 1999). The CFTR inhibitory factor (Cif), an epoxide hydrolase, reduce apical 
membrane CFTR and Cl- secretion by epithelial cells as well as a drug efflux pump,  
P-glycoprotein, inhibiting the microbicidal activity of neutrophils by limiting Cl- import  
to endosomes and preventing hypochlorous acid formation in P. aeruginosa-containing 
vesicles (Painter et al., 2008; Bonvillain et al., 2010). A high expression of the secreted 
alkaline protease (AprA) correlates with mucoidy aid in P. aeruginosa survival by cleaving 
transferrin to facilitate iron acquisition by siderophores (Firoved et al., 2003; Jaffar-
Bandjee et al., 1995; Kim et al., 2006), as well as inhibiting immune recognition by TLR5 
and degradation of complement proteins and gamma interferon (IFNγ), halting 
phagocytosis and killing by neutrophils (Laarman et al., 2012; Butterworth et al., 2012; 
Ballok et al., 2013). Along with these extracellular proteins, in many CF strains production 
of the EPS alginate increases, which promotes mucin production, thereby limiting immune 
recognition and clearance (Kishioka et al., 1999; Ohman et al., 1981; Deretic et al., 1987).  
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Figure 1.3: Development of chronic infection of P. aeruginosa in the cystic fibrosis airway. Inhaled 
pathogens expressing flagella, pili and T3SS aggregate within the lung, resulting in the formation of biofilm. 
Within the biofilm, bacteria lose flagella, pili and the T3SS, increase alginate production and express a diverse 
range of virulence factors promoting evasion of the host immune system. P. aeruginosa also releases Cif  
in outer membrane vesicles to inhibit the recycling of CFTR in the host. Furthermore, the lipid A structure  
of the LPS is altered through the addition of palmitate and aminoarabinose, resulting in increased antibiotic 
resistance and increased induction of IL-8 production by host cells (Cohen et al., 2012). 
Phenotypes and genotypes selection during persistence in the CF lung 
The adaptation process to CF airways can be accelerated by the emergence  
of mutator phenotypes (or hypermutable phenotypes), that can have mutation rates  
up to 1000–fold in compare to non-mutator phenotypes (Oliver et al., 2000; Rodriguez-
Rojas et al., 2012; Mena et al., 2008). In the hostile, extremely selective conditions  
of the CF airways, this sophisticated mechanism improves P. aeruginosa microevolution 
and its intraclonal diversification. The development of phenotypic variants and mutators 
can be intrinsic, relying on mutations or recombinations generated by defects on DNA 
repair or error avoidance systems (Sousa et al., 2014). Mutators can also be influenced  
by environmental factors, e.g. reactive oxygen species (ROS) generated from inflammatory 
responses, that can trigger the generation of phenotypic variants damaging DNA and cause 
mutations in bacteria (Ciofu et al., 2005; Sousa et al., 2014). Furthermore, the antibiotic 
sub-inhibitory or sub-lethal concentrations can also induce mutations and recombinations 
(Kohanski et al., 2010; Sousa et al., 2014).  
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Despite the selective advantage of mucoid P. aeruginosa, isolates from a single 
patient may differ greatly in their morphotypes including mucoid, smooth, rough, dwarf, 
non-pigmented variants, small-colony variants, and variants with visible autolysis  
or autoaggregative behavior that further may all differ in their antibiotic susceptibility 
patterns (clonal diversification to different niches in CF airways) (Hogardt et al., 2007; 
Sousa et al., 2014). Non-mucoid isolates may be either wild-type P. aeruginosa  
or revertants from mucoid phenotypes. The mucoid phenotype is unstable during ongoing 
CF lung disease, probable due to high energy requirement for alginate production (Sousa 
et al., 2014).  
Mucoid P. aeruginosa isolates typically lack twitching and swimming motility due 
to non-piliation and loss of the flagellum, probably since motility is not needed during 
static, non-gradient growth conditions within anaerobic biofilms and might enhance 
survival by decreasing neutrophil recruitment and phagocytosis by alveolar macrophages 
and granulocytes in the airway (Lau et al., 2005; Hajjar et al., 2002). Moreover, chronic  
P. aeruginosa CF isolates typically show a rough colony phenotype due to modification  
of the lipid A moiety of LPS (Hancock et al., 1983), associated with increased resistance 
to antimicrobial peptides. Further, the EPS alginate is overproduce, which is widely 
considered to be a marker for the transition to chronic infection (Winstanley et al., 2016).  
Small-colony variants (SCV) are often selected for by prolonged antibiotic 
exposure, common during chronic infections. They have a much slower growth rate, 
smaller colony morphology and exhibit normally hyperpiliated, hyperadherent and 
autoaggregative behavior which can favor biofilm formation and persistence (Cullen  
et al., 2015). Further, it has been demonstrated that the increased expression of the pel and 
psl EPS gene clusters and elevated intracellular cyclic di-GMP (c-di-GMP) levels 
contribute to SCV morphotype (Starkey et al., 2009). 
1.1.2.2. Quorum sensing 
The quorum sensing (QS) is a coordination mechanism, responsible for regulation 
of gene expression of many virulence factors (Miller et al., 2001; Winstanley et al., 2009). 
Bacteria produce and release autoinducers, a small diffusing molecules, which 
concentration increases as function of cell density. When minimal stimulatory 
concentration threshold of these autoinducers is detected, an alteration in gene expression 
occur (Miller et al., 2001). The quorum sensing is a form of communication between 
microorganisms, which optimizes their metabolism and behavior while living in dense 
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colonies. The switch from planktonic to sessile lifestyle depends on two conflicting sensor 
systems: 1) RetS, responsible for initiation of acute virulence with the production of toxins 
and expression of T3SS; 2) LadS/GacS, that leads to chronic infections by selection  
of the sessile mode with the expression of genes involved in type VI secretion system, EPS 
production and biofilm formation (Coggan et al., 2012; Balasubramanian et al., 2013; 
Cornelis et al., 2013; Jimenez et al., 2012; Sousa et al., 2014). 
1.1.2.3. Iron deprivation  
In the human body, iron ions are not readily available due to iron sequestration  
by different iron-binding proteins, including transferrin, lactoferrin and ferritin (Wang  
et al., 2011; Qaisar et al., 2016; Minandri et al., 2016). To survive iron deprivation  
P. aeruginosa utilizes multiple systems and strategies to obtain iron from its environment: 
1) siderophores, an extracellular Fe3+ chelating molecules, including pyoverdine and 
pyochelin with high and low affinities for iron respectively, and the uptake  
of ferrisiderophores via TonB-dependent receptors; 2) the uptake of xenosiderophores- 
siderophore piracy from other microorganisms (e.g. E. coli enterobactin); 3) the heme 
molecule uptake from the host hemoproteins, through the Has and Phu systems;  
4) the extracellular reduction of Fe3+ to Fe2+ involving phenazine compounds and a Fe2+ 
dedicated iron uptake system under microaerobic or anaerobic conditions (the TonB-
independent Feo system) (Hamood et al., 2004; Anzaldi et al., 2010; Cornelis, 2013; Nairz 
et al., 2010; Cox, 1993; Minandri et al., 2016). The iron acquisition process is highly 
regulated and involves multiple regulators including the ferric uptake regulator (Fur) 
(Cornelis et al., 2009), a repressor of iron uptake genes when bound to its co-repressor Fe2+ 
(Escolar et al., 1999). Qaisar et al.(2016) showed, that the pvcA-D operon, indirectly 
through a new discovered virulence factor isonitrile functionalized cumarin, paerucumarin, 
influences biofilm development by enhancing the expression of fimbrial chaperone/usher 
(cup) pathway genes. Paerucumarin as well as Pseudomonas quinolone signal (PQS) also 
chelates iron within the extracellular environment to facilitate the induction  
of P. aeruginosa siderophores, but does not function as a siderophore. When iron  
is available extracellularly, the level of intracellular iron increases and Fur is activated. 
Activated Fur then represses the expression of the siderophores. Depending on the type  
of infection, P. aeruginosa can therefore adapt by switching from one iron uptake system 
to another (Cornelis, 2013). 
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1.1.2.4. P. aeruginosa biofilm and its influence on multidrug resistance 
General characteristics 
Most bacteria have a propensity to adhere to surfaces to create a structured 
multicellular communities embedded in a self-produced polymer matrix, that provide  
a protective mode to hostile or rapidly changing environments (Wei et al., 2013; Battin  
et al., 2007; Abedon, 2011; Høiby et al., 2010). They occur in natural, industrial and 
medical environments (Wei et al., 2013; Hughes et al., 1998; Sutherland et al., 2001).  
In humans biofilms cause chronic infections, due to increased tolerance to antibiotics and 
disinfectant chemicals, as well as resisting phagocytosis and other components  
of the immune defense system (Høiby et al., 2010). The metabolism, physiology and 
phenotype of biofilm-related cells differ from their free-living planktonic counterparts 
(Wei et al., 2013; Flemming et al., 2010). Moreover, gradients of access to nutrients and 
oxygen exist through whole biofilms structure. These gradients are associated with 
decreased bacterial metabolic activity, dormancy and anaerobic conditions in the center  
of biofilm (Khalifa et al., 2011; Hanlon, 2007; Høiby N et al., 2010). Within a biofilm, 
Pseudomonas cells are in close proximity and strongly interact with each other, including 
competition (e.g. for nutrients), commensalism (e.g. a metabolic intermediate or waste 
product of one species can serve as the substrate for another species), mutualism and 
parasitism. Importantly, the majority of natural biofilms subsist multiple bacterial species 
and each may implement different specialized tasks (Khalifa et al., 2011).  
Biofilms in nature have many different forms, ranging from smooth, flat biofilms 
to three-dimensional mushroom-shaped structures. The amount of water channels and size 
of pores between the microcolonies can also vary substantially. In this manner, the mature 
biofilm resembles primitive, multicellular organisms (Høiby et al., 2010). The shape  
of the formed biofilm is determined by the motility, which is influenced by the carbon 
source and QS (Flemming et al., 2010). 
Matrix composition 
In a biofilm, bacteria are embedded in the extracellular polymeric substances matrix, 
which contains EPS, extracellular DNA (eDNA), proteins, lipids and ions, which strongly 
interact with each other and associate in a complex network that holds mainly  
by electrostatic forces and hydrogen bonds (Flemming et al., 2010; Kaur et al., 2015).  
The composition and structure depends on many factors, including the component 
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microbial cells, their physiological state, the physical environment, the available nutrients 
and substrates, and the surface to which the cells are attached (Kaur et al., 2015).  
In addition, the chemical environment plays a role in the biofilm structure, e.g. calcium 
ions can form a bridge between the negatively charged alginate polymers and increase  
the thickness of biofilms (Parsek et al., 2008).  
The matrix is important since it provides protection to the biofilm. It is necessary for 
adhesion to surfaces, it holds the biofilm cells together and provides mechanical stability. 
Furthermore, it protects the resident cells against environmental stresses  
(e.g. dehydratation, metals, UV radiation, pH extremities, antimicrobial agents, 
immunological defense mechanisms, etc.) and acts as a reservoir by providing retention  
of water, nutrients and other compounds (Wei et al., 2013).  
P. aeruginosa exopolysaccharides  
At least three exopolysaccharides have been shown to be produced  
by P. aeruginosa, alginate, Psl, and Pel (Colvin et al., 2011). In case of non-mucoid strains, 
Psl and Pel EPS plays a major role in biofilm formation. While in mucoid counterparts 
alginate is overproduced. Furthermore, alginate-containing biofilms are structurally 
heterogeneous, whereas biofilms produced by non-mucoid strains are flat and more 
homogeneous (Flemming et al., 2010). Not all of three polymers are required for biofilm 
formation. Mutants that lack Psl, alginate or Pel can still form biofilms, whereas mutants 
that lack both Psl and Pel are not able form biofilms (Ghafoor et al., 2011).  
Psl 
Polysaccharide synthesis locus (psl) enncodes a polysaccharide composed  
of L-rhamnose, D-mannose and D-galactose monomers, however the exact structure is not 
yet revealed (Wei et al., 2013). Psl expression is controlled by a two-component regulatory 
system and autoregulation by stimulation of the second messenger c-di-GMP production 
(Harmsen et al., 2010). The Psl polysaccharide forms a helical structure around  
the bacterial cells and is important for adhesion. It increases cell-to-cell interactions which 
are essential for biofilm formation assembly at the air-liquid interface and maintenance  
of non-mucoid P. aeruginosa strains (Coulon et al., 2010; Harmsen et al., 2010). Psl  
is responsible for the formation of a fabric-like matrix and it holds the cells closely together, 
thereby impeding antibiotic penetration throughout the biofilm. This EPS is mainly situated 
in the outer layers of three dimension-structured microcolonies, whereas it is uniformly 
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distributed in flat biofilms (Ma et al., 2009). Psl can reduce neutrophil phagocytosis and 
the oxidative response via limiting complement-mediated opsonization (Mishra et al., 
2012). It provides a first line of defense against cationic and anionic antibiotic during initial 
stages of biofilm formation.  
Pel 
Pel is a positively charged exopolysaccharide composed of partially acetylated  
1→4 glycosidic linkages of N-acetylgalactosamine and N-acetylglucosamine, synthesized 
by a highly conserved, seven-gene operon (pelA-F) (Jennings et al., 2015; Wei et al., 2013). 
The pel locus is regulated by a two-component regulatory system and involves  
c-di-GMP (Harmsen et al., 2010). Pel plays a role in the later stages of biofilm development 
and is required for solid surface-associated biofilms. It imparts a wrinkled colony 
phenotype, can compensate as an attachment factor in the absence of other adhesins  
(e.g. type IV pili) and is necessary for the maintenance of cell-cell interactions in mature 
biofilms (Friedman et al., 2004). Coulon et al. (2010) studies suggesting that pel locus 
might be also involved in the LPS production.  
Alginate 
Alginate is a linear co-polymeric EPS composed of non-repetitive monomers  
of β-1,4-linked L-guluronic and D-mannuronic acids and is associated with mucoidy  
of P. aeruginosa (Lau et al., 2005). It is a polyanionic polymer, that provides a physical 
barrier for some antibiotics (e.g. aminoglycosides) by binding them to its positively charged 
molecules (Yan et al., 2014; Khalifa et al., 2011). Most mucoid isolates have mutations  
in the anti-sigma factor gene, mucA, that leads to activation genes involved in alginate 
biosynthesis by AlgT(U). These polysaccharides have a large molecular mass and are 
relatively soluble, resulting in the formation of highly viscous aqueous solutions 
(Sutherland, 2001). Furthermore, alginate plays important role in structural stability  
of biofilms and protects against human antibacterial defense mechanisms such  
as phagocytosis, antibodies and ciliary movements (Ma et al., 2009). 
Other biofilm components 
Up to 97% of the biofilm matrix is composed from water (Wei et al., 2013), that 
can exist as a solvent for solutes or bound within the capsules of microbial cells. Three- 
dimensional biofilms may contain water channels, that allow transfer of oxygen, nutrients, 
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substrate, metabolites, waste products and other solutes throughout the biofilm (Sutherland, 
2001).  
The matrix also contains nucleic acids, mainly in the form of eDNA, found 
primarily within the stalks of mushroom-shaped microcolonies. eDNAs are random 
chromosomal DNA segments that are either actively secreted in small membrane vesicles 
or released from cells after lysis caused by bacteriocins, bacteriophages or QS.  
For migrating bacteria, they serves as adhesisn and are bound with high affinity by type IV 
pili. The eDNA stabilizes the biofilm, contribute in antibiotic resistance and cation 
gradients, genomic DNA release, as well as a nutrient source for starving bacteria after 
degradation by extracellular deoxyribonucleases (Wei et al., 2013). In addition, eDNA 
forms bundles with F-actin liberated from necrotic neutrophils and can initiate biofilm 
development (Parks et al., 2009). 
A cellular appendages such as pili, fimbriae and flagella are also consider  
as a matrix components. These structures are important for adhesion and/or motility,  
as well as structural support (Mann et al., 2012).  
Biofilm formation 
Biofilm formation has been divided into five stages: 
1. Attachment and reversible adhesion- planktonic bacteria encounter a surface and with 
the use of flagella and type IV pili attach loosely and reversibly to it. This is primarily 
influenced by electrostatic forces, van der Waals forces and Brownian motion. At this stage, 
the bacteria are still susceptible to antibiotics, in accordance with the success  
of perioperative antibiotic prophylaxis (Høiby et al., 2010; Wagner et al., 2008). 
2. Irreversible adhesion- within a few hours from the initial adhesion, the bacteria starts  
its multiplication and extracellular metabolites production (EPS and proteins), which lead 
to matrix formation bind to the surface irreversibly. The main role is played by non-specific 
interactions (e.g. hydrophobic, hydrogen and ionic bonds) and specific interactions  
(e.g. adhesins) (Høiby et al., 2010). 
3. Maturation I – biofilm grows in thickness (up to 50µm) and mushroom-like or tower-
like structures are often observed (in vitro conditions). The type IV fimbriae play  
an important role here.  
4. Maturation II- depends on the availability of nutrients, osmolarity, the oxygen 
concentration and pH within the biofilm. New proteins are synthetized, that were absent  
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in planktonic form, and alginate is overproduced. At this stage, the biofilm shows 
maximum tolerance/resistance to antibiotics (Høiby et al., 2010). 
5. Dispersion- local areas of the biofilm dissolve and cells can detach via active  
or mechanical (e.g. increased external fluid shear) means and then spread to another 
location where new biofilms may form. This liberation process may also be caused  
by bacteriophage activity within the biofilm (Høiby et al., 2010). 
  
Figure 1.4: Representation of P. aeruginosa flat and structured biofilm development. Initial attachment 
involves adherence of free-swimming cells to the surface. In the case of a flat biofilm, cells continue  
to multiply and move on the surface, forming a confluent, flat mat of cells. In the case of structured biofilms, 
there are two alternative routes to their formation. The first is ‘Structured Biofilm I’. Here, orange cells 
represent the immobile ‘stalks’ of structured biofilms, while light blue cells represent the motile 
subpopulation. The second is ‘Structured Biofilm II’. In this case small cell aggregates grow clonally, forming 
large cell aggregates consisting of cells primarily derived from cells in the small cell aggregates. This  
is indicated by the large aggregate of orange cells in the figure. The cells in aggregate are progeny derived 
from the initial small aggregates. Finally, cells can actively leave the biofilm to reinitiate the cycle in a process 
called dispersion or detachment (Kirisits et al., 2006). Below the scheme are a two-dimensional projection  
of the three-dimensional image shown as a top-down view for 2 h (I), 1 day (II), 2 days (III), 3 days (IV), and 
4 days (V) after inoculation. Maximal thickness of the biofilm is reported for each time period. Biofilm 
images were collected by a Leica confocal scanning light microscopy using a 488-nm wavelength. Images 
are at ×400 and represent a 250×250-μm field (Wagner et al., 2008).  
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The impact of biofilms in industry 
In industry, biofilms have become problematic in a wide range of food industries, 
such as brewing (Flemming et al., 2009), seafood processing (Shikongo-Nababi, 2011), 
dairy processing (Chmielewki et al., 2003), poultry processing (Harvey et al., 2007), meat 
processing (Sofos et al., 2010) and equipment contamination (e.g. pipelines) (Stewart  
et al., 2008). In medicine, up to 80% of persistent bacterial infections were found  
to be biofilm associated (Janssens et al., 2008; Srey et al., 2013; Blair et al., 2014). It occurs 
on natural surfaces such as teeth, heart valves (endocarditis), in the lungs of CF patients 
causing chronic bronchopneumonia, in the middle ear in patients with chronic and secretory 
otitis media, in chronic rhinosinusitis, in chronic osteomyelitis and prosthetic joint 
infections, in intravenous catheters and stents and in chronic wounds (Høiby et al., 2011). 
Biofilms are highly resistant to antibiotics and chemical disinfectants, as well  
as the host immune system (Khalifa et al., 2011). There are several factors of unique biofilm 
defense: 1) size exclusion and delay of antibiotic diffusion through the pores of EPS matrix 
(e.g. aminoglycosides); 2) synthesis of periplasmic glucans that sequester cationic 
antibiotics (Ghafoor et al., 2011); 3) an altered metabolic activity correlated to cell position 
in the heterogeneous biofilm structure (e.g. β−lactams, ciprofloxacin) (Klausen et al., 
2003); 4) unequal cells susceptibility to antimicrobial agents, presence of subpopulations 
with a resistant phenotype: persisters in dormant state and phenotypic variants originate 
from mutations and genetic rearrangements, that can grow normally in the presence  
of elevated levels of antibiotics (Harmsen et al., 2010).  
1.1.3. Antibiotic resistance: bad bugs, no drugs: No ESKAPE! 
The arrival of the antibiotic era largely palliated the previously fatal outcomes  
of acute infections in patients. Standard antibiotic therapy in use against P. aeruginosa 
infections include a number of β-lactams such as cephalosporins (e.g. ceftazidime), 
carbapenems (e.g. imipenem, meropenem), monobactams (e.g. aztreonam), and penicillin 
(e.g. piperacillin). Other major classes of antibiotics used for treatment comprise 
aminoglycosides (e.g. gentamicin, tobramycin, amikacin), quinolones (e.g. ciprofloxacin), 
and polymyxins (e.g. colistin, polymyxin B) (Taylor et al., 2014). However,  
the inappropriate antibiotic treatments and the development or acquisition of multidrug-
resistant strains lead to resistant chronic P. aeruginosa infections (Kang et al., 2005, Lodise 
et al., 2007, Micek et al., 2005). 
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Antibiotic resistance results from several independent mechanisms. They can  
be divided into three models: intrinsic, acquired and adaptive resistance. First, include  
a reduced permeability of the outer membrane by presence of small size porins  
(e.g. vancomycin resistance) (Nicas et al., 1983; Hancock, 1998; Blair, 2014). Second, 
active removal of antibiotics by efflux pumps and degradation through enzymatic 
modifications. These factors make P. aeruginosa resistant to penicillin G, aminopenicillins, 
macrolides, cephalosporins I and II generation, tetracyclines, sulfonamides, and 
chloramphenicol. Acquired resistance may be of endogenous (mutational variation)  
or exogenous origin (horizontal gene transfer by e.g. by conjugation, plasmids, transposons, 
integrons). The endogenous factors include: cephalosporinases AmpC derepression, 
overexpression of efflux pumps, porin OprD repression, mutations in gyrase and 
topoisomerase IV (Blair, 2014). Third, resistance can develop during treatment  
(e.g. repeated exposure to sublethal concentrations of antibiotics). In this case, the bacteria 
adapt themselves to survive by undergoing chromosomal mutations in genes. Other 
mechanisms of resistance, such as ESBL (β-lactamase extended substrate spectrum) and 
MBL (metallo-β-lactamase) and aminoglycosides modifying enzymes arise from 
horizontal gene transfer (Wolska et al., 2013). P. aeruginosa resistance mechanisms  
to antibiotics are presented in Table 1.3. 
Finally, persister cells of P. aeruginosa exhibit multidrug tolerance, which,  
in contrast to resistance, results from dormancy rather than mutations. The cells can survive 
but not grow in the presence of antibiotics. When antibiotic pressure drops, the persister 
cells can restore the population, with the same antibiotic susceptibility features as original 
one with additional small pool of persister cells (Fauvart et al., 2011). In CF environment 
resistance of chronic P. aeruginosa infections largely results from multidrug-tolerant 
subpopulation of persister cells (Lewis, 2007; Fauvart et al., 2011). Moreover, high 
persister (hip) mutants have been isolated from CF patients, the appeared probably  
in response to the periodical administration of antibiotics (Lewis, 2007, Mulcahy et al., 
2010). 
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Table 1.3: Resistance mechanisms (Gellatly et al., 2013; Strateva et al., 2009). 
Mechanism Resistance class Examples 
Outer membrane 
impermeability 
Intrinsic Outer membrane channels OprF, OprD, OprB 
(carbapenems, aminoglycosides, quinolones) 
EPS 
Efflux pumps Intrinsic MexAB–OprM (Quinolones, macrolides, tetracyclines, 
lincomycin, chloramphenicol, novobiocin, b-lactams 
except imipenem) 
MexCD–OprJ (Quinolones, macrolides, tetracyclines, 
lincomycin, chloramphenicol, novobiocin, penicillins 
except carbenicillin and sulbenicillin, cefepime, 
cefpirome, meropenem) 
MexEF–OprN (Fluoroquinolones, carbapenems) 
MexXY–OprM (Quinolones, macrolides, tetracyclines, 
lincomycin, chloramphenicol, aminoglycosides, 
penicillins except carbenicillin and sulbenicillin, 
cefepime, cefpirome, meropenem) 
β-lactamases Intrinsic AmpC (penicillins) 
Targeted mutation Acquired DNA gyrase, DNA topoisomerase IV, 16s rRNA 
methylation (quinolones) 
Horizontal transfer Acquired Metallo-β-lactamases, ESBLs (penicillins, 
cephalosporins, carbapenems) 
Membrane changes Adaptive Lipid A modification (aminoglycosides, polymyxins) 
AmpC upregulation (penicillins) 
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1.2. Bacteriophages 
1.2.1. Short history of phage research 
In 1896 British bacteriologist Ernest Hanbury Hankin observed during a cholera 
epidemic in India, that people drinking water from the Ganges and Yamuna rivers do not 
get sick. Examination of the water samples revealed the existence of “substances” with 
antibacterial properties, that prevented the spread of the epidemic. Several years later, two 
scientists, British bacteriologist Frederick Twort (1915) and French-Canadian 
microbiologist Félix d'Herelle (1917) independently observed virus-associated cell lysis  
of Micrococcus (currently Staphylococcus aureus) and Shigella sp. D'Herelle was also  
the first scientist who applied the term “bacteriophage” as "an invisible, antagonistic 
microbe of the dysentery bacillus" (Adams, 1959; Kutter, 2005). In the 1920s and 1930s 
Lilly and Squib started to work on bacteriophage preparations for the treatment  
of Staphylococcus infections. In 1923, the Eliava Institute was opened in Tbilisi, Georgia, 
which was the phage therapy center behind the ‘Iron Curtain’ for almost 70 years. To date, 
it is the most well known phage therapy institute. However, a number of factors including 
antibiotic discovery caused the decreased use of bacteriophages for medical applications 
for the next decades (Sabouri Ghannad et al., 2012). 
1.2.2. Bacteriophage classification 
The name “bacteriophage” is derived from the Greek bacterion (bakteria, rod, 
stick) and phagein (eat, devour). Bacteriophages (phages) are obligatory intracellular 
bacterial parasites. They are highly diversified and abundant in biosphere, outnumbering 
prokaryotes approximately ten fold (Donlan, 2009; Kohanski et al., 2010). The bacterial 
host is required for viral progeny reproduction (Donlan, 2009). This situation leads  
to an continuous arms race and coevolution of host and its infecting virus, resulting  
in vast variety of phage species with different mechanisms of host infection (Le et al., 
2014). Most of phages are highly specific and have a narrow host-range, targeting only few 
strains within a species (Stewart et al., 2008). 
Phages are classified based on (i) infection cycle (lytic or temperate),  
(ii) morphology (filamentous or icosahedral phages with/without tails, phages with  
a lipid-containing envelope or contain lipids in the particle shell) (Fig. 1.5), (iii) genome 
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composition (dsDNA, ssDNA, ssRNA, dsRNA or segmented) and (iv) genome 
organization (subfamilies & genera).  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1.5: Classification of microbial viruses based on morphology. Virion morphotypes  
of prokaryotic and archaeal viruses. Abbreviations: APOV1, Aeropyrum pernix ovoid virus 1; APSV1, 
Aeropyrum pernix spindle-shaped virus 1; PAV1, Pyrococcus abyssi virus 1; SMV1, Sulfolobus monoca. 
Viruses infecting archaea and bacteria are marked blue, only bacteria orange and only archaea green (Pietilä 
et al., 2014).  
 
Phages have evolved at least three distinct types of infection cycles: strictly lytic, 
lysogenic or pseudolysogenic. The lytic cycle leads to cell lysis and obviously death of the 
bacterial host. It has several steps: 1) phage attachment to specific receptor on the host cell 
surface (e.g. LPS, OM porins, flagella or pili) with/without production of EPS degrading 
enzymes. This step determines phage specificity and its host range; 2) injection of genomic 
DNA into the bacterial cell; 3) transcription and translation of early, middle and late phage 
genes by hijacking the host synthesis machinery; 4) formation of new virion particles;  
5) disruption of the bacterial cell wall by peptidoglycan degrading enzymes, called 
endolysins, and release of the progeny (Donlan, 2009). In general terms, temperate phages 
have genetic switches, which allows them to determine if lytic infection occurs  
or expression of phage genome will shutoff and the genome will frequently be incorporate 
in the bacterial genome (prophage state). The switch occurs at random or can be triggered 
by environmental stresses when the survival of the host bacterium is not assured (Clokie  
et al., 2011). Finally, when bacteria are starved or experience suboptimal growth, and 
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exhibit low metabolism and reduced growth, pseudolysogeny may occur. It is a stalled 
phage development in a host cell without multiplication of the phage genome  
or its replication, a survival mechanism in hostile environment. Phage genome is present 
within the host cells in an unstable, inactive state and may stay present unexpressed  
for a long period. When nutrients become again available, the pseudolysogenic state can  
be reversed and gene expression can take place (Los et al., 2012). 
Approximately 96% of phages have a complex morphology structure (icosahedral 
head and tail), while ~ 4% have isometric, helical or pleomorphic structure (Fig. 1.6) 
(Matsuzaki et al., 1998).  
Figure 1.6: Phage capsid morphology. From left to right: icosahedral (naked), icosahedral (enveloped), 
helical (naked) and helical (enveloped) structures (Towar K, 2011). 
 
On the basis of the tail morphology, order Caudovirales is divided into three 
families (Fig. 1.7): 1) Myoviridae with contractile tails consisting of a sheath and a central 
tube; 2) Siphoviridae with long, noncontractile tails, and 3) Podoviridae with short tails 
(Kurtböke et al., 2012). The viral capsid holds packed genetic material and proteins, while 
tail and its fibers are responsible for the host cell recognition, attachment, cell envelope 
penetration and delivery of the phage DNA into the host cell cytoplasm (Leiman et al., 
2004 and 2012; Davidson et al., 2012). 
 
 
 
 
 
 
 
 
 
 
 
 
 
45 
 
Figure 1.7: Morphology of phages belonging to order Caudovirales. From left to right, schematic drawings 
of a Siphoviridae family (icosahedral head and long noncontractile tail, e.g. λ phage), Myoviridae family 
(icosahedral head and long contractile tail, e.g. T4 phage) and Podovidae family (icosahedral head and short 
tail, e.g. T7 phage) are shown (Serwer et al., 2008). 
 
The phage virion may consist of different genetic material (ss/dsDNA  
or ss/ds RNA), enclosed within a protein or lipoprotein coat. The size of the phage genomes 
vary from a few kilobase pairs (kbp) to several hundred. In last decades the number  
of sequenced phage genomes increased as well as the number of unknown ORFs (Open 
Reading Frames) without or low sequence homology. These genes are called ‘viral dark 
matter’ and are a vast reservoir of genetic information (Rohwer et al., 2011). Many of them 
are non-essential, however some might have important function and influence on e.g. phage 
fitness in specific environments (Hargreaves et al., 2014). 
1.2.2.1. Pseudomonas bacteriophages 
In 1964 Lindberg assembled a P. aeruginosa typing set, among which Ackermann 
et al. (1988) found eight different morphotypes (Fig. 1.7).  
Figure 1.7: Scale drawing of the different morphotypes of the phages belonging the Lindberg typing 
set (Ackermann et al., 1988). 
Later, Ackermann also examined after negative staining over 5500 phages  
in the electron microscope among which 511 infected Pseudomonas genus (Ackermann, 
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2007). More than 97% of this pool were tailed phages, while only 3% were polyhedral, 
filamentous or pleomorphic. Moreover, the majority belong to the Siphoviridae family 
(47%). In recent years, formal taxonomy has relied heavily on the availability of complete 
genome sequences of these phages, which has led to the creation of several new genera and 
subfamilies based on genome organization. Interestingly, this molecular classification still 
corresponds well to the original morphotype classification (www.ICTVonline.org). 
Among the Myoviridae family six types infecting Pseudomonas can  
be distinguished: P2virus, a genus of the Tevenvirinae subfamily and several independent 
genera: Kpp20virus, Pakpunavirus, Pbunavirus and Phikzvirus (according to International 
Committee on Taxonomy of Viruses, ICTV). The most well know and studied is phage 
φKZ, originally isolated in 1975 from sewage sample in Alma Ata, Kazakhstan.  
It represents a giant and broad-range genus of Phikzvirus. Its virion has large head  
of 145 nm diameter and long contractile tail of 200 nm, surrounded by a loose fibrous 
network (Ackermann et al., 1988; Mesyanzhinov et al., 2002). Its capsid contains  
no less than 50 different proteins and holds a 280 kb dsDNA, circularly permuted and 
terminal redundant genome, spooled around protein inner body (Thomas et al., 2012).  
The majority of predicted ORFs (75% out of 369 predicted ORFs) share no homology with 
other proteins in NCBI database, which results in low relatedness to other phages (Krylov 
et al., 2007), except Pseudomonas phage PA7.  
All Pseudomonas phages within the Siphoviridae family described to date are 
temperate and represent transposable phages, such as phage B3, D3112 and D3.  
The ICTV database lists five types of Pseudomonas Siphoviridae: D3112virus, D3virus, 
Septima3virus and Yuavirus, which are often isolates from clinical environments (Krylov 
et al., 2007, Zegans et al., 2009). Currently, it is the most studied group among 
Pseudomonas phages. Phage D3112 is one of the representative siphoviruses. It has  
a number of important characteristic features: 1) rare palindrome GTCGAC and CTGCAG  
in its genomes; 2) absence of autoxotrophic mutants among lysogens; 3) many sites for 
integration into a bacterial chromosome and 4) modular genomes (around 37 kbp, 50 - 60 
predicted ORFs) with the ability to exchange modules by recombination (Krylov et al., 
2007).  
Currently, the ICTV database distinguishes five types of Podoviridae phages 
infecting Pseudomonas: Phikmvvirus, T7virus, F116virus, Lit1virus, Luz24virus. They are 
divided based on genome organization and behavior during infection. The lytic 
Pseudomonas phage gh-1, isolated in 1966, is a representative of T7virus, that forms large 
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clear plaques and requires O-antigen on the bacterial surface as a receptor. It has a 37 kbp 
linear genome and 42 predicted ORFs. Among the T7virus genus there is strong correlation 
in genome organization and conserved replication strategy (Kovalyova et al., 2003;Rehm, 
2009). 
1.2.3. Bacteriophage - based therapeutics 
Phages exhibit several advantages for application as antimicrobials: 1) high 
diversity and abundance; 2) bacteriolytic activity; 3) high specificity to one genus  
or species; 4) they can work in synergy with other phages with different lysis mechanisms 
and/or bacterial surface receptors in cocktail preparations, as well as with antibiotics;  
5) self-dosing therapy; 6) low costs preparations (Hyman et al., 2012; Bikard et al., 2014; 
Brown-Jaque et al., 2015; Roach et al, 2016). However, also number of key disadvantages 
are present, including the presence of toxins or integrases encoded by temperate phages, 
and the potential for horizontal gene transfer between phages and host (e.g. transfer  
of virulence genes) via specialized or generalized transduction (Brown-Jaque et al., 2015; 
Roach et al, 2016). In the last decades, the absence of preclinical and clinical data led  
to prohibition of phage therapy around the world, except in Georgia, Russia and Poland 
(Chanishvili, 2012). Currently, the commercial interest has been recovered by small 
pharmaceutical companies focusing on phages (Table 1.4) and phage-derived proteins (this 
section will be discussed in details in further sections).  
Table 1.4: Current phage therapeutics development for human diseases treatment (Cooper et al., 2016). 
Company Product Type Target Application Company 
website 
Intralytix ShigActive Phage  Shigella Ingested http://www.int
ralytix.com/in
dex.php?page
=prod 
AmpliPhi AmpliPhage-001 
AmpliPhage-002 
AmpliPhage-004 
Phage P. aeruginosa 
S. aureus 
C. difficile 
-* 
Topical 
- 
http://www.a
mpliphibio.co
m/product-
pipeline.html 
Technophage T TP-102 
TP-122 
TP-132 
TP-107 
Phage -* 
-* 
-* 
-* 
 
Ulcers 
Respiratory 
-* 
Topical 
 
http://www.tec
hnophage.pt/in
dex.php/r-
d/productpipel
ine 
Pherecydes 
Pharma 
PP021 
PP1131PP1231 
PP2351 
Phage E. coli 
Pseudomonas 
Staphylococcus 
Burn and Skin 
Burn, Skin, and 
Respiratory tract 
infection 
Bone, Joint, and 
Prosthesis 
http://www.ph
erecydes-
pharma.com/p
ipeline.html 
(*) information not available 
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Within the field of food and agriculture industry, several phage preparations have 
already been approved in USA as a food protecting agents (LISTEXTM, 
SALMONELEXTM, ListshieldTM, EcoshieldTM, SalmoFreshTM) (Rodríguez-Rubio et al., 
2015).  
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1.3. Phage enzymes with antimicrobial properties & 
applications  
1.3.1. Peptidoglycan degrading enzymes 
1.3.1.1. Bacterial cell wall structure  
The bacterial cell wall consist of several layers and its rigidity depends  
on an internal pressure, correlated with the osmotic forces (Schlegel, 2008). Bacteria 
possess a peptidoglycan (PG) layer, also known as a murein sacculus (Slonczewski et al., 
2011; Hyman, 2012). Murein is a heteropolymer composed of alternating  
N-acetylglucosamine (GlcNAc; an amino sugar derivative) and N-acetylmuramic acid 
(MurNAc; glucosamine with a lactic acid group) chains, which are linked  
by β-1,4-glycosidic bonds. These glycan chains are connected by short peptides consisting 
of four to six amino acids, such as L-alanine, D-glutamic acid, meso-diaminopimelic acid 
(mDAP) or L-lysine and D-alanine (Schlegel, 2008). The MurNAc lactic acid residue,  
L-alanine, is the link between the amino acid of the stem and the sugar backbone (Schleifer 
et al., 1972).  
In Gram-positive bacteria murein layer is thick (~40 layers, 20 – 80 nm) and 
comprises 30 - 70% of a cell wall weight. Often instead of mDAP, LL-diaminopimelic acid 
or L-lysine occur in the third amino acid position. Another characteristic feature  
is the presence of teichoic acids, composed of 8 - 50 glycerol or ribitol molecules 
conntected by phosphodiester bridges. Teichoic acids might be attached to peptidoglycan 
layer by phosphates in amide-like bond (Fig. 1.8) (Schlgel, 2008). In contrast, Gram-
negative bacteria have a thinner peptidoglycan layer (1 to 3 layers, 10 nm) which comprises 
less than 10% of cell wall weight. The murein lacks a lysine residue at the third amino acid 
position of the dipeptide and instead has mDAP, interlinked with a D-alanine of an adjacent 
peptide stem from another glycan chain. Importantly, the cell wall has an additional outer 
membrane rich in lipopolysaccharides, lipoproteins and phospholipids (Fig. 1.8) (Madigan 
et al., 2008; Schlgel, 2008; Cornelissen et al., 2012).  
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Figure 1.8: The Gram-positive and Gram-negative bacteria cell wall comparison. From left to right: 
Gram-positive bacteria with an inner cell membrane and thick peptidoglycan layer; Gram-negative bacteria 
with inner cell membrane, thin peptidoglycan layer and outer membrane layer with surface proteins, porins 
and lipids (Aryal, 2015). 
1.3.1.2. General characteristics of PG degrading enzymes 
Bacteriophage-encoded peptidoglycan degrading enzymes are bacterial cell wall 
degrading proteins which play a key role in the lytic replication cycle (Fig. 1.9). First, 
virion-associated lysins locally degrade peptidoglycan and allow the virus to penetrate 
through the cell wall and inject its genome. Further, in the late stage of the cycle, genes 
responsible for a two component holin-endolysin mechanism (specific to Caudovirales) 
and spannins are overexpressed and phage progeny are released by bursting the cell 
envelope (Stone, 2002).  
Figure 1.9: Timeline of the T4 phage replication pathway. The chronological order of T4 lytic cycle and 
expression of early, middle and late genes. Early genes include enzymes modifying the host’s DNA 
replication and transcription. Middle genes are responsible for phage DNA replication and late genes 
activation. Late genes play key role in production and assembly of structural proteins followed by self-
assembly and progeny release (Madigan et al., 2008). 
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Peptidoglycan degrading enzymes are considered to be efficient antimicrobials 
against most common pathogens such as: Staphylococcus sp., Streptococcus pneumoniae, 
Enterococcus faecium, Bacillus anthracis, Clostridum sp., Klebsiella pneumonie and  
P. aeruginosa (Stone, 2002).  
1.3.1.3. Structure of PG degrading enzymes  
There are three types of phage bacteriolytic PG degrading enzymes: endolysins, 
virion-associated PG hydrolases (VAPGHs) (Fig. 1.10) and spannins. They have similar 
mode of action, yet differ in structure and time of action during phage lytic cycle. 
 
 
 
 
 
 
  
 
 
 
 
 
Figure 1.10: Schematic representation of PG layer degradation by application of endolysins, VAPGHs 
and holins. The peptidoglycan bonds are cleaved, which leads to cell wall instability and the high internal 
pressure of cell protrudes the plasma membrane resulting in osmolysis (lysis from without) (Roach et al., 
2015).  
 VAPGHs are tail-associated muralytic enzymes, important at the beginning  
of the replication cycle. They are located beneath the baseplate and assist in phage genome 
injection by localized PG degradation (Rodríguez-Rubio et al., 2015). Their activity  
is rather superficial since the cell wall stability has to be ensured for the bacterial host 
survival (Rodríguez-Rubio et al., 2013). They are present in Gram-positive and Gram-
negative phages, however not all are required for successful genomic transfer (Roach et al., 
2015). VAPGHs consist one or two enzymatically active domains (EADs), that can cleave 
PG on several positions, either in the glycan moieties (by glycosylases) or the peptide stem 
(by amidases/peptidases) (Fenton et al., 2010; Fischetti, 2010; Nelson et al., 2012). 
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In contrast, endolysins act from within. In the final step of replication cycle they are 
accumulated in the cytosol to lyse the bacterial cell wall (Fenton et al., 2010; Nelson et al., 
2001). However, the enzymes have several strategies to cross the cell membrane  
(Fig. 1.11). Often, they require assistance of secondary proteins, called holins. These small 
hydrophobic proteins with transmembrane domains are able to permeabilize  
the cytoplasmic membrane by forming pores in a concentration-dependent manner (Wang  
et al., 2000). This results in release of the endolysins to the periplasm and PG layer 
destabilization (Wang, 2006).  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1.11: Schematic representation of different models for export and activation of phage 
endolysins. (a) In phages such as λ the export of the active endolysin to the cell wall is through the holin 
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pores. Holin-independent, Sec-mediated export of endolysins is observed in: (b) phages producing endolysins 
with typical signal peptides (SP), such as oenophage fOg44; (c) in phages synthesizing signal-arrestrelease 
(SAR) endolysins, as observed in coliphage P1; and (d) in mycobacteriophage Ms6, where export of the full-
length endolysin (Lysin384) is assisted by the chaperone Gp1. When endolysins are exported through the Sec 
translocase, they are maintained in an inactive state in the cell wall compartment until holins dissipate  
the membrane pmf. The endolysin activation after pmf collapse is schematically represented by the change 
of the enzyme spherical configuration to a ‘pacman’ shape. Lysin241 in (d) is an N-terminally truncated 
version of the Ms6 endolysin produced by internal translation signals in the same reading frame. (?) indicates 
that export of this shorter version to the extracytoplasmatic environment is not known. (PG) peptidoglycan, 
(CM) cytoplasmic membrane, (Cyt) cytoplasm (Catalão et al., 2013). 
Despite their conserved biological function, endolysins are heterogeneous  
in structure and enzymatic activity. This divergence is directly related to the Gram-positive 
and Gram-negative bacterial cell wall structure. They can be globular or modular enzymes. 
The globular enzymes are mainly associated with phages infecting Gram-negative bacteria 
and usually contain a single EAD that cleaves specific bonds within PG (Briers et al., 
2007). Modular enzymes are usually associated with phages of Gram-positive bacteria, and 
contain an N-terminal EAD and a C-terminal cell wall-binding domain (CBD) (Fischetti, 
2010; Nelson et al., 2012; Walmagh et al., 2012) with few exceptions. The CBD  
is responsible for high specificity through recognition and noncovalent binding to epitopes 
on the bacterial cell wall, such as carbohydrates, teichoic acids or peptides (Fenton et al., 
2010). Also endolysins with two EADs and absence of CBD have been reported. 
Sometimes an additional flexible interdomain linker sequence can be present. It provides 
additional flexibility in the structure, which allows domains to work autonomously (Fenton 
et al., 2010; Rajaure et al., 2015). 
The CBDs prevent the diffusion of enzyme to intact with adjacent cells, by tightly 
binding the cell wall, even after cell lysis. However, the Gram-negative infecting phages 
have to overcome a much thinner PG layer but with the presence of the OM, the collateral 
damage by endolysin diffusion after lysis is prevented, which eliminates the need for CBDs. 
This is why most of those phages possess smaller, globular endolysins (Briers et al., 2015).  
In phages infecting Gram-negative bacteria the third class of lysis proteins called 
‘spanins’ are present, responsible for OM disruption, possibly due to fusion with  
the cytoplasmic membrane (Young, 2014; Briers et al., 2007). 
1.3.1.4. Mode of action of PG degrading enzymes 
The conserved overall composition and architecture of the bacterial PG permits  
the cleavage of only limited types of covalent bonds. However, there is a clear discrepancy 
between Gram-positive and Gram-negative bacteria. The first lack an OM and have  
a diverse PG composition, which results in over 100 different known chemotypes.  
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The GlcNAc and MurNAc backbone is conserved, with only rare examples  
of O-acetylation, N-glycosylation or N-deacetylation (e.g. Bacillus sp., Micrococcus luteus 
or Mycobacterium smegmatis), while the peptide moiety (amino acids composition and 
interpeptide cross bridging) is a source of PG diversity (Schleifer et al., 1972; Vollmer, 
2008). This is why phages infecting Gram-positive bacteria have to be armed with highly 
diverse and specific endolysins. In case of Gram-negative the diversity and specificity  
is lower, due to reduced selective pressure of PG in the presence of OM, low variation  
in the polysaccharide backbone, the interpeptide bridges and crosslinks. As a result,  
the endolysins of phages infecting Gram-negative bacteria have broad enzymatic activity 
(Walmagh et al., 2013; Schleifer et al., 1972).  
The EADs comprise the catalytic activity of the endolysins and VAPGHs. 
Depending which specific bond is cleaved, they are classified into six groups (Fig. 1.12): 
(1) N-acetyl-β-D-muramidases (similar to lysozyme) cleave the N-acetylmuramoyl- 
β-1,4-N-acetylglucosamine bond, one of the two alternating glycosidic bonds of glycan 
strand. (2) N-acetyl-β-D-glucosaminidases hydrolyze the other glycosidic bond  
(N-acetylglucosaminyl-β-1,4-N-acetylmuramine) between the PG sugars. Both types  
of enzymes are hydrolases, requiring water to break the bond. However, there also exist 
lytic transglycosylases, which cleave the β-1,4 linkages between MurNAc and GlcNac 
resulting in the formation of a 1,6-anhydromuramoyl product, without water presence for 
reaction catalysis. This enzymes catalyzes an intramolecular reaction, in which  
the neighboring sugar moieties serve as an electron acceptors and destroy the covalent bond 
between them. (3) N-acetylmuramoyl-L-alanine amidases that cleave the amide bond 
between sugar (glycan, MurNAc) and the peptide (L-alanine). This allows for 
disengagement of glycan polymer from the stem peptide and PG destabilization. Further 
are endopeptidases, divided in two classes: (4) L-alanoyl-D-glutamate endopeptidases and 
(5) interpeptide bridge-specific endopeptidases. Both types cleave the peptide bonds 
between two amino acids in the interpeptide bridges and crosslinks. Finally,  
(6) γ-D-glutaminyl-L-lysine endopeptidases cleave peptide bonds between amino acid 
residues within the peptide stem that interconnects the PG strands (Hyman, 2012; Fischetti, 
2010; Fenton et al., 2010; Loessner, 2005; Young, 2014; Briers et al., 2007). 
 The most common, universal and broad spectrum are endolysins comprising 
amidase or muramidase activity, because they target the most conserved PG bonds.  
In contrast endopeptidases are more species-specific, hydrolyzing the most variable parts 
of PG, interpeptide bridges and crosslinks (Schmelcher et al., 2012).  
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Figure 1.12: Mode of action of the PG-degrading enzymes. (A) Schematic representation of Gram-positive 
and Gram-negative bacteria cell wall structure. PG network marked as a grey balls, teichoic acids are marked 
as yellow chains. Holin proteins (blue) form membrane lesions by insertion of themselves into  
the cytoplasmic membrane and oligomerization. Next, the endolysins (red) pass through these pores to access 
the peptidoglycan. In case of Gram-positive cell walls with the thick and highly cross-linked peptidoglycan 
network lysis occur from the outside, while in Gram-negative cells lysis by free endolysin is prevented  
by the presence of the outer membrane. (B) PG structure magnification with possible PG hydrolase cleavage 
sites. The PG consists of alternating MurNAc and GlcNAc, which are crosslinked by peptide stems.  
The interpeptide bridge consists of a diamino acid (m-DAP) that is directly cross-linked to the terminal  
D-Ala of the opposite peptide chain. The bonds that can be cleaved by the EADs of endolysins are indicated. 
1. N-acetyl-β-D-muramidase; 2. N-acetyl- β-D-glucosaminidase; 3. N-acetylmuramoyl-L-alanine amidase;  
4. L-alanoyl-D-glutamate endopeptidase; 5. interpeptide bridge-specific endopeptidase; 6. γ-D-glutaminyl-
L-lysine endopeptidase. Abbreviations: CCWP, carbohydrate cell wall polymer; GlcNAc, N-acetyl 
glucosamine; LU, linkage unit; m-DAP, meso-diaminopimelic acid; MurNAc, N-acetyl muramic acid;  
P, phosphate group (Loessner, 2005). 
1.3.1.5. Bacterial resistance to PG degrading enzymes 
To date, there are no reports describing endolysin resistance mechanisms or lost 
sensitivity to ‘lysis from without’(Roach et al., 2015). Several studies failed in resistance 
generation in vitro by repeated pathogen exposure to sub-lethal concentrations  
of endolysins or endolysin- sensitive strains mutagenesis (Schuch et al., 2002).  
No resistance occurred or resistant mutants were not promoted, while in control groups, 
treated with only antibiotics, resistance increased 10- 100,000 fold. 
However, the resistance to other types of PG hydrolases have been documented  
in case of human lysozyme with muramidase and cationic antimicrobial peptide activities. 
Resistance occurs due to modifications of peptidoglycan and/or cell wall linked 
components, such as teichoic acids (Davis et al., 2011). Staphylococcus simulans secreted 
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lysostaphin, that binds to the cell wall envelope and cleaves the pentaglycine cross bridges 
of the S. aureus peptidoglycan matrix (Gründling et al., 2006). Resistance occurs due  
to mutations and the subsequent formation of monoglycine cross-bridges, which eliminates 
the target site for the bacteriocins’ catalytic site (Roach et al., 2015). Pesticin secreted  
by Yerisnia pestis cells are protected by small immunity proteins, that binds and inactivates 
the enzyme (Lukacik et al., 2012). Importantly, the extracellular mode of action  
of PG degrading enzymes hamper the majority of known antimicrobial resistance 
mechanisms, that act intracellularly (e.g. reduced membrane permeability, efflux pumps, 
inactivation by cytoplasmic enzymes). Moreover, the high abundance and variety of phages 
as well as protein engineering strategies provide a inexhaustible source of new enzymes 
(Roach et al., 2015).  
1.3.1.6. Potential applications 
Phage endolysins and VAPGHs applied as a purified recombinant proteins can 
serve as efficient antimicrobial therapy alternative. Importantly, endolysins do not required 
holins to overcome membrane barrier and gain an access to PG layer. The external 
application of these enzymes to overcome common Gram-positive pathogenic bacteria such 
as streptococci, enterococci, Clostridium difficile, Bacillus anthracis, MRSA, etc. has been 
already extensively studied (Fenton et al., 2010). Microbes can be lysed in few seconds 
after exogenous application of even a small amount of purified endolysins.  
In the case of Gram-negative bacteria situation is more complicated, due  
to the presence of the OM, which serves as a very efficient shield against PG hydrolases.  
To circumvent this barrier several strategies were proposed. One idea is the combined 
administration with OM-permeabilizing agents, such as ethylenediaminetetraacetic acid 
(EDTA), detergents, etc. On the other hand, endolysins can be fused with protein 
transduction domains or peptides of non-endolysin origin to enable crossing the OM (Briers 
et al., 2014). In 2014 Briers et al. presented the idea of protein- engineered endolysin 
(Artilysin®), where phage enzyme was fused with an OM permeabilizing peptide (OMP). 
This peptide can either be polycationic, in order to disrupt the stabilizing ionic bounds 
between divalent cations and the negatively charged phosphate groups, or hydrophobic,  
to interfere with the hydrophobic moieties present in the lipid A part of LPS (Briers et al., 
2014). Furthermore, Lukacik et al. (2012) developed hybrid protein, a three domain 
endolysin (‘pesticin’), highly efficient against strains actively expressing FyuA, such  
as Escherichia coli, Y. pestis or Yersinia pseudotuberculosis. It consist the N-terminal 
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translocation domain, the FyuA OM transporter (a major virulence factor of Y. pestis) 
binding domain, and the C-terminal EAD, structurally similar to T4 lysozyme, that cleaved 
bonds in the PG layer (Lukacik et al., 2012). 
The advantages and limitations of PG degrading enzymes are summarized  
in Table 1.5. 
Table 1.5: The benefits and challenges of PG degrading enzymes as antimicrobials (Rodríguez-Rubio  
et al., 2016, Drulis-Kawa et al., 2012, 2015). 
Benefits Challenges 
high affinity  salinity, pH and temperature range limitations 
fast kinetics outcompeting the host immune 
response 
immunogenicity of proteins 
synergy with antibiotics or other PG hydrolases 
with different catalytic specificity 
release of immunomodulatory cell debris, such  
as teichoic acids, LPS etc. 
lack of documented resistance development lack of OM penetration ability (overcome by the 
Artilysin strategy) 
single dose, continuous or repeated administration  protein dependent half- time 
specificity with no effect on the commensal flora . 
noncorrosive and biodegradable 
reduction of antibiotic resistant mutants 
diversity in activity and structure 
high activity of low dosage 
suitable candidates for rational design and directed 
evolution 
The presented phage PG degrading enzymes opens the door to variety applications  
in biotechnology, food industry, agriculture and medicine (Fischetti, 2010). Table 1.6 
shows several examples, where single or periodical phage enzymes administration 
overcome bacterial infections. 
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Table 1.6: The PG hydrolases potential application in industry and medicine 
Application Problem Example Reference 
oral, nostril 
and topical 
administration 
infections of eye, ear, skin and 
mucous membranes 
(1) Streptoccocal C1 phage endolysin (PlyC, 500 U) administrated to the oral cavity 
impede group A streptococci colonization in upper respiratory track. Treatment fully 
eradicated bacterial infection up to 2h post treatment, while in control group infection 
occurred in 70% of mice. 
(2) single dose of phage-born endolysins reduced a Streptococcus agalactiae vaginal 
infections. 
(3) engineered VAPGH P128 (muralytic domain combined with specific cell wall 
targeting domain) was active against methicillin-resistant S. aureus in a nasal 
colonization model. 
Nelson et al., 2001 
Cheng. et al., 2005 
Paul et al., 2011 
interperitoneal 
injection 
systemic infections  PlyG endolysin of B. anthracis γ phage increased 70-80% mice survival in 72h long 
experiment, while control group died after 2h post infection. 
Schuch et al., 2002 
vaccinations  The stimulation of the human adaptive immune system by viral nanoparticles (VNPs) 
vaccination employing the cell wall anchor of bacteriophage endolysin for surface 
display. Already recombinant endolysin Lyb5 with CBD domain from Lactobacillus 
fermentum temperate bacteriophage φPYB5 was successfully displayed on the 
surface of lactic acid bacteria, such as Lactococcus lactis, Lactobacillus casei, Lb. 
brevis, Lb. plantarum, Lb. fermentum, Lb. delbrueckii, Lb. helveticus, and 
Streptococcus thermophiles. 
Proetzel. et al., 2012 
Hu et al., 2010 
food 
preservation 
food contamination  
by S. aureus, Listeria 
monocytogenes, Salmonella sp., 
Campylobacter sp., E. coli, 
Clostridium sp. and many other 
microbes 
(1) direct endolysin application (e.g. LysH5 endolysin against S. aureus bovine and 
human strains in pasteurized milk); (2) diary fermentation strains engineering and 
direct endolysin secretion during fermentation process (e.g. Ply118 and Ply511 genes 
of L. monocytogenes phages introduced in a Lactococcus lactis fermentation strain); 
(3) developing of transgenic potato, expressing the T4 phage lysine active against 
infections of Erwinia carotovora; (4) detection of pathogenic strains by use of coated 
magnetic beads (e.g. CBD molecules fused with fluorescent labels identifying 
pathogen serovars) or biosensors, a gold screen printed electrodes with immobilized 
CBDs, used for rapid detection of L. monocytogenes. 
Obeso et al., 2008 
Gaeng et al., 2000 
Kretzer et al., 2007 
de Vries et al., 1999 
Tolba et al., 2012 
surface 
cleansing 
the surface contamination 
of biofilm forming bacteria  
on medical devices, food 
processing machines  
or pipelines 
(1) endolysins CHAPk and LysH5 successfully used for eradication of S. aureus 
biofilms formed on artificial surfaces.  
(2) LysSMP removed up to 80% of Streptococcus suis biofilm, an important animal 
pathogen and a zoonotic agent. 
Fenton et al., 2013 
Gutierrez et al., 2014 
Meng et al., 2011 
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To date, endolysins have not yet been approved for human therapy. However, 
several clinical trials are in process, e.g. S. aureus treatment via (1) intra-nasal use  
of P128 by GangaGen (phase I -safety and phase II- efficacy trial, ClinicalTrials.gov 
Identifier NCT01746654), (2) intravenous use of PlySs2(CF-301) by ContraFect (phase 
I trial, ClinicalTrials.gov Identifier NCT02439359), or (3) topical application  
of Staphefekt™ XDR.300 by Micreos (study phase not provided, ClinicalTrials.gov 
Identifier NCT02840955). The results have not yet been published.  
1.3.2. Polysaccharide depolymerases – novel tools for bacterial biofilms 
study 
To reach biofilm-embedded bacteria for infection and/or destroy the bacterial 
envelope to facilitate access to the host receptors, phages have to degrade  
the macromolecular carbohydrates associated with the cell surface (Yan et al., 2014; Pires 
et al., 2016). This is achieved by virion-assoicated polysaccharide depolymerases  
or by polysaccharide depolymerases released by lysis of other bacteria, that have 
previously been infected by the phage (Azeredo et al., 2008). These specific enzymes 
also play important role in the release of bacteriophages trapped within a biofilm (Yan  
et al., 2014). If a phage infects bacteria within a ‘young’ biofilm and enters the lysogenic 
state, the maturation of the biofilm may later inhibit the release of phage when it returns 
to the lytic stage. Indeed, the increased thickness of host biofilms may result in a phage 
becoming trapped in the basal layers of a biofilm community if it does not possess  
the enzymatic capacity to liberate itself from the EPS mass that surrounds it (Skillman  
et al., 1999). To date, this group of enzymes has been reported only in tailed dsDNA 
phages (Roach et al., 2015). 
1.3.2.1. Structure and mode of action 
The polysaccharide depolymerases, exhibiting bacteriostatic activity, are highly 
specific enzymes and can only degrade polysaccharides of a certain composition  
or structure (Drulis-Kawa et al., 2012; Kaur et al., 2015). They can act on the bonds inside 
(endo) the polysaccharide chain or from the ends (exo) (Barbirz et al., 2008).  
 
 
 
 
60 
 
Figure 1.13: Polysaccharide depolymerases distribution through the structure of tailed 
bacteriophages. Affiliation to different polysaccharide deplymerase classes is presented in the frame. 
Levanases, xylosidades, hyaluronidases, dextranases, and lipases represent rare depolymerases domains 
and therefore the location was difficult to identify. The Bacillus phage CampHawk represents the only 
known to date phage, that comprises four depolymerases in different genes (one sialidase and three pectate 
lyases) (Pires et al., 2016). 
 
During phage path towards the bacterial surface, depolymerases bind to their 
specific secondary receptors (e.g. capsular polysaccharides) surrounding the phage target 
cell and degrade the sugar bonds. As soon as the phage reaches the bacterial cell surface, 
it can attach to its primary receptor and start infection (Fig. 1.14) (Waseh et al., 2010).  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1.14: The mode of action of polysaccharide depolymerases. Capsule staining of the bacteria  
in the outside bacterial (A) and in the halo (B) zone after infection caused by lytic Pseudomonas putida 
phage φ15. Within the outside halo zone, bacteria are all surrounded by white capsules and packed closely 
together. In contrast, bacteria in the halo zone are separated and some of them have lost their white capsules 
(Cornelissen et al., 2011). (C) The phage depolymerase binds to the macromolecule carbohydrates within 
extracellular polysaccharides (capsules, biofilm EPS) or lipopolysaccharides (LPS) surrounding bacterial 
cells (secondary receptors) and degrades them to gain access to the specific primary receptor on the bacterial 
cell surface. Next, they can inject their genetic material and start the lytic or lysogenic cycle (Hughes et al., 
1998; Labrie et al., 2010, Roach et al., 2015). 
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The polysaccharide depolymerase activity can be observed on a bacterial lawn  
as a constantly increasing halo zone surrounding the phage plaques (Fig. 1.15) 
(Cornelissen et al., 2011, 2012; Harper et al., 2014). Bacteria located within haloes areas 
are decapsulated due to diffusion of EPS-degrading enzymes (Sutherland et al., 2004; 
Hughes et al., 1998; Lu et al., 2011). However, some phages with active polysaccharide 
depolymerases do not form clear halo zones, e.g. the Salmonella phage PVP-SE1 with 
pectate-lyase (Santos et al., 2009).  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1.15: Depolymerase activity of phage φ15. (A) Halo formation around phage plaques  
on a bacterial lawn of P. putida PpG1 performed by double layer agar method. (B) Halo formation of phage 
φ15 (above) and purified tail spike protein (below). The halo created by dropping 10 μl of recombinant 
purified Gp17 (1 mg/ml) on a bacterial lawn of P. putida PpG1 looks similar to the halo around the lysis 
zone produced by a drop of 108 pfu/ml of φ15 phage. The diameter of both halo zones increases over  
the course of time (A and B). Scale bar represents 1 cm (Cornelissen et al., 2011). 
Depending on catalytic activity, phage polysaccharide depolymerases can  
be classified into two main classes hydrolases (or polysaccharases) and polysaccharide 
lyases (Sutherland, 2001; Waseh et al., 2010). First hydrolytically break the glycosyl-
oxygen bound in the glycosidic linkage. Among this class six different groups can  
be distinguished: 1) sialidases or neuraminidases, that hydrolyze the α-linkage  
of the terminal sialic acids of glycans; 2) levanases, that catalyze the hydrolysis  
of the β-2,6-linked main chain of levan (member of fructans); 3) xylosidases hydrolyzing 
xylan sugar; 4) dextranases hydrolyzing dextran sugar, 5) rhamnosidases hydrolyzing 
rhamnogalacturonan sugar, especially interesting are endorhamnosidases that hydrolyze 
LPS of Gram-negative species and 6) peptidases, that act on peptide bonds, such as poly-
γ-glutamate (γ-PGA) hydrolase (Pires et al., 2016; Davies et al., 1995; Kim et al., 2011, 
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Murakami et al., 1992; Miasnikov, 1997; Sunna et al.,1997; Jiménez 2009; Yadav et al., 
2010; Kimura et al., 2003). Polysaccharide lyases cleave 1,4- glycosidic bonds between 
the monosaccharide and the C4 of uronic acid and introduce a double bond between  
the C4 and C5 of this molecule (Waseh et al., 2010; Drulis-Kawa et al., 2012). This class 
can be divided into three groups: 1) hyaluronidases or hyaluronate lyases, that are able  
to digest the hyaluronate, a linear unsulfated glycosaminoglucan polymer and cleave  
the β-1-4 glycosidic linkage by β-elimination; 2) alginate lyases can have mannuronate  
or guluronate lyases activity, that catalyze the degradation of α-L-guluronate and its C5 
epimer β-D-mannuronate (alginate), and 3) pectin/pectate lyases, that degrade 
galacturonic acid (Pires et al., 2016; Hynes et al., 2000; Wong et al., 2000; Kim et al., 
2011; Frirdich et al., 2005; Garron et al., 2010). Furthermore, there is a small pool  
of phages exhibiting lipases or triacylglycerol hydrolase (degrade the carboxyl ester 
bonds) activities (Pires et al., 2016; Jaeger et al., 1994; Gupta et al., 2004). 
Phage EPS depolymerases can comprise one or two domains in one gene  
or be separated in different genes, as it is in case e.g. E. coli phage ϕK1-5 with two 
different enzymatic tail fiber proteins (endosialidase and lyase activity) (Scholl et al., 
2001). 
1.3.2.2. Current state of art  
An innovative polysaccharide depolymerase approach exploits the weapons  
of the bacteriophage. Available literature is limited, focusing mainly on Gram-negative 
bacteria depolymerases and enzymes of bacterial origin.  
Phages intimately coevolved with their host bacteria for 3 billion years, and 
therefore evolved highly efficient but specific enzymes. They offer a novel stand-alone 
strategy to control biofilm growth, as well as complementary to existing strategies. 
Unfortunately, phages exhibiting enzymes with strong polysaccharide depolymerase 
activity are less abundant, however already few examples can be found in literature.  
In Tait et al. study (2002) the cocktail application of three Enterobacter cloacae phages 
completely eradicated the bacterial biofilm. Hanlon et al. (2001) as well as Glonti et al. 
(2010) demonstrated alginate degradation caused by phage polysaccharide 
depolymerases among biofilms formed by mucoid P. aeruginosa strains, facilitating 
dispersion of the biofilm matrix and its viscosity reduction. Alginate lyase  
of P. aeruginosa phage PT-6 was able to reduce mucus viscosity by 62 - 66% during  
15 min treatment. This is an important observation, that may be of interest  
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for the treatment of CF patients’ infection. Furthermore, Gutiérrez et al. (2015) research 
focusing on EPS depolymerase (Dpo7) isolated from a S. epidermidis phage for S. aureus 
and S. epidermidis biofilms supported the specificity of these enzymes. Dpo7 was able  
to remove staphylococcal biofilms formed by polysaccharide producer strains, while  
it failed in polysaccharide-independent biofilms. The oral administration of tail spike 
protein, P22sTsp specific to Salmonella, significantly reduced Salmonella infection  
in chickens. The P22sTsp possess endorhamnosidase activity and/or binding activity  
of O-antigen in LPS (Waseh et al., 2010; Roah et al., 2015).  
On the other hand, also few enzymes of bacterial origin have been examined, such 
as B. anthracis capsule depolymerase (CapD) with a gamma-glutamyl transpeptidase 
activity. The treatment of B. anthracis cells with purified enzyme, caused capsule 
degradation and increased susceptibility to innate immune responses (e.g. phagocytosis) 
(Scorpio et al., 2010). Another approach is a synergistic action with antibiotics. Bansal  
et al. (2014) successfully treated K. pneumoniae mouse infection model with combinatory 
therapy of bacterial EPS depolymerases and gentamicin, where proteins efficiently 
removed the bacterial capsule and improved the gentamicin activity. Importantly, 
bacterial depolymerases have weaker activity compared to their phages counterparts, 
because they regulate biofilm formation, while phage depolymerases are tailed by nature 
to degrade bacterial biofilms.  
Other approaches include phage engineering, where phages deprived  
of polysaccharide depolymerases can be armoured with phage enzymes. This was 
presented in Lu et al. (2007) study, where T7 phage was engineered with the dispersin B 
and gained antibiofilm activity. Another possibility is application of side-directed 
mutagenesis strategies, such as domain shuffling, which could have possibility to ‘relax’ 
their natural specificity and to create broad-spectrum polysaccharide depolymerases. 
1.3.2.3. Potential applications of phage polysaccharide degrading enzymes  
The positive effects of polysaccharide depolymerase administration are 
promising, however there are still some obstacles, such as: 1) the risk for elimination  
by the host immune system; 2) lack of stability in the human body; 3) high specificity 
hindering the multispecies biofilms treatment (Fernebro, 2011). Additionally, the major 
drawbacks is also low homology in current databases and a small pool of genes with 
correctly assigned function as well as lack of structural analysis of these enzymes (Drulis-
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Kawa et al., 2012). From the production perspective, the generation of cost-efficient 
recombinant protein can also be a challenge. 
Nevertheless, these interesting enzymes can have potential applications  
in medicine, as well as in industry. Xylanases could be used in biobleaching of wood pulp 
in textile industry (Juturu et al., 2012). Rhamnosidases could remove the bitterness from 
citrus fruit juices or serve as aroma enhancement in wine-making industry (Manzanares 
et al., 2007). Further, pectin/pectate lyases could assist in fruit juice extraction and 
clarification (Sieiro et al., 2012). In medicine, alginate lyases have potential to treat cystic 
fibrosis patient infections in combination with other antimicrobial therapies (Kim et al., 
2011; Born et al., 2014). They can facilitate the diffusion of antibiotics, such  
as aminoglycosides (Hay et al., 2009) through biofilm. Moreover, polysaccharide 
degrading enzymes can serve as a diagnostic agents, e.g. in neurological tumors, such  
as neuroblastoma and meningitis, by creation of hybrid proteins consisting the green 
fluorescent protein (GFP) tag with a catalytically inactive endosialidase, that bind but not 
degrade polySia (Jokilammi et al., 2004; Yan et al., 2014). 
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The increasing frequency of multi-drug-resistant strains is particularly concerning 
as treatment options are severely limited by the absence of effective antibacterials as well 
as malpractice in the drugs delivery in clinical settings (Breidentein et al., 2011; Poole, 
2011). Bacterial infections become severe causing further complications and prolonged 
hospital treatment, which leads as a consequence to higher tangible as well as intangible 
costs (Gould, 2006; Haecker, 2009; Hübner et al., 2012).  
P. aeruginosa is one of the leading Gram-negative organisms associated with 
nosocomial infections. As an opportunistic pathogen it is particularly well known for 
causing infections in immune deficient individuals and presents resistance to many 
antibiotics (Cornelis et al., 2008). It is responsible for 16.6% of all infections in ICUs 
(ECDC surveillance report 2014). Despite extensive research to improve  
the pharmacokinetic and/or pharmacodynamic properties of different classes of antibiotic, 
only ten new drugs targeting Gram-negatives were introduced in recent years. 
Unfortunately, six of them are based on combinations of already used antibiotics, to which 
resistance mechanisms have been already evolved in clinical strains (Mangili et al., 
2005). The above results in an urgent need for the development of alternative therapies.  
Currently, bacteriophages are in the spotlight. They intimately co-evolved with 
their host bacteria for 3 billion years, and therefore developed highly efficient predator 
strategies. There is a variety of approaches for phage therapy implementation in medicine 
and industry, including use of individual lytic phages or phages cocktails, as well as 
phage-borne enzymes, such as PG degrading enzymes or polysaccharide depolymerases. 
Because of a high interest for phages and their products, there is a need for in-depth 
research of their biology, genome characteristics and antibacterial potential. 
The main objective of presented doctoral dissertation is the characterization  
of bacteriophages lytic towards P. aeruginosa as well as two classes of phage-borne 
enzymes: PG degrading enzymes targeting bacterial cell walls and polysaccharide 
depolymerases as potential anti-biofilm agents. Achieving the overall aim requires  
the definition of intermediate objectives: 
The characterization of Pseudomonas phages and their therapeutic potential (Chapters 
4 through 6) 
1) Characterization of basic phage biology, including morphology, host surface 
receptor, reproduction cycle, viral particle stability and a host range. 
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2) Study of phage genome organization and proteome composition and their 
influence for phage structure and fitness. 
3) Comparative genome analysis and construction of protein-sharing networks  
to reveal phage evolution.  
4) Evaluation of phage antibacterial activity in vitro with the use of a novel Airway 
Surface Liquid model on non-CF and CF epithelial cells lines, in an effort  
to mimic in vivo conditions of the respiratory tract. 
The exploration of phage-encoded PG degrading enzymes and polysaccharide 
depolymerases from a functional and application perspective (Chapters 7 and 8) 
1) Bioinformatics search of a set of phage genes encoding PG degrading enzymes 
and polysaccharide depolymerases, and identification of enzymatic activity and 
structure prediction, based on available homology. 
2) Preparation of recombinant proteins, including gene amplification, protein 
expression optimization and purification to obtain pure and active phage enzymes. 
3) Assessment of recombinant protein stability. 
4) Evaluation of bactericidal activity and biofilm eradication potential  
of recombinant enzymes.  
The presented project was a part of COST BM1003 Work Group1 activity which 
focus on phenotypic assessment of bacterial cell surface virulence markers from clinically 
relevant CF pathogens at different stages of CF lung disease and on the development  
of new antibacterial therapies. 
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3.1. Phage manipulations 
3.1.1. Microbiology techniques 
3.1.1.1. Phage isolation and propagation 
The P.aeruginosa PAO1 strain was purchased from the American Type Culture 
Collection (ATCC 15692) and was used as a host for phage propagation. Environmental 
water samples from irrigated fields in Wrocław, Poland were centrifuged (15,000 × g for 
15 min) and the supernatant was filtered through a 0.22 μm Millex-GP filter (Merck 
Millipore) to remove bacterial debris. For phage propagation 0.5 ml of filtered water 
sample and 5 μl of bacterial host strain in logarithmic phase were added to 5 ml of Mueller 
Hinton broth (MHB) (Bio-Rad Laboratories) and incubated at 37°C with agitation for  
18 h. Every 3, 6, 18 hours each tube was visually inspected. When bacterial lysis occurred, 
incubation was stopped and sample was centrifuged (5,000 × g for 15 min at 4°C). Next, 
the supernatant was used for large scale phage propagation. An overnight culture  
of bacterial host strain (5 ml) was added to 500 ml MHB culture and incubated at 37°C 
with constant shaking. When the bacterial culture reached an optical density at 600 nm 
(OD600) of ± 0.5, the appropriate phage supernatant was added to infect the host cells.  
The infected culture was incubated overnight at the same conditions until complete lysis 
occurred. Next, chloroform was added (10% v/v final concentration, Merck) for  
an additional 30 min at 37°C and culture was kept overnight at 4°C without shaking.  
The bacterial debris was further removed by centrifugation (5,000 × g, 15 min, 4°C) and 
supernatant was filtered through a 0.22 μm Millex-GP filter (Danis-Włodarczyk et al., 
2015).  
3.1.1.2. Phage lysate purification 
For phage purification and concentration, first, traditional polyethylene glycol 
(PEG) precipitation was used, according to the Sambrook and Russell (2001).  
A 25% PEG8000 solution [25% w/v polyethylene glycol, with an average molecular weight  
of 8,000 Da, 1M NaCl (Acros Organics), demineralized water] was added to filter-
sterilized phage lysate to a final concentration of 8% PEG8000 and stirred overnight at 4°C. 
The supernatant was discarded by centrifugation (4,600 × g, 45 min, 4°C). The resulting 
pellet was resuspended in 2 ml of phage buffer (10 mM Tris-HCl, 10 mM MgSO4,  
150 mM NaCl, pH 7.5, Acros Organics) and stored at 4°C in the dark. Next, phage lysate 
was purified with CsCl-gradient ultracentrifugation as described by Ceyssens et al. 
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(2008). In short, the phage solution was layered on a CsCl (MP Biomedicals) step gradient 
(1.33, 1.45, 1.50 and 1.70 g/cm3), subsequently centrifuged (140,000 × g, 3 h, 4°C) and 
dialyzed three times for 30 min against 250 volumes of phage buffer using Slide-A-Lyzer 
Dialysis Cassettes G2 (Thermo Fisher Scientific Inc.). Purified phages samples were 
stored at 4°C in the dark.  
3.1.1.3. Phage titration 
The titer of phage solution was assessed using the classic double-agar layer 
technique according to methods described previously (Adams et al., 1959). A serial 
dilution was made and added to a soft agar heated to 56°C [5 g/L yeast extract (LabM), 
10 g/L NaCl (Acros Organics), 10 g/L tryptone (LabM) supplied with 0.7% agar, LabM]. 
This solution was gently mixed and plated on LB agar [5 g/L yeast extract (LabM),  
10 g/L NaCl (Acros Organics), 10 g/L tryptone (LabM) supplied with 1.5% agar, LabM]. 
After overnight incubation at 37°C the phage titer was determined as plaque forming units 
per ml (pfu/ml). All titrations were performed in triplicate and the result was the average 
pfu/ml. 
3.1.1.4.  Transmission electron microscopy  
A filtered high-titer phage lysate (108 - 1010 pfu/ml) was centrifuged at 25,000 × g 
for 60 min. The pellet was washed twice in ammonium acetate (0.1 M, pH 7.0, Acros 
Organics). Phages were deposited on copper grids with carbon-coated Formvar films and 
stained for 10 s with uranyl acetate (2%, pH 4.5, Acros Organics) or phosphotungstate 
(2%, pH 7, Acros Organics). Excess liquid was blotted off and phages were examined 
using a Zeiss EM 900 electron microscope by technician Sylwia Nowak at the Laboratory 
of Microscopy Techniques, University of Wrocław, Poland and/or Prof. Hans W. 
Ackermann, Department of Microbiology-Infectiology and Immunology, Medical 
School, Laval University, Quebec, Canada. The magnification was calibrated using T4 
phage tail length (114 nm) as a standard (Drulis-Kawa et al., 2014). 
3.1.1.5. Time - lapse microscopy 
To follow phage infection at the bacterial single-cell level, a bacterial host culture, 
grown to logarithmic phase, was mixed with phage solution in multiplicity of infection 
(MOI) of 10 and spotted on 0.2% LB agar pads, as described previously by Cenens et al. 
(2013). Infection process was recorded at 37°C immediately post infection in real time 
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for 5 h with a Nikon Eclipse Ti Time-Lapse Microscope (Nikon, Champigny-sur-Marne, 
FR) using the NIS-Elements AR 3.2 software (Nikon), available at the Laboratory  
of Food Microbiology (KULeuven; Prof. A. Aertsen) with the help of Dr. William 
Cenens. Images were acquired using NIS-Elements (Nikon) and resulting pictures were 
further handled with open source software ImageJ (Downloaded from 
http://rsbweb.nih.gov/ij/). 
3.1.1.6. Burst size experiments  
A one-step growth curve was performed according to the method of Pajunen  
et al. (2000), with modifications. An equal volume of bacterial culture at OD600 of 0.4 
was mixed with phage suspension (106 pfu/ml) to obtain a MOI of 0.01. Phages were 
allowed to adsorb for 8 min at 37°C, after which the mixture was diluted to 10–4. Triplicate 
samples were taken every 5 min during 1-1.5 h and titrated (Danis-Włodarczyk et al., 
2015). 
3.1.1.7. Sensitivity of phage particles to heat, chloroform and pH 
The sensitivity to heat was determined by incubating phage suspension  
(108 pfu/ml) in phage buffer at various temperatures (40, 50, 60, 70, and 80°C) and for  
5, 15, 30, 45 and 60 min. Chloroform sensitivity was determined by the incubation  
of equal volumes of phage suspension (108 pfu/ml) and chloroform for 1 and 24 h at 4°C 
with intermittent shaking. The pH stability was tested by incubation of 100 μl of phage 
suspension (108 pfu/ml) in 900 μl of universal buffer (10 mM Tris-HCl pH 7, 10 mM 
MgSO4, 150 mM NaCl) at pH range 2–12 (pH 1 to 13 adjusted with NaOH, or HCl). 
Phage titer was assessed after 1h incubation at room temperature as previously described 
(Danis-Włodarczyk et al., 2015). 
3.1.1.8. Phage typing  
The lytic activity of isolated viruses was examined on 57 clinical P. aeruginosa 
strains from the Military Hospital Neder-Over-Heembeek, Brussels, Belgium (Pirnay  
et al., 2003) and compared to the activity of different phages groups: Lit1virus (LIT1), 
Luz7virus (LUZ7), LUZ24virus (LUZ24), Kmvvirus (LUZ19, LKD16, LKA1, φKMV), 
Pbunavirus (LBL3, LMA2, LSL4, KT28, KTN6), Phikzvirus (KTN4, φKZ) and a new 
giant phage PA5oct. Phage suspension in phage buffer (106 pfu/ml) was spotted (10µl) 
on bacterial lawn formed on LB agar. The plates were checked for confluent lysis  
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or plaque formation against negative, uninfected controls after 4–6 h and again after  
18 h. Experiment performed in triplicates (Danis-Włodarczyk et al., 2015, 2016). 
3.1.1.9. Phage receptor analysis 
The phage specificity to particular bacterial receptors was tested on PAO1 mutants 
deficient in biosynthesis of A-band and B-band O antigen, flagella, type IV pili,  
or alginate production (Table 3.1). To determine bacterial susceptibility to phage-
mediated lysis, a 10 µl drop of the phage suspension (106 pfu/ml) was put on a bacterial 
lawn and incubated at 37 °C, in three independent experiments. The plates were checked 
for confluent lysis or plaque formation against negative, uninfected control after 4–6 h 
and again after 18 h (Danis-Włodarczyk et al., 2015, 2016). 
Table. 3.1: List of P. aeruginosa PAO1 mutants used for phage receptor identification. 
Bacterial strain Phenotype Origin 
PAO1 (ATCC 15692) Wild type American Type Culture 
Collection 
PAO1 Pirnay Wild type with inactive type IV pili Military Hospital Neder-Over-
Heembeek, Brussels, Belgium 
PAO1 Krylov Wild type 
PAO1 Δrmd (A-, B+) Deficiency in D-rhamnose 
biosynthesis; lack of A-band LPS 
 
 
Department of Molecular and 
Cellular Biology,  
University of Guelph, Canada 
PAO1 ΔrmLC (A-, B-, core-) Deficiency in L-rhamnose 
biosynthesis; truncate core region, 
lack of A-band and B-band LPS 
PAO1 ΔwaaL (A-, B-) Lack of WaaL ligating O-polymer  
to core-lipid A; LPS is devoid  
of A-band and B-band, semirough 
(SR-LPS, or core-plus-one  
O-antigen)  
PAO1 ΔwbpL (A-, B-) Lack of glucosyltransferase WbpL 
essential for initiation of both  
A-band and B-band synthesis 
PAO1 ΔfliC ΔalgC ΔpilA Lack of flagella; lack of AlgC 
required for A-band, core 
oligosaccharide, and alginate 
biosynthesis; lack of type IV pili 
 
 
Technical University Hamburg, 
Germany 
PAO1 ΔfliC wt algC ΔpilA Lack of flagella; lack of type IV 
pili 
PAO1 ΔfliC wt algC wt pilA Lack of flagella 
PAO1 wt fliC wt algC wt pilA Wild type 
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3.1.1.10. Phage inactivation by LPS and LPS- binding assay 
Experiments were performed by Dr. D. Augustyniak in Department of Pathogen 
Biology and Immunology (University of Wrocław, Poland). The LPS was isolated with 
the use of hot phenol/water method by Westphal et al. (1965) with modifications.  
The phage inactivation by LPS was performed as previously described by Kropinski 
(2009), with modifications. LPS-binding assay was developed by Dr. D. Augustyniak. 
The detailed description can be found in Danis-Wlodarczyk et al. (2015). 
3.1.2. Functional analysis 
3.1.2.1. Biofilm eradication analysis 
The P. aeruginosa PAO1 biofilms were formed on µ-Slide 8 Well plates (ibidi 
GmbH). Overnight bacterial culture was refreshed and grown in LB broth till OD600  
of 0.2 (107 cfu/ml) and 100 µl/well was introduced. Plates were sealed to avoid water loss 
due to evaporation and biofilms were allowed to grow for 24 h or 48 h at 37 °C, 5% CO2 
without shaking. After 24 h 100 µl of fresh LB broth was added to biofilms. Finally,  
to assess biofilm degradation by phage particles, 24 h and 48 h old biofilms were treated 
with 100 µl of the appropriate CsCl purified phage suspension in phage buffer (10 mM 
Tris-HCl pH 7, 10 mM MgSO4, 150 mM NaCl) and 20 µl of the LIVE/DEAD BacLight 
stain (LIVE/DEAD BacLight Bacterial Viability Kit, Thermo Scientific Inc.) and 
incubated for further 24 h at 37 °C. Untreated biofilm served as an negative control and 
as a positive control cells were treated with 400 µg/ml of gentamicin. Biofilms were 
visualized by confocal laser scanning microscopy (Zeiss LSM 510 Meta 40× objective, 
Jena). For quantitative and qualitative analysis of biofilm degradation further experiments 
were introduced, i.e. interferometry and goniometry performed by Prof. M. Arabski 
(Department of Microbiology, Institute of Biology, The Jan Kochanowski University  
in Kielce, Kielce, Poland) and profilometry executed by Nikos Ekizoglou (Zeta 
Instruments Co., San Jose, USA), as described by Danis-Włodarczyk et al. (2015, 2016).  
3.1.2.2. Gentamicin exclusion assay on Airway Surface Liquid infection model 
NuLi-1 cells (Normal Lung, University of Iowa), derived from human airway 
epithelium of normal genotype, and a CF cell line, called CuFi-1 (Cystic Fibrosis, 
University of Iowa), derived from bronchial epithelium of a homozygous CFTR 
F508del/F508del individual, were kindly provided by Dr. J. Zabner (University of Iowa, 
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Iowa City, IA). The ASL model was prepared according to methods described by Zabner 
et al. (2003). The experiment was conducted as described by Danis-Włodarczyk et al., 
2016. Both cell lines were inoculated with 25 μl of P. aeruginosa PAO1 reference strain 
(6.2 × 107 cfu/ml), nonCF0038 isolate from burn wound (6.5 × 107 cfu/ml) and CF708 
small colony variant (1.0 × 106 cfu/ml) at OD600 nm of 0.1, and incubated for 1.5 h at 37 °C, 
5% CO2. A 25 μl volume of the appropriate CsCl purified phage suspension in phage 
buffer was added to each millicell hanging cell culture insert. Subsequently, cells were 
incubated for 1.5 h at 37 °C, 5% CO2. Next, the cells were washed with PBS and apical 
washes were serially diluted in DMEM:F12 medium (Sigma-Aldrich) and quantified  
by viable counts on LB agar (Sigma-Aldrich) after 24 hours. To evaluate the ability  
of P. aeruginosa to invade into epithelial cells and the ability of phage to prevent this 
invasion, extracellular and adherent bacteria were killed by addition of 400 μg/ml 
gentamicin (Thermo-Fisher Scientific) and incubated for 1 h at 37 °C, 5% CO2. The drug 
was subsequently removed by PBS washing and epithelial cells were lysed with 100 μl 
of 0.4% Triton-X100 (Sigma-Aldrich) for 15 min at 37 °C, 5% CO2. The resulting lysate 
was serially diluted in DMEM:F12 medium and quantified by viable counts on LB agar 
after 24 hours. Several controls of epithelial cells viability were prepared: (i) a negative 
control without treatment, (ii) a negative control with TC media; (iii) a positive control 
containing Triton-X100; (iv) 1.5 h after phage treatment; (v) 1.5 h after strains treatment. 
The Nuli-1 and CuFi-1 cells were stained with 8 μM Calcien AM (live staining) (Life 
Technologies) and 3 μM propidium iodide (PI) (dead staining) (Life Technologies) 
according to manufacturer’s instructions. Negative controls (untreated) and positive 
controls (0.25% Triton-X100 treated) were included in the experimental set up. After 
staining, in all cases, filter inserts were XZ scanned using a confocal microscope (Zeiss 
LSM 510 Meta 40× objective, Jena). No toxicity influence of cell lines was noticed for 
phage and bacterial samples. The data were analyzed using the Statistica software 
package (StatSoft, Tulsa, OK, USA). All the values were expressed as mean ± SD and 
significant differences between variations (denoted p-values < 0.05) were found by means 
of the Snedecor-Fisher test using one-way ANOVA. 
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3.1.3. DNA manipulation techniques 
3.1.3.1. Phage DNA isolation and sequencing 
Phage DNA was isolates according to the modified protocol for λ DNA isolation, 
as previously described by Ceyssens et al. (2009). Purified phage particles (1010 pfu/ml) 
were disrupted by 1 h incubation at 56 °C in 0.5% (w/v) SDS (Janssen Chimica), 20 mM 
EDTA (Acros Organics) and 5 μg/ml proteinase K (Thermo Fisher Scientific Inc.). After 
a phenol/chloroform DNA extraction and ethanol precipitation, an additional RNase A 
treatment (100 μg/ml; Roche Applied Science) was used to remove residual RNA. Next,  
the high throughput sequencing was performed using the Illumina MiSeq platform 
available at the Nucleomics Core (VIB, Belgium). A 2*150 bp paired-end library 
(Nextera XT sample prep) was prepared and sequenced. The reads were assembled  
in a single contig with a 100–6000 fold coverage using CLC genomics Workbench  
de novo assembly algorithm (CLC bio, Cambridge, MA), as described previously (Danis-
Wlodarczyk et al., 2015, 2016). 
3.1.3.2. Phage RNA isolation and sequencing 
P. aeruginosa PAO1 Krylov strain was grown overnight in 5 ml LB medium  
at 37 °C. Next, cells were diluted 1:100 in 50 ml fresh medium and further grown  
at 37 °C till OD600 reached 0.3 (~1.2 x 108 cfu/ml, early exponential phase). This culture 
was infected further by PA5oct phage at a MOI of 50, that allowed less than 5%  
of bacterial survivors to remain within five minutes post infection, producing  
a synchronous infection. Three time points were selected to represent early, middle and 
late transcription (5, 15 and 25 min). Over the course of infection, 13.5 ml of infected 
culture (~2.5 x 107 cfu/ml) was halted by rapid cooling with a 1.5 ml of stop solution 
(RNA buffered phenol diluted with 96% ethanol in 1:9 ratio), to inhibit RNA transcription 
and degradation at the indicated time points. Collected cells were harvested  
by centrifugation (5,000 × g for 20 min) and stored at -80 °C until use. The efficiency  
of infection was always checked by CFU counts of the infected culture 5 min post 
infection, which contained 5% surviving cells compared to the non-infected culture. Total 
RNA was extracted from the resulting cell pellet by resuspending it in 500 µl  
of TRIzol (Ambion), to inactivate the RNAses produced by the host, and a classical 
phenol/chloroform extraction was performed followed by ethanol precipitation. Residual 
genomic DNA was then removed using TURBO DNase® (Thermo Scientific) and rRNA 
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was depleted with the Ribo-Zero rRNA Removal Kit (Gram-Negative Bacteria) (Illumina 
Inc.). The remaining RNA was then processed into cDNA libraries using the TruSeq 
stranded mRNA sample preparation kit and run on an Illumina NextSeq 500 High 75  
at the Nucleomics Core (VIB, Belgium). Each sequence library contained more than 10 
million reads aligning to non-ribosomal regions of both the phage and host genome. After 
trimming, sequencing reads were aligned separately to both the phage and host genomes 
with the CLC Genomics workbench v7.5.1.  
3.1.4. In silico analysis 
3.1.4.1. Genome analysis  
The genome analysis was performed as described by Danis-Włodarczyk et al. 
(2015 and 2016). Potential ORFs were identified using GeneMark S (Besemer et al., 
2001), GeneMark.hmm (Lukashin et al., 1998), OrfFinder (Sayers et al., 2011) and were 
manually analyzed. Translated ORFs were compared to known proteins using  
the BLASTP (Altschul et al., 1990), HHpred (Soding et al., 2005) and HMMER (Finn et 
al., 2011), providing further insight into the predicted function of proteins. Conserved 
protein domains were identified using Pfam (Finn et al., 2006), InterPro (Mitchell et al., 
2015) and PHYRE2 (Kelley et al., 2015). Putative tRNA genes were searched for using 
tRNAscan-SE (Lowe et al., 1997). The intergenic regions were screened for the presence 
of regulatory elements using fuzznuc (Rice et al., 2000) and MEME/MAST (Bailey  
et al., 1998) and manually inspected to search for putative -35 (TTGACA) and  
-10 (TATAAT) boxes. Putative factor-independent terminators were identified with 
ARNold (Naville et al., 2014). Whole analysis performed on DNA-seq was compared  
to results from RNA-seq, which were conduced according to Ceyssens and  
co-workers (Ceyssens et al., 2014). Shortly, the total gene reads mapped to the host  
(P. aeruginosa PAO1) and phage PA5oct were used to annotated gene features using  
the CLC Genomics Workbench 6.0.2. software for comparative analysis. A genome map 
representation was constructed with CGview (Stothard et al., 2005).  
3.1.4.2. Protein-protein sharing network  
To represent the genetic relationships of chosen phages with other bacterial and 
archaeal viruses from NCBI Refseq as a gene (protein)-sharing network was generated 
by Dr. Ho Bin Jang, in which each predicted protein was clustered into protein families 
using the ACLAME database (version 0.4) with the database of “viruses” and  
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an E-value < 0.001 (Leplae et al., 2010; Lima-Mendez et al., 2008). Additionally, for  
the phages that share significant gene contents, but are absent in the ACLAME database, 
protein sequences were retrieved from φKZ (NC_004629), φPA3 (HQ630627), 201φ2-1 
(NC_010821), EL (NC_007623), OBP (NC_016571), φJM-2012 (JQ340088), SPN3US 
(NC_027402), CR5 (NC_021531), φEaH2 (NC_019929), JG024 (NC_017674), PB1 
(NC_011810), 14–1 (NC_011703), NH-4 (NC_019451), SPM-1 (NC_023596), LMA2 
(NC_011166), LBL3 (NC_011165), KPP12 (NC_019935), SN (NC_011756), and 
ECML-117 (JX128258). The proteins that could not be assigned into any ACLAME 
protein families were defined as the unclassified protein families (UPFs) as previously 
described (Jang et al., 2013). We accepted the transitive nature of sequence families 
(Casjens, 2003), i.e., a sequence is added to a cluster if it shares a reciprocal best hit 
relationship with at least one of the sequences of the cluster. The degree of similarity 
between other phages was generated as the minus logarithmic score by multiplying 
hypergeometric similarity P-value by the total number of pairwise comparisons (Lima-
Mendez et al., 2008).  
For the giant phage PA5oct analysis, protein sequences were subjected  
to all-to-all BLASTP searches, with an E-value threshold  < 0.001, and defined  
as the homologous protein clusters (PCs) in the same manner as previously described 
(Lima-Mendez et al., 2008; Roux et al., 2015). Based on the number of shared PCs 
between the genomes, the degree of similarity was calculated using vContact 
(https://bitbucket.org/MAVERICLab/vcontact), as the negative logarithmic score  
by multiplying hypergeometric similarity P-value by the total number of pairwise 
comparisons. The protein-sharing relationships among the genomes with similarity 
values ≥ 2 (E-value ≥ 0.01) were represented (Lima-Mendez et al., 2008). Afterwards,  
the network was visualized with Cytoscape (version 3.1.1; http://cytoscape.org/), using 
an edge-weighted spring embedded model, which places the genomes or fragments 
sharing more PCs closer to each other. In addition, the Markov clustering algorithm 
(MCL) was used to group each genome into viral cluster (VC). To maximize the cluster 
homogeneity, the optimal inflation factor was determined by exploring values ranging 
from 1.0 to 5 by steps of 0.2. The taxonomic affiliation was taken from the ICTV 
(http://www.ictvonline.org/virusTaxonomy) and/or NCBI taxonomy 
(http://www.ncbi.nlm.nih.gov/taxonomy). Topological properties of the network were 
estimated with the Network Analyzer 2.7 Cytoscape plug-in (Brohee et al., 2008). 
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3.1.5. ESI-MS/MS phage proteome analysis 
Phage proteins were extracted from a purified phage suspension by a single 
methanol/chloroform extraction (1:1:0.75, v/v/v) (Acros Organics) and subsequently 
precipitated by addition of an equal volume of methanol (16,060 × g, 6 min). The dried 
phage protein pellet was resuspended in 4x SDS-PAGE loading buffer [200 mM Tris  
pH 6.8, 8 mM EDTA, 40% (v/v) glycerol, 4% (w/v) SDS, 0.4 % (w/v) bromophenol blue] 
and boiled for 5 min before loading onto a 12% SDS-PAGE gel. Protein gels were stained 
afterwards with GelCode Blue Safe (Thermo Scientific). Further, the entire lane  
of a phage protein profile was prepared for ESI-MS/MS as previously described  
by Van den Bossche et al. (2014) and Ceyssens et al. (2014). Shortly, the SDS-PAGE gel 
was cut into slices, that were subjected to trypsin digestion (Shevchenko et al., 1996) 
prior to mass spectrometry analysis. Protein digests were analyzed by ESI-MS/MS  
on a LCQ Classic (ThermoFinnigan) equipped with a nano-LC column switching system 
(Prof. J-P Noben, UHasselt) as described in Dumont et al., 2004. The analysis of the mass 
spectrometric RAW data was carried out using Proteome Discoverer software v.1.3 
(Thermo Scientific) with build-in Sequest and interfaced with an in-house Mascot v.2.4 
server (Matrix Science). 
3.2. Protein characterization techniques 
3.2.1. In silico analysis 
The protein domains were identified by BLASTP, HHPRED, HMMER, PHYRE2 
and InterPro. The PDBsum database was used for protein secondary and tertiary structure 
predictions (de Beer et al., 2014), that was further manually analyzed with the use  
of the PyMole and the MOE programs. Clustal W2 and Clustal Omega were used for 
protein sequence comparison (Larkin et al., 2007; Sievers et al., 2011). The ligand 
binding site could be predicted with the use of the 3DLigandSite-Ligand binding site 
prediction server (Wass et al., 2010).  
3.2.2. DNA manipulations and cloning 
3.2.2.1. Polymerase chain reaction 
Purified genomic DNA of Pseudomonas phages, KT28, KTN6, PA5oct, KTN4, 
LUZ7 and LKA1 served as a template for amplification of the different ORFs  
in a polymerase chain reaction (PCR). Reactions were performed with 0.02 units/µl  
79 
 
of Phusion High-Fidelity DNA Polymerase (Thermo Scientific Inc.), 200 µM of each 
dNTP (Thermo Scientific Inc.) and 0.5 μM of both primers (Table 3.2) in the supplied  
5X Phusion HF buffer and subjected to 35 cycles of amplification using  
a Trio Thermoblock (Biometra). Primer annealing temperatures were adapted  
to the specific primer pair and extension times on the length of the PCR-product. Next, 
single deoxyadenosine (A) was added to PCR products to the 3′ ends by 0.5 units  
of DreamTaq™ polymerase (Thermo Scientific) to enable TOPO® T/A cloning.  
The PCR products were separated by 1% agarose gel electrophoresis in TAE 
electrophoresis buffer (40 mM Tris-HCl pH 7.2, 500 mM sodium acetate, 50 mM EDTA, 
Acros Organics). DNA fragments were stained with ethidium bromide and visualized by 
UV illumination. To estimate the size and the quantity, a reference λ/PstI ladder was run  
in parallel with the fragments. 
Table 3.2: The overview of constructs and corresponding cloning conditions. The first column refers 
to the name of the encoded protein. For each construct, the vector together with cloning site and primers 
for PCR reaction are listed. The PCR reaction was always performed on phage genomic DNA. The ATG 
start triplet and TAA/TGA/TAG stop triplets are written in italic for the forward and reverse primers with 
stop codon, respectively.  
Insert  Vector and Cloning site Primers 
LKA1 gp49 * pEXP5-NT/TOPO ®, * 
pBAD/Thio TOPO® 
TA-cloning  
ATGGCGCAAACACCCAG* 
TCACACCTCATAAATACCTG* 
CACCTCATAAATACCTG* 
LKA1 gp49 
domain  
pEXP5-NT/TOPO®,  
pEXP5-CT/TOPO® 
pBAD/Thio TOPO® 
TA-cloning 
ATGGGACTGTTAGTGGAGGCTG 
TTACGTTGTATTTGTAGTGAGGAC 
CGTTGTATTTGTAGTGAGGAC 
LUZ7 gp56 pEXP5-NT/TOPO®,  
pEXP5-CT/TOPO® 
pBAD/Thio TOPO® 
TA-cloning 
ATGACCACAAAGGTGATCTTC 
TTAGTACCACCTCCCGATGGCCAT 
GTACCACCTCCCGATGGCC 
LUZ7 gp56 
domain 
pEXP5-NT/TOPO®,  
pEXP5-CT/TOPO® 
pBAD/Thio TOPO® 
TA-cloning 
ATGAATGGCACCTGGCAGAAGG 
TTAACCCGTGAACGACGGACTC 
ACCCGTGAACGACGGACTCT 
KT28 gp41 pEXP5-NT/TOPO®,  
pEXP5-CT/TOPO® 
pBAD/Thio TOPO® 
TA-cloning 
ATGTCTAGTGATTTGGATGAATT 
TCAGTAGAGTATCTTAGTTGCG 
GTAGAGTATCTTAGTTGCGG 
KT28 gp41 
domain 
pEXP5-NT/TOPO®,  
pEXP5-CT/TOPO® 
pBAD/Thio TOPO® 
TA-cloning 
ATGGGCGCCCAGTCTCTT 
TAATTCCATCAGCTCGATTG 
TTCCATCAGCTCGATTGGAG 
KT28 gp29 pEXP5-CT/TOPO® 
TA-cloning 
ATGAAAATCACGAAGGATGT 
GGAGCCTTGATTGATCGC 
KTN6 46 pEXP5-CT/TOPO® 
TA-cloning 
ATGAAAATCACAAAGGATATTCTTATC 
GGAGCCTTGATTGATCGC 
PA5oct gp214 pEXP5-CT/TOPO® 
TA-cloning 
ATGAGTACATATTCTAGAACAGTAGGTG 
TGCTCCTTTATTTTTGTGCTC 
PA5oct gp250 pEXP5-NT/TOPO® 
TA-cloning 
ATGGATAATAATATTAGAAAAAAATTAATTGC 
ATTTAAGTTTCCTAAACATACATTCC 
KTN4 gp48 pEXP5-CT/TOPO® 
TA-cloning 
ATGACTGAATCAACTACTTTTAGTTTTACC 
TTTTACTTTAGCAGTTGATACTTCACATAC 
(*) Full length LKA1 gp49 construct made and described by A. Corenlissen, 2011. 
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3.2.2.2. Plasmids and cloning  
The commercially available pEXP5-NT/TOPO®, pEXP5-CT/TOPO® and 
pBAD/Thio TOPO® vectors (Invitrogen) are provided as linearized vectors, which 
allows a direct TA-cloning strategy due to the covalently coupled topoisomerase I  
(Fig. 3.1, 3.2). In these vectors, genes are fused to a N- or C-terminal 6x His-tag 
respectively, which allows the expressed proteins to be purified on a Ni2+-NTA 
(nitrilotriacetic acid) column by affinity chromatography. In case of pBAD/Thio TOPO® 
vector recombinant proteins are expressed also as fusions to N-terminal thioredoxin, 
introduced for high-level expression and simple purification. The TA-cloning into  
a TOPO® vectors was conducted according to the manufacturer protocols. For ORFs 
cloned into the pEXP5-CT/TOPO® and pBAD/Thio TOPO® expression vectors no stop 
codon was included in the reverse primer, whereas those intended for pEXP5-
NT/TOPO® had a stop codon in the reverse primer. The PCR products were checked for 
correct length by gel electrophoresis with 1% (w/v) agarose [0.70 g agarose (Sigma-
Aldrich), 70 mL TAE-buffer (40 mM Trizma base (Acros Organics), 20 mM acetate 
(Merck), 1 mM EDTA (Sigma-Aldrich)]. All constructs selected for further analysis and 
their corresponding details concerning cloning are summarized in Table 3.2. In case  
of pEXP5-NT/TOPO®, pEXP5-CT/TOPO® vectors transcription of the insert is strictly 
controlled by a strong bacteriophage T7 promoter. In contrast, pBAD/Thio TOPO® 
vector uses the araBAD promoter (pBAD). 
3.2.2.3. Transformation into TOP10 E. coli competent cells  
For constructs storage and clone analysis E. coli TOP10 cells [genotype F– mcrA 
Δ(mrr-hsdRMS-mcrBC) Φ80lacZΔM15 ΔlacX74 recA1 araD139 Δ (araleu) 7697 galU 
galK rpsL (StrR) endA1 nupG] were used since they allow stable replication of high-
copy plasmids. Chemically competent E. coli TOP10 cells were prepared according  
to the Rubidium Chloride Method (New England Biolabs). The transformation efficiency 
was verified with the pUC18 vector (Thermo Scientific). Each construct was gently 
mixed with 50 μl chemically competent E. coli TOP10 cells and incubated for 30 min  
on ice to enable attachment of the DNA to the bacterial membrane. Next, a 30 sec heat 
shock at 42 °C was applied to enable the introduction of DNA into the cell. Subsequently,  
250 µl of SOC medium [Super Optimal broth with Catabolite repression [5 g/L yeast 
extract (LabM), 5 g/L NaCl (Acros Organics), 20 g/L tryptone (LabM), 0.1 M MgSO4 
(VWR International), 0.1 M MgCl2 (VWR International), 4% (w/v) D-glucose (VWR 
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International)] was added and the cells were incubated for 1 h with shaking at 37°C  
to enable recovery and expression of the antibiotic resistance genes. Finally, cells were 
plated out on LB agar containing 100 μg/ml ampicillin (VWR International) as selection 
pressure for plasmid maintenance and 2% (w/v) D-glucose (VWR International) for 
catabolite repression of the lac operon. Plates were incubated overnight at 37 °C. Single 
colonies were picked and colony PCR was performed using DreamTaq™ polymerase 
(Thermo Scientific) and one primer of the gene and one primer of the vector to enable 
identification of colonies with the correct construct by gel electrophoresis. Glycerol 
stocks for storage at -20 °C were made by mixing 800 μl overnight culture  
of the appropriate colonies with 200 μl of 100% glycerol (Acros Organics). Plasmids were 
isolated using the GeneJET Plasmid Miniprep kit (Thermo Scientific) according  
to the manufacturer protocol. The sequence of the plasmids was determined  
by ‘LIGHTrun sequencing’ (GATC Biotech) and analyzed by Sequencher software 
version 4.8 (Gene Codes Corporation). 
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Figure 3.1: Map and features of pBAD/Thio TOPO® vector. The araBAD promoter (PBAD) provides 
tight, dose-dependent regulation of heterologous gene expression. HP-thioredoxin allows a highly efficient 
fusion partner for translation of the fusion protein. TOPO® Cloning site enable quick insertion of PCR 
product for expression. The C-terminal V5 epitope tag (Gly-Lys-Pro-Ile-Pro-Asn-Pro-Leu-Leu-GlyLeu-
Asp-Ser-Thr) grants detection of the fusion protein by the Anti-V5 Antibody or the Anti-V5-HRP 
Antibody. Polyhistidine (6xHis) tag is further required for detection of the recombinant fusion protein with 
purification with metal-chelating resin (i.e. Ni-NTA). (STOP) rrnB transcription termination region. 
Ampicillin resistance gene (β-lactamase) is used for selection of the plasmid in E. coli. pUC origin provides 
replication and growth in E. coli and araC gene encodes the regulatory protein for tight regulation  
of the PBAD promoter.  
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Figure 3.2: Maps and features of pEXP5-NT/TOPO® and pEXP5-CT/TOPO® vectors. From left to right pEXP5-CT/TOPO®, pEXP5-NT/TOPO® maps. T7 promoter 
provides a high-level expression of recombinant protein in E. coli strains expressing the T7 RNA polymerase. T7 forward priming site (T7) allows sequencing in the sense 
orientation. Ribosome binding site (RBS) is optimally spaced from the initiation ATG for efficient translation of the PCR product. Initiation (ATG) enable translation initiation 
of the recombinant fusion protein. Polyhistidine (6xHis) tag is further required for detection of the recombinant fusion protein with purification with metal-chelating resin  
(i.e. Ni-NTA). (TEV) recognition site (Glu-X-X-Tyr-X-Gln-Ser) that allows removal of the N-terminal tag from recombinant fusion protein using TEV protease. TOPO® 
Cloning site is used for rapid cloning of Taq-amplified PCR product. T7 transcription terminator (T7 term) from bacteriophage T7 that allows efficient transcription termination. 
Ampicillin resistance gene (β-lactamase) grants selection of the plasmid in E. coli. (pUC origin) is ori of replication for high-copy replication and maintenance of the plasmid 
in E. coli. 
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3.2.3. Recombinant expression  
3.2.3.1. Bacterial strains and manipulations 
Five different E. coli strains [Lemo21(DE3), BL21-Codon Plus(DE3), 
ArcticExpress(DE3), BL21(DE3)pLysS, BL21 A1] were used to optimize expression  
of the recombinant proteins (Table 3.3). Therefore, correct plasmid constructs were 
freshly transformed in these chemically competent E. coli cells as described in section 
3.2.2.3.  
Table 3.3: Characteristics of E. coli expression strains and antibiotics requirements for protein 
expression.  
Strain name Genotype Features Features Additional 
requirements 
Lemo21(DE3) fhuA2 [lon] ompT gal 
(λ DE3) [dcm] ΔhsdS/ 
pLemo (CamR) λ DE3 
= λ sBamHIo ΔEcoRIB 
int:lacI::PlacUV5::T7 
gene1) i21 Δnin5 
pLemo = pACYC184-
PrhaBAD-lysY 
- lysogenic for λ-DE3 
- tunable level of T7 
lysozyme by L-
rhamnose, that can 
alleviate inclusion 
body formation or 
growth inhibitory 
effects from toxic 
proteins 
100 μg/mL Amp 
30 μg/mL Cm 
L-rhamnose 
(in expression 
medium 
BL21-Codon 
Plus(DE3) 
E. coli B F- ompT 
hsdS(r-mB) dcm+ Tetr 
E. coli gal λ (DE3) 
endA Hte [argU ileY 
leuW Camr] 
- lysogenic for λ-DE3 
- T7 expression 
system 
- tRNAs for E. coli 
codons that frequently 
limit translation 
100 μg/mL Amp 
34 μg/mL Cm 
- 
ArcticExpress 
(DE3) 
E. coli B F– ompT 
hsdS(rB-mB) dcm+ 
Tetr gal λ(DE3) endA 
Hte [cpn10 cpn60 
Gentr] 
- lysogenic for λ-DE3 
- T7 expression 
system 
- cold-adapted 
chaperonins 
100 μg/mL Amp 
20 μg/mL Gm 
low 
temperature 
cultivation 
(10-13°C) 
BL21(DE3) 
pLysS 
 
E. coli B F- dcm ompT 
hsdS(r-mB) gal λ(DE3) 
[pLysS Camr ] 
- lysogenic for λ-DE3 
- T7 lysozyme 
100 μg/mL Amp 
34 μg/mL Cm 
- 
BL21 A1 E. coli B F– ompT gal 
dcm lon hsdSB(rB–
mB–) [malB+]K-
12(λS) araB::T7RNAP-
tetA 
- T7 RNA 
polymerase into 
araBAD operon 
100 μg/mL Amp L-arabinose 
(at time  
of induction) 
Amp = ampicillin; Cm = chloramphenicol; Gm = gentamicin; λ-DE3 = lysogen construct with T7 RNA 
polymerase under control of lacUV5 promoter. 
 
Protein expression in BL21(DE3) pLysS competent cells is influenced  
by the presence of T7 lysozyme, which reduces the background of the targeted protein 
expression without disturbing the inducer activity of IPTG (isopropyl-1-thio-β-D-
galactopyranoside). It suppresses the activity of T7 RNA polymerase, reduces the basal 
level of protein expression from the gene of interest and increases the tolerance  
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of the E. coli cells against the toxicity. BL21(DE3) pLysS lacks both the Lon and OmpT 
proteases, which may degrade expressed proteins. 
Lemo21(DE3) consist the T7 RNA polymerase, encoded by the lambda DE3 
prophage present within the chromosome, expressed from the lacUV5 promoter, which 
is less sensitive to catabolite repression than the wt lac promoter. Furthermore, DE3 
strains may exhibit uninduced target protein expression, which is remedied by expression 
of T7 lysozyme (LysY). Membrane protein expression and protein export in E. coli are 
both limited by the throughput capacity of the Sec translocase and in some cases the Tat 
translocase. T7 expression of proteins targeted to the Sec translocase often leads  
to accumulation of inclusion bodies or inhibition of cell division, if expression is not 
regulated. This is why Lemo21(DE3) has a tunable level of T7 lysozyme, controlled  
by L-rhamnose, which can alleviate inclusion body formation or growth inhibitory effects 
from toxic proteins. In many cases, decreased expression can result in more protein  
of interest produced in the desired form. Cells naturally lack the Lon protease, which can 
degrade recombinant proteins. 
The efficiency of heterologous protein high-level expression in E. coli  
is frequently limited by the scarcity of certain tRNAs, that are abundant in the organisms 
from which the proteins are derived. BL21-CodonPlus(DE3) strain overcomes codon bias 
as a result of the extra copies of tRNAs genes that frequently limit translation in E. coli. 
Thus a high-level expression of heterologous recombinant genes can be improved  
in BL21-CodonPlus cells in compare to conventional BL21 strains. Cells lack the Lon 
and the OmpT proteases.  
Further, the ArcticExpress competent cells address the common protein 
expression hurdle, protein insolubility. They are engineered to increase the yield  
of soluble protein produced in E. coli in low-temperature cultivation, which slows down 
protein expression. The important role in protein folding play E. coli chaperonins, 
especially the complex GroEL/ES, that retains only about 30% refolding activity  
at 12 °C, compared to its optimal activity at 30 °C. The ArcticExpress competent cells 
co-express the cold-adapted chaperonins Cpn10 and Cpn60 from the psychrophilic 
bacterium, Oleispira antarctica, and have 74% and 54% amino acid identity to the E. coli 
GroEL and GroES chaperonins, respectively. They allow for a potent protein refolding  
at low temperatures of 4–12°C, which potentially may increase the yield of active, soluble 
recombinant protein. Cells also lack Lon and OmpT proteases. 
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Finally, BL21-AI™ competent E. coli strain offers the maximum protein 
expression with the tightest regulation available for a T7 expression system.  
The BL21-AI™ strain also does not contain the Lon and OmpT proteases. In contrast to 
above strains expression of T7 RNA polymerase is regulated by the araBAD promoter 
and depends on L-arabinose concentrations. 
3.2.3.2. Expression conditions 
Freshly transformed E. coli expression cells were inoculated in LB broth  
(1/20 of the expression medium volume) and grown overnight at 37°C with shaking. 
Next, cultures were inoculated in the expression medium with proper antibiotics.  
For E. coli Lemo21(DE3) cells, also 0.5 mM L-rhamnose (Sigma-Aldrich) was added. 
Cultures were grown to OD600 of ± 0.6 and induced with IPTG or arabinose in case  
of pBAD/Thio TOPO® vector (GE Healthcare). For E. coli BL21 A1, also 0.2% (w/v) 
L-arabinose (Sigma-Aldrich) was added at time of induction. Next, cells were allowed  
to grow and express the recombinant protein for 4.5 h at 37 °C or overnight at 16 °C with 
shaking. For expression in autoinduction medium, cells were grown to OD600 of ± 0.8 and 
further incubated at 16 °C with shaking for exactly 24 h. Media used for expression 
optimization were as follows: LB [5 g/L yeast extract (LabM), 10 g/L NaCl (Acros 
Organics), 10 g/L tryptone (LabM)], 2xTY [16 g/L tryptone (LabM), 10 g/L yeast extract 
(LabM), 5 g/L NaCl (Acros Organics)], modified LB [15 g/L tryptone (LabM), 8 g/L 
yeast extract (LabM), 5 g/L NaCl (Acros Organics), pH 7.8], TB [12 g/L tryptone (LabM), 
24 g/L yeast extract (LabM), 2.3 g/L KH2PO4 (VWR Int.), 16.4 g/L K2HPO4 (Acros 
Organics), 0.4% (v/v) glycerol (Acros Organics)], autoinduction medium [10 g/L 
tryptone (LabM), 5 g/L yeast extract (LabM), 0.1% (v/v) 1 M MgSO4 (Sigma-Aldrich), 
2% (v/v) 50 x 5052-solution (25% (w/v) glycerol (UCB), 2.5% (w/v) D-glucose (Acros 
Organics), 10% (w/v) D-lactose monohydrate (Sigma Aldrich), 5% (v/v) 20 x NPS-
solution (6.6% (w/v) (NH4)2SO4 (Acros Organics), 13.6% (w/v) KH2PO4 (VWR Int.), 
14.2% (w/v) Na2HPO4.2H2O (Acros Organics)]. 
3.2.3.3. Protein presence analysis 
After expression, the cell culture was centrifuged (4000 × g, 10 min, 4 °C) and  
the pellet was stored at -80°C until purification. The presence of recombinant protein was 
checked by SDS-PAGE and Western Blot. Therefore, 10 ml sample taken post expression 
was centrifuged (4000 × g, 10 min, 4°C) and the pellet was resuspended in 1 ml lysis 
87 
 
buffer, respectively. The 1 mM Pefabloc® SC (Merck-Millipore) was added to inhibit 
serine proteases, that could damage the recombinant protein. Next, cells were disrupted 
by three times freeze-thawing in liquid nitrogen and sonication (6 min, 30 s pulse/30 s 
rest, 40% amplitude; Vibra-Cell™, Sonics & Materials Inc.) in the presence of 10 μg/ml 
DNase I (Invitrogen) to reduce the sample viscosity. Total, soluble and insoluble fractions 
were separated and collected by centrifugation (18,000 × g, 30 min, 4 °C). Not induced 
fraction was harvested from 1 ml sample taken before expression culture induction. 
Sample was centrifuged (4,000 × g, 10 min, 4°C) and the pellet was resuspended in 1 ml 
lysis buffer. All samples were mixed with 4 x loading buffer and boiled for 5 min  
at 95 °C prior to loading on the SDS-PAGE gel. The protein concentration was 
determined by spectrophotometric measurement of absorption at 280 nm using 
Nanodrop® ND-1000 spectrophotometer (Nanodrop Technologies, Wilmington, USA). 
The protein molecular weight and extinction coefficient (ε) was determined using 
EXPASY-ProtParam. 
3.2.3.4. Sodium dodecyl sulfate polyacrylamide gel electrophoresis (SDS-PAGE) 
The purity and composition of the protein samples were visualized  
by SDS-PAGE. Both 12% and 15% (v/v) polyacrylamide separation gels were prepared, 
depending on the size of the proteins. Therefore, respectively 3.6 and 3.25 ml MQ water 
(Merck-Millipore), 2 and 2.5 ml 4 x Tris/SDS buffer pH 8.8 [1.5 mM Trizma base (Acros 
Organics), 0.4% (w/v) SDS (Janssen Chimica)], 2.4 and 3.75 ml 40% (v/v) acrylamide 
(Bio-Rad), 0.01% (v/v) ammonium persulfate (APS; Sigma-Aldrich), 0.001% (v/v) 
N,N,N’,N’-tetramethylethylenediamine (TEMED; IBI Scientific) were mixed for  
the preparation of 2 gels. The two stacking gels were prepared by mixing 2.1 ml MQ 
water (Merck-Millipore), 800 μl 4x Tris/SDS buffer pH 6.8 [1.5 mM Trizma base (Acros 
Organics), 0.4% (w/v) SDS (Janssen Chimica)], 300 μl 40% (v/v) acrylamide (Bio-Rad), 
0.01% (v/v) APS (Sigma-Aldrich) and 0.001% (v/v) TEMED (IBI Scientific). Gels were 
placed in the reservoirs filled with SDS-PAGE running buffer [25 mM Trizma base pH 
8.3 (Acros Organics), 192 mM glycine (Sigma-Aldrich), 0.1% (w/v) SDS (Janssen 
Chimica)] and 10 μl of each sample was loaded. Also 7 μl of PageRuler™ Prestained 
Protein Ladder (Thermo Scientific) was loaded as a reference to estimate the molecular 
weight (MW) of the proteins. Gels were run at a constant voltage of 200 V and 
subsequently stained with the GelCode™ Blue Safe Protein Stain (Thermo Scientific). 
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3.2.3.5. Western blot analysis 
Western blotting was performed to verify the presence of the 6 x His-tag in the 
expressed proteins. The protein fractions (5 μl/well) were loaded on a 12% or 15% (v/v) 
polyacrylamide gel and SDS-PAGE was performed. Next, proteins were transferred onto 
an Amersham Hybond P 0.45 PVDF blotting membrane (GE Healthcare) in a presence 
of a transfer buffer [600 ml MQ (Merck-Millipore), 200 ml 5x Tris-glycine buffer  
(15 g/L Trizma base (Acros Organics), 75 g/L glycine (Sigma-Aldrich), 200 mL 100% 
ethanol (Fisher Scientific, Loughborough, UK)]. The membrane was blocked for 1 h  
at room temperature with PBST buffer [100 ml 10 x PBS, phosphate buffered saline,  
[80 g/L NaCl (Acros Organics), 2 g/L KCl (Janssen Chimica), 14.4 g/L Na2HPO4 
(Merck), 2.4 g/L KH2PO4 (Merck)], 0.1% (v/v) Tween 20, pH 7.5 (Sigma-Aldrich),  
900 ml MQ water (Merck-Millipore)], containing 5% (w/v) powdered milk (Nestlé NAN 
Pro 2) to avoid unspecific binding of the antibodies and background signals. Afterwards, 
the membrane was incubated for 1 h with a 1:3000 dilution of mouse monoclonal Anti-
polyhistidine antibodies (Promega, Madison) in 10 ml PBST buffer containing 1% (w/v) 
milk powder at room temperature with gentle shaking. After three washing steps with 
PBST buffer, the membrane was incubated for 1 h at room temperature with a 1:5000 
dilution of Anti-Mouse IgG (H+L) antibodies conjugated to horseradish peroxidase 
(HRP) (Promega). Subsequently, three washing steps with PBST buffer were performed. 
Revelation was carried out by enhanced chemiluminescence (ECL) using the Pierce™ 
ECL Western Blotting Substrate kit (Thermo Scientific). The chemiluminescence signal 
was trapped on an Amersham Hyperfilm ECL (GE Healthcare). 
3.2.4. Protein purification 
3.2.4.1. Sample preparation 
Expression culture pellets were resuspended in 10 ml lysis buffer [pH 8, 50 mM 
NaH2PO4 (Merck), 300 mM NaCl (Acros Organics), 10 mM imidazole (Acros 
Organics)] containing 30% (v/v) glycerol (Acros Organics) to improve stability and  
1 mM Pefabloc® SC (Merck-Millipore) was added. The suspension was frozen and 
thawed three times using liquid nitrogen. After addition of 5 μl 10 μg/mL DNase I 
(Invitrogen), the suspension was sonicated (6 min, 30 s pulse/30 s rest, 40% amplitude; 
Vibra-Cell™) to lyse the cells further. Next, the suspension was centrifuged (4600 × g, 
50 min, 4°C) and the supernatant was collected.  
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3.2.4.2. Ni2+-NTA affinity chromatography  
The protein lysate, collected from large scale expression, was incubated with 1 ml 
Ni2+-NTA Superflow (Qiagen) for 1 h rotating at 4°C. After short centrifugation  
(300 × g, 5 min, 4°C), the resin was gently resuspended in 10 ml lysis buffer with 30% 
(v/v) glycerol and loaded on chromatographic columns (diameter 25 mm, height 180 mm, 
CHEMLAND). Subsequently, the resin was washed with 25 ml lysis buffer [pH 8,  
50 mM NaH2PO4 (Merck), 300 mM NaCl (Acros Organics), 10 mM imidazole (Acros 
Organics)] with 30% (v/v) glycerol and 2 L of wash buffer [50 mM NaH2PO4 (Merck), 
300 mM NaCl (Acros Organics), 20 mM imidazole (Acros Organics), pH 8, 30% (v/v) 
glycerol (Acros Organics)] at 4 °C. Two elution fractions were collected by addition  
of 1 ml elution buffer [50 mM NaH2PO4 (Merck), 300 mM NaCl (Acros Organics),  
250 mM imidazole (Acros Organics), pH 8, 30% (v/v) glycerol (Acros Organics)] and 
stored at 4 °C. Purity of the purified proteins was checked by SDS-PAGE and the yield 
was determined using a Nanodrop®. 
3.2.4.3. Fast Protein Liquid Chromatography (FPLC) 
Large scale purification of the recombinant proteins was conducted on a 1 ml 
HisTrap HP column (GE Healthcare) in combination with an Akta FPLC-system  
(GE Healthcare) and UNICORNTM 5.01 software. After column equilibration with  
10 column volumes washing buffer [20mM NaH2PO4 pH 7.5, 0.5 M NaCl, protein 
specific imidazole (Acros Organics) concentration, 10% glycerol], the protein lysate was 
loaded onto the column. Next, the column was washed with 15 column volumes  
of washing buffer and subsequently eluted with elution buffer (20 mM NaH2PO4 pH 7.5, 
0.5 M NaCl, 0.5 M imidazole, 10% glycerol). 
3.2.4.4. Size-exclusion chromatography 
Further recombinant protein purification was conducted with the size-exclusion 
chromatography (SEC) in combination with the Äkta System. Depends on recombinant 
protein size and its concentration after affinity chromatography purification, three 
different columns were used: HiLoad 16/600 Superdex 75 Prep grade gel filtration 
column, the HiLoad 16/600 Superdex 200 Prep grade gel filtration column and Superdex 
200HP GL10/30 gel filtration column (GE Healthcare). The mobile phase buffer [50 mM 
Tris, 150 mM NaCl (Acros Organics), pH 7.6] was run through the column and 
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subsequently recombinant protein were eluted based on their molecular weight. Columns 
were calibrated by the LMW Calibration Kit (GE Healthcare). 
3.2.4.5. Buffer exchange 
Elution buffer was exchanged for PBS (for putative EPS depolymerases) or 5 mM 
HEPES (Acros Organics)/NaOH (UCB), pH 7.4 (for putative PG hydrolsases) 
supplemented with 30% (v/v) glycerol (Acros Organics) to improve stability and provide 
an appropriate medium for activity. Therefore, Amicon Ultra-0.5 mL Centrifugal Filters 
(10K and 30K, Merck) were used according to manufacturer protocol. Protein 
concentrations were determined by Nanodrop® ND-1000 spectrophotometer). 
3.2.5. Functional assays 
3.2.5.1. Halo formation plate assay 
To get an indication of the potential polysaccharide degrading activity of putative 
depolymerases, a spot test was performed. P. aeruginosa PAO1 strain Krylov cells were 
grown overnight in LB broth and refreshed till OD600 ± 0.4. Next, 200 µl of this culture 
was added into 5 ml of 0.7% (w/v) soft agar and the mixture was poured on LB agar. 
Further, 10 μl protein and 10 μl negative control (either elution buffer or PBS) were 
spotted and incubated at 37°C. Plates were observed for halo formation after 24 h, 48 h 
and 72 h. 
3.2.5.2. EPS staining and microscopy 
P. aeruginosa PAO1 Krylov cells were removed from halo and bacterial zones 
created on LB agar. Cells were resuspended in a 10 μl droplet of 1% (w/v) aqueous Congo 
red solution (Sigma-Aldrich) on a microscopic glass slide. The suspension was spread 
over the entire slide and air-dried. A 10 μl drop of Maneval’s solution [3.33% (v/v) phenol 
(VWR International), 4.44% (v/v) acetic acid (VWR International), 2.67% (w/v) Iron (III) 
chloride (UCB), 0.02% (w/v) fuchsin (Sigma-Aldrich)] was added and spread over  
the slide to acidify the Congo red background. Cells were observed under a light 
microscope at 100x magnification with immersion oil (Leica DM LB microscope;  
Mc Bain Instruments). 
3.2.5.3. Biofilm degradation assay using the Calgary device 
P. aeruginosa PAO1 Krylov cells were grown overnight in LB broth. Next, 1:200 
dilution of overnight culture was inoculated in each well of a 96-well round-bottom plate. 
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The plate was covered with a peg lid and incubated at 37°C for 24 h, 48 h or 72 h without 
shaking. For 48 h and 72 h biofilms, the LB broth was refreshed every day. Next, the peg 
lids were rinsed with PBS buffer to remove planktonic cells and exposed to negative 
control (190 μl of LB broth), positive control (400 μg/ml gentamicin) or protein. Biofilms 
were further incubated at 37°C for 30 min without shaking. Next, the peg lids were 
washed with PBS buffer to remove planktonic cells and transferred to a 96-well flat-
bottom plate containing 99% methanol (Chem-Lab) to fix the biofilm cells. After 15 min 
incubation at room temperature, the peg lids were air-dried and incubated for further  
15 min with 0.01% (w/v) crystal violet (Merck). Next, biofilms were washed with tap 
water and air-dried. Finally, 33% (v/v) acetic acid (VWR International) was introduced 
for 5 min to dissolve the crystal violet and OD600 was measured using a Multiskan EX 
Microplate Reader (Thermo Scientific). 
3.2.5.4. Activity assay of endolysins on permeabilized bacterial cells  
To quantify the enzymatic activity of phage endolysins, the drop in OD655  
of OM permeabilized P. aeruginosa PAO1, APEC or Salmonella Enteritidis substrate 
was monitored over time. Protoplasts of each strain were prepared by treating cells with 
chloroform-saturated Tris buffer according to the standard protocol of Lavigne et al. 
(2004). With this treatment, the protective effect of the OM is destroyed and the EAD  
of PG hydrolases can easily reach its target in the PG. Briefly, 20 ml overnight culture 
was inoculated in 500 ml of LB broth and grown to the mid-exponential phase  
(OD600 ± 0.6). Next, the culture was centrifuged (3220 × g, 30 min, 4 °C) and the pellet 
was resuspended in 240 ml of chloroform-saturated 0.05 M Tris buffer [chloroform 
(Merck), Trizma base (Acros Organics), pH 7.7]. After 45 min shaking at room 
temperature, the suspension was again centrifuged (3220 × g, 30 min, 4 °C) and the pellet 
was washed with 90 ml PBS. Finally, pellets were resuspended in 5 mM HEPES/NaOH 
(pH 7.4) to an OD600 of 1.5 and substrates were stored at -20°C. Prior to the assay,  
the substrate was thawed and sonicated to reduce the substrate viscosity and increase  
the homogeneity.  
A volume of 30 μl of protein or its dilutions was mixed with 270 μl of substrate 
in a flat-bottom 96-well plate and the OD655 was measured over time using a Model 680 
Microplate Reader (Bio-Rad). Positive controls (φKZ gp144 endolysin) and negative 
controls (5 mM HEPES/NaOH, pH 7.4) were included in the assay. The experiment was 
performed in triplicate and data were analyzed as described in Briers et al. (2007). 
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3.2.5.5. pH stability analysis of the endolysins 
To assess the pH-dependency of PG hydrolases, the P. aeruginosa PAO1 substrate 
prepared as described in section 3.2.5.4 and resuspended in universal buffer adjusted  
to pH range 3-10 [150 mM KCl (Janssen Chimica), 10 mM KH2PO4 (Acros Organics), 
10 mM sodium citrate dehydrate (Sigma-Aldrich) and 10 mM H3BO4 (Acros Organics)]. 
The experiment was performed in triplicate as previously described. The highest average 
slope, corresponding to a certain pH, was normalized and the relative activity of the other 
samples was calculated in percentage with standard deviation.  
3.2.5.6. Zymography with crude peptidoglycan 
The PG-degrading capacity of the purified proteins was assessed by zymography. 
P. aeruginosa PAO1 Krylov cells were inoculated in 500 ml LB broth and incubated 
overnight at 37 °C. Next, the culture was autoclaved and centrifuged (4570 × g, 30 min, 
4 °C). Further, 300-600 mg of crude PG was copolymerized in a 15% or 12% (v/v) 
polyacrylamide separation gel. Additionally, a classical 15% or 12% (v/v) separation gel 
was prepared for comparison afterwards. A volume of 10 μl of purified protein samples 
were loaded on both gels, as well as 7 μl PageRuler™ Prestained Protein Ladder (Thermo 
Scientific) and two concentrations (10 μg/ml, 5 μg/ml) of HEWL (Sigma-Aldrich)  
as a positive control. SDS-PAGE was performed to separate the proteins according  
to their MW. Next, the gel was incubated for 48 h in renaturation buffer  
[150 mM NaH2PO4 pH 7 (Merck), 10 mM MgCl2 (Sigma-Aldrich), 0.1% (w/v)  
TritonX-100 (Sigma-Aldrich)] and 24 h in distilled water to allow renaturation  
of the proteins and regeneration of the enzymatic activity. Finally gels were stained with 
zymography staining solution [0.10% (w/v) methylene blue (ICN Biomedicals),  
0.001% (w/v) KOH (UCB)]. 
3.2.5.7. Antibacterial activity of endolysins  
P. aeruginosa PAO1 Pirnay, APEC and S. Enteritidis cells were grown in LB 
broth to the mid-exponential phase (OD600 ± 0.6). Then, cultures were diluted 200-fold 
in 5 mM HEPES/NaOH (pH 7.4) to a final density of 106 cfu/ml. A volume of 100 μl  
of diluted cells were mixed with 50 μl of protein (2.5 μM final concentration) and  
50 μl 5 mM HEPES/NaOH (pH 7.4) or 50 μl 2 mM Na2-EDTA (Acros Organics)  
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in 5 mM HEPES/NaOH (pH 7.4) (final concentration 0.5 mM). As controls, cells were 
incubated with only 2 mM Na2-EDTA in 5 mM HEPES/NaOH (pH 7.4) or 5 mM 
HEPES/NaOH (pH 7.4). After 30 min of incubation at room temperature, mixtures were 
10-, 100- and 1000-fold diluted in PBS and 100 μl of each dilution was plated on LB agar. 
The antibacterial activity of endolysins was quantified after 18 h incubation at 37 °C  
as the relative inactivation in logarithmic units (= log10(N0/Ni) with N0= number  
of untreated cells and Ni = number of treated cells counted after incubation).  
All experiments were performed in triplicate.  
3.2.5.8. Time-lapse microscopy to visualize enzymatic activity 
To visualize the mode of action of the proteins, a time-lapse microscopy was 
performed. P. aeruginosa PAO1 Pirnay cells were grown to mid-exponential phase 
(OD600 ± 0.6) and centrifuged (4570 × g, 10 min, 4°C). Cell pellet was washed three times 
with PBS. Finally, cells were concentrated five times by resuspension in PBS buffer 
containing 0.5 mM Na2-EDTA (Acros Organics). Equal amounts of protein and bacterial 
cells were mixed and fixed on a PBS-0.2% agar pad for observation under a temperature 
controlled Eclipse Ti-E inverted microscope (Nikon) equipped with a Ti-CT-E motorized 
condenser and a CoolSNAP HQ2 FireWire CCD camera, available at the Laboratory  
of Food Microbiology (KULeuven; Prof. A. Aertsen), with the help of Dr. Sander Govers. 
Images were recorded using NIS-Elements (Nikon) and further processed with ImageJ 
(http://rsbweb.nih.gov/ij/). 
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Contribution 
 Transmission electron microscopy phage visualisation and morphology analysis was 
performed by Prof. Hans-W. Ackermann (Department of Microbiology-Infectiology 
and Immunology, Medical School, Laval University, Quebec, Canada) and 
technician of University of Wrocław Sylwia Nowak.  
 Time-lapse microscopy experiment was conducted in the Centre for Food and 
Microbial Technology (Prof. Abram Aertsen, KU Leuven, Belgium) with a help  
of Dr. William Cenens.  
 LPS assay was performed by Dr. Daria Augustyniak (Department of Pathogen 
Biology and Immunology, University of Wrocław, Poland). 
 Protein-sharing network was constructed and analyzed by Dr. Ho Bin Jang 
(Laboratory of Gene Technology, KU Leuven, Belgium) and Katarzyna Danis-
Włodarczyk. 
 Genome analysis was performed by Katarzyna Danis-Włodarczyk under supervision 
of Dr. Dieter Vandenheuvel. 
 All remaining experiments and analysis were performed by Katarzyna Danis-
Włodarczyk. 
4.1. Introduction 
The genus of Pbunavirus is a well characterized and widespread clade of closely-
related phages, belonging to the Myoviridae family. Their genomes are highly conserved 
(more than 85% of nucleotide identity) and organized in at least seven transcriptional 
blocks. Their size varies between 64,427 and 66,530 bp with 88 to 95 encoded proteins 
(Ceyssens et al., 2009). Phages from this group do not encode a recognizable integrase, 
suggesting their obligatory virulent nature (Lavigne et al., 2009). They have a solid, acid 
resistant isometric capsid, with a diameter of ~74 nm and a contractile tail of ~140 nm 
(Ceyssens et al., 2009). The LPS serves as the host receptor (Jarrell et al., 1977). Over 
the years, no less than 44 phages have been reported to be Pbunavirus, mainly based  
on cross-DNA hybridization and morphological studies (Garbe et al., 2010). Phages from 
this genus are described as a suitable candidates for therapy, especially when applied  
in phage cocktails (Merabishvili et al., 2009). In this chapter, we describe two new broad 
host range Pbunavirus phages KT28 and KTN6, isolated from environmental water 
samples. Their genomes have been sequenced and a detailed comparison with other 
members of the Pbunavirus clade was made. The morphology, burst size, and host range 
were established as well as viral particle stability and LPS interactions.  
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4.2. Microbiological characteristics 
4.2.1. Isolation and morphology 
The KTN6 and KT28 phages were isolated from sewage samples collected  
in natural wastewater treatment plant (irrigated fields) located in Wrocław, Poland. Both 
lytic viruses propagate well on P. aeruginosa PAO1 reference strain. After purification 
phage titres were 109 - 1010 pfu/ml and caused 1.2–1.5 mm wide clear plaques on 0.6% 
soft agar with small halo zone, particularly evident in case a 167/DON clinical strain 
infection (Fig. 4.1). The bacteriophages were examined by transmission electron 
microscopy (TEM) and classified on the basis of their morphological features  
to Pbunavirus, family Myoviridae, order Caudovirales (Fig. 4.1). The isolates were 
formally named as vB_PaeM_KT28 (KT28) and vB_PaeM_KTN6 (KTN6). Their 
isometric head size was estimated to be 74 nm and 72 nm between opposite apices, and 
contractile tails 136 nm and 123 nm in the extended state, for KT28 and KTN6, 
respectively.  
Figure 4.1: Particle analysis of the Pseudomonas phages KT28 (A) and KTN6 (B) belonging  
to Pbunavirus genus. From left to right, an electron microscopic image, a CsCl purification with phage 
band marked red, plaque morphology on P. aeruginosa PAO1 Krylov reference strain and 167/DON 
clinical isolate from the Academic Teaching Hospital in Wrocław, Poland. The scale bar represents  
100 nm. 
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4.2.2. Phage infection 
One-step growth experiments, constructed under standard laboratory conditions, 
indicated a latent period of 35 min and a burst size of about 64 ± 0.98 and 96 ± 0.2 phage 
particles per infected bacterial cell (pfu/cell), for KT28 and KTN6, respectively (Fig 4.2).  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4.2: The one-step growth curves of KT28 and KTN6 phages. An equal volume of bacterial 
culture (at OD600 of 0.4, 108 cfu/ml) was mixed with phage suspension (106 pfu/ml) to obtain 
 a multiplicity of infection (MOI) of 0.01. Phages were allowed to adsorb for 8 min at 37°C. Triplicate 
samples were taken during 70 min at 5 min intervals and titrated. The phage titre [pfu/cell] of the solution 
was assessed using the double-agar layer technique, according to methods described by Adams (1959).  
(A) KT28 and (B) KTN6 one-step growth curves with a latent period of 35 min and burst size of 64 ± 0.98 
and 96 ± 0.2 phage particles per infected bacterial cell (pfu/cell), respectively. A trend line is marked with 
blue dots. All data are collected from three independent experiments, error bars indicate the standard 
deviation. 
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4.2.3. Time-lapse microscopy 
The P. aeruginosa infection caused by phage KT28 or KTN6 in the real time was 
visualized with a time-lapse microscopy (Eclipse Ti Time-Lapse Microscope).  
P. aeruginosa PAO1 Krylov cells were grown to mid-exponential phase (OD600 of 0.6) 
and infected on a 0.2% PBS - agar pad by CsCl purified KT28 or KTN6 phages  
(6.5 x 1010 and 7.26 x 1010 pfu/ml, respectively) with MOI 10. In the course of infection 
cells only marginally increases their size and between 10 and 30 min post infection host 
cells started to burst (Fig. 4.3). The latent period of both phages achieved in this 
experiment cannot be compared to one step growth experiments, due to different 
conditions. 
Figure 4.3: The time-lapse recordings of P. aeruginosa PAO1 Krylov cells infected with KT28 (A)  
or KTN6 (B) phages. A snapshots were taken from the start of phage infection, MOI 10, using a Nikon 
Eclipse Ti Time-Lapse Microscope. Scale bar represents 10 µm. In the left bottom corner is presented time 
in hours counted from the beginning infection. 
4.2.4. Stability tests 
The phage stability in the presence of physical and chemical agents was very 
similar for KT28 (1.01 x 109 pfu/ml) and KTN6 (1.26 x 109 pfu/ml).  
No reduction of pfu/ml was noticed over a period of 60 min at a temperature range 
of 40 - 70°C and 5 min at 80°C (Fig. 4.4). The KT28 phage titre drops at 80°C by 2 logs 
after 15 min, 4 logs after 30 min, 5 logs after 45 min and 60 min of incubation  
(Fig. 4.4 A). The KTN6 phage titre drops at 80°C incubation by 2 logs after 15 min and 
30 min, from 45 min phage titre drops to zero (Fig. 4.4 B). Both phages did not survived 
temperature of 90°C and 100°C. 
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Figure 4.4: The temperature stability of phage KT28 (A) and KTN6 (B). Each bar represents the mean  
of three independent experiments, error bars indicate the standard deviation. Results obtained with spot 
test.  
Phage particles were stable within a pH range of 3 - 12 after 1 hour incubation  
at room temperature. At pH 2 phage titre drops by 4 and 3 logs for KT28 and KTN6, 
respectively. At pH 1 both phages were not active (Fig. 4.5). 
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Figure 4.5: The pH stability of phages KT28 (A) and KTN6 (B). Phage titers (pfu/ml) were validated  
at the different pH values after 1h exposure at room temperature. Each bar represents the mean of three 
independent experiments, error bars indicate the standard deviation. Results obtained with spot test.  
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Phage infectivity was not affected after 1 h and 24 h incubation with chloroform 
(an equal volume of phage solution and chloroform) at room temperature and at 4°C. 
(Fig. 4.6).  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4.6: The chloroform stability of phage KT28 (A) and KTN6 (B). Phage titers (pfu/ml) were 
validated after chloroform treatment for 1 h and 24 h incubation at room temperature (RT) and at 4°C. Each 
bar represents the mean of three independent experiments, error bars indicate the standard deviation. Results 
obtained with spot test.  
4.2.5. Determination of phage receptor 
Jarrell and Kropinski (1977) showed that phage E79 use the bacterial LPS layer  
as a receptor. In our study with knock-out PAO1 mutants, it was also confirmed that 
phages KT28 and KTN6 recognize the LPS elements as its specific receptor, and only 
absence of A- and B-band O-antigen inhibits phage propagation (Table 4.1).  
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Table 4.1. Host range analysis of KT28 and KTN6 phages with the use of P. aeruginosa PAO1 
mutants.  
Bacterial strain Phenotype Origin KT28 KTN6 
PAO1 (ATCC 
15692) 
Wild type American Type 
Culture Collection 
+ + 
PAO1 Pirnay Wild type with inactive type IV pili Military Hospital 
Neder-Over-
Heembeek, 
Brussels, Belgium 
+ + 
PAO1 Krylov Wild type 
 
+ + 
PAO1 Δrmd  
(A-, B+) 
Deficiency in D-rhamnose biosynthesis; 
lack of A-band LPS 
 
 
 
Department  
of Molecular and 
Cellular Biology,  
University  
of Guelph, 
Canada 
+ + 
PAO1 ΔrmLC 
(A-, B-, core-) 
Deficiency in L-rhamnose biosynthesis; 
truncate core region, lack of A-band and 
B-band LPS 
- - 
PAO1 ΔwaaL 
(A-, B-) 
Lack of WaaL ligating O-polymer  
to core-lipid A; LPS is devoid  
of A-band and B-band, semirough  
(SR-LPS, or core-plus-one O-antigen) 
- - 
PAO1 ΔwbpL 
(A-, B-) 
Lack of glucosyltransferase WbpL 
essential for initiation of both A-band 
and B-band synthesis 
- - 
PAO1 ΔfliC 
ΔalgC ΔpilA 
Lack of flagella; lack of AlgC required 
for A-band, core oligosaccharide, and 
alginate 
 
Technical 
University 
Hamburg, 
Germany 
- - 
PAO1 ΔfliC  
wt algC ΔpilA 
Lack of flagella; lack of type IV pili 
 
+ + 
PAO1 ΔfliC  
wt algC wt pilA 
Lack of flagella 
 
+ + 
PAO1 wt fliC  
wt algC wt pilA 
Wild type + + 
+ activity, bacterial lysis. - no activity. 
These results were verified by the experiments performed with pure LPS isolated 
from PAO1 strain. The phage inactivation assay revealed direct correlation between LPS 
concentration and viral particles infectivity inhibition (Fig. 4.7), and that 36.0 μg/ml and  
43.3 μg/ml of LPS was needed to inhibit the activity of 50% of 3 x 103 pfu, for KT28 and 
KTN6, respectively. The LPS-binding experiments based on biotinylated phages showed 
similar OD values for both phages (0.74 and 0.75). 
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Figure 4.7: The KT28 and KTN6 phage inactivation assay by pure LPS. The curve represents direct 
correlation between LPS concentration (µg/ml) and viral particles infectivity inhibition (%). The light grey 
curve represents KTN6 phage and dark grey KT28 phage. All data are collected from three independent 
experiments, error bars indicate the standard deviation. 
 
4.2.6. Host range analysis 
Phage typing showed, that phage KTN6 exhibited a broader spectrum of activity 
against tested P. aeruginosa strains, lysing 68%, compared to 60% for phage KT28. This 
finding was also confirmed during phage typing of an international P. aeruginosa panel 
collection described by de Soyza et al. (2013). The KTN6 and KT28 propagated on 42% 
and 28% of the panel strains, respectively. Moreover, both phages were more active 
compared to three Pbunavirus phages: LMA2 25%, LBL3 47% and LSL4 17%  
(Table S 4.1).  
Among 57 clinical strains of the Pirnay’s P. aeruginosa panel seven were resistant 
to all phages used (Aa249, Lo049, Lw1047, Br667, Bu004, PAO29, Br229), 10 were 
sensitive to all five Pbunavirus phages chosen for treatment (Bu007, US448, Br906, 
PhDW6, Br642, LMG2107, Aa246, Pr335, Is580, Be136), eight to only KT28 and KTN6 
(LMG14083, Lo053, So099, Is579, C, C1, LMG14084, B0548, PA6), four to KTN6 
alone (Li004, C17, C18, US447), 3 to KT28 alone (C19, Br735, So095), 2 to LSL4 alone 
(US449, Br680) and 4 to LBL3 alone (Lo050, LMB5031, C2, Mi151).  
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4.2.7. Phage influence on biofilm  
To initially evaluate biofilm eradication ability of KT28 and KTN6 phages,  
the 24 h and 48 h old P. aeruginosa PAO1 biofilms were grown on 8-well slide 
microscopy chambers and infected with KT28 or KTN6 phage suspension (1.5 x 1010 
pfu/ml and 1.25 x 1010 pfu/ml, respectively), and further incubated for 24 h at 37°C. Two 
controls were set: 1) negative control of biofilm treated with LB broth, 2) positive control  
of a high dose gentamicin treatment (400 µg/ml). The MIC of gentamicin for tested strain 
was 0.5 µg/ml, however biofilm forming bacteria present different susceptibility  
to antibiotics in compare to their planktonic counterparts, thus a high dose of gentamicin 
was chosen. Biofilms were stained with LIVE/DEAD BacLight Bacterial Viability Kit 
and visualized by confocal laser scanning microscopy (Fig. 6.7). We observe that  
the biofilm negative control presented a dense structure, with a thickness increasing over 
the time. However, the structure of the 24 h old biofilm was degraded after gentamicin 
and both phage treatments. In case of the 48 h old biofilm, gentamicin had a strong effect, 
degrading large areas of biofilm. In contrast, the phages treatment caused only small 
tunnels in biofilm structure in comparison to the control. This study show only 
preliminary assessment of KTN6 and KT28 antibiofilm activity, which was further 
evaluated with more qualitative and quantitative techniques by Drulis-Kawa group 
(Department of Pathogen Biology and Immunology, Institute of Genetics and 
Microbiology, University of Wrocław, Poland) and collaborators (Department  
of Microbiology, Institute of Biology and Department of Molecular Physics, Institute  
of Physics, The Jan Kochanowski University, Kielce, Poland). Their results are published  
in Danis-Wlodarczyk et al., 2015. 
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Figure 4.8: Antibiofilm activity of phage KT28 and KTN6 tested on P. aeruginosa PAO1 biofilms. (A) 24 h and (B) 48 h old biofilm. I) negative control: biofilm treated 
with LB broth; II) positive control: biofilm treated with gentamicin (400 µg/ml); III) KT28 treatment (1.5 x 1010 pfu/ml); IV) KTN6 treatment (1.25 x 1010 pfu/ml). Biofilms 
were grown at 37°C, 5% CO2, stained with the LIVE/DEAD BacLight stain (LIVE/DEAD BacLight Bacterial Viability Kit) and visualized by confocal laser scanning 
microscopy (Zeiss LSM 510 Meta 40× objective, Jena, Germany). Live bacteria are stained green.  
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4.3. Genome analysis 
4.3.1. Genome properties and annotation 
 Using high throughput sequencing by the Illumina MiSeq platform, the complete 
genome sequences of KTN6 and KT28 were determined (Fig. 4.9 and 4.10).  
Figure 4.9: The circular representation of the KT28 genome. Blue arrows represent genes with predicted 
functions involved in DNA metabolism & replication, host infection and particle formation & host lysis. 
Grey arrows represent hypothetical proteins. Predicted (non-confirmed) promoters are labelled green while 
terminators red. The inner circle represents the GC content. 
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Figure 4.10: The circular representation of the KTN6 genome. Blue arrows represent genes with 
predicted functions involved in DNA metabolism & replication, host infection and particle formation & 
host lysis. Grey arrows represent hypothetical proteins. Predicted (non-confirmed) promoters are labelled 
green while terminators red. The inner circle represents the GC content. 
Both viruses carry a non-permuted, linear double-stranded DNA genomes with 
GC content of 55.64% and 55.51%, respectively for KT28 and KTN6 (Table 4.2).  
Table 4.2: General properties of phages KT28 and KTN6 and comparison to other Pbunaviruses. 
Phage Isolation details Year Genome size 
(%GC) 
ORFs Accession 
No. 
KT28 irrigated fields, Wrocław, Poland 2011 66,381 bp (55.6) 96 KP340287 
KTN6 irrigated fields, Wrocław, Poland 2011 65,994 bp (55.5) 91 KP340288 
PB1 Sewage, Edinburgh, Scotland 1960 65,764 bp (55.5) 93 NC_011810 
14-1 Sewage, Regensburg, Germany 2004 66,238 bp (55.6) 90 NC_011703 
F8 Unknown 1972 66,015 bp (55.6) 93 NC_007810 
LBL3 Pond, Blanes, Spain 2006 64,427 bp (55.5) 88 NC_011165 
LMA2 River, Maastricht, Holland 2007 66,530 bp(55.6) 95 NC_011166 
SN Lake, Pokrov, Russia 2004 66,390 bp (55.6) 92 NC_011756 
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Phage KT28 has a genome size of 66,381 bp and KTN6 of 65,994 bp. In total,  
94 and 91 open reading frames (ORFs) could be predicted, varying in size from 31  
to 1036 and 46 to 1036 amino acid residues, respectively. Function was predicted for 32% 
(31 genes - KT28) and 40% (36 genes - KTN6) (Table S 4.2 and 4.3). The genomes have 
little intragenic space (6.96% - KT28 and 7.06% - KTN6) and 18 overlapping start/stop 
codons in case of both phages. Genes are organized in operons alternating on both strands. 
Furthermore, 4 and 3 bacterial promoters with AT-rich intergenic motifs were identified, 
for KT28 and KTN6, respectively (Fig. 4.11 A). For KTN6 additional 4 phage promoters 
were found, recognizable by the sigma factor, a bacterial transcription initiation factor, 
that enables specific binding of RNA polymerase to gene promoters.  
Figure 4.11 Alignments of KT28 and KTN6 promoters. (A) Bacterial promoters prediction.  
The AT-rich intergenic motifs: -10 box and -35 box are marked with pink colour. The corresponding 
sequence logos from MEME/MAST are depicted below the alignments. On the left site are listed ORFs  
in front of which promoters are located, on the right side is sequence locus in the phage genome. (B) Phage 
promoters predicted for KTN6. On the right side is sequence locus in the phage genome. 
Further, 15 and 12 rho-independent transcription terminators were predicted, 
respectively for KT28 and KTN6 (Fig. 4.12). 
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Figure 4.12: The rho-independent transcription terminators in the genome of phage KT28 and 
KTN6. From the left site: list of ORFs after which terminators are located, strand and motif of terminator, 
terminator sequence with conserved stem-loop structures marked blue, dG (ΔG, the Gibbs free energy  
of stem-loop formation in kcal/mole) and location in phage genome. 
Only two enzymes involved in nucleotide metabolism could by predicted:  
a thymidylate synthase (KT28 gp62 and KTN6 gp59) and a polynucleotide kinase (KT28 
gp60 and KTN6 gp57). For DNA replication phages often use the DNA polymerase III 
enzyme, which consists alpha (KT28 gp58 and KTN6 gp 55) and epsilon (KT28 gp59 
and KTN6 gp56) subunits of the catalytic core. The first subunit catalyses  
the polymerization reaction and have two conserved motifs (342PDIDIDF and 
492LLKIDALG). Second is a DEDDh-type 3’-5’ exonuclease important  
in the polymerase proofreading activity (Bernad et al., 1989). These phages lack a phage-
encoded RNA polymerase and they depend entirely on the host transcriptional machinery. 
Probably the replication elongation is independent of the host machinery, due to presence 
in both phage genomes phage-encoded DNA primase (KT28 gp77 and KTN6 gp74) and 
helicase (KT28 gp56, gp57 and KTN6 gp53, gp54). 
The SDS-PAGE of CsCl purified KT28 and KTN6 virions presented a highly 
conserved banding pattern, which is consistent with the high sequence identity among 
Pbunavirus phages (Fig. 4.13). For both phages several structural proteins were predicted: 
two minor head proteins (KT28: gp20, gp21 and KTN6: gp17, gp18), 14 and 16 structural 
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proteins respectively, two baseplate related proteins (KT38: gp44, gp45 and KTN6: gp41, 
gp42), tail protein (KT28 gp47 and KTN6: gp44, gp38), tail fiber component (KTN6 
gp45), tail assembly protein (KT28 gp65 and KTN6 gp62) and tail tape-measure protein 
(KT28 gp96 and KTN6 gp91). 
 
 
 
 
 
 
 
 
Figure 4.13: Phage particle proteins separated on a 12% SDS-PAGE gel. From left to right, a LMW 
molecular weight marker (kDa) and structural proteins of KT28, KTN6 and PB1 phages.  
4.3.2. Comparative genome analysis and protein-sharing network  
Phages show 96.4% nucleotide similarity to each other, but when compared to other 
Pbunavirus phages (14–1, F8, LBL3, LMA2, PB1, SN) they display nucleotide similarity 
between 47.7 – 96.2% for KT28 and 46.9 – 96.6% for KTN6 (Tab. 4.3), with most 
similarity to LMA2, 96.2% and 96.6%, respectively.  
Table 4.3: The comparison of KT28 and KTN6 to sixn other Pbunavirus phages (14-1, F8, LBL3, 
LMA2, PB1 and SN) based on nucleotide similarity. Percent Identity Matrix created by Clustal2.1 
(http://www.ebi.ac.uk/Tools/msa/clustalw2/). 
Phage 14-1 F8 LBL3 LMA2 PB1 SN KT28 KTN6 
14-1 100 89 93 94 89 95 94 93 
F8 89 100 91 89 94 89 89 90 
LBL3 92 91 100 92 91 93 92 92 
LMA2 93 89 92 100 88 95 96 97 
PB1 89 94 91 88 100 88 88 89 
SN 95 89 93 95 88 100 96 95 
KT28 94 89 92 96 88 96 100 96 
KTN6 93 90 92 97 89 95 96 100 
 When comparing in silico the protein identity of these new phages to PB1 phage, 
71% of the proteins showed more than 90% similarity, especially in the regions 
responsible for particle formation & host lysis, and DNA metabolism & replication  
(Fig. 4.13). It confirms that the main core of Pbunavirus phage genomes is highly 
conserved. The largest protein variation was observed at the beginning and the end  
of the genomes.  
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Figure 4.14 shows the resulting network consisting of 274 phages belonging  
to the Myoviridae, Siphoviridae, Podoviridae, or uncharacterized and another phages, and 
4,928 relationships between them. In the network, KTN6, KT28, and other 13 phage 
members belonging to Pbunavirus group, together with Bcep78virus phages, were 
primarily placed into a small component at the periphery. Aaphi23 bridged such 
component comprising two phage groups with the largest component, whereas B054 
linked to JG024, PB1, and 14–1; both of which are temperate phages (Dorscht et al., 
2009; Resch et al., 2004). In addition, JG024 showed connections with the two 
mycobacteriophages PBI1 and PLot. 
Figure 4.14: Protein-sharing network and reticulate relationship of Pbunavirus-related and 
Bcep78virus-related phage populations. (A) A network representation was produced using the edge-
weighted spring embedded layout of Cytoscape version 3.1.1. Nodes indicate phages and edges between 
two nodes indicate their statistically weighted pairwise similarities with significance (Sig) scores of >1.  
In this way, 4,928 edges from 274 phages, including KTN6, KT28, and additional Pbunavirus phage 
members (JG024, PB1, 14–1, NH-4, SPM-1, LMA2, LBL3, KPP12, and SN) are shown and 159 phages 
that did not show any connections to those candidate phages were excluded for clarity. The node color 
corresponds to a given ICTV taxonomic classification of the Myoviridae, Siphoviridae, and Podoviridae, 
and uncharacterized and other phages. (B) Assigning of the phage clusters onto population network 
composed of interactions among Pbunavirus phages, Bcep78virus phages, Aaphi23, and others. Node pie 
charts show the proportion of homogeneity (membership) as estimated by estimating the proportion  
of the weight of connections to a given node to the nodes within a particular cluster. A color code for each 
cluster is represented in the legend box. Each membership value relevant to the represented phage  
is illustrated as the membership matrix in the lower panel. 
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To validate their positioning in the network, we used two classical population 
topologies such as the clustering coefficient (the extent to which the neighbors of a given 
node are interlinked) and the betweenness (a centrality estimating the proportion  
of shortest paths that pass through a node) (Assenov et al., 2008). We found that with  
the highest clustering coefficient of 1 (1 means absolute cohesiveness) (Table 4.4), 
Pbunavirus phages including KTN6, KT28, F8, NH-4, SPM-1, LMA2, LBL3, KPP12, 
SN, ECML-117 and BcePB1A were tightly interconnected with Bcep78virus phages, 
implying their closest evolutionary relationship. However, compared to Pbunavirus 
members of a given component, JG024, PB1, and 14–1 showed lower clustering 
coefficients and higher betweenness distributions due to their more connected parts. 
Aaphi23 can be characterized by one of the highest betweenness node in the network. 
Table 4.4: Clustering coefficient and betweenness centrality in the protein-sharing network of phage 
Aaphi23, and Pbunavirus/Bcep781-like phages. 
Names 
Clustering 
coefficient 
Betweenness 
centrality 
Aaphi23 0.56084656 0.10306764 
JG024 0.76679842 0.03102882 
141 0.91904762 0.0092124 
PB1 0.91904762 0.0092124 
KT28 1 0 
KTN6 1 0 
SN 1 0 
BcepF1 1 0 
OP2 1 0 
Bcep781 1 0 
KPP12 1 0 
LBL3 1 0 
BcepNY3 1 0 
LMA2 1 0 
Bcep1 1 0 
Bcep43 1 0 
F8 1 0 
ECML 1 0 
SPM1 1 0 
NH-4 1 0 
BcePB1A 1 0 
Furthermore, we retrieved the reticulate clusters of Pbunavirus and Bcep78virus 
phages with the methodology used by Lima-Mendez et al. (2008), in which the weight  
of intracluster connection of a phage, called the membership, is used to differentiate 
cluster and membership > 0.79 can be a rough estimate of vertical evolution. In this 
reticulate classification, most phage members were highly assigned to their respective 
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ICTV genera with membership > 0.97 (Fig. 4.14). Notably, BcepF1, ECML-117, and 
BcePB1A showed lower memberships to PB1 cluster ranging from 0.841 to 0.948, which 
is consistent with their marginal relationships to Pbunavirus phages (Lavigne et al., 2009; 
Carter et al., 2012). Also, OP2 displayed a lower membership to Bcep781 cluster = 0.640 
and thus more divergent among Bcep78virus members. 
4.3.3. The lysis cassettes of KT28 and KTN6 
Both analyzed phages have a globular endolysins, KT28 gp48 and KTN6 gp46, 
encoding lysozyme-like domains. A detailed description and experimental analysis  
is given in Chapter 8. Moreover, structural proteins KT28 gp41and KTN6 gp38 carry  
a transglycosylase SLT (soluble) domain (98.47% amino acid similarity, Clustal Omega) 
(Fig. 4.15), that degrade murein via cleavage of the beta-1,4-glycosidic bond between  
N-acetylmuramic acid and N-acetylglucosamine, with the concomitant formation  
of a 1,6-anhydrobond in the muramic acid residue. The muralytic activity of gp38 and 
gp41 was confirmed by use of a zymogram assay, showing specific degradation  
of peptidoglycan of autoclaved P. aeruginosa PAO1 cells upon phage protein 
renaturation (data shown in Chapter 8). These murein hydrolases assist the efficient DNA 
transfer to the host cell. 
Figure 4.15: The KT28 gp41 (above) and KTN6 gp38 (below) transglycosylase domains predicted  
by InterPro (www.ebi.ac.uk/interpro/). 
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 The general features of KT28 and KTN6 phages are summarize in table 4.5. 
Table 4.5: Major features of KT28 and KTN6 phages. 
Phage KT28 KTN6 
Water source Irrigation field 
City/Country/ Date Wrocław/Poland/ 2011 
Host PAO1 
Genome size (bp) 66,381 65,994 
GC (%) 55.64 55.51 
ORFs 94 92 
Unique ORFs 1 - 
Virion dimensions head/tail [nm] a 74/136 72/123 
Latent period [min] 35 35 
Burst size [pfu/cell] 65 96 
Heat stability for 1h [ºC] 40 - 70 40 - 70 
pH stability for 1h at RT 3 - 12 3 - 12 
Chloroform sensitivity at RT/4 ºC [h] 24 24 
Phage infectivity inhibition by LPS (PI50) [ug/ml] a 36.0 43.3 
LPS-binding assay [OD 450nm]a 0.74 0.75 
Biofilm eradication [CFU reduction] a  70 - 80% 70 - 90% 
Pyocyanin production inhibition in biofilm structure b + + 
Pyoverdin production inhibition in biofilm structure b + + 
Increase of diffusion though biofilm structure b + + 
Biofilm eradication measured by goniometry analysis b + + 
aExperiment performed by Department of Pathogen Biology and Immunology, Institute of Genetics and 
Microbiology, University of Wrocław, Wrocław, Poland (Danis-Wlodarczyk et al., 2015).  
bExperiments performed by Department of Microbiology, Institute of Biology and Department  
of Molecular Physics, Institute of Physics, The Jan Kochanowski University in Kielce, Kielce, Poland; 
Department of Pathogen Biology and Immunology, Institute of Genetics and Microbiology, University  
of Wrocław, Wrocław, Poland (Danis-Wlodarczyk et al., 2015). 
4.4. Discussion 
Microbiological characteristics 
The virions of newly isolated KT28 and KTN6 show characteristic features  
of Pbunavirus with respect to head/tail size and LPS host receptor recognition.  
The activity of phage virions was inhibited by 36.0 μg/ml and 43.3 μg/ml of pure LPS for 
KT28 and KTN6, respectively. The KT28, with a larger genome encapsulated in a bigger 
virion, exhibits the same latent period, but much lower burst size in comparison to KTN6 
phage (64 ± 0.98 pfu/cell versus 96 ± 0.2 pfu/cell). Both phages possess similar 
susceptibility to chemical and physical agents such as high temperature, chloroform and 
pH. Phage infectivity tested on clinical strains revealed that both phages have broad host 
range. However, phage KTN6 was more potent than KT28, propagating on 68% versus 
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60% of the strains, respectively. The broad host range was also observed in case  
of other, previously described Pbunaviruses, such as LBL3, SN (Plenteneva et al., 2009) 
or 14-1 (Merabishivili et al., 2009). 
Biofilm matrix degradation 
The opportunistic pathogen P. aeruginosa has evolved a number of virulence 
features including: (i) biofilm formation, (ii) secretion of factors that impair neutrophil 
phagocytosis and activation, (iii) type III secretion system-dependent cytotoxicity 
(Dacheux et al., 2000; Mahajan-Miklos et al., 1999). Antibacterial therapies using these 
newly isolated phages may target all the above features to reduce the severity of infection 
and increase the efficacy of immune response in the bacteria eradication process. In this 
chapter we presented only preliminary evaluation of biofilm degradation ability of KT28 
and KTN6 phages. Further experiments were conducted by the Drulis-Kawa group and 
collaborators on both peg-lid plate assay and PET membrane surface (Danis-Włodarczyk 
et al., 2015) (data not shown). Their results showed that biomass evaluation  
by CV staining was not sensitive enough to detect any significant changes after phage 
treatment. Moreover, CV staining revealed unstable results with high standard deviations. 
As a consequence, other methods were used to evaluate phage potency to affect biofilm 
forming bacterial cells. For this purpose, a colony count technique was applied,  
the analysis of pyocyanin and pyoverdin secretion by spectrophotometry and fluorometry  
as well as laser interferometry and goniometry for the growth medium diffusion through 
biofilm matrix analysis. The standard CFU evaluation revealed a significant reduction 
(70% - 90%) in 24 - 72 h old biofilm cultures for both Pbunavirus phages treatments, 
suggesting that phage particles were able to penetrate the biofilm matrix. Both active 
phages showed also a strong inhibitory activity on P. aeruginosa biofilm, regardless  
of the bacteria origin (laboratory, clinical isolate from wound infection and clinical isolate 
from CF patient). Furthermore, phage KT28 was able to influence the amount  
of pyoverdin secreted by PAO1 strain and burn wound isolate 0038. The KTN6 phage 
affected only 72 h old culture in active form, but of all three tested strains. Moreover,  
the amounts of the most important dyes secreted by the Pseudomonas (pyocyanin and 
pyoverdin) decreased significantly, which may prove the potency of isolated phages  
to be applied as efficient antibacterials in Pseudomonas biofilm treatment. Further 
analysis, including diffusion and goniometry experiments, support this statement.  
The increase of diffusion rate through the biofilm matrix after phage application, 
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indicated the degradation of the biofilm structure associated with the loss of biofilm 
matrix elements on membrane surface and the reversion to hydrophobic properties  
of membrane, or partial degradation of matrix/biofilm structure. The increase  
of the diffusion was also obtain after the application of UV inactivated particles, 
suggesting that both tested phages KT28 and KTN6 are equipped with exopolysaccharide 
depolymerases responsible for phage particle spread within the biofilm matrix, however 
gene identification was difficult due to lack of homology in available databases.  
Unfortunately, the biofilm treatment by these phages caused also the emergence  
of phage-resistant variants of P. aeruginosa from the biofilms. The persistent cells turned 
out to be cross resistant to both phages, probably by the loss or changes in O-antigen 
structure. This feature was relatively stable and persistent bacteria had a small colony 
variant morphology. It may put the applicability of Pbunavirus phages into question, 
although such enveloped modification may also decreases the fitness of the microbe and 
made them more susceptible to immune system defense.  
Genome features  
Using high throughput sequencing by the Illumina MiSeq platform, the complete 
genome sequences of KTN6 and KT28 phages were determined. The GC content (55.64% 
and 55.51%, respectively for KT28 and KTN6) is fairly constant throughout the genome 
and significantly lower than that of their host P. aeruginosa (66.6%). The genomes  
of both phages present high degree of DNA sequence similarity to the other Pbunavirus 
representatives. The biggest sequence variations occurred at the beginnings and  
at the ends of genomes. The ORFs are organized in operons situated on both strands and 
closely packed with little intergenic species (6.96% - KT28 and 7.06% - KTN6) and 
several overlapping start/stop codons.  
Function was predicted for only 32% (31 genes-KT28) and 40% (36 genes-
KTN6), including proteins involved in nucleotide metabolism & replication, host 
interaction and well as several structural proteins. Numerous small genes encoded 
proteins with unknown function. These phages lack phage-encoded RNA polymerases 
and are entirely dependent on host transcription, as was observed in other Pbunaviruses, 
such as LBL3, LMA2, 14-1 and SN (Ceyssens et al., 2009). Phages from this clade have 
also a highly conserved proteome pattern, which is consistent with the high sequence 
identity among phages from this genus.  
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Furthermore, both phage genomes encode a globular endolysins, KT28 gp48 and 
KTN6 gp46 with lysozyme-like domains, and proteins with transglycosylase SLT domain 
(KT28 gp41 and KTN6 gp38), that have potential ability to degrade bacterial 
peptidoglycan.  
Protein-sharing network  
Genome comparison showed that KT28 and KTN6 are highly related  
to the widespread and conserved Pbunavirus phages. This group of viruses shows a high 
sequence similarity and limited horizontal gene transfer (Ceyssens et al., 2008).  
To investigate genome evolution of KTN6 and KT28, we used a mathematical model  
of protein-sharing network, extending to probable close relatives. A graphical 
representation of the network can reveal several evolutionary connections of Pbunavirus 
-related genomes to other phage genomes. A major observation is that most  
of the Pbunavirus members were densely interconnected to those of the Bcep781virus 
group, as measured by their clustering coefficients. Such near-one clustering indicates  
the conservation of a core genome among those two groups (Lima-Mendez et al., 2008). 
However, more importantly, they did not form a single group due to multiple connections 
of JG024, PB1, and 14–1 of the Pbunavirus group to the temperate phage B054 (Dorscht 
et al., 2009) or two mycobacteriophages PBI1 and PLot. Based on this observation, two 
homologous genes were observed which only exist in all six corresponding phages and 
their positions in the limited conservation regions of the genomes of JG024, PB1, and 
14–1 (Dagan, 2011); ORF 13 of JG024 and 14–1, and ORF 94 of JG024 and PB1, and 
ORF90 of 14–1. This may indicate that gene gain or loss in such variable regions could 
be important for their diversity, despite the limited lateral gene transfer in Pbunavirus 
group (Ceyssens et al., 2009). Such interesting links are revealed through our 
evolutionary reconstruction of gene phylogenies (Dagan, 2011). In addition, another 
temperate phage Aaphi23, that shows some chimeric features (Lima-Mendez et al., 2008; 
Resch et al., 2004), acts as a bridge for both Pbunavirus and Bcep781virus groups. This 
reflects the tendency of temperate phage-mediated genetic exchange between strictly lytic 
phages, Pbunavirus and/or Bcep781virus phages, and the rest of the phage population 
(Lima-Mendez et al., 2008; Lawrence et al., 2002). Collectively, together with a reticulate 
classification, our phage population network revealed that Pbunavirus and Bcep781virus 
phages most likely have diverged through vertical evolution with some vertically 
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inherited modules and their ancestral relationship might be beyond the genus level  
at the subfamily level. 
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Contribution 
 TEM phage visualisation and morphology analysis was performed by Hans-W. 
Ackermann (Department of Microbiology-Infectiology and Immunology, Medical 
School, Laval University, Quebec, Canada) and Sylwia Nowak, technician  
of University of Wrocław.  
 Time-lapse microscopy experiment was conducted in the Centre for Food and 
Microbial Technology (Prof. Abram Aertsen, KU Leuven, Belgium) with a help  
of Dr. William Cenens. 
 ASL and biofilm experiments were performed during research visit in Department  
of Molecular Medicine, Royal College of Surgeons in Ireland, Education and 
Research Centre, Beaumont Hospital, Dublin, Ireland (Prof. Brian J. Harvey) with 
the support of Dr. Gerard Higgins and Dr. Jean Tyrrell.  
 The protein-sharing network was constructed and analyzed by Dr. Ho Bin Jang 
(Laboratory of Gene Technology, KU Leuven, Belgium) and Katarzyna Danis-
Włodarczyk. 
 ESI-MS/MS was conducted in Biomedical Research Institute and Transnationale 
Universiteit Limburg, School of Life Sciences, Hasselt University, Diepenbeek, 
Belgium (Prof. Jean-Paul. Noben). 
 All remaining experiments and analyses were performed by Katarzyna Danis-
Włodarczyk. 
5.1. Introduction 
To date, over twenty φKZ-related phages have been found in diverse geographic 
locations. They belong to a group of “giant” myoviruses and are infective for a variety  
of Pseudomonas species (Krylov et al., 2007). Typically, they have a very large 
icosahedral head, ~122 nm in diameter, and a long (~190 nm) contractile tail surrounded 
by fibers. The capsid contains an inner body, which has been speculated to organize  
the packaged DNA (Fokine et al., 2007; Krylov et al., 1984). Furthermore, φKZ-related 
phages have an exceptionally large and complex circularly permuted, and terminally 
redundant linear dsDNA genomes (between 211 and 317 kb) (Mesyanzhinov et al., 2002; 
Thomas et al., 2008 and 2012). They display a pronounced difference in GC content  
(36.8 - 48%) and all have markedly lower GC content than the chromosomes of their GC-
rich Pseudomonas hosts (60 to 66% GC) (Cornelissen et al., 2012).  
The φKZ-related phages have diverged strongly from the Myoviridae and present  
a higher divergence rate than T4virus genus or host genomes (Thomas et al., 2008 and 
2012). Therefore, a straightforward functional assignments of their encoded proteins has 
been seriously hampered even for the conserved core genes (e.g. those encoding tail 
fibers, baseplate module and DNA polymerase), as a result of low protein sequence 
similarity. Nevertheless, the φKZ-related phages and their gene products are important 
due to their potential to control pathogenic pseudomonads (Briers et al., 2008; 
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Miroshnikov et al., 2006; ParadisBleau et al., 2007; Mesyanzhinov et al., 2002) and 
genetically manipulate their hosts (Monson et al., 2011). Representative of Phikzvirus 
clade, φKZ, have already been incorporated into traditional phage therapy cocktails and 
continue to be examined for novel therapeutic applications [e.g., (Golshahi et al., 2011; 
Matinkhoo et al., 2011)].  
In this chapter we describe the morphology, genome organization, biology and 
antibacterial potential of a novel φKZ isolate KTN4, a potentially suitable candidate for 
in vivo phage therapy. 
5.2. Microbiological characteristics 
5.2.1. Isolation and morphology  
Lytic phage KTN4 was isolated from sewage samples collected from irrigated 
fields located in Wrocław, Poland. After purification phage titres were 1010–1011 pfu/ml 
and caused ~1.7 mm wide clear plaques with halo zone on 0.6% soft agar (Fig. 5.1).  
The KTN4 morphology was examined by TEM and classified to the Phikzvirus, order 
Caudovirales, family Myoviridae (Fig. 5.1). The isolate was formally named 
vB_PaeM_KTN4 (KTN4). The size of icosahedral head can be estimated at 130 nm 
between opposite apices, the contractile tail 168 nm long surrounded by fibers.  
Figure 5.1: Particle analysis of the KTN4 phage. From left to right, an electron microscopic image with 
the scale bar representing 100 nm, a CsCl gradient purification (4 different CsCl densities are marked:  
1.33 g/ml, 1.45 g/ml, 1.50 g/ml, 1.70 g/ml; phage band bracketed in red), plaque morphology  
on P. aeruginosa PAO1 Krylov reference strain. 
5.2.2. Phage infection  
One-step growth experiments indicated a latent period of 40 min and a burst size  
of about 8 ± 2 phage particles per infected bacterial cell (Fig. 5.2). 
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Figure 5.2: The one-step growth curve of phage KTN4. An equal volume of bacterial culture  
(at OD 600 of 0.4, 108 cfu/ml) was mixed with phage suspension (106 pfu/ml) to obtain a multiplicity  
of infection (MOI) of 0.01. Phages were allowed to adsorb for 8 min at 37 °C . Triplicate samples were 
taken during 65 min at 5 min intervals and titrated. The phage titre [pfu/cell] of the solution was assessed 
using the double-agar layer technique, according to methods described by Adams (1959). Latent period  
of 40 min and burst size of 8 ± 2 phage particles per infected bacterial cell were established. A trend line  
is marked with dots. All data are collected from three independent experiments, standard deviations are 
indicated. 
5.2.3. Time-lapse microscopy 
In order to specifically tract in the real time the P. aeruginosa during KTN4 
infection, a time-lapse microscopy was applied. P. aeruginosa PAO1 cells were grown 
to mid-exponential phase (OD600 of 0.6) and infected by CsCl purified KTN4 phage  
1010 pfu/ml (MOI 10) on a PBS - 0.2% agar pad, for observation under the phase-contrast 
microscope. In the early stage of infection (between 2 and 5 min post infection) the small 
circular mass was observed, which migrates toward the cell midpoint and increases  
in size (Fig. 5.3 I, II, white arrow). It is likely the site of genome encapsidation as it was 
previously demonstrated by Kraemer et al., 2012. After arrival at midcell, circular mass 
(presumably the phage nucleoid) oscillates slightly about the central axis (Fig. 5.3 IV, V). 
In further step of infection, bacteria cell continues to increase in size to finally achieve  
a significantly enlarged lemon-like shape (Fig. 5.3 V, VI). Around 30 min post infectoin, 
bacterial cell burst and phage progeny was released (Fig. 5.3 VI and 5, 6). The latent 
period of KTN4 achieved in this experiment cannot be compared to one step growth 
experiment, due to different conditions. 
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Figure 5.3: Time-lapse microscopy of the P. aeruginosa PAO1 infected by phage KTN4 on a 0.2% 
PBS-agar pad. A snapshots were taken from the start of phage infection, MOI 10, using a Nikon Eclipse 
Ti Time-Lapse Microscope. (1 - 6) snapshots taken every 15 min post infection, scale bare represents 10µm. 
(I - VI) zoom snapshots on a group of a P. aeruginosa PAO1 infected cells, scale bare represents 5 µm. 
The white arrow marks the small circular mass, that migrates from cell pole toward the cell midpoint and 
increases in size. 
5.2.4. Stability tests 
The KTN4 phage is relatively stable in a broad range of temperature and pH.  
No reduction in titre was observed over a period of 60 min at a temperature range  
of 40 - 70°C and after 30 min incubation at 80°C. After 45 min incubation at 80°C and 
30 min at 90°C the phage titer decreased by 4 log units. Between 30 and 60 min incubation  
at 90°C the titer dropped by 6 log (Fig. 5.4). After incubation at 100°C, KTN4 particles 
were inactivated. 
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Figure 5.4: The temperature stability of phage KTN4. Each bar represents the mean of three independent 
experiments, error bars indicate the standard deviation. Results obtained with spot test.  
After 1 hour incubation at room temperature at pH between 6 and 12 phage remain 
stable. At pH 3 - 5 a 1 log and at pH 2, a 2 log reduction in phage titer was observed.  
At pH 1 KTN4 phage is immediately inactived (Fig. 5.5).  
 
 
 
 
 
 
 
Figure 5.5: The pH stability of KTN4 phage. Phage titers (pfu/ml) were validated at the different pH 
values after 1h exposure at room temperature. Each bar represents the mean of three independent 
experiments, error bars indicate the standard deviation. Results obtained with spot test.  
Furthermore, no significant change in KTN4 titer was observed after incubation 
with chloroform (an equal volume of phage solution and chloroform) for 1 h incubation  
at room temperature and at 4 °C (Fig. 5.6). 
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Figure 5.6: The KTN4 phage stability against chloroform treatment. Phage titers (pfu/ml) were 
validated after chloroform treatment for 1 h and 24 h incubation at room temperature (RT) and at 4 °C. Each 
bar represents the mean of three independent experiments, error bars indicate the standard deviation.  
Results obtained with spot test.  
5.2.5. Determination of phage receptor  
In the study based on knock-out P. aeruginosa PAO1 mutants it was observed that 
KTN4 requires the IV type pili on the host cell surface as its receptor (Table 5.1). 
Table 5.1. The KTN4 phage receptor identification on P. aeruginosa PAO1 mutants. 
+ activity, bacterial lysis. - no activity. 
 
Bacterial strain Phenotype Origin KTN4 φKZ 
PAO1 (ATCC 
15692) 
Wild type American Type 
Culture Collection 
+ + 
PAO1 Pirnay Wild type with inactive type IV pili Military Hospital 
Nederoverheembeek, 
Brussels, Belgium,  
- - 
PAO1 Krylov Wild type + + 
PAO1 Δrmd  
(A-, B+) 
Deficiency in D-rhamnose 
biosynthesis; lack of A-band LPS 
 
 
Department  
of Molecular and 
Cellular Biology,  
University  
of Guelph, Canada  
+ + 
PAO1 ΔrmLC 
(A-, B-, core-) 
Deficiency in L-rhamnose 
biosynthesis; truncate core region, 
lack of A-band and B-band LPS 
+ + 
PAO1 ΔwaaL 
(A-, B-) 
Lack of WaaL ligating O-polymer  
to core-lipid A; LPS is devoid of A-
band and B-band, semirough (SR-
LPS, or core-plus-one O-antigen) 
+ + 
PAO1 ΔwbpL 
(A-, B-) 
Lack of glucosyltransferase WbpL 
essential for initiation of both A-band 
and B-band synthesis 
+ + 
PAO1 ΔfliC 
ΔalgC ΔpilA 
Lack of flagella; lack of AlgC 
required for A-band, core 
oligosaccharide, and alginate 
 
 
 
Technical University 
Hamburg, Germany,  
- - 
PAO1 ΔfliC  
wt algC ΔpilA 
Lack of flagella; lack of type IV pili - - 
PAO1 ΔfliC  
wt algC wt pilA 
Lack of flagella + + 
PAO1 wt fliC 
wt algC wt pilA 
Wild type + + 
1,00E+00
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5.2.6. Host range analysis 
The lytic activity of KTN4 was examined on Pirnay’s Pseudomonas panel. This 
phage isolate was able to infect 35% of tested strains. However, the highly similar phage 
φKZ exhibits a broader host range, lysing 37% (Table S 4.1). This observation was also 
confirmed in the study of de Soyza et al. (2013), where KTN4 lytic activity was tested 
against the LMG Pseudomonas panel. In this case KTN4 was able to infect 33% isolates, 
compared to 46% for φKZ. 
To explain host range discrepancy between these highly similar phages, several 
proteins involved in infection process were compared between KTN4 and φKZ genomes 
(a detailed description is provided in section 5.3.3.). Proteins involved in tail apparatus, 
lysis cassette, nucleotide metabolism and DNA replication as well as β/β′-like virion-
associated non-canonical multi-subunit viral RNA polymerases (RNAP) present high 
similarity (99% - 100%) to their φKZ counterparts (Table 5.2, section 5.3.3.). However, 
when intron-encoded endonucleases and non-virion RNA polymerase subunits 
(nvRNAP) were examined significant variations between both phages were observed 
(Mesyanzhinov et al., 2002, Yakunina et al. (2015) (Table 5.2, section 5.3.3.).  
This analysis suggest, that there are no differences in host receptor recognition, 
destabilization of bacterial peptidoglycan as well as DNA metabolism and RNSP. 
Potentially the host range discrepancy could be related with variations between 
replication and DNA modification genes.  
5.2.7. Phage influence on biofilm  
To initially evaluate KTN4 biofilm eradication ability, 24 h and 48 h old  
P. aeruginosa PAO1 biofilms were grown on 8-well slide microscopy chambers and 
further infected with KTN4 phage suspension (8.5 × 1010 pfu/ml, 24 h incubation  
at 37°C). The experiment was conducted as described previously in chapter 4 section 
4.2.6., where treatment with LB medium served as a negative control and a high dose  
of gentamicin (400 µg/ml) as a positive control. Biofilms were stained with the use  
of LIVE/DEAD BacLight Bacterial Viability Kit and visualized by confocal laser 
scanning microscopy (Fig. 5.7). We observe that in both 24 h and 48 h old biofilms, KTN4 
and gentamicin treatments alter the structure of the biofilm compared to the control.  
The untreated biofilm has a dense structure, of which the thickness increases over time. 
However, after both phage or gentamicin treatments, the biofilm structure is less dense 
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and has clear areas of biofilm disruption. This study shows the initial KTN4 antibiofilm 
activity, which was further evaluated with more qualitative and quantitative techniques 
by Drulis-Kawa group (Department of Pathogen Biology and Immunology, Institute  
of Genetics and Microbiology, University of Wrocław, Wrocław, Poland) and 
collaborators (Department of Microbiology, Institute of Biology and Department  
of Molecular Physics, Institute of Physics, The Jan Kochanowski University in Kielce, 
Kielce, Poland and Zeta Instruments Co., San Jose, USA). Results are published in Danis-
Wlodarczyk et al., 2016. 
Figure 5.7: Antibiofilm activity of phage KTN4. The 24 h (A) and 48 h (B) old biofilm. 1) negative 
control: biofilm treated with LB broth; 2) positive control: biofilm treated with gentamicin (400 µg/ml);  
3) KTN4 treatment (8.5 × 1010 pfu/ml). Biofilms were grown at 37°C, 5% CO2, stained with  
the LIVE/DEAD BacLight stain (LIVE/DEAD BacLight Bacterial Viability Kit) and visualized by confocal 
laser scanning microscopy (Zeiss LSM 510 Meta 40 × objective, Jena, Germany). Live bacteria are stained 
green.  
5.2.8. Antibacterial efficacy of KTN4 phage analyzed in gentamicin 
exclusion assay on Airway Surface Liquid infection model 
In our study, the in vitro antibacterial activity of KTN4 phage was assessed  
in a gentamicin exclusion assay on Airway Surface Liquid (ASL), which is to our 
knowledge, the first report showing phage treatment efficacy in that infection model.  
For experiments, two cell lines were selected: 1) NuLi-1 derived from normal human 
bronchial epithelium and 2) CuFi-1 derived from CF patient bronchial epithelium with 
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significantly thinner ASL (Zabner et al., 2003). Three P. aeruginosa strains were selected 
for these experiments: PAO1 reference strain (piliated, motile strain, effective biofilm 
former), a nonCF0038 isolate from burn wound (highly expressing type IV pili), both 
reflecting CF early colonizing isolates, which are non-mucoid with typically smooth LPS 
and more virulent. The third strain was CF708 from late infection phase, presenting 
slowly growing and less virulent small colony variants with low expression of type IV 
pili, and biofilm formation (Olszak et al., 2015).  
Several controls of epithelial cells viability were prepared at different points  
of the experiment: (i) a negative control without any treatment, (ii) a negative control with 
TC media; (iii) a positive control with Triton-X100; (iv) 1.5 h after KTN4 application; 
(v) 1.5 h after Pseudomonas infection. The Nuli-1 and CuFi-1 cells were stained with 
8 μM Calcien AM (live staining) (Life Technologies, NY, USA) and 3 μM propidium 
iodide (PI) (dead staining) (Life Technologies, NY, USA) according to manufacturer’s 
instructions. After staining, in all cases, filter inserts were XZ scanned using a confocal 
microscope (Zeiss LSM 510 Meta 40 × objective, Jena, Germany). No toxicity influence 
of the cell lines was observed for phage and bacteria samples after 1.5 h (Fig. 5.8). 
Figure 5.8: Live/dead staining of lung epithelia cells prepared at different time points of experiment.  
(1) a negative control without any treatment, (2) a negative control with TC media; (3) a positive control 
with Triton-X100; (4) 1.5 h after KTN4 application; (5) 1.5 h after Peudomonas infection. Cells were 
imaged using confocal microscopy (Zeiss LSM 510 Meta 40 × objective, Jena, Germany).  
 First, both epithelial cell lines were infected with selected strains for 3 h and 
colony count showed P. aeruginosa efficiently propagated in both ASLs (107 - 109 cfu/ml) 
(Fig. 5.9). Although PAO1 and nonCF0038 pathogens grew better on NuLi-1 cell line, 
reaching around 1 log higher compared to CuFi-1 ASL, no statistically significant 
differences have been found (p > 0.05). The small colony variant CF708 grew equally 
well in both types of mucus layer. In the second step of experiment, the KTN4 phage 
eradication ability of the extracellular bacterial load was evaluated. The CFU counts  
of P. aeruginosa were significantly (p < 0.05) reduced for normal NuLi-1 epithelia cells. 
A 7 log, 6 log and 4 log decrease was observed for PAO1, nonCF0038 and CF708, 
respectively (Fig. 5.9 A). In the case of the CuFi-1 epithelia, the phage treatment was also 
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very effective, giving 4 log, 6 log and 5 log reductions in the colony count of PAO1, 
nonCF0038 and CF708 (p < 0.05), respectively (Fig. 5.9 A). PAO1 was significantly 
more susceptible (p < 0.05) to phage treatment in NuLi-1 cells compared to CuFi-1 cells, 
contrary to the CF708 isolate. It was confirmed that the KTN4 phage could freely diffuse 
and gain access to the bacterial hosts in both ASL models, but the outcome  
of the treatment was strongly dependent on the strain features or were influenced  
by the differences in ASL pH between NuLi-1 and CuFi-1 cells. A possible explanation 
of this phenomenon was observed by Worlitzsch’s studies (2002) where P. aeruginosa 
was not interacting with the CF epithelium directly, but was rather found trapped in mucus 
plugs formed in the airways. Thus, the phage receptors could be masked by mucus 
elements, which have an influence on phage adsorption to bacterial cell surface. 
Moreover, the CF strain is better adapted to CuFi-1 environment and may presumably 
express the type IV pili more efficiently, which are receptors for KTN4 phage. 
Figure 5.9: Phage KTN4 treatment of P. aeruginosa infected NuLi-1 and CuFi-1 epithelial cells.  
(A) Colony count of bacteria collected from apical wash; (B) colony count of bacteria internalized  
in epithelial cells. The results are presented as the means ± SD. Statistical analysis was made  
by the ANOVA test (denoted p-values < 0.05) (Danis-Wlodarczyk et al., 2016). 
In the next step of our experiment, the ability of P. aeruginosa strains to invade 
into epithelial cells was investigated (Fig. 5.9 B). Although P. aeruginosa was generally 
thought to be an extracellular pathogen, a number of different groups have found that  
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it can be internalized into a range of different cell types, including epithelial cells 
(Schroeder et al., 2001; Fleiszig et al., 1995). The results showed that CF and non-CF 
strains could indeed be internalized into both cell lines. No statistically significant 
differences (p > 0.05) were observed for all pathogens. Nonetheless, the PAO1 and 
nonCF0038 were less internalized into the epithelial cells compared to the CF708 isolate, 
where only 4.50E-05% and 2.00E-04–5.00E-05% of infecting population were able  
to internalize into NuLi-1 and CuFi-1 cells, respectively, in contrast to 0.05% and 0.06% 
for the CF708 isolate. Therefore, internalization capability and adaptations of CF708 
strain was more effective compared to the nonCF strains, consistent with previous 
observations (Fleiszig et al., 1995). This suggests that the Pseudomonas strains with high 
cytotoxicity are low invasive and vice versa, bacteria that are less virulent enter  
the epithelial cells to survive intracellularly without killing the host cell. 
In the final step, the influence of KTN4 phage treatment on the number of invaded 
bacteria was evaluated (Fig. 5.9 B). In the NuLi-1 cell line there were no significant 
changes (p > 0.05) in CFU counts for all P. aeruginosa invading strains after phage 
application. A possible explanation is that during the 3 h of pretreatment, all bacterial 
cells were already internalized, thus the phage had no access to these host cells.  
In contrast, the phage application was significantly more effective (p < 0.05) for CuFi-1 
internalization prevention by wild type P. aeruginosa strains, since CF lung cells due  
to lack of CFTR, show significantly less ingestion rate of LPS-smooth bacteria and 
significantly greater lung burdens post-infection than wild-type epithelium (Schroeder  
et al., 2001). As previously mentioned (Worlitzsch et al., 2002), wild strains not well 
adopted to the ‘sticky’ and dense CF environment are absent on epithelial surface. They 
remain as macrocolonies within intraluminal material, slowing down efficient 
internalization. Simultaneously, phage application cause effective eradication of bacterial 
cells trapped in the mucus plugs. The CF708 isolate evolving in CF lung environment  
is able to internalize with the CuFi-1 epithelium in relatively short time after infection 
evading phage lytic activity. 
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5.3. Genome analysis  
5.3.1. Genome properties  
Using high throughput sequencing by the Illumina MiSeq platform, the complete 
genome sequence was determined. KTN4 has a linear, circularly permutated and 
terminally redundant, A+T-rich (36.9% GC) double-stranded DNA molecule  
(279,593 bp) (Fig. 5.10).  
Fig. 5.10: Circular representation of the KTN4 genome. Blue arrows represent genes with predicted 
functions, grey arrows represent hypothetical proteins. The inner circle represents the GC content. 
Structural proteins, which presents was confirmed by ESI-MS/MS analysis are marked with red dots.  
The KTN4 genome was deposited at GenBank under accession number KU521356. 
In total, 368 ORFs could be predicted, varying in size from 36 to 2237 amino acid 
residues (Table S 5.1), as well as six tRNAs (Leu (UUA), Pro (UUG), Met (CAU),  
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Asp (GUC), Asn (GUU), Thr (UGU). Only 87 proteins have a predicted function. 
According to the orientation of transcription, the ORFs are organized into 134 operons 
most of which are on a positive strand. The KTN4 shows a genome-wide nucleotide 
sequence similarity to: φKZ 99%, PA7 99%, phiPA3 84%, 201phi2-1 78% (BLASTN). 
As such, it can be defined as an isolate of the Pseudomonas phage φKZ species. However, 
there are a few significant differences. Nineteen additional proteins of unknown function 
are present in KTN4 genome (gp14, gp23, gp24, gp25, gp26, gp30, gp31, gp32, gp34, 
gp59, gp75, gp93, gp94, gp150, gp286, gp287, gp315, gp321, gp357) and absent in the 
φKZ genome. Also 17 φKZ proteins of unknown function are missing in KTN4 genome 
(gp24.1, gp24.2, gp70.1, gp76.2, gp117.1, gp117.2, gp144.1, gp179, gp232.1, gp239, 
gp260.1, gp290.1, gp294.1, gp294.2, gp295, gp295.1, gp296).  
Based on φKZ RNA-seq analysis performed previously by Ceyssens et al. (2014) 
and using the PISE EMBOSS fuzznuc program and MEME-MAST, 47 promoters were 
predicted for phage KTN4. Among them, 31 are early phage-specific promoters with 
highly conserved, uni-directionally distributed AT-rich intergenic motifs  
(5’-TATATTAC-3’) (Fig. 5.11). Furthermore, less conserved upstream (5’-TTTaA-3’) 
and downstream (5’-TG-3’) motifs were found. The middle promoters are located on both 
strands and distributed throughout the whole genome. They are linked by only a weak 
AT-rich motif (5’-AAanntTAC-3’; lowercase letters represent a lower level  
of conservation) centered at position 24 with respect to the transcription start site  
(Fig. 5.11 B). For late transcription no sequence conservation upstream of 5’ ends could 
be detected apart from a 5’-TATG-3’ motif overlapping the transcription start site  
(11 late promoters) (Fig. 5.11 C). This findings are consistent with previous studies  
of φKZ phage (Ceyssens et al., 2014). 
Using ARNold, 107 of putative factor-independent terminators were predicted. 
Most potential stem loop transcription terminators contain the tetranucleotide UUCG 
loops (Fig. 5.12).  
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Figure 5.11: Alignments of KTN4 promoters. (A) Early promoters. The 5’ ends of primer extension products, which correspond to the transcription start sites, are located   
~ 10 bp downstream from the center of the core TATATTAC motif and are associated with an additional conserved 5’-TG-3' motif. (B) Middle promoters. They are united  
by only a weak AT-rich motif (5’-AAanntTAC-3’; lowercase letters represent a lower level of conservation) centered at position 24 with respect to the transcription start site  
(C) Late promoters. No sequence conservation upstream of 5’ ends of late transcripts could be detected apart from a 5’-TATG-3’ motif overlapping the transcription start site. 
The corresponding sequence logos are depicted below the alignments. Pink bars delineate conserved promoter elements. 
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Figure 5.12: Phage KTN4 predicted terminators with palindromes marked blue. From the left site: 
list of ORFs after which terminators are located, strand and motif of terminator, terminator sequence with 
conserved stem-loop structures marked blue, ΔG (the Gibbs free energy of stem-loop formation  
in kcal/mole) and location in phage genome. 
5.3.2. ESI-MS/MS proteome analysis 
Using ESI-MS/MS analysis of proteins from denaturated phage particles 
fractionated on SDS-PAGE, 111 gene products have been identified, among which five 
virion-unrelated enzymes, 36 virion associated proteins and 70 structural gene products, 
with sequence coverages ranging between 5.9% to 89.0% (Fig. 5.13, Table S 5.2).  
 
 
 
 
 
 
 
 
 
 
 
Figure 5.13: The SDS-PAGE pattern of KTN4 structural proteome against PageRuler Prestained 
Protein Ladder (Thermo Scientific) in the first line. The corresponding molecular weight is mentioned 
left. The numbered fractions on the right, correspond to gel slices analyzed individually by ESI-MS/MS. 
The proteins are mentioned in the slice in which they were most abundantly present. The 12% SDS-PAGE 
gel stained with GelCode™ Blue Safe Protein Stain (Thermo Scientific). 
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The KTN4 structural proteins were compared to their homologues from φKZ 
(NC_004629.1 from 2008 and AF399011.1 from 2013), PA7 (JX233784.1), phiPAK3 
(HQ630627.1) and 201phi2-1 (NC_010821.1) phages (BLASTP). As expected,  
the highest similarity was found for φKZ structural proteins, ranging from 63% to 100%, 
except for gp93, which was identical to PA7 hypothetical protein (AFO71119.1).  
5.3.3. Functional annotation of KTN4 genome 
Capsid 
ESI-MS/MS analysis identified 31 structural head proteins (97 - 100% similarity 
with φKZ counterparts) including gp215 head protease identical to φKZ gp175 and  
a major head protein gp155 with 98% similarity to φKZ gp120 (Thomas et al., 2012) 
(Table S 5.2). 
Tail apparatus 
The contractile tail of φKZ, the closest homologue of KTN4 (98 - 100% 
similarity), is built from at least 32 different proteins, but a definitive structural function 
was assigned to only two of them: the tail sheath protein (KTN4 gp39 identical to φKZ 
gp29, ESI-MS/MS hit) and the tail tip protein (KTN4 gp166, 99% similar to φKZ gp131, 
ESI-MS/MS hit) (Table 5.2). The φKZ gp131, located at the periphery of the baseplate 
and possibly associates with fibers that emanate from baseplate (Sycheva et al., 2012), 
has several paralogs in the φKZ genome: gp132, gp133, gp134, and gp135 (KTN4 gp167, 
gp168, gp169 and gp179, respectively, 99% similarity). They show a notable sequence 
similarity at their N termini and appear to form a paralogous cluster, a common 
characteristic of tail fiber/tail spike genes. Sycheva et al. (2012) hypothesized that gp131 
might play a role in host cell recognition by binding to some cell surface receptors, 
however does not participate in irreversible adsorption of the φKZ particle to PAO1 cells 
in the laboratory conditions, neither cleaves the peptidoglycan nor the expolysaccharide 
of PAO1 cells. Moreover, in the ESI-MS/MS analysis two additional proteins were 
identified gp181 (putative tail sheath protein, φKZ gp145, 99% similarity) and gp182 
(putative tail fiber, φKZ gp146, 98% similarity).  
Lysis cassette 
The KTN4 endolysin (gp180) is highly identical (99%) to the endolysin  
of P. aeruginosa φKZ gp144. This enzyme is well studied both at the molecular, 
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biochemical (Briers et al., 2007, 2009; Paradis-Bleau et al., 2007; Cloutier et al., 2010) 
and structural level (Fokine et al., 2008). It comprises a N-terminal peptidoglycan binding 
domain that has high binding affinity for its substrate (295 nM) (Briers et al., 2009) and 
a C-terminal transglycosylases domain that cleaves the glycosidic linkage between  
N-acetylmuramic acid and N-acetylglucosamine with the concomitant formation  
of 1,6-anhydromuramic acid (Paradis-Bleau et al., 2007). Moreover, the ESI-MS/MS 
analysis identified the presence of tail associated enzyme gp221 (structural peptidoglycan 
hydrolase), that correspond to gp181 of φKZ phage (99% similarity) (Table 5.2).  
This enzyme cleaves the host cell wall during the first stage of the life cycle (Briers et al. 
2008). In the centre of the φKZ baseplate, there is a density that resembles the needle-like 
‘‘cell-puncturing’’ device of T4, which is most likely composed of gp181. 
Table 5.2: Comparative analysis of proteins involved in infection process. 
KTN4 
proteins 
Predicted function φKZ 
homologs 
Amino acid 
sequence 
similarity 
General 
characteristics 
gp39 tail sheath protein gp29 100% Tail apparatus 
gp40 tail tube protein gp30 100% 
gp166 tail tip protein gp131 99% 
gp167 structural protein, φKZ gp131 paralog gp132 99% 
gp168 structural protein, φKZ gp131 paralog gp133 99% 
gp169 structural protein, φKZ gp131 paralog gp134 99% 
gp170 structural protein, φKZ gp131 paralog gp135 99% 
gp181 tail sheath protein gp145 99% 
gp182 tail fiber gp146 98% 
gp180 endolysin  gp144 99% Lysis cassette 
 gp221 peptidoglycan hydrolase  gp181 99% 
gp106 β/β′-like RNAP gp80 a 99% RNA 
polymerase gp185 β/β′-like RNAP gp149 a 99% 
gp219 β/β′-like RNAP gp178 a 99% 
gp220 β/β′-like RNAP gp180 a 99% 
gp74 nvRNAP gp55 Identical, but 
shorter by 41 
amino acids 
gp95 nvRNAP gp71 99% 
gp96 nvRNAP gp73 100% 
- nvRNAP gp72 - 
gp97 nvRNAP gp74 100% 
gp158 nvRNAP gp123 100% 
gp90 unknown function gp68 100% 
gp04 dihydrofolate reductase gp04 98% Nucleotide 
metabolism 
 
gp229 thymidylate kinase gp188 100% 
gp258 deoxycytidine triphosphate deaminase gp214 100% 
gp284 thymidylate synthase gp235 99% 
gp367 ribonucleosidediphosphate reductase, 
beta chain 
gp305 99% 
gp368 ribonucleoside-diphosphate reductase, 
alpha chain 
gp306 100% 
gp52 chain A of monomeric subunit  
of Tubz 
gp39 100% 
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KTN4 
proteins 
Predicted function φKZ 
homologs 
Amino acid 
sequence 
similarity 
General 
characteristics 
gp98 Helicase gp75 99% DNA 
replication and 
modification 
 
gp244 Helicase gp203 100% 
gp114 prosite ATP-dependent DNA ligase gp87 99% 
gp191 RNase H gp155 100% 
gp76 intron-encoded endonuclease gp56 99% 
- intron-encoded endonuclease gp179 - 
- intron-encoded endonuclease gp296 - 
 
β/β′-like RNAP - β/β′-like virion-associated non-canonical multi-subunit viral RNA polymerase 
nvRNAP non-virion RNA polymerase  
 
DNA replication and modification 
The analysis revealed that gp52 is homologus to the chain A of monomeric subunit 
of Tubz protein of φKZ (φKZ gp39, 100% similarity, ESI-MS/MS hit). Aylett et al. 
structural studies suggest, that this protein preasumably is essential for the correct 
centering of replicated bacteriophage virions within the bacterial host (Aylett et al., 2013).  
Moreover, four β/β′-like virion-associated proteins in KNT4 phage (gp106, 
gp185, gp219, and gp220, ESI-MS/MS hit) were assigned as a non-canonical multi-
subunit viral RNA polymerase (RNAP), 99% similar to φKZ gp80, gp149, gp178, gp180 
(Ceyssens et al., 2014) (Table 5.2). Furthermore, the analysis of φKZ RNAP performed 
by (Yakunina et al., 2015) allowed to identify five homologous subunits in KTN4 
genome, the products of early phage genes (Table 5.2). Four of these are cellular RNAP 
subunits homologs of the non-virion set (nvRNAP): 1) gp74, homologous to gp55 φKZ; 
2) gp95 and gp96 (φKZ gp71 and gp73); φKZ gp72, a part of φKZ subunit has  
no homologue in KTN4 genome; 3) gp97 identical to gp74 φKZ and 4) gp158 identical  
to gp123 φKZ. The fifth subunit, gp90 identical to gp68 φKZ, is a protein of unknown 
function with no similarity to known RNAP subunits or any other known protein family. 
Gp74 and gp97 together correspond to msRNAP largest (bacterial β’) subunits and gp95 
and gp96 subunit corresponds to the C-terminal half of msRNAP second largest  
(β in bacteria) subunits. Gp158 is a highly diverged homolog of the N-terminal half  
of the second largest (β in bacteria) msRNAP subunits. This complex initiates 
transcription from the late promoters in rifampicin-resistant manner, tested in vitro  
in φKZ, which suggests that the virus relies on its own transcription machinery for  
the entire infection process. However, the late promoter 5’-TATG-3’ conserved motif  
is necessary for transcription by nvRNAP in vitro (Yakunina et al., 2015).  
Furthermore, genes associated with nucleotide metabolism (KTN4 gp04, 
dihydrofolate reductase; gp229 thymidylate kinase; gp258, deoxycytidine triphosphate 
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deaminase; gp284, thymidylate synthase; gp368, ribonucleoside-diphosphate reductase, 
alpha chain, and gp367, ribonucleosidediphosphate reductase, beta chain) were identified. 
All are identical or highly similar to φKZ genes: gp04 (98%), gp188 (100%), gp214 
(100%), gp235 (99%), gp306 (100%) and gp305 (99%), respectively (Mesyanzhinov  
et al., 2002).  
Also proteins playing role in DNA replication (KTN4 gp98 and gp244, a potential 
helicase; gp114, a prosite ATP-dependent DNA ligase AMP-binding site pattern, gp191, 
a putative RNase H have homologs in φKZ genome [gp75 (99%), gp203 (100%),  
gp87 (99%) and gp155 (100%), respectively] (Mesyanzhinov et al., 2002).  
However, when intron-encoded endonucleases (Mesyanzhinov et al., 2002) were 
examined significant variations between both phages were observed. The φKZ gp179 and 
gp296 are missing homologs in KTN4 genome and only gp56 is 99% similar to KTN4 
gp76.  
5.3.4. Comparative genome analysis and protein-sharing network  
The protein sharing network for jumbo phage KTN4 is presented in Fig. 5.14.  
A resulting network comprises 495 phages (nodes) belonging to Myoviridae, 
Siphoviridae, Podoviridae, or uncharacterized and other phages and 6,948 relationships 
(edges) between them (Fig. 5.14 A). In this graph, phage KTN4 was placed in a single 
component with nine well-known giant phages including φKZ, φPA3, 201φ2-1, EL, OBP, 
ΦJM-2012, SPN3US, CR5 and PhiEaH2. When the network topology was computed with 
two classical measures such as the clustering coefficient (CL) and betweenness centrality 
(BC) (Brohée et al., 2008), this component shows the highest CL = 1 (absolute 
cohesiveness) and the lowest BC = 0 (none of node acting as a bridge among other pairs 
of nodes). This network structure reflects the distinct core gene-sets shared between their 
genomes (Jang et al., 2013), which form a tight-knit clique of full interconnectivity. Next, 
the connectivity pattern of this component has been investigated not only on the basis  
of protein sequence identities, but also according to phage-phage similarity score after 
normalizing the number of shared genes between genomes (Leplae et al., 2010; Lima-
Mendez et al., 2008). As a result, over the threshold of 60% identity, phages KTN4, φKZ, 
phiPA3, and 201φ2-1 kept forming an in-group relationship with φKZ being the closest 
relative to KTN4 (Fig. 5.14 B). In addition, KTN4 was more closely related to φKZ, 
phiPA3, and 201φ2-1 with the phage-phage similarity score ranging from 157.2 to 999.9, 
indicating more shared homologous genes between them than others. The other 
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Pseudomonas phages including EL and OBP were connected for identity values less than 
35% and similarity score, 79.9. The phages PhiEaH2, SPN3US, CR5, and ΦJM-2012, 
having different host ranges (i.e., Erwinia, Salmonella, Cronobacter, and Vibrio sp., 
respectively), were weakly connected to other φKZ-related members in terms of both 
shared gene contents and sequence identity. The genetic relationships of KTN4 have been 
investigated by constructing a mathematical model of gene (protein)-sharing network, 
extending to possible close relatives. In our phage population network, KTN4  
is constricted to a single isolated component comprising the four φKZ-related phages and 
other potential relatives. Subsequent network decomposition strongly indicates that 
KTN4 belongs to the Phikzvirus (Cornelissen et al., 2012), with the large proportion  
of φKZ specific core gene-sets in common to the φKZ, φPA3, and 201φ2-1. More 
specifically, the connectivity patterns suggest that φKZ appears to be the closest relative 
to KTN4 as their protein families with more than 90% sequence identity can  
be considered more recently shared than those of other phage members in this group 
(Halary et al., 2010). In addition, our population network can reveal other informative 
connections. The phages phiEaH2, SPN3US, and CR5 were found to interconnect solely 
with the φKZ-related phages, indicating that they are probably diverged member  
of the φKZ-related group as observed in ΦJM-2012 (Jang et al., 2013). These results 
suggest that the Phikzvirus  phages’ diversity has not been fully delimited and that there 
are additional more distant relatives yet to be discovered. 
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Figure 5.14: Protein-sharing network for KTN4. (A) A network representation was produced using  
the edge-weighted spring embedded layout of Cytoscape version 3.1.1. Nodes indicate phage genomes and 
edges between two nodes indicate their statistically weighted pairwise similarities with phage-phage 
similarity scores of ≥ 1. There are 495 nodes and 6,948 edges in this network. (B) An enlarged view 
 of the circle in Panel B. Values are the similarity scores estimated with the hypergeometric equation shown  
in Materials and methods. Edge thickness is proportional to protein sequence identity, which is represented 
in the legend box. 
 The general features of KTN4 phage are presented in table 5.3. 
Table 5.3: Major features of KTN4 phage. 
Phage KTN4 
Water source Irrigation field 
City/Country/ Date Wrocław/Poland/ 2011 
Host PAO1 
Genome size (bp) 279,593 
GC (%) 36.9 
ORFs 368 
Unique ORFs 19 
Virion dimensions head/tail [nm] 130/168 
Latent period [min] 40 
Burst size [pfu/cell] 8±2 
Heat stability for 1h [ºC] 40-70 
pH stability for 1h at RT 6-12 
Chloroform sensitivity at RT/4 ºC [h] 24 
Pyocyanin production inhibition in biofilm structure a + 
Pyoverdin production inhibition in biofilm structure a + 
Increase of diffusion though biofilm structure a + 
aExperiments performed by Department of Microbiology, Institute of Biology and Department  
of Molecular Physics, Institute of Physics, The Jan Kochanowski University in Kielce, Kielce, Poland; 
Department of Pathogen Biology and Immunology, Institute of Genetics and Microbiology, University  
of Wrocław, Wrocław, Poland (Danis-Wlodarczyk et al., 2015). 
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5.4. Discussion 
In this chapter we report the discovery and characterization of a giant virus KTN4, 
a φKZ isolate, that belongs to the Myoviridae family and infects P. aeruginosa.  
Microbiological characteristics 
KTN4 has an enlarged capsid and a long contractile tail (130 nm and 168 nm, 
respectively). It uses the IV type fimbriae as receptor on bacterial surface. KTN4 was 
stable in a broad range of temperature (40 - 70°C), pH (6 - 12) and was resistant  
to chloroform treatment. This lytic virus has a broad spectrum of activity with prevalence  
to clinical isolates, especially from CF patients (36.8% and 32.6% in two independent  
P. aeruginosa panels). However, a highly similar phage φKZ exhibited broader host 
range, lysing 37% and 46%. The detailed comparison of KTN4 and φKZ genes have been 
done, especially for tail fibers and its C-terminal elements as responsible for host receptor 
recognition. We have looked also for differences in auxiliary genes conditioning for 
instance DNA modification which may result in phage DNA resistance to host restriction 
digestion mechanism. There was no differences in tail fibers gene sequences. However, 
the φKZ genome possess several unique genes (no. 17) in the area of auxiliary genes such 
as hypothetical proteins surrounding terminase large subunit, non-virion DNA- dependent 
RNA polymerase subunit, DnaB helicase, similar to putative endonuclease 
(Pseudomonas phage φPA3), cyclic GMP-AMP synthase; DNA sensor, transferase, 
putative dimetal phosphatase; dinuclear metal center phosphatase, metalloprotein, 
metallophosphoesterase, endonuclease S subunits; coiled-coil, type I methyltransferase, 
DNA binding and homing endonuclease. The comperative analysis suggest, that there are 
no differences in host receptor recognition, destabilization of bacterial peptidoglycan  
as well as DNA metabolism and RNSP. Potentially the host range discrepancy could  
be related with variations between replication and DNA modification genes.  
One-step experiment revealed a latent period of 40 min and a burst size of 8 ± 2 
phage particles per infected cell. P. aeruginosa PAO1 cell infection cause by KTN4 was 
examined in the real time with the use of time-lapse microscopy. In the early stage  
of infection the small circular mass was observed, which migrates toward the cell 
midpoint and increases in size. It is likely the site of genome encapsidation as it was 
previously demonstrated by Kraemer et al. (2012). After arrival at midcell, the mass 
oscillates slightly about the central axis. Erb et al. (2014) hypothesized that this 
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oscillatory movement is reminiscent of eukaryotic chromosomes lined up at midcell  
by the mitotic spindle. In contrast to eukaryotes, where DNA replication is temporally 
separated from segregation, the phage nucleoid continued to increase in mass as it moved 
toward midcell, suggesting that DNA replication and positioning occur simultaneously. 
This observation demonstrates that bacteriophage have possibility to harness  
the properties of a tubulin-like cytoskeleton for efficient propagation. In further step  
of infection, bacteria cell continues to increase in size to finally achieve a significantly 
enlarged lemon-like shape. Erb et al. (2013 and 2014) observed very similar observation 
during P. chlororaphis cells 201ϕ2-1 phage infection. In their study a long fibers of PhuZ, 
a type of tubulin, form and arrange into a structure that resembles a simple form of the 
spindle apparatus. These structures are only formed if a virus has invaded a cell. During 
the early stages of infection, viral DNA localizes to the cell poles, but rearranges at around 
the same time that PhuZ fibers form. At this point, the viral DNA moves towards  
the middle of the bacterial cell with fibers on either side of the DNA, suggesting that  
the fibers play a role in moving the DNA. Kraemer et al. (2012) also hypothetized, that 
PhuZ tubulins play a role in spatially organizing DNA during lytic growth and thereby 
contribute to efficient phage production. This bacteriophage system may  
be an evolutionary ancestor of the spindle apparatus. In conclusion, bacteriophage can 
exploit the advantages of a well-defined cytoskeletal organization to faithfully propagate 
themselves. The PhuZ spindle appears to play a key role in organizing viral reproduction 
by positioning the phage nucleoid at midcell. Since polar localization is phage infection-
dependent, Erb et al. (2014) hypothesized that a phage protein is necessary  
for the organization of the spindle. Whether the putative phage polar protein also acts  
to nucleate de novo filament formation or facilitate bundling is unclear.  
Biofilm eradication ability  
 Since Pseudomonas common infections are usually associated with biofilm 
formation, the ability of KTN4 to disrupt the biofilm has been examined. Initial evaluation 
was performed on 24 h and 48 h old P. aeruginosa PAO1 biofilms with the use of confocal 
scanning microscopy. Untreated biofilm presented a dense structure, which thickness 
increased over the time. However, after phage treatment biofilm structure was less dense 
with clear areas of biofilm removal. Further evaluation with more qualitative and 
quantitative techniques was performed by Drulis-Kawa group (Department of Pathogen 
Biology and Immunology, Institute of Genetics and Microbiology, University  
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of Wrocław, Wrocław, Poland) and collaborators (Department of Microbiology, Institute 
of Biology and Department of Molecular Physics, Institute of Physics, The Jan 
Kochanowski University in Kielce, Kielce, Poland and Zeta Instruments Co., San Jose, 
USA). Results are published in Danis-Wlodarczyk et al., 2016.  
 The analysis of pyocyanin and pyoverdin/pyochelin secretion to the medium  
was carried out using spectrophotometry and fluorometry, allowing detection of highly 
diffusible pigmented signaling molecules levels of quorum sensing and a siderophor.  
The analysis of pyocyanin concentration in growth medium showed that active phages, 
colistin and active phage/colistin treatment significantly decreased the level of this 
compound for the tested biofilms (24, 48 or 72 h) compared to UV-inactivated phages.  
It turned out that the infective form of our giant phage significantly reduced  
the concentration of pyocyanin, whether combined with colistin or alone. The level  
of pyoverdin determined by the fluorescence was significantly lowered after colistin 
application on 24 h biofilm and in combination with both phage preparations on PAO1 
biofilm formed for 72 h. The reduction of siderophore concentration was also observed 
when 72 h biofilms were exposed to active KTN4. The combined treatment consisting  
of phage and antibiotic did not showed a synergistic effect in either biomass or dyes 
determination assays. Statistically significant (p < 0.005) inhibition observed for 
pyocyanin and pyoverdin/pyochelin production was elicited by phages (lysis of cells  
in biofilm). The quantities of the most important pigmented signaling molecules secreted 
by the pathogen decreased significantly, which proves the potency of these phages  
to be applied in Pseudomonas biofilm treatment. 
The phage application effect on biofilm disruption was analyzed also by laser 
interferometry, a biophysical technique which measures quantitative changes in biofilm 
matrix permeability for low molecular compounds. The diffusion of TSB medium though 
biofilm was evaluated, which indirectly indicated its structure degradation.  
The hydrophilic Nephrophane membrane overgrown by 72 h biofilm was chosen  
for the interferometry analysis. The PAO1 biofilm was treated with active and  
UV-inactivated KNT4 phage for 4 h. The diffusion rate of medium transported though 
the biofilm-covered membrane (0.86 × 10−3 mg/h) was significantly higher than for intact 
biofilm (p < 0.001) after active and inactivated phage treatment, reaching 
1.65 × 10−3 mg/h and 1.39 × 10−3 mg/h, respectively. The increase of diffusion rate 
through the overgrown membrane after phage application indicated the degradation  
of the biofilm structure associated with the disintegration of matrix elements.  
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Airway Surface Layer Infection model 
 A strong antibacterial activity (4 - 7 logs decrease in extracellular bacterial load) 
was observed in an infected Airway Surface Layer Infection model using NuLi-1 and 
CuFi-1 cell lines. This assay also showed that KTN4 successfully prevented wild-type 
Pseudomonas internalization to epithelial cells. These properties indicate giant KTN4 
phage as an excellent candidate for phage therapy purposes and is a source for 
antimicrobials and biotechnologically relevant proteins. To our knowledge this is the first 
study of phage application using this lung epithelia infection assay. The gentamicin 
exclusion assay on ASL in vitro model is flexible, generates reproducible data with well-
controlled and standardized conditions, mimicing the normal and CF lung environments. 
Moreover, it provides a basis for understanding the host-pathogen interactions and is,  
as such, an important step towards experimental in vivo studies. 
Genome properties 
Phage KTN4 has a genome size of 279,593 bp with 368 predicted ORFs and  
6 tRNAs. It shows a genome-wide nucleotide sequence similarity to: φKZ 99%, PA7 
99%, φPA3 84%, 201φ2-1 78% (BLASTN). As such, it can be defined as an isolate  
of the Pseudomonas phage φKZ species. The average GC content of KTN4 (36.9% GC)  
is significantly lower than that of the host P. aeruginosa (66% GC). The tRNAs are not 
conserved among the other φKZ-related phages, which also have a lower GC content 
[φKZ (36.8% GC), EL (49.3%), and 201φ2-1 (45.3%)] than the respective Pseudomonas 
species they infect. The absence of notable homology to other bacteriophages on the DNA 
level indicates clearly that KTN4 represents an evolutionarily distinct group  
in the Myoviridae family. In total, only 21.5% of all predicted proteins have defined 
function and ESI-MS/MS analysis allowed identification of 111 virion-associated 
proteins. According to the orientation of transcription, ORFs are organized into operons 
and most are on a positive strand. Moreover, 47 promoters and 107 putative factor-
independent terminators were predicted.  
Lysis cassette 
The KTN4 endolysin (gp180) is highly identical (99%) to the endolysin  
of P. aeruginosa φKZ gp144. This enzyme is well studied both at the molecular, 
biochemical (Briers et al., 2007, 2009; Paradis-Bleau et al., 2007; Cloutier et al., 2010) 
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and structural level (Fokine et al., 2008). φKZ gp144 is one of the first reported modular 
endolysins active against Gram-negative peptidoglycan (chemotype A1γ) (Briers et al., 
2007). It comprises a N-terminal peptidoglycan binding domain that has high binding 
affinity for its substrate (295 nM) (Briers et al., 2009) and a C-terminal transglycosylases 
domain that cleaves the glycosidic linkage between N-acetylmuramic acid and  
N-acetylglucosamine with the concomitant formation of 1,6-anhydromuramic acid 
(Paradis-Bleau et al., 2007). The crystal structure has been determined for free gp144  
(2.5 Å) and complexed with chitotetraose (2.6 Å) (Fokine et al., 2008). The consensus 
motifs for peptidoglycan binding (underlined) and the catalytic residue (boxed) are fully 
conserved in KTN4 gp180. Whereas Briers et al. (2007) could purify high amounts  
of recombinant gp144 from the cytosolic fraction, Paradis-Bleau et al. (2007) found that 
φKZ gp144 expression results in host cell lysis and that the endolysin is also secreted 
independent of a holin, the Sec (or TAT) secretion machinery. Bacterial membrane 
permeabilizing activity has been demonstrated for φKZ gp144 using fluorescence 
spectroscopy, putatively initiated by its weakly positively charged N-terminus (Cloutier 
et al., 2010). Extensive bio-informatical analysis did not predict any typical holin in φKZ. 
In line with these findings, no clear holin sequence could be predicted in KTN4 as well. 
It remains to be elucidated how Phikzvirus phages achieve lysis in in vivo conditions, and 
if the lysis system differs from previously described systems such as the canonical lambda 
lysis system (Young et al., 2000), endolysins with a signal peptide (São-José et al., 2000) 
or a signal-arrest-release sequence (Xu et al., 2004). 
Moreover, the ESI-MS/MS analysis identified the presence of tail associated 
enzyme gp221 (structural peptidoglycan hydrolase), that correspond to gp181 of φKZ 
phage (99% similarity). This enzyme cleaves the host cell wall during the first stage  
of the life cycle (Briers et al., 2008). In the centre of the φKZ baseplate, there is a density 
that resembles the needlelike ‘‘cell-puncturing’’ device of T4, which is most likely 
composed of gp181. 
Protein sharing network 
The genetic relationships of KTN4 have been investigated by constructing  
a mathematical model of gene (protein)-sharing network, extending to possible close 
relatives. In our phage population network, KTN4 is constricted to a single isolated 
component comprising the five Pseudomonas φKZ related phages and other potential 
relatives. Subsequent network decomposition strongly indicates that KTN4 belongs  
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to the Phikzvirus clade (Cornelissen et al., 2012), with the large proportion  
of φKZ-specific core gene-sets in common to the φKZ, φPA3, and 201φ2-1. More 
specifically, the connectivity patterns suggest that φKZ appears to be the closest relative 
to KTN4 as their protein families with more than 90% sequence identity can  
be considered more recently shared than those of other phage members in this group 
(Halary et al., 2010). In addition, our population network can reveal other informative 
connections. The phages phiEaH2, SPN3US, and CR5 were found to interconnect solely 
with the φKZ-related phages, indicating that they are probably diverged member  
of the φKZ-related group as observed in ΦJM-2012 (Jang et al., 2013). These results 
suggest that the diversity of Phikzvirus phages has not been fully delimited and that there 
are additional more distant relatives yet to be discovered. 
Considering all these characteristics, KTN4 phage is a suitable and promising 
candidate for in vivo trials, for applications in treatment and prophylaxis in lung 
infections. 
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of Gene Technology, KU Leuven, Belgium). 
 Promoters identification performed with the support of Dr. Dieter Vandenheuvel 
(Laboratory of Gene Technology, KU Leuven, Belgium). 
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Włodarczyk. 
6.1. Introduction  
 Viruses have the genome represented by either RNA or DNA, that can be either 
single-stranded or double-stranded, either circular or linear, and consists of either a single 
or multiple molecules (Agol, 1974; Baltimore, 1971). The genomes are typically smaller 
compared to genomes of cellular life forms. However, over the past few years  
the discovery of several groups of giant/jumbo viruses has dramatically expanded  
the viral genome size range that now spans three orders of magnitude, from about 2 kb  
to over 2 Mb. Often they are larger than the genomes of numerous bacteria and archaea, 
obliterating the gulf between cells and viruses in terms of genome size and complexity 
(Claverie et al., 2009; Koonin et al., 2015). 
To our knowledge, 34 Myoviridae and 9 Siphoviridae jumbo phages have been 
described and sequenced to date (Table 6.1). These include seven Pseudomonas phages, 
EL (211 kbp, Krylov et al., 2003), φKZ (280 kbp, Mesyanzhinov et al., 2002), phiPA3 
(309 kbp, Monson et al., 2011), 201phi2-1 (316 kbp, Thomas et al., 2008), PaBG  
(258 kbp, Sykilinda et al., 2014), Lu11 (280 kbp, Adriaenssens et al., 2012) and OBP 
(284 kbp, Cornelissen et al., 2012).  
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Table 6.1: Representatives of sequenced jumbo bacteriophages (NCBI).  
Phage Accession no. Length Protein no. Host 
Myoviridae 
Phikzvirus 
φKZ NC_004629 280334 nt 306 Pseudomonas 
Elvirus 
EL NC_007623 211215 nt 201 Pseudomonas 
Rsl2virus 
RSF1 NC_028899 222888 nt 230 Ralstonia 
RSL2 NC_028950 223932 nt 224 Ralstonia 
Rslunavirus 
RSL1 NC_010811 231255 nt 343 Ralstonia 
Spn3virus 
SPN3US NC_027402 240413 nt 264 Salmonella 
Agrican357virus 
Ea35-70 NC_023557 271084 nt 318 Erwinia 
Unclassified T4-like phages 
PX29 NC_023688 222006 nt 330 Aeromonas 
phiAS5 NC_014636 225268 nt 343 Aeromonas 
CC2 NC_019538 231743 nt 427 Aeromonas 
Aeh1 NC_005260 233234 nt 352 Aeromonas 
65 NC_015251 235229 nt 437 Aeromonas 
phiN3 NC_028945 206713 nt 402 Sinorhizobium 
ACG-2014f NC_026927 228143 nt 292 Synechococcus 
KVP40 NC_005083 244834 nt 381 Vibrio 
VH7D NC_023568 246964 nt 327 Vibrio 
nt-1 NC_021529 247511 nt 405 Vibrio 
P-SSM2 NC_006883 252401 nt 334 Prochlorococcus 
unassigned Myoviridae 
G NC_023719 497513 nt 675 Bacillus 
unclassified Myoviridae 
0305φ8-36  NC_009760 218948 nt 246 Bacillus 
φPA3 NC_028999 309208 nt 375 Pseudomonas 
201φ2-1 NC_010821 316674 nt 461 Pseudomonas 
PAU NC_019521 219372 nt 295 Sphingomonas 
CR5 NC_021531 223989 nt 231 Cronobacter 
S-SSM7 NC_015287 232878 nt 319 Synechococcus 
PaBG NC_022096 258139 nt 308 Pseudomonas 
phiR1-37 NC_016163 262391 nt 367 Yersinia 
Lu11 NC_017972 280538 nt 391 Pseudomonas 
OBP NC_016571 284757 nt 309 Pseudomonas 
vB_KleM-RaK2 NC_019526 345809 nt 534 Enterobacteria 
K64-1 NC_027399 346602 nt 64 Klebsiella 
PBECO 4 NC_027364 348113 nt 551 Escherichia 
121Q NC_025447 348532 nt 611 Escherichia 
vB_CsaM_GAP32 NC_019401 358663 nt 545 Cronobacter 
Siphoviridae 
Phicbkvirus 
phiCbK NC_019405 215710 nt 338 Caulobacter 
Magneto NC_019407 218929 nt 347 Caulobacter 
Swift NC_019411 219216 nt 343 Caulobacter 
karma NC_019410 221828 nt 353 Caulobacter 
Rogue NC_019408 223720 nt 350 Caulobacter 
unclassified Siphoviridae 
phiEaH1 NC_023610 218339 nt 241 Erwinia 
phiEaH2 NC_019929 243050 nt 262 Erwinia 
CcrColossus NC_019406 279967 nt 448 Caulobacter 
S-SKS1 NC_020851 208007 nt 281 Synechococcus 
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However, there is a high possibility, that jumbo phages are more abundant  
in the environment and have important impact on bacteria. Difficulties of their isolation 
and identification are due to the fact that some of them form very small plaques  
(< 0.5 mm on 0.7% soft agar), which are not visible or visible only in very low 
concentrations of soft agar (0.15 - 0.2%). This leads to their omission during classical 
phage propagation procedures and a major pool of them remains undetected. A good 
example is Bacillus megaterium phage G, the biggest isolated bacterial virus with genome 
size of 497,513 bp, discovered only by accident through electron microscopy of another 
bacteriophage preparation (Serwer et al., 2007).  
 The general knowledge of jumbo phages is limited, therefore it is very important  
to study their genome organization, mechanisms of evolution and biology (Hendrix, 
2009). In this chapter we present a new jumbo myovirus, PA5oct lytic against  
P. aeruginosa. We focus on the biology, genome structure, proteome, evolutionary 
relationships and possibilities of application in phage therapy to combat infections caused 
by P. aeruginosa.  
6.2. Microbiological characteristics 
6.2.1. Isolation and morphology  
PA5oct is a novel jumbo Pseudomonas phage isolated from a sewage sample 
collected from irrigated fields near Wrocław, Poland. After purification phage titres were 
108 - 1010 pfu/ml and caused < 0.5 mm wide clear plaques on 0.7% soft agar. PA5oct was 
classified to order Caudovirales, family Myoviridae (Drulis-Kawa et al., 2013; Lavigne 
et al., 2009) and formally named vB_PaeM_PA5oct (PA5oct). TEM images analysis 
revealed, that heads measured 131 nm between opposite apices (60 measurements) and 
were icosahedral as shown by the simultaneous observation of capsids with hexagonal 
and pentagonal outlines. Tails measured 136 x 19 nm in the extended state and consisted 
of a neck of 10 nm, a sheath with about 25 transverse striations, and an indistinct baseplate 
of 33 x 7 - 10 nm with short fibers of 30 x 2 nm. No collar was observed, but many phages 
carried amorphous material at the neck. Contracted tail sheaths measured 50 x 30 nm and 
were separated from the baseplate by a space of about 2 nm (Fig. 6.1). 
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Figure 6.1: Particle analysis of PA5oct phage. (I) an electron microscopic images with the scale bar 
representing 100 nm, uranyl acetate, final magnification 297,000 ×; (A) and (B) phage with pentagonal 
head and an extended tail, (C) phage with a contracted tail; (II) a CsCl gradient purification (four different 
CsCl densities are marked: 1.33 g/ml, 1.45 g/ml, 1.50 g/ml, 1.70 g/ml; phage band pronounced red). 
6.2.2. Phage infection  
One-step growth experiments indicated a latent period of 40 min and a burst size  
of about 30 - 40 phage particles per infected bacterial cell (Fig. 6.2). 
Figure 6.2: One-step growth curve of phage PA5oct. An equal volume of bacterial culture (at OD600  
of 0.4, 108 cfu/ml) was mixed with phage suspension (106 pfu/ml) to obtain a MOI of 0.01. A trend line  
is marked with dots. All data are collected from three independent experiments, error bars indicate  
the standard deviation. 
6.2.3. Time-lapse microscopy 
The P. aeruginosa cells infection caused by phage PA5oct in the real time was 
visualized with a time-lapse microscopy (Eclipse Ti Time-Lapse Microscope).  
P. aeruginosa PAO1 Krylov cells were grown to mid-exponential phase (OD600 of 0.6) 
and infected on a 0.2% PBS-agar pad by CsCl purified PA5oct phage (9.79 x 109 pfu/ml) 
with MOI 10. In the course of infection cells only marginally increases their size and after 
40 - 45 min from the start of infection bacterial cells burst and phage progeny was released 
(Fig. 6.3). The latent period of PA5oct achieved in this experiment cannot be compared 
to one step growth experiment, due to different conditions. 
0,00E+00
1,00E+08
2,00E+08
3,00E+08
4,00E+08
5,00E+08
6,00E+08
7,00E+08
8,00E+08
9,00E+08
1,00E+09
0 10 20 30 40 50 60 70
PA5oct MOI 0.01pfu/cell
t 
154 
 
Figure 6.3: Time-lapse microscopy of the P. aeruginosa PAO1 Krylov infection caused by phage 
PA5oct on a 0.2% PBS-agar pad. A snapshots were taken from the start of phage infection every 15 min, 
MOI 10, using a Nikon Eclipse Ti Time-Lapse Microscope. Scale bare represents 10 µm.  
6.2.4. Stability tests 
Phage PA5oct (9.79 x 108 pfu/ml) was stable at temperatures from 4 - 60°C, where 
no reduction of pfu/ml was observed over a period of 60 min, while 5 min and over than 
15 min incubation at 70°C decreased the titre by 4 and 6 logs, respectively (Fig. 6.4).  
Figure 6.4: The temperature stability of phage PA5oct. Each bar represents the mean of three 
independent experiments, error bars indicate the standard deviation. Results obtained with spot test.  
Phage particles were also stable within a pH range of 5 - 11 after 1 h incubation 
at room temperature. When exposed to pH 4.0 and 3.0 for 1 h, phage titers dropped  
by 1 log, pH 2.0 and pH 12.0 by 3 and 4 logs, respectively (Fig. 6.5). 
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Figure 6.5: The pH stability of PA5oct phage. Phage titers (pfu/ml) were validated at the different pH 
values after 1h exposure at room temperature. Each bar represents the mean of three independent 
experiments, error bars indicate the standard deviation. Results obtained with spot test.  
No reduction in infectivity was observed after treatment with chloroform (an equal 
volume of phage solution and chloroform) for 1 h and 24 h at room temperature or at 4°C 
(Fig. 6.6). 
Figure 6.6: The chloroform stability of phage PA5oct. Phage titers (pfu/ml) were validated after 
chloroform treatment for 1 h and 24 h incubation at room temperature (RT) and at 4 °C. Each bar represents 
the mean of three independent experiments, error bars indicate the standard deviation. Results obtained 
with spot test.  
6.2.5. Determination of phage receptor 
Experiment with P. aeruginosa PAO1 mutants revealed that PA5oct possibly 
requires three receptors on bacterial cell surface: the type IV pili, LPS and flagella  
(Table 6.2). However, LPS mutations can have influence on overall makeup of the cell 
wall and how well flagella and pili are exposed on the bacterial surface. Good example 
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are Abeyrathne et al. (2005) studies of PAO1 waaL mutants. They proved, that this 
particular mutation drastically affected the swimming and twitching motilities  
of P. aeruginosa. The waaL encodes a functional O-antigen ligase, that has substantial 
influence on cell wall integrity and bacteria motility. For this reason, bacterial surface 
receptors of PA5oct should be further studied, by e.g. atomic force microscopy. 
Table 6.2: Phage receptor identification on P. aeruginosa PAO1 mutants. 
Bacterial strain Phenotype Origin PA5oct 
PAO1 (ATCC 
15692) 
Wild type American Type 
Culture Collection 
+ 
PAO1 Pirnay Wild type with inactive type IV pili Military Hospital 
Nederoverheembeek, 
Brussels, Belgium 
- 
PAO1 Krylov Wild type + 
PAO1 Δrmd  
(A-, B+) 
Deficiency in D-rhamnose biosynthesis; lack  
of A-band LPS 
 
 
Department  
of Molecular and 
Cellular Biology,  
University  
of Guelph, Canada 
- 
PAO1 ΔrmLC 
(A-, B-, core-) 
Deficiency in L-rhamnose biosynthesis; truncate 
core region, lack of A-band and B-band LPS 
- 
PAO1 ΔwaaL 
(A-, B-) 
Lack of WaaL ligating O-polymer to core-lipid 
A; LPS is devoid of A-band and B-band, semi 
rough (SR-LPS, or core-plus-one O-antigen) 
- 
PAO1 ΔwbpL 
(A-, B-) 
Lack of glucosyltransferase WbpL essential for 
initiation of both A-band and B-band synthesis 
- 
PAO1 ΔfliC 
ΔalgC ΔpilA 
Lack of flagella; lack of AlgC required for  
A-band, core oligosaccharide, and alginate 
 
Technical University 
Hamburg, Germany  
- 
PAO1 ΔfliC  
wt algC ΔpilA 
Lack of flagella; lack of type IV pili - 
PAO1 ΔfliC  
wt algC wt pilA 
Lack of flagella -/+ 
PAO1 wt fliC 
wt algC wt pilA 
Wild type + 
+ activity, bacterial lysis. - no activity. 
 
6.2.6. Host range analysis 
The lytic activity of PA5oct was examined on Pirnay’s P. aeruginosa panel 
(Pirnay et al., 2002), excluding “lysis from without” spots. Phage activity spectrum was 
tested against 57 clinical isolates from Military Hospital Neder-Over-Heembeek, 
Brussels, Belgium (Table S 4.1). PA5oct was able to infect 26% strains, whereas 
representatives of the Luz7virus group (LUZ7 32%), Lit1virus group (LIT1 17%), 
Luz24virus group (LUZ24 28%), Phikmvvirus group (LUZ19 40%, LKD16 39%, LKA1 
5%, phiKMV 37%), Pbunavirus group (LBL3 46%, LMA2 21%, LSL4 17%, KT28 28%, 
KTN6 42%) and Phikzvirus group (KTN4 35%, φKZ 37%). Phage narrow host range was 
also confirmed by de Soyza et al. (2013) on 43 clinical P. aeruginosa strains from COST 
LMG international reference panel. The PA5oct phage was able to infect 24% isolates, 
compared to representatives of the Luz7virus group (LUZ7 42%), the Phikmvvirus group 
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(LUZ19 44%), the Pbunavirus group (LBL3 39%, KT28 28%, KTN6 42%) and  
the Phikzvirus genus (φKZ 46%, KTN4 33%). 
6.2.7. Phage influence on biofilm  
To initially evaluate PA5oct biofilm eradication ability, 24 h and 48 h old  
P. aeruginosa PAO1 biofilms were grown on 8-well slide microscopy chambers and 
further infected with PA5oct suspension (6.5 x 1010 pfu/ml), and incubated for 24 h  
at 37°C. Biofilm treated with LB broth served as a negative control and treatment with  
a high dose of gentamicin (400 µg/ml) as a positive control. The MIC of gentamicin for 
tested strain was 0.5 µg/ml. Biofilms were stained with LIVE/DEAD BacLight Bacterial 
Viability Kit and visualized by confocal laser scanning microscopy (Fig. 6.7). We observe 
that in both 24 h and 48 h old biofilms, PA5oct and gentamicin treatments altered  
the structure of biofilm in comparison to the control. Biofilm negative controls presented 
a dense structure, with a thickness that increased over the time. However, after phage  
or gentamicin treatments, the biofilm structure was less dense with clear areas of biofilm 
disruption. This study shows the initial assessment of PA5oct antibiofilm activity, which 
was further evaluated using more qualitative and quantitative techniques by Drulis-Kawa 
group (Department of Pathogen Biology and Immunology, Institute of Genetics and 
Microbiology, University of Wrocław, Poland) and collaborators (Department  
of Microbiology, Institute of Biology and Department of Molecular Physics, Institute  
of Physics, The Jan Kochanowski University in Kielce, Poland and Zeta Instruments Co., 
San Jose, USA). Results are are currently in preparation for publication. 
 
 
 
 
 
 
 
 
Figure 6.7: Antibiofilm activity of phage PA5oct tested on P. aeruginosa PAO1 biofilms. (A) 24 h and 
(B) 48 h old biofilm. 1) negative control: biofilm treated with LB broth, 2) positive control: biofilm treated 
A 
B 
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with gentamicin (400 µg/ml), 3) PA5oct treatment (6.5 x 1010 pfu/ml). Biofilms were grown at 37°C,  
5% CO2, stained with the LIVE/DEAD BacLight stain (LIVE/DEAD BacLight Bacterial Viability Kit) and 
visualized by confocal laser scanning microscopy (Zeiss LSM 510 Meta 40× objective, Jena, Germany). 
Live bacteria are stained green.  
6.2.8. Antibacterial efficacy of PA5oct phage analyzed in gentamicin 
exclusion assay on Airway Surface Liquid infection model 
The in vitro antibacterial activity of PA5oct was assessed using the gentamicin 
exclusion assay on ASL. The experimental set up was identical to the experiment with 
phage KTN4, section 5.1.8., including NuLi-1 and CuFi-1 bronchial epithelium cell lines 
(Zabner et al., 2003), and three P. aeruginosa strains (PAO1, nonCF0038 and CF708) 
(Olszak et al., 2015). The epithelial cells viability controls were established, as was shown 
in section 5.1.8. No toxicity influence of cell lines was observed for phage and bacterial 
samples. 
First, both epithelial cell lines were infected with selected strains for 3 h and 
colony count showed, that all P. aeruginosa strains could efficiently propagated in both 
ASLs (107 - 109 cfu/ml), as it was previously presented in section 5.1.8. Next, the capacity 
of phage PA5oct to eradicate the extracellular bacterial load was evaluated. CFU counts 
of P. aeruginosa were significantly (p < 0.05) reduced for the normal NuLi-1 and CF 
CuFi-1 epithelia cells. In the case of NuLi-1 a 4.5 log, 6.5 log and 3 log decrease was 
observed for PAO1, nonCF0038 and CF708, respectively (Fig. 6.8 A). The phage 
treatment of the CuFi-1 epithelia infection was also very effective (p < 0.05) giving 5 log, 
2.5 log and 5 log reductions in CFU of PAO1, nonCF0038 and CF708, respectively  
(Fig. 6.8 B). PAO1 and CF708 was significantly more susceptible (p < 0.05) to phage 
treatment in CuFi-1 cells compared to NuLi-1 cells, contrary to the nonCF0038 isolate. 
It was confirmed that the PA5oct phage could freely diffuse and gain access  
to the bacterial hosts in both ASL models, but the final result of the treatment was strongly 
dependent on the strain features, as it was previously notified in section 5.1.8. (Danis-
Włodarczyk et al., 2016; Worlitzsch et al., 2002). In Worlitzsch et al. (2002) study  
P. aeruginosa was not interacting with the CF epithelium directly, but was rather found 
trapped in mucus plugs formed in the airways.  
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Figure 6.8: Phage PA5oct treatment of P. aeruginosa infected NuLi-1 and CuFi-1 epithelial cells.  
(A and B) Colony count of bacteria collected from apical wash; (C and D) colony count of bacteria 
internalized in epithelial cells. The error bars indicate the standard deviation. The results are presented as 
the means ± SD. Statistical analysis was made by the ANOVA test (denoted p-values < 0.05).  
(*) p-values < 0.05. 
In the final step of the experiment, the ability of P. aeruginosa strains to invade 
into epithelial cells was assessed, as it was presented in section 5.1.8. and the influence 
of PA5oct phage treatment on the number of invaded bacteria (Fig. 6.8 C and D).  
The CF708 strain was significantly (p <0.05) more capable to invade the epithelial cells  
in comparison to PAO1 strain in NuLi-1 line and in compare to both nonCF strains  
in case of CuFi-1 line. When PA5oct treatment was applied, in the NuLi-1 cell line  
we observe significant reduction in CFU counts (p < 0.05) by 3 logs and 1 log for 
nonCF0038 and CF708 isolates, respectively (Fig. 6.8 C). Moreover, treatment  
of nonCF0038 strain was the most efficient (p < 0.05). In contrast, no influence  
on internalization was observed in CuFi-1 line (Fig. 6.8 D). Phage treatment was not 
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effective and we observe a significant (p < 0.05) increase of invasion by 0.5 log and 1 log 
for PAO1 and nonCF0038, respectively. In case of CF708 there is no significant 
difference between untreated and treated samples.  
6.3. Genome analysis 
6.3.1. Genome properties  
Phage PA5oct has a giant linear A+T-rich (33.3% GC) double-stranded DNA 
genome (287,182 bp), making it the third largest sequenced Pseudomonas phage genome 
and the eighth jumbo genome among Myoviridae phages (Table 6.1). Based on DNA 
sequencing 397 genes were predicted with the use of GeneMark S, GeneMark.hmm, 
OrfFinder and manual inspection (Fig. 6.9).  
 
Figure 6.9: Circular representation of the PA5oct genome. Blue arrows represent predicted ORFs  
on the Watson and Crick strands. The inner black circle represents the GC content and the green-violet 
represents GC skew. Structural proteins confirmed by ESI-MS/MS analysis are marked with red dots. 
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RNA sequencing allowed for identification of 65 additional ORFs (+14.1%) and 
confirm presence of previously predicted genes (Fig. 6.10). Alternative start codons were 
proposed for nine genes (encoding gp37, gp169, gp283, gp294, gp330, gp333, gp341, 
gp372, gp444). In total, 462 ORF’s (open reading frames) and ten tRNAs [Met (CAT), 
Leu (TAA), Asn (GTT), Met (CAT), Leu (TAA), Arg (TCT), Pro (TGG), Gly (TCC),  
Ser (TGA) and Ser (GCT)] were identified (Table S 6.2). This result can be comparable 
to the smallest known bacterium, Mycoplasma genitalium G37, which has 470 genes 
(Fraser et al., 1995). 
Figure 6.10: Comparison of PA5oct genome annotation in the region between 3 and 8 kb based  
on DNA and RNA-seq. The reads on a Watson strand are marked red for samples taken 5, 15 and 25 min 
post infection. 
According to the orientation of transcription, ORFs are organized into operons 
and most of them are located on the positive strand (Fig. 6.11). The PA5oct protein sizes 
range from 33 to 3858 amino acid residues, within 8.87% (41 ORF’s) is ≤ 50 amino acids, 
47.83% (221 ORF’s) is ≤ 100 amino acids, 45.45% (210 ORF’s) is > 100 and <500 amino 
acids, and 6.49% (30 ORF’s) ≥ 500 amino acids. Based on bioinformatics and  
ESI-MS/MS analysis function was assigned to 117 genes (25.32% of all proteins), 
including 73 structural proteins (62.39% of proteins with appointed function and 15.80% 
of all proteins). Importantly, none of them were related to integration proteins (integrase, 
transposase) or antimicrobial resistance, which allows to consider this phage as a potential 
antimicrobial.  
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Figure 6.11: RNA-seq analysis of the PA5oct transcriptome after P. aeruginosa PAO1 infection. 
Genome-wide overview of reads mapped to the Watson (red) and Crick (green) strand of PA5oct genome 
for samples taken 5, 15 and 25 min post infection. The blue graph on top present the relative abundance  
of each position of the genome normalized by the total amount of sequencing reads in each sample. 
Furthermore, 39 promoters with highly conserved, AT-rich intergenic motifs  
(5’-TATAATA-3’) and (5’-TTGAC-3’) were identified (Fig. 6.12).  
 
 
 
 
 
 
 
 
 
 
 
 
Figure 6.12: Alignments of PA5oct promoters. The conserved AT-rich intergenic motifs: -10 box  
(5’- TATAATA - 3’) and -35 box (5’ - TTGAC - 3’) are marked with pink colour. The corresponding 
sequence logos from MEME/MAST are depicted below the alignments. On the left site are listed ORFs  
in front of which promoters are located, on the right side is sequence locus in the phage genome. 
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Using ARNOLD software and RNA seq analysis, 60 putative factor-independent 
terminators were predicted with conserved stem loops (Fig. 6.13).  
Figure 6.13: Phage PA5oct predicted terminators with palindromes marked blue. From the left site: 
list of ORFs after which terminators are located, strand, location in phage genome, motif of terminator, 
terminator sequence with conserved stem-loop structures marked blue, ΔG (the Gibbs free energy of stem-
loop formation in kcal/mole). 
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6.3.2. Transcriptomics analysis with RNA-seq 
Reads originating from the phage and the host at each stage of infection were 
mapped to the phage and host genomes respectively, revealing that PA5oct progressively 
dominates host transcription. Indeed PA5oct transcripts represented 21% of total 
transcripts within 5 minutes and eventually proceed to 69% then 92% by middle and late 
infection, respectively (Fig. 6.14). The strand specificity of the results showed that early 
transcription is almost exclusively performed on the Watson strand, in sense with what 
can now be defined as early coding sequences. Specifically, gp32, gp33, gp99 and gp450 
(uncharacterized proteins) can now be defined as early genes, which are classically 
understood to be typically involved in the transition from host to phage metabolism. 
PA5oct also appears to have a distinct middle phase of transcription captured at 15 min 
centering around the region between 70 kb and 200 kb with gene features predicted  
to be responsible for structural proteins as well as DNA metabolism and replication. 
Outside of this region, gp99 and gp213 (uncharacterized proteins) are particularly 
strongly expressed in middle infection, which continues into late infection, where gp99 
is the second most strongly expressed protein. In the late phase of infection, gp250,  
a glycosyl hydrolase lysozyme-like protein, is more strongly expressed compared  
to the early and middle phase, which could suggest that it is required for destabilization 
of cell wall and phage progeny release.  
Figure 6.14: RNA-seq analysis of the PA5oct transcriptome after P. aeruginosa PAO1 infection. 
Genome-wide overview of reads mapped to the Watson (red) and Crick (green) strands of PA5oct genome 
for samples taken 5, 15 and 25 min post infection. Four barely transcribed regions are highlighted with blue 
bars. Each of the three samples were normalized to each other by the total count of phage reads. 
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Additionally, five non-coding RNAs which lack similarity to any known DNA 
sequence in GenBank could be described (Table 6.3). Notably, ncRNA003 produces  
44%, 46%, and then 29% of phage transcripts over the course of the infection process, 
even though this feature comprises only 235 bp of the 287 kb genome. 
Table 6.3 Identified non-coding RNA species. 
Name Location Strand 
ncRNA001 4113..4883 + 
ncRNA002 31367..31616 + 
ncRNA003 44676..45001 + 
ncRNA004 126878..127154 + 
ncRNA005 269893..271298 - 
Remarkably, four regions, including two of the three major regions transcribed  
on the Crick strand, were found to be only barely transcribed in spite of significant 
sequencing depth. This could potentially reflect either recently acquired morons that have 
not yet been adapted to the transcriptional strategy of PA5oct, or perhaps these regions 
could require host transcription factors not found in PAO1 for optimum expression. 
6.3.3. ESI-MS/MS proteome analysis 
ESI-MS/MS analysis of gel-separated phage particle proteins led  
to the experimental identification of 93 virion-associated gene products, including seven 
virion-unrelated enzymes, 13 virion-associated proteins and 73 structural gene products, 
with sequence coverages ranging between 2.9% to 98.0% (Fig 6.15, Table S 6.3).  
The PA5oct particle proteins were compared to their homologues from Cronobacter 
phage vB_CsaM_GAP32 (JN882285.1), Escherichia phage PBECO 4 (NC_027364.1), 
Escherichia phage 121Q (NC_025447.1), Enterobacteria phage vB_KleM_RaK2 
(NC_019526.1) and Klebsiella phage K64-1 (NC_027399.1) (BLASTP). The highest 
amino acids similarity was found with Cronobacter phage vB_CsaM_GAP32 ranging 
from 28% to 68% for 23 proteins, Escherichia phage 121Q ranging from 21% to 66% 
also for 23 proteins and Enterobacteria phage vB_KleM_RaK2 ranging from 22% to 66% 
for 22 proteins.  
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Figure 6.15: The SDS-PAGE pattern of PA5oct structural proteome against LMW Ladder (Thermo 
Scientific) in first line. The corresponding molecular weight is mentioned left. The numbered fractions  
on the right, correspond to gel slices analyzed individually by ESI-MS/MS. The proteins are mentioned  
in the slice in which they were most abundantly present. 
6.3.4. Functional annotation of PA5oct genome 
Capsid 
ESI-MS/MS analysis identified three structural head related proteins, gp228 
(portal vertex protein of head), gp231 (prohead core scaffolding protein and protease) and 
gp233 (precursor of major head subunit). Additional protein, gp277, a head completion 
protein, was annotated based on homology with the Enterobacteria phage 
vB_KleM_RaK2 head completion protein (e-value 1E-32). 
Tail apparatus 
Neck protein, gp270 and four tail proteins, gp238 (phage tail fiber protein H), 
gp240 (tail sheath stabilizer and completion protein), gp243 (tail fiber protein) and gp272 
(tail sheath monomer) as well as three baseplate proteins, gp210 (baseplate wedge), gp211 
(baseplate protein) and gp214 (baseplate hub subunit and tail lysozyme) were identified 
during ESI-MS/MS analysis. Gp238, putative phage tail fiber protein H,  
has on C-terminal putative endo-N-acetylneuraminidase region (868 - 1008 amino acids 
position), which has possibility to hydrolase (28)-alpha-sialosyl linkages in oligo-  
or poly(sialic) acids, activity associated with the tail spikes and EPS depolymerases 
(Kwiatkowski et al., 1982).  
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Peptidoglycan degrading enzymes 
Several genes associated to the peptidoglycan layer degradation were identified: 
gp45, gp46, gp214, gp250, gp321 and gp447 (BLASTP, HHpred, HMMER, InterPro, 
Phyre2). Gp45 is a predicted murein hydrolase, peptidase M23 with a 103 amino acids 
long domain (30 - 133 aa) and gp46 is a putative peptidase M, both capable of cleaving 
bonds in polymeric peptidoglycan. Gp214 is a putative baseplate hub subunit with tail-
associated lysozyme (ESI-MS/MS hit), homologues to gp05 of E. coli bacteriophage T4, 
which has a needle-like structure attached to the end of a tube through which the DNA 
passes on its way out of the head and into the host. The gp05 needle punctures the outer 
cell membrane and then digests the peptidoglycan cell wall in the periplasmic space 
through hydrolysis of (14)-beta-linkages between N-acetylmuramic acid and N-acetyl-
D-glucosamine residues in a peptidoglycan and between N-acetyl-D-glucosamine 
residues in chitodextrins (Kanamaru at al., 2005). Gp250 was assigned as glycosyl 
hydrolase, lysozyme-like protein with a 159 amino acids long domain (11 - 170 aa) and 
it can possibly assists in the hydrolysis of glycosidic bonds between two or more 
carbohydrates or between a carbohydrate and a non-carbohydrate moiety. Gp321  
is a putative baseplate hub and tail lysozyme, a muramoyl-pentapeptidase  
(ESI-MS/MS hit). It contains a PAAR motif (61 - 97 aa) and a muramyol-pentapeptide 
carboxypeptidase hydrolase (180 - 320 aa), which cleaves a peptide bond at the carboxy-
terminal (C-terminal). Finally, gp447 a cell wall hydrolase domain protein, SleB (domain 
between 80 - 186 aa), which encodes N-acetylmuramyl-L-alanine amidase and cleaves 
the link between N-acetylmuramoyl residues and L-amino acid residues in cell-wall 
glycopeptides.  
DNA metabolism and genome replication 
PA5oct encodes proteins required for the formation of the replisome, comprising  
a helicase (gp292), several endonucleases (gp219, gp220, gp228, gp273, gp390, gp403, 
gp417, gp418), exonuclease (gp316), RNA polymerase sigma factor (gp218),  
DNA polymerases (gp346, gp366, gp369, gp389, gp391), DNA primase (gp299, gp300), 
DNA ligase (gp343) and DNA terminase (gp281). Also RecA- like proteins (gp285, 
gp287) were annotated, that play a role in homologous recombination, DNA repair and 
induction of the SOS response. Gp239 encodes a putative MutT/NUDIX hydrolase family 
protein involved in diverse metabolic pathways. Moreover, a GTP cyclohydrolase 
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(gp329) was identified, responsible for the hydrolysis of guanosine triphosphate (GTP) 
to form 7,8-dihydroneopterin triphosphate (7,8-DHNP-3'-TP, 7,8-NH2-3'-TP) and MazG 
pyrophosphatase (gp356), which catalyzes the hydrolysis of all eight canonical 
ribonucleoside triphosphates (NTP) and deoxyribonucleoside triphosphates (dNTP)  
to their corresponding nucleoside monophosphates [(d)NMP] and PPi, and subsequently 
hydrolyzes the resultant PPi to Pi (Zhang et al., 2003). Finally gp400 is a radical SAM 
domain-containing protein, that catalyze diverse reactions, including unusual 
methylations, isomerization, sulfur insertion, ring formation (Sofia et al., 2001). 
6.3.5. Comparative genome analysis and protein-sharing network  
To better represent genetic relationships between the jumbo bacteriophages with 
genomes of more than 200 kbp (Hendrix, 2009) and other sequenced viruses, a gene-
sharing network was built. Viruses that do not show significant similarity to 42 jumbo 
phages were excluded for clarity. The resulting network was composed of 1,355 viral 
genomes (nodes) belonging to Myoviridae, Siphoviridae, Podoviridae, or uncharacterized 
phages and 37,955 relationships (edges) between them.  
In the network, 21 jumbo phages have been placed into the largest connected 
component that mostly consists of the double-stranded DNA phages; whereas  
the remaining 20 phages into three isolated components (Fig. 6.16 A) and a single isolate 
with no genetic relatives, i.e. Sphingomonas phage PAU (data not shown). Of these,  
the PA5oct, together with 11 jumbo phages belonging to the T4 superfamily and seven 
taxonomically unclassified myoviruses, fell within a highly interconnected region,  
i.e., subnetwork (Fig. 6.16 A and Table S 6.4). A subsequent MCL-based network 
partitioning assigned 168 phage members of this subnetwork into 5 coherent groups  
of phages (i.e., viral clusters, VCs); these include VC_2 that are rich in the T4-like viruses 
and VC_8 mainly comprising T4-related cyanomyoviruses as well as VCs_18, 77, and 
111 (Fig. 6.16 B and Table S 6.5). Notably, PA5oct and Escherichia phages 
121Q/PBECO 4, Klebsiella phages vB_KleM_RaK2 and K64-1, and Cronobacter phage 
vB_CsaM_GAP32 were grouped into VC_77, with strong connections to each other  
in terms of genome-genome similarity value (Fig. 6.16 B). The inclusion of phages into 
the same VC, which is indicative of a group sharing more conserved gene pools (Lima-
Mendez et al., 2008), approximately corresponds to genus-level phage group (Lima-
Mendez et al., 2008; Roux et al., 2015). 
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Additional inspection revealed informative connections between jumbo phages 
and/or other viruses. For example, the Phicbkvirus including phiCbK, Magneto, Swift, 
Karma, Rogue, and CcrColossus as well as phages RSL1, PaBG, and Lu11, which 
belonged to VCs 87 and 172, respectively (Table S 6.5), formed two isolated components. 
This discontinuous positioning of two viral groups clearly reflects their lack of genetic 
relationships to other viruses as evolutionary distinctive braches (Gill et al., 2012, 
Yamada et al., 2010, Adriaenssens et al., 2012). In addition, the φKZvirus including φKZ, 
φPA3, 201φ2-1, EL, and OBP and eight jumbo phages as well as a smaller phage,  
i.e., Vibrio phage ΦJM-2012 (Jang et al., 2013), were found in an individual component 
(Fig. 6.16 A). Interestingly, however, phage members in this φKZ-related component 
were assigned into two VCs 44 and 150 (Table S 6.5), possibly suggesting that  
the diversity of this group would be much larger than previously known (Jang et al., 
2013). Further, in VCs 43 and 184 (Table S 6.4), the Bacillus phages G and 0305φ8-36 
shared proteins with only smaller phages having genomes of approximately 126 to 168 
kbps (data not shown). This observation may support the hypothesis that these giant 
phages could be derivatives of smaller phages (Hendrix RW. 2009). 
Here, a mathematical modeling of a gene-sharing network showed genetic 
relationships of the giant phages across 1,999 viral genomes at the gene content level.  
Of 42 jumbo phages, 20 phages fell into three genetically distinct groups that had  
no recognizable similarity to other viral genomes, whereas nearly 90% of the remaining 
phages had similarity to the Tevenvirinae phages or their relatives. In particular, network 
positioning and decomposition suggested that PA5oct appears to be most closely related 
to a recently emerged new subfamily including phages vB_CsaM_GAP32, 121Q, 
PBECO 4, vB_KleM-RaK2, and K64-1 as distant relatives of the T4 superfamily 
(Abbasifar et al., 2014). Collectively, a network-based approach provided more 
comprehensive views for the diversity of giant phages in various viral lineages.  
 
Figure 6.16: Protein-sharing network for PA5oct and jumbo phages. (A) A network representation was produced using the edge-weighted spring embedded layout  
of Cytoscape version 3.1.1. Each node is depicted as a different shape, representing bacteriophages belonging to Myoviridae (rectangle), Podoviridae (diamond), Siphoviridae 
(circle), or uncharacterized phages (triangle). Selected jumbo phages are shown in red. Edges between two nodes indicate their statistically weighted pairwise similarities with 
similarity scores of ≥ 2. (B) An enlarged view of the subnetwork comprising PA5oct and its relatives. Edge thickness is proportional to similarity values estimated with  
the hypergeometric equation (Materials and methods) and viral clusters are represented in the legend boxes. 
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Figure 6.17: Protein-sharing network and reticulate relationship of PA5oct and T4-related phage 
populations. (A) A network representation was produced using the edge-weighted spring embedded layout 
of Cytoscape version 3.1.1. Nodes indicate phages and edges between two nodes indicate their statistically 
weighted pairwise similarities with significance (Sig) scores of >1. Each node is representing 
bacteriophages belonging to Myoviridae (orange), Podoviridae (violet), Siphoviridae (light blue),  
or uncharacterized phages (dark blue). Edges between two nodes indicate their statistically weighted 
pairwise similarities with similarity scores of ≥2. (B I, II) Assigning of the phages onto population network 
composed of interactions among T4-like phages and unclassified P. aeruginosa phage PA5oct, 
Cronobacter sakazakii phage GAP32 and Escherichia O157-specific phage PBECO4.  
A 
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Moreover, phages 31 and 25 (Secunda5virus), 4RR2.8t (Biquartavirus), and 
phages JS98, RB69, RB32, and T4 (Tevenvirinae) showed relatively strong relationships 
to each other’s genomes due to the significant number of shared protein families, 
indicating large portion of vertically inherited genetic pool (Figure 6.17 A). 
PA5oct (novel), PBECO4 and GAP32 (unclassified Myoviridae), T5 (T5virus), 
FelixO1 (Felixo1virus) appears to be diverged members. Importantly, among these five 
phages, there are two phages that appear to act as bridge for T4-related components due 
to their links to other phage groups. These are T5 and FelixO1 (Figure 6.17 B).  
 General characteristic of PA5oct are presented in table 6.4. 
Table 6.4 Major features of PA5oct phage. 
Phage PA5oct 
Water source Irrigation field 
City/Country/ Date Wrocław/Poland/ 2011 
Host PAO1 
Genome size (bp) 287,182 
GC (%) 33.3 
ORFs 462 
Virion dimensions head/tail [nm] a 131/136 
Latent period [min] 40 
Burst size [pfu/cell] 30-40 
Heat stability for 1h [ºC] 4-60 
pH stability for 1h at RT 5-11 
Chloroform sensitivity at RT/4ºC [h] 24 
6.4. Discussion 
In this chapter we presented characterization of a novel and unique virus PA5oct, 
that belongs to the Myoviridae family and infects P. aeruginosa. It is a member  
of an emerging group of giant phages, which possibly represents a new genus, based  
on genome organization and clustering and the existing parameters for taxonomic 
guidelines (R. Lavigne, personal communication). This group would include coliphage 
121Q, E. coli 157:H6 phage PBECO4, Klebsiella phage RaK2 and Cronobacter phage 
GAP32. The representatives of this group have very large heads, relatively short tails, and 
limited genomic relationships with other phages (Abbasifar et al., 2014).  
In contrast to previously characterized Pbunaviruses KT28 and KTN6, as well  
as φKZ isolate KTN4, PA5oct presented narrow host range and lower stability in a range 
of temperature and pH. These features could become a potential obstacle in phage 
preparations for therapeutic purposes. Nevertheless, initial biofilm degradation 
assessment clearly presented potential of PA5oct for biofilm degradation. This phage was 
able to create visible tunnels in 24 h and 48 h old biofilm structure. This ability is currently 
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further evaluated by Drulis-Kawa group and collaborators (Department of Microbiology, 
Institute of Biology and Department of Molecular Physics, Instituteof Physics,  
The Jan Kochanowski University in Kielce, Poland). Furthermore, the experiments using 
the ‘Airway Surface Layer’ infection model proved its potent antibacterial activity  
(2.5 - 6.5 logs reduction of an extracellular bacterial load). PA5oct phage was only 
slightly less efficient compared to the previously characterized KTN4 phage (4 -7 logs 
reduction of bacterial CFUs) (chapter 5). In the NuLi-1 cell line infection, caused  
by PAO1 and CF708 strains, KTN4 treatment was more efficient. However, the infection 
caused by the non-CF0038, burn wound isolate was more susceptible to PA5oct 
treatment. In case of CuFi-1 infection, treatment with KTN4 reduced greater CFUs  
of nonCF0038 strain (6 log reduction compared to a 2.5 log reduction by PA5oct), 
whereas the treatment of PAO1 and CF708 was almost identical for both phages. 
Morever, substantial differences can be observed during the bacterial internalization 
process. PA5oct significantly (p < 0.05) reduced internalization level of nonCF0038 and 
CF708 strains into NuLi-1 epithelial cells, by 3 and 1 log respectively, while KTN4 
treatment was not effective. The opposite situation was found for the CuFi-1 cell line, 
where PA5oct treatment was not effective, while KTN4 reduced invasion of nonCF 
strains by 1 log. These results show, that considering the entire experiment, the efficacy 
of treatment was highly strain and condition dependent. This analysis confirms that 
potential phage therapy should be considered in a form of phage cocktails, which would 
comprise phages with different, complementary features. However, their synergistic 
effects should be studied in detail. Moreover, both giant phages, KTN4 and PA5oct, could 
serve as antimicrobial agents, however in altered lung environment their activity could 
possibly be supported by viscosity reduction agents and/or other antimicrobials.  
The PA5oct DNA sequencing revealed a giant linear double-stranded DNA 
genome, which is the eight largest sequenced myovirus and third largest among 
Pseudomonas phages. Only P. aeruginosa phage φPA3 (309 kbp, Monsonet al., 2011) 
and P. chlororaphis phage 201φ2-1 (316 kbp, Thomas et al., 2008) possess bigger 
genomes. Importantly, to date, the largest myovirus known, and also the largest phage  
in terms of capsid size and DNA content, is Bacillus megaterium phage G (head  
of 160 nm in diameter and 497,513 bp genome). However, some giant phages, especially 
those reported prior to the 1990s, were identified only by electron microscopy  
(e.g. Gluconobacter phage GW6210) (Abbasifar et al., 2014).  
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Unfortunately, only for a small number of phage proteins a putative function was 
predicted. A large pool of ORFs was unique, without any sequence similarity  
in the currently databases. The highest amino acids similarity was found with 
Cronobacter phage vB_CsaM_GAP32, Escherichia phage 121Q and Enterobacteria 
phage vB_KleM_RaK2. Limited sequence similarity may result from low availability  
of annotated giant genomes. Most databases consist vast pool of genomes < 100 kbp,  
in which gene features differ greatly compared to giant viruses. For this reason  
the functional annotation of giant phage genomes is of utmost importance. It will help 
assess phage safety and explain basic phage biology properties. The biological functions 
of these pool of unknown proteins could be revealed by e.g. screening the libraries  
of unknown genes toward e.g. inhibitory, antibiofilm or metabolism modulation 
functions. However, this research is complex and time consuming (Van den Bossche  
et al., 2014, Wagemans et al., 2014). Another option is ESI-MS/MS and RNA seq. Mass 
spectrometry can reveal the presence of proteins involved in virion structure, while RNA 
seq in general significantly improves genome annotation. Whole genome analysis  
of transcription using RNA seq is a powerful way to elucidate differential expression  
of gene features across different conditions. The RNA sequencing has revolutionized 
genome annotation. By experimentally defining the timing and expression levels  
of transcripts in both phage and host, directional RNA seq has the ability to discover novel 
coding sequences, particularly for non-coding RNAs and small phage peptides falling 
below gene prediction thresholds (Ceyssens et al., 2014). In this manner, we can refine 
annotations of existing coding sequences, predicted strictly in silico, based  
on the presence of open reading frames and often distant orthology to other often 
hypothetical features. 
To examine the genetic relationships between PA5oct and other jumbo 
bacteriophages as well as Myoviridae, Siphoviridae, Podoviridae viruses, a protein-
sharing network was constructed. The PA5oct, Escherichia phages 121Q/PBECO 4, 
Klebsiella phage vB_KleM-RaK2, Klebsiella phage K64-1, and Cronobacter phage 
vB_CsaM_GAP32 presented closer relationships based on shared conserved core genes. 
Furthermore, PA5oct, PBECO4, GAP32, T5, FelixO1 appears to be distantly diverged 
members of Tevenvirinae. The T5 and FelixO1 phages appear also to act as bridge for 
T4-related components due to their links to other phage groups. Unlike the marker genes 
of bacteria (i.e.,16S rRNA genes), which can be used for their taxonomic classification, 
viruses often lack those universal genes. Thus, a traditional single-gene-based phylogeny 
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can be limited to several viral groups. That is why presented here protein-sharing network 
introduce another approach, which provides a global view and is consistent with current 
taxonomic groupings. Using this approach, the possible genetic relationships for not only 
PA5oct, but all giant phages among whole phage population could be observed.  
In the network, viral clusters for the giant phages are not always consistent with genus 
levels as currently defined by ICTV. Specifically, the hypergeometric formula used  
in this study can measure the significance based on the possibility of gene sharing 
between genomes, rather than their magnitude, whereas the ICTV uses the magnitude  
of gene-sharing to define the genus and subfamily (i.e., 40% genus and 20% for 
subfamily). Thus, some inconsistency can be expected. Presented here connections  
of PA5oct with other giant viruses as well as their clustering into the same clusters can 
indicate their closest relationships. Considering all these characteristics, PA5oct phage  
is an interesting subject to study, which present unique features and should be further 
explored.  
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Włodarczyk, promoters: Prof. Rob Lavigne and Dr. Lorena Rodriguez-Rubio). 
 The identification and recombinant protein expression of LKA1 gp49 have been 
presented in doctoral dissertation of Anneleen Cornelissen (Laboratory of Gene 
Technology, KU Leuven, 2011). 
 The LKA1 gp49 crystal structure was provided by Dr. Petr G. Leiman (École 
Polytechnique Fédérale de Lausanne, Lausanne, Switzerland). 
 The size exclusion chromatography was performed in the Centre of Microbial and 
Plant Genetics with the help of technician Jos Desair (Prof. Jan Michiels,  
KU Leuven). 
7.1. Introduction 
 Highly diverse bacterial polysaccharides are composed of single sugars linked 
together to complex high molecular weight branching moieties of three or more sugar 
residues. Based on localization they are classified as intracellular (covalently or ionically 
associated with the cell peptidoglycan), structural (i.e. LPS) or extracellular (EPS). They 
play important role in structural cell integrity, cell adherence to surfaces, as well  
as in biofilm structure (Roach et al., 2015; Campodonico et al., 2008). 
Exopolysaccharides protect the embedded bacteria from desiccation as well  
as phagocytosis or antimicrobial agents, promote virulence and mask cells surface 
receptors, necessary for phage adsorption (Kumar et al., 2007; Looijesteijn et al., 2001; 
Mushtaq et al., 2005). EPS is the most abundant polysaccharide and can be in form  
of polysaccharide capsules covalently bound to the cell surface or secreted outside  
the cell in the form of mucus (Roach et al., 2015).  
In nature, specific bacteriophages may possess EPS/LPS depolymerases  
to degrade bacterial polysaccharides during phage infection. These enzymes can  
be overproduced and release to the environment during cell lysis or associated to viral tail 
structure as for example tail spike proteins (Sutherland, 1999; Casjens et al., 2011).  
The presence of these enzymes is manifested in vitro as a halo zone around the phage 
plaques, which results from the enzymatic degradation of bacterial EPS without phage 
infection (Azeredo et al., 2008). However, the knowledge about depolymerases  
is currently very limited and mainly derived from E. coli phages (Leiman et al., 2007). 
Little is known about their substrate binding and cleaving domains. It is also unknown  
to what extent the depolymerase activity is required for the infection process and how 
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possible variations in the amount and density of the polysaccharide influence this process 
(Pelkonen et al., 1992). 
The LoGT (KU Leuven) possess a large collection of Pseudomonas phages 
characterized for intended use in the phage therapy of the multidrug resistant bacteria. 
From this pool two phages with potential virion-associated EPS/LPS degrading enzymes 
were selected. In this study we isolated the enzyme domains and characterized their 
structure as well as the expression and purification conditions. The activity of each protein 
was assessed against bacterial EPS, LPS knock out Pseudomonas mutants and biofilms.  
7.2. Detection and bioinformatics analysis- a search for polysaccharide 
depolymerases  
 For the purpose of this study, two phages, Luz7virus LUZ7 and phiKMVvirus 
LKA1 with potential EPS/LPS depolymerases were selected. The presence of these 
specific enzymes was identified by the formation of opaque-looking halo zones around 
phage plaques (Fig. 7.1). Diameter of LKA1 halo zone on PAO1 Krylov lawn increased 
from 0.5 ± 0.1 cm after 24 h, to 0.6 ± 0.2 after 48 h and 0.8 ± 0.1 cm after 72 h incubation  
at 37°C. In case of LUZ7 the increase in diameter of the halo zone was not observed. 
Figure 7.1: Plaque morphology of Luz7virus LUZ7 and phiKMVvirus LKA1. (A) Plaques of phage 
LUZ7 and (B) LKA1 upon infection of PAO1 Krylov. In cases of phage LKA1, in the course of time,  
the diameter of the halo zone surrounding a plaque increases. 
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After detailed analysis of phage genomes, two large ORFs (LKA1 gp49, 2310 bp; 
and LUZ7 gp56, 3210 bp) encoding putative polysaccharide depolymerases, were 
selected for further study. Both genes present only 9.1% similarity to each other 
(ClustalW2). The LKA1 gp49 was successfully prepared by Anneleen Cornelissen a few 
years ago (LoGT, KU Leuven, 2011). Unfortunately, the corresponding PCR product  
of LUZ7 gp56 was very difficult to clone into expression vectors (pEXP5-NT/TOPO®, 
pEXP5-CT/TOPO®, pBAD/TOPO ThioFusion®) and further express in order to achieve 
soluble active protein (variation of competent cells and expression conditions, Table 7.3). 
For this reason, we focused on the depolymerase domains (both LKA1 gp46 and LUZ7 
gp56), that in the future could be also suitable candidates for protein engineering  
(e.g. fusion with other protein domains). 
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Table 7.1: The list of polysaccharide depolymerases and their domain candidates chosen for this study. 
Abbreviations: (*) amino acid locus in a full length protein; (pI) a isoelectric point; (Ext. coeff.) an extinction coefficient parameter; (NCBI) National Center for Biotechnology 
Information. 
. 
  
Protein 
(NCBI code) 
Origin Nucleotide 
length 
Amino acids 
length 
Theoretical 
pI 
Ext. coeff. 
(M-1 cm-1) 
Putative catalytic 
specificity 
Protein homologue 
(hhpred, NCBI code, e-value) 
LKA1 gp49 
(YP_001522890.1) 
 
P. aeruginosa 
phiKMVvirus 
LKA1 
2310 769 
(80.34 kDa) 
4.77 75470 
 
 
 
 
Pectin/pectate lyase 
Pseudomonas phage phi297 tail 
spike gp61 (4RU5, e-value 1.1E-74) 
(Browning, to be published) 
Yersinia enterocolitica family 28 
exopolygalacturonase (2UVF,  
e-value 1.9E-20) (Abbott et al., 
2007) 
LKA1 gp49 domain 
(389 - 584 aa)* 
294 198 
(20.81 kDa) 
4.89 23545 
 
LUZ7 gp56 
(YP_003358338.1) 
 
 
P. aeruginosa 
Luz7virus 
LUZ7 
3210 1070 
(115.74 kDa) 
5.32 195985  
GDSL-like 
Lipase/Acylhydrolase 
family or SGNH 
hydrolase 
Pseudomonas phage KPP21 gp96,  
a putative SGNH hydrolase-type 
esterase domain protein (e-value 
0.0) 
GDSL-like Lipase from 
Parabacteroides distasonis ATCC 
8503 (3P94,e-value 1E-06) 
LUZ7 gp56 domain 
(410 - 673 aa)* 
798 266 
(29.00 kDa) 
6.51 58900 
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LKA1 gp49 
Gp49 is a tail spike protein of phiKMVvirus LKA1. Bioinformatics analysis revealed 
that its C-terminal part (136 - 769 aa) consist of a right-handed β-helical structure elements 
typical for carbohydrate-binding proteins, recognizing LPS or EPS structures (Fig. 7.2), and 
often serves as the determinant of phage host cell specificity (Molineux, 2006; Barbirz et al., 
2008; Muller et al., 2008; Walter et al., 2008). It is similar to the C-terminal region  
of P. aeruginosa siphovirus D3 gp27 (Kropinski, 2000). The external part of the C-terminus 
has no amino acid sequence or secondary structure homology. In other tail spike proteins, this 
C-terminal part have been shown to be important in the folding and trimerization processes 
(Schwarzer et al., 2007; Walter et al., 2008; Xiang et al., 2009). A centrally located putative 
pectate lyase domain (Phyre1 136 - 769 aa, Phyre2 180 - 681 aa, InterPro 222 - 546 aa, HMMER 
389 - 584 aa, HHpred 223 - 559 aa) was also identified. The pectate lyase superfamily  
is important in galacturonan components degradation of pectin (Jenkins et al., 2001).  
The conserved N-terminus of LKA1 gp49 is similar to N-terminal region of the T7 phage tail 
spike protein gp17 and provides the stable association of the catalytic C-terminal region with 
the tail structure (Steven et al., 1988).  
 
 
 
 
 
Figure 7.2: Pfam analysis of LKA1 gp49 structure. Predicted conserved N-terminus associated with tail 
structure is marked violet, C-terminal domain with catalytic activity marked olive (Hmmer). 
The crystal structure of LKA1 gp49, lacking the highly flexible N-terminal phage tail 
fiber region was resolved in a collaboration with Dr. Petr G. Leiman (École Polytechnique 
Fédérale de Lausanne, Lausanne, Switzerland) (Fig. 7.3). The crystallography experiments 
elucidated a hexamer composed of two homo trimer A3 structures, built of six chains, A-F, 
(resolution of 1.9 Å, R-factor 0.132, R-free 0.174, PDB code 4RU4).  
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Figure 7.3: Representation of three dimensional structure of LKA1 gp49 based on crystallography.  
(A) hexamer composed of two trimeric structures. (B) trimeric structure composed of three chains, marked red, 
blue, green. (C) single chain. Cartoon representation, PyMol modelling. 
Further structure modelling in PyMol and MOE programs allowed us to identify  
the localization of enzyme active center (Fig. 7.4). This area constitutes a group of amino acids 
which are close to each other in a three-dimensional molecule. They are responsible for  
the binding of substrates and the prosthetic groups to form a complex of enzyme-substrate, 
wherein the reactive moieties are located near the center of the catalyst. This may occur with 
changes in the conformation of both, the substrate and enzyme.  
 
 
 
 
 
 
 
 
 
 
Figure 7.4: Crystal structure of LKA1 gp49. (A) schematic representation of LKA1 gp49 active center  
in protein trimer. Blue arrows and purple sticks represent amino acid sequences belonging to enzyme active site 
in the individual trimer subunits, marked as green cartoons. View from top of trimer. (B) schematic representation 
of LKA1 gp49 active center in the single chain. Red, purple and blue sticks represent three sites of active center. 
Green cartoons represent structure of single subunit. Side view. PyMol modelling. 
B C A 
A B 
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MOE analysis allowed for prediction of three sites of enzyme active center, that could 
in the future be targets of a side-directed mutagenesis (Fig. 7.5). 
Site 1 (168-454 aa) 
GSVGQSLQFLEMGRVTPAQFGAVGDGASHPLSERYATLAEAQTVYPHAVALSDEIDWAALQAAVDSGAPVHIPSGDYQINRG
ISSTGSLQIAGDGATSIIRPTAAFTGTSVLSCVGSLVALPNISSVSAGSLTIDFASTPNLVAGDVFIIYNPTDSSFSGFRTSYRAGEFCEV
RAVSGNTVTIRSALYAAYDGATVAIYKVVSGVVDIASIQIVGGTVPMNGLLVEAVVSPRVDDVTVTLANNAGVYFARCYDAKIT
NSNISNIGDGGDDYGIIFGNCHDGGADNCK 
Site 2 (289-470 aa) 
PNISSVSAGSLTIDFASTPNLVAGDVFIIYNPTDSSFSGFRTSYRAGEFCEVRAVSGNTVTIRSALYAAYDGATVAIYKVVSGVVDIA
SIQIVGGTVPMNGLLVEAVVSPRVDDVTVTLANNAGVYFARCYDAKITNSNISNIGDGGDDYGIIFGNCHDGGADNCKVYARRHAI
ATGGDAEV 
Site 3 (193-454 aa) 
GASHPLSERYATLAEAQTVYPHAVALSDEIDWAALQAAVDSGAPVHIPSGDYQINRGISSTGSLQIAGDGATSIIRPTAAFTGTSVLS
CVGSLVALPNISSVSAGSLTIDFASTPNLVAGDVFIIYNPTDSSFSGFRTSYRAGEFCEVRAVSGNTVTIRSALYAAYDGATVAIYKV
VSGVVDIASIQIVGGTVPMNGLLVEAVVSPRVDDVTVTLANNAGVYFARCYDAKITNSNISNIGDGGDDYGIIFGNCHDGGADNC
K 
Figure 7.5: Three sites of enzymatic active center of LKA1 gp49 predicted with MOE. Bolded amino acids 
are predicted to play the key role in the active center. 
 The secondary structure analysis revealed, that a single chain is composed of: 6% helical 
(8 helices; 37 residues) and 48% β-sheet (15 β-bridges and 47 β-strands; 291 residues) 
structures. The results are summarized on figure 7.6. This analysis was crucial to properly 
defined LKA1 gp49 domain, without cutting secondary structures, i.e. helices and strands. 
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Figure 7.6: The secondary structure analysis of LKA1 
gp49 single chain. Legend is provided below diagram. 
PDBsum analysis. 
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Based on above analysis LKA1 gp49 domain was chosen for further analysis  
(Fig. 7.7, Table 7.1). Additional margin of amino acids was added to prevent cuts  
in the secondary structures, i.e. helices and strands, that could have an impact on protein 
folding. 
 
 
Figure 7.7: Prediction of LKA1 gp49 domain. From top to bottom: whole length protein and domain 
(389 - 584 aa, pfam). Amino acid position is given on the left and right side.  
LUZ7 gp56 
Gp56 is a tail fiber protein of Luz7virus LUZ7 with centrally located putative 
GDSL-like Lipase/Acylhydrolase family (SGNH hydrolase) domain (453 - 653 aa, 
BLAST P, hhpred, InterPro Scan; 459-641 aa pfam) (Fig. 7.8).  
Figure 7.8: Pfam analysis of LUZ7 gp56 structure. The GDSL-like Lipase/Acylhydrolase family (SGNH 
hydrolase) domain is marked blue (Hmmer). 
GDSL lipases are hydrolytic enzymes with multifunctional properties, such  
as broad substrate specificity and regiospecificity. All representatives have five conserved 
sequence blocks (I–V) and are further classified based on the strict conservation  
of the catalytic residues Ser, Gly, Asn, and His within conserved blocks I, II, III, and V, 
respectively (Fig. 7.9) (Dalrymple et al., 1997; Ling et al., 2006; Mølgaard et al., 2000). 
They exhibit a GxSxxxxG motif, in which the active site serine is located near  
the N-terminus and display a Gly-Asp-Ser-(Leu) [GDS(L)] motif in conserved block I 
(Jiang et al., 2012; Brick et al., 1995; Lee et al., 2009; Updegraff et al., 2009; Upton  
et al., 1995). These enzymes have little sequence homology with true lipases and have  
a similar fold to flavoproteins, i.e. a three-layer α/β/α structure, where the β-sheets are 
composed of five parallel strands (Akoh et al., 2004).  
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Figure 7.9: Sequence alignment of four conserved blocks in the GDSL-like Lipase family. Sequence 
alignment of conserved blocks and flanking residues in LUZ7 gp56 (GP56); GCAT: Aeromonas hydrophila 
lipase/acyltransferase (SWISS-PROT P10480); EtpA: Vibrio mimicus arylesterase (SWISS-PROT 
Q07792); EstA: Lactobacillus helveticus CNRZ32 arylesterase (TrEMBL Q9LAH7). Four consensus 
blocks I, II, III, and V are boxed by a black line. Conserved residues are masked in red (absolutely 
conserved) or yellow (in at least two sequences). The number in parentheses indicates the location  
of the end residue. The secondary element assignment, above the alignment, corresponds to the LUZ7 gp56 
structure. Yellow arrow corresponds to strand, violet cylinder to helix. The catalytic triad and oxyanion 
hole residues are indicated by red-filled down triangles and blue-filled circles, respectively.  
 Analysis of secondary structure revealed, that LUZ7 gp56 domain is composed  
of 8 α-helices, 4 β-strand, 48 β-turns and 6 γ-turns. The results are summarized in figure 
7.10. As previously described, this analysis was crucial for precise definition of domain 
length.  
 
 
 
 
 
 
 
 
 
 
 
Figure. 7.10: The secondary structure analysis of LUZ7 gp56. Legend is provided below diagram. 
PDBsum analysis. 
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 The tertiary structure predictions of the whole length LUZ7 gp56 showed low 
homology (Phyre2). However, when we focused only on the centrally located domain 
with additional margin of amino acids estimated based on secondary structure prediction 
(410 - 673 aa), the tertiary structure could be predicted with the highest homology 
corresponding to Flavodoxin-like SGNH acetylhydrolase (98.2% confidence in Phyre2) 
(Fig. 7.11).  
 
 
 
 
 
 
Figure 7.11: Prediction of LUZ7 gp56 domain tertiary structure. Tertiary structure with loops and turns 
marked green, β-sheets yellow and α-helices red. Cartoon representation. PyMol modelling.  
The ligand binding site could be predicted with the use of 3DLigandSite-Ligand 
binding site prediction Server (Table 7.2, Fig. 7.12). The GDSL lipases have a flexible 
active site, which alters its conformation in the presence and binding of the different 
substrates (Akoh et al., 2004; Ling et al., 2006). 
Table 7.2: Prediction of the LUZ7 gp56 domain ligand binding site based on structure homology 
(3DLigandSite-Ligand binding site prediction Server).  
Protein The closest protein structure homologue Amino acid composition of ligand 
binding side 
LUZ7 gp56 
domain 
crystal structure of bovin brain platelet 
activating factor acetylhydrolase covalently 
inhibited by soman (85% coverage, PDB 
code 3DT9, Epstein et al., 2009) 
52 ASP, 53 SER, 54 ILE, 60 GLU, 100 
VAL, 101 GLU, 102 GLY, 103 ARG, 
104 ARG, 126 HIS, 129 THR, 130 ASN, 
134 ASP, 170 LYS, 171 LEU, 172 TYR, 
173 ASN, 210 VAL, 217 PHE, 218 ASP, 
219 PRO, 224 ASP, 225 ASP, 226 GLY, 
227 LEU, 228 HIS, 229 LEU, 233 SER 
 
 
 
 
 
 
 
 
 
 
 
Figure 7.12: Predicted binding site of the LUZ7 gp56 domain. The binding site marked with purple 
sticks, the rest of the protein presented as a green cartoons. PyMol modelling.  
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 For further analysis one domain was selected (410 - 673 aa), based on analysis 
presented above (Fig. 7.13). 
 
 
 
 
Figure 7.13: Representation of selected LUZ7 gp56 domain. Amino acid position is given on the left 
and right side. 
7.3. Cloning, recombinant expression and purification 
The gene sequences encoding two putative EPS/LPS depolymerases and their 
domains (Table 7.1) were amplified by Phusion® High-Fidelity DNA polymerase with 
low error rate. First, all PCR products were cloned into pEXP5-CT/TOPO®  
or pBAD/TOPO ThioFusion® vector, however protein expression did not occurred  
or proteins were poorly expressed in soluble fraction with the presence of inclusion bodies 
(0.06 - 0.21 mg/ml). Changing conditions, such as competent cells [E. coli 
BL21(DE3)pLysS, BL21 A1, E. coli Lemo21(DE3), E. coli BL21-Codon Plus(DE3),  
E. coli ArcticExpress(DE3), Rosetta(DE3)], medium (LB, modified LB, TB, 2xTY  
or autoinduction), expression temperature (37°C or 16°C) or inducer concentration  
(1M - 0.1 mM) did not improved protein expression. Finally, the expression vector was 
changed to pEXP5-NT/TOPO® with a 6x His-tag in the N-terminus and expression was 
successful, except full length LUZ7 gp56 that still remained unexpressed. The optimal 
conditions, i. e. where protein is the most abundant in the soluble fraction, were  
as follows: 1) E. coli BL21(DE3)pLysS, 2xTY medium, 0.1 mM IPTG and overnight 
incubation at 16°C for LUZ7 gp56 domain; 2) E. coli Lemo21(DE3), 2xTY medium,  
0.4 mM IPTG and 0.5 mM L-rhamnose for full length LKA1 gp49 (prepared from  
A. Cornelissen construct) and its domain. A summary of the expression optimization  
is presented in table 7.3.  
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Table 7.3: Protein expression optimization process for four putative EPS/LPS degrading enzymes. 
Gray color marks conditions were expression was successful and protein appeared in soluble fraction, 
however not in all cases expression yield was sufficient.  
Type Name LKA1 gp49 LUZ7 gp56 
gp49 domain gp56 domain 
vector pEXP5-CT/TOPO   √ √ 
pEXP5-NT/TOPO √ √ √ √ 
pBAD/TOPO 
ThioFusion 
√ √   
expression 
strain 
Lemo21 (DE3) √ √ √ √ 
BL21 CodonPlus (DE3)   √ √ 
BL21 (DE3) pLysS  √ √ √ √ 
BL21 AI  √ √ √ √ 
Rosetta(DE3)    √ 
Arctic Express (DE3)    √ 
medium LB √ √ √ √ 
2xTY √ √ √ √ 
Modified LB √ √  √ 
TB √ √  √ 
Autoinduction √ √  √ 
temperature 
post 
induction 
37°C (4.5 h)   √  
16°C (overnight) √ √ √ √ 
L-rhamnose 0.5 mM √ √ √ √ 
IPTG 0.1 mM √ √ √ √ 
0.4 mM √ √ √ √ 
final conditions pEXP5-NT/TOPO 
Lemo21 (DE3) 
LB medium 
0.4 mM IPTG 
0.5 mM L-rhamnose 
16°C (overnight 
expression) 
---- pEXP5-NT/TOPO 
E. coli BL21 
(DE3)pLysS,  
2xTY medium,  
0.1 mM IPTG 16°C 
(overnight 
expression) 
 
The presence of recombinant proteins was checked after expression with the use  
of SDS-PAGE and Western Blot methods (Fig. S 7.1 - 7.3). It also has to be stressed, that 
expression of LUZ7 gp56 domain was still difficult and inconsistent with presence  
of inclusion bodies. Moreover, despite keeping all the time the same expression 
conditions, protein was not always active, probably due to an incorrect fold or a poor 
stability after purification. 
Finally, a large scale expression (500 ml culture) was performed and proteins were 
purified with the use of ÄKTA FPLC system in combination with HisTrapTM HP 1 ml 
columns (Fig. S 7.1 - 7.3). The purity of all proteins was further increased by filtration 
through 10 K or 30 K filter units, depending on the protein size, and the size exclusion 
chromatography (Fig. S 7.1 - 7.3). Pure proteins were kept in elution buffer at 4°C with 
precipitation inspections. 
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Based on the molecular weight of the fraction eluted after exclusion 
chromatography, the theoretical size of pure protein could be determined in native state. 
This could be accomplished with the use of column calibration curve of the HiLoad 
16/600 Superdex 200 Prep grade gel filtration column (GE Healthcare) and Superdex 
200HP GL10/30 gel filtration column (GE Healthcare). In the case of LKA1 gp49 there 
was a protein peak present at 59.31 ml of elution, which corresponds to 286.70 kDa. 
Unfortunately, this protein peak was out of range of column and cannot be precisely 
assessed. However, this result suggest that protein (80.34 kDa) creates a trimer. This was 
also observed for other polysaccharide-degrading tail spike proteins interacting with LPS-
structures (Miller et al., 1998; Freiberg et al., 2003; Walter et al., 2008) or EPS-molecules 
(Muhlenhof et al., 2003; Stummeyer et al., 2006). The crystal structure of LKA1 gp49 
confirms this result. The chromatogram of LKA1 gp49 domain was highly unusual. Seven 
protein peak were registered at 46.25, 57.59, 69.68, 83.66, 86.65, 99.16 and 110.22 ml  
of elution, which corresponds to 872.27, 331.95, 118.51, 36.01, 27.92, 9.62 and 3.75 kDa, 
respectively. First two protein peaks were also out of range of column and cannot  
be precisely assessed. Protein (20.81 kDa) is the most abundant in the second protein 
peak, and later in first, third and fourth protein peak, the rest of the protein peaks 
represented expression impurities. This means that LKA1 gp49 domain possibly 
aggregates. Further analysis is required using e.g. Multiangle Light Scattering – SEC  
or Circular Dichroism methods to determine if the domain is properly folded and what 
kind of multimer is formed. Finally, the chromatogram of LUZ7 gp56 domain recorded 
4 protein peaks at 11.65, 14.34, 15.66 and 16.55 ml of elution, which corresponds  
to 454.20; 123.16; 64.91 and 42.15 kDa. First protein peak is out of range of column and 
cannot be precisely assessed, however gp56 domain (29.00 kDa) was the most abundant 
in that protein peak. The 12% SDS-PAGE gel analysis of elution fractions of that protein 
peak elucidated a band on the weight corresponding to dimer of this domain or the protein 
could aggregate (Fig. S 7.3). Further analysis would be also required. The protein 
expression yields are presented in table 7.4. The highest concentration was achieved for 
LKA1 gp49 (1.36 g/500ml). 
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Table 7.4: The average yields of purified proteins. Measurements were performed on a Nanodrop  
at wavelength of 280nm with specific parameters of molecular weight and extinction coefficient (Expasy 
Protparam). 
Protein Total protein yield (g/ 500 ml) after 
FPLC affinity purification 
Total protein yield (g/ 500ml) 
after size exclusion purification 
LKA1 gp49  7.64 1.36 
LKA1 gp49 domain 0.97 0.1 
LUZ7 gp56 domain 0.99 0.2 
(FPLC) Fast Protein Liquid Chromatography 
7.4. Activity assessment of polysaccharide degrading enzymes 
 To assess recombinant protein activity first an elution buffer with imidazole was 
exchanges to PBS pH 7.5 with the use of 10 K or 30 K Amicon filter units. Next, 10 µl  
of pure recombinant protein from the highest purification elution fraction was dropped  
on a P. aeruginosa PAO1 Krylov lawn (Fig. 7.14).  
The recombinant LKA1 gp49 and its domain preparations (Fig. 7.14 A) created  
an opaque-looking halo zones (> 2.0 cm), which diameter increased upon incubation  
at 37°C. For LUZ7 gp56 no enlargement in diameter was observed and area of spotting 
was unusual, resembling rather phage plaques with resistant colonies on it (Fig. 7.14 B). 
Protein was manufactured two more times, but the same effect was achieved or there was 
no activity. It is required to repeat this protein preparation and activity evaluation. 
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Figure 7.14: The activity assessment of potential polysaccharide depolymerases on P. aeruginosa PAO1 Krylov lawn. In all plates 10 µl of sample was spotted. 
(A) From left to right: 1) CsCl pure LKA1 phage solution (8.84 x 108 pfu/ ml) with PBS control below visible spot; 2) pure recombinant protein of LKA1 gp49  
(2.00 mg/ml, 24.89 µM, left halo zone) and LKA1 gp49 domain (0.5 mg/ml, 24.03 µM) with PBS control below visible spots; (B) From left to right: 1) CsCl pure LUZ7 
phage solution (1.39 x 109 pfu/ ml) with PBS control below visible spot; 2) 1 mg/ml (34.48 µM) LUZ7 gp56 domain (2 repeats) with PBS control above visible spot. 
The size of each phage plaque and spot area is comparable. In case of phage LKA1 gp49 and its domain diameter of halo zones increases upon incubation at 37°C. 
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LKA1 phage uses the LPS B-band O-antigen as a primary host cell receptor.  
LPS is the outermost polysaccharide molecule of P. aeruginosa PAO1 outer membrane. 
Based on this information, putative pure recombinant proteins were spotted (10µl, same 
protein concentrations as described above) on P. aeruginosa PAO1 LPS mutants lawn  
(Table 7.5). Proteins created halo zone only in case of PAO1 Δrmd (A-, B+) mutant, 
which suggest that they are able to degrade B-band of PAO1 LPS.  
Table.7.5: Recombinant EPS depolymerases halo formation on P. aeruginosa PAO1 LPS mutants.  
Strain Feature LKA1  LUZ7 gp56 
domain gp49 domain 
PAO1 Δrmd 
(A-, B+) 
Deficiency in D-rhamnose biosynthesis; 
lack of A-band LPS 
H H H 
PAO1 ΔrmLC 
(A-, B-, core-) 
Deficiency in L-rhamnose biosynthesis; 
truncate core region, lack of A-band and  
B-band LPS 
/ / / 
PAO1 ΔwaaL 
(A-, B-) 
Lack of WaaL ligating O-polymer to 
core-lipid A; LPS is devoid of A-band and 
B-band, semirough (SR-LPS, or core-
plus-one O-antigen) 
/ / / 
PAO1 ΔwbpL 
(A-, B-) 
Lack of glucosyltransferase WbpL 
essential for initiation of both A-band and 
B-band synthesis 
/ / / 
(H=halo formation). 
Further microscopic analysis of halo zones and the outside bacterial zone was 
performed (Fig. 7.15). It was clearly showed that EPS material keeps cells closely 
associated with small clusters. Bacteria taken from halo zone were separated from each 
other and their EPS slime was reduced.  
 
 
 
 
 
 
 
Figure 7.15: Negative staining of P. aeruginosa PAO1 cells in the outside bacterial and in the halo 
zone. Within the outside bacterial zone (top left) bacteria are surrounded by withe EPS slime and backed 
closely together, while in the halo zone cells are spread separately and the surrounding EPS was reduced. 
Scale bar represents 100 µm. Under protein name are presented enlarged bacterial cells images. 
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Finally, to assess the biofilm-degradative properties of EPS/LPS depolymerase 
domains, a 24 and 48 h old biofilms of P. aeruginosa PAO1 Krylov were formed on peg 
lid plates under static conditions (Fig. 7.16). The incubation temperature was 37°C and 
the treatment time with protein domains was 30 min. Both conditions were demonstrated 
to be most suitable for the activity in case of other depolymerases reported so far,  
e.g. Dpo7 (Gutiérrez et al., 2015). All the assays were performed twice, with four repeats 
for each. As a negative control served biofilm treated with LB broth [(-) LB].  
The positive control was a treatment with high concentration (837.53 µM, 0.4 mg/ml)  
of gentamicin. The gentamicin MIC for the tested strain was 0.5 µg/ml (1.05 µM).  
The final protein domains concentrations, chosen based on the expression efficiency, 
were as follows: 1) LKA1 gp46: 2 mg/ml (24.89 μM); 1 mg/ml (12.44 μM), 0.5 mg/ml  
(6.22 μM); 2) LKA1 gp46 domain: 0.1 mg/ml (4.80 μM), 0.05 mg/ml (2.40 μM) and 
0.025 mg/ml (1.20 μM); 3) LUZ7 gp56 domain: 0.07 mg/ml (2.4 μM) and 0.03 mg/ml 
(1.2 μM) (Fig. 7.16). For statistic assessment a standard t-tests (p < 0.05) were performed. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 7.16: The antibiofilm effect of LKA1 gp49 and its domain and LUZ7 gp56 domain 24 h and 
48 h P. aeruginosa PAO1 biofilm formed on peg-lid plates. As a negative control serves biofilm treated 
with LB broth [(-) LB], as a positive gentamicin treatment [(+) gentamicin (0.4 mg/ml, 837.53µM)]. Further 
are presented activities of domains and their two-fold dilutions: 1) LKA1 gp46: 2 mg/ml (24.89 μM);  
1 mg/ml (12.44 μM) and 0.5 mg/ml (6.22 μM); 2) LKA1 gp46 domain: 0.1 mg/ml (4.80 μM) and  
0.05 mg/ml (2.40 μM) and 0.025 mg/ml (1.20 μM); 3) LUZ7 gp56 domain: 0.07 mg/ml (2.4 μM) and  
0.03 mg/ml (1.2 μM). The results are presented as the means ±SD. (*) statistical significant biofilm 
reduction. 
In the case of 24 h old biofilm treatment there was a significant (p < 0.05) 
difference between negative control and gentamicin. The high dose of antibiotic treatment 
was able to reduce biofilm by 29%. However, the protein treatments had no influence  
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on biofilm formation. The gentamicin treatment presented also a significant (p < 0.05) 
degradation of 48 h old biofilm, (21% reduction), whereas all the rest recombinant 
proteins again did not reduced biofilm matrix.  
7.5. Protein stability 
 Since LKA1 gp49 domain presented the strongest activity against P. aeruginosa 
PAO1 polysaccharides, its stability was further evaluated in compare to full length gp49. 
After 1h incubation at temperature range of 40 - 100 °C, LKA1 gp49 preserved its activity 
at temperature range of 40 - 90°C (Fig. 7.17 A). In contrast, LKA1 gp49 domain was less 
stable and preserved its activity at temperature range of 40 - 70 °C. After 1 h incubation 
at 70 °C, the halo zone is clearly weaker and less visible (Fig. 7.17 B). 
A 
 
 
 
 
 
B 
 
 
 
Figure 7.17: Thermal stability of LKA1 gp49 and its domain. A 10µl smple of (A) LKA1 gp49  
(0.5 mg/ml, 6.22 μM) and (B) LKA1 gp49 domain (0.1 mg/ml, 4.80 μM) was spotted on P. aeruginosa 
PAO1 Krylov lawn. Samples were spotted after 1h incubation at temperature range of 40 - 100°C.  
 Further, the protein pH dependency was tested. First freshly purified LKA1 gp49 
and its domain were filtered through 10 K Amicon filters and elution buffer was 
exchanged to PBS at pH range of 1 - 11. After 1 h incubation at room temperature 10µl 
sample from each preparation was spotted on P. aeruginosa PAO1 Krylov lawn. Both, 
LKA1 gp49 and its domain presented activity in a broad pH range of 1- 11 (Fig. 7.18). 
* 
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Figure 7.18: The pH dependency of LKA1 gp49 and its domain. A 10 µl sample of (A) LKA1 gp49  
(0.5 mg/ml, 6.22 μM) and (B) LKA1 gp49 domain (0.1 mg/ml, 4.80 μM) treated for 1 h treatment at room 
temperature with PBS adjusted to pH between 1 and 11, was spotted on P. aeruginosa PAO1 lawn.  
PBS with pH between 1-11 was also spotted and served as a negative control.  
7.6. Discussion  
 The polysaccharide depolymerases have the potential to degrade bacterial biofilm 
and EPS/LPS, the important factors of the P. aeruginosa pathogenesis (Yan et al., 2014). 
This would allow to disperse biofilm embedded cells or make bacterial cell wall surface 
more accessible for antibacterial agents, such as antibiotics, detergents, disinfectants, 
phages or host immune system components. To date polysaccharide depolymerases were 
only reported in the tailed dsDNA phages from order Caudovirales (Sutherland, 1999; 
Casjens et al., 2011).  
In this study we identified and characterized gp49, a pectin lyase and its domain 
as well as an acylhydrolase domain of gp56, encoded by P. aeruginosa phiKMVvirus 
LKA1 and Luz7virus LUZ7, respectively.  
The gp49 domain and gp56 domain probably aggregated and their native structure 
should be further evaluated. Crystal structure of LKA1 gp49 allowed to precisely locate 
the enzyme active center, which in the case of gp56 could only be predicted based  
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on protein homology. To our knowledge the depolymerase crystal structure was solved 
only in the case of the catalytic part of the K1F endosialidase, endoNF (Stummeyer et al., 
2005) or gp47, a tail spike protein with endosialidase activity, highly identical in E. coli 
phages K1E and K1-5 (Leiman et al., 2007). 
LKA1 gp49 and its domain formed the halo zones on P. aeruginosa PAO1 lawn. 
In case of LUZ7 domain halo formation was absent. Further microscopic analysis 
showed, that EPS material is keeping bacteria closely in small aggregates, while after 
protein treatment bacteria were spread out and their EPS slime were reduced. The same 
observation was presented in several studies (e.g. Cornelissen et al., 2011, 2012; Dubos 
et al., 1931). Furthermore, with the use of P. aeruginosa PAO1 mutants it was elucidated, 
that all protein samples were able to degrade the B-band O-antigen, while with B-band 
deficient PAO1 strains the halo zone was not present, as it was also reported for LKA1 
phage in A. Cornelissen studies.  
The biofilm assay with the use of peg lid plates and CV staining method did not 
revealed antibiofilm activity of recombinant proteins used in this study. The biofilm 
degradation analysis should be repeated and discussed in details in the future, preferably 
with more qualitative and quantitative techniques. In literature, we can find, that Turk  
et al. (2013) and Gutiérrez et al. (2015) demonstrated the biofilm-degrading activity  
of DispersinB and Dpo7, EPS-degrading enzymes active against the staphylococcal 
biofilm. Biofilm matrix was reduced up to 85% and 90%, respectively.  
The stability test revealed that both LKA1 gp49 and its domain are stable  
in a broad pH range. LKA1 gp49 was also very thermostable and presented the activity 
even after 1 h incubation at 90°C. Interestingly, its shorter version was less stable and 
presented activity only up to 70°C. This difference in thermal stability possibly  
is influence by the absence of full length C-terminal region, responsible for protein 
trimerization. We hypothesize, that gp49 domain creates a trimeric structure, because  
it possess partial amino acid sequence from gp49 C-terminus. However, this trimer is less 
stable and disintegrates after application of high temperatures. It would be interesting  
to create a new domain, i.e. extended till the end of C-terminal region of gp49  
(389 - 769 aa), to assess the influence of C-terminal region of gp49.  
In conclusion, we confirmed that LKA1 gp49 is LPS depolymerase, however  
its influence on bacterial LPS should be further analyzed in details. Moreover, further 
analysis should be conducted, focusing also on e.g. protein mode of action and substrate 
specificity with the use of different Pseudomonas biofilm matrix components (i.e. Psl, 
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Pel or alginate, or pure LPS). The bacterial EPS can also be used to quantify  
the hydrolyzing activity of domain according to e.g. Chai et al. (2014) method, were  
the purified protein was incubated with EPS substrate for 4 h at 32°C and the reduction  
of sugars that were released was measured by spectrophotometry and analyzed by HPLC. 
Moreover, depolymerase domains could be fused with other polysaccharide 
depolymerase and/or endolysin domains and/or antibacterial peptides with the use  
of synthetic biology techniques. 
Encapsulated bacteria can lead to broad range of severe infections, such  
as meningitis, septicemia, osteomyelitis, pneumonia, septic arthritis etc. (Moxon et al., 
1990). Mushtaq et al. (2005) have proven, that systemic infection caused by encapsulated 
pathogens may be treated with EPS-degrading enzymes. In their study, the low doses  
of the endosialidase E administrated intraperitoneally to rats at early stage of infection  
of E. coli K1 strain increased the survival rate by removal of bacterial polysaccharide 
capsule, in comparison to lethal systemic infection in control samples. Moreover,  
the per os administration of tail spike protein P22sTsp reduced also Salmonella infections  
in chickens (Waseh et al., 2010).  
We conclude, that polysaccharide depolymerases present an innovative approach, 
that exploits phage natural weapons. Enzymes could serve as a new antibacterial tool, that 
enables the access to bacterial cell for commonly used antimicrobials or host immune 
system. The polysaccharide depolymerases could also be used for the treatment of plant 
and animal infections (Kim et al., 2000; Mushtaq et al., 2004; Scorpio et al., 2008), 
eradication or prevention of biofilm formation (Hughes et al., 1998; Verma et al., 2010) 
or oligosaccharides production derived from polysaccharides (Niemann et al., 1977; 
Altmann et al., 1990).  
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specialists in the field of peptidoglycan degrading enzymes. 
8.1. Introduction 
 Phage PG degrading enzymes (VAPGHs and endolysins) are rapid, highly 
specific and efficient enzymes, that exert their action at the beginning and at the end  
of virus reproduction cycle, respectively. VAPGHs operate exogenously, assisting  
in the viral genetic material injection, while endolysins accumulate in cytoplasm and acts 
from within, allowing the release of a newly assembled phage progeny (Rodriguez-Rubio  
et al., 2016). In last decades, several recombinant PG hydrolases have proven  
to be bactericidal towards Gram-positive bacteria, such as Staphylococcus, Streptococcus 
and Bacillus strains, when applied in vitro or with the use of different animal infection 
models (Nelson et al., 2001; Loeffler et al., 2001; Schmelcher et al., 2012; Schuch et al., 
2002). However, in the case of Gram-negative bacteria, the situation is more complicated, 
since the OM is a highly effective permeability barrier. To overcome this obstacle,  
PG degrading enzymes must be delivered in combination with a high hydrostatic pressure 
(150 - 200 MPa) or OM permeabilizers, such as EDTA, citric acid or malic acid (Briers 
et al., 2011; Oliveira et al., 2014). Nevertheless, this recombinant phage borne proteins 
have proven to be highly effective against permeabilized cells of P. aeruginosa, P. putida, 
Burhholderia pseudomallei, E. coli, S. Typhimurium, Acinetobacter baumannii  
or Klebsiella pneumoniae strains (Briers et al., 2014b; Oliveira et al., 2014; Walmagh  
et al., 2013).  
Recently, Briers et al. (2014a) presented also another approach focusing  
on engineered endolysins named ‘Artilysin®s’. These engineered enzymes consists  
of a recombinant modular endolysin and an antimicrobial peptide, enabling transport 
through the OM (Briers et al., 2014b). Bacteriolytic phage-borne proteins are currently 
of high interest as an alternative antimicrobials (Briers et al., 2014). Importantly, to date 
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there was no case of resistance occurrence in vitro and in vivo (Schuch et al., 2002; 
Rodriguez-Rubio et al., 2013; Loeffler et al., 2003; Pastagia et al., 2011, O’Flaherty  
et al., 2009).  
In this chapter we focus on PG degrading enzymes of P. aeruginosa phages 
presented in chapters 4 - 6. With the use of bioinformatics analysis six putative  
PG hydrolases genes were identified. Based on their homology with other phage proteins, 
the theoretical secondary and tertiary structure was elucidated. Further, the methodology  
of recombinant protein expression and purification was optimized, allowing to achieve 
pure and active phage enzymes. In the final part, bactericidal activity and stability  
of phage enzymes was examined. 
8.2. Bioinformatics analysis, a search for genes encoding  
PG degrading enzymes 
 The present dissertation started with the analysis of phage genomes (chapters  
4 - 6) and identification of the promising phage ORFs encoding PG degrading enzymes, 
with the use of BLASTP, HHpred, HMMER, Phyre2 and InterPro bioinformatics tools 
(Altschul et al., 1990; Remmert et al., 2011; Finn et al., 2011; Kelley et al., 2015; Jones 
et al., 2014). Table 8.1. presents the list of selected phage-encoded proteins and their basic 
features. All chosen proteins exhibit lower than 25% similarity to each other, except two 
proteins, KT28 gp49 and KTN6 gp46 with only 4 amino acids difference in the amino 
acid sequence (98.2% identity). 
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Table. 8.1: List of PG degrading enzymes candidates chosen for study. 
Protein 
(NCBI code) 
Origin Nucleotide 
length  
Amino 
acids length 
Theoretical 
pI 
Ext. coeff.  
(M-1 cm-1) 
Predicted 
structure 
Predicted catalytic 
specificity 
Phage protein homologue 
(BLASTP, NCBI code,  
e-value) 
KT28 gp49 
(AKJ71487) 
putative 
endolysin 
 
 
 
P. aeruginosa 
KT28 phage 
(Pbunavirus) 
663 220 
(24.14 kDa) 
8.76 
 
39545 
 
globular chitinase, glycoside 
hydrolase 19 family, 
lysozyme-like 
domain,  
putative lysozyme 
gp48 of P. aeruginosa phage 
SN (YP_002418854.1,  
e-value 7e-163) 
KT28 gp41 
(AKJ71479.1) 
putative 
VAPGH 
2577 942  
(94.23 kDa) 
8.20 
 
58790 
 
globular 
 
 
 
 
lytic transglycosidase 
 
putative transglycosidase 
gp40 of P. aeruginosa phage 
SN (YP_002418846.1,  
e-value 0.0) 
 KT28 gp41 
domain 
(463-605 aa) 
putative 
VAPGH 
432 144 
(16.22 kDa) 
9.36 17420 
KTN6 gp46 
(AKJ71578.1) 
putative 
endolysin 
P. aeruginosa 
KTN6 phage 
(Pbunavirus) 
663 220 
(24.17 kDa) 
8.76 
 
39545 
 
globular chitinase, glycoside 
hydrolase 19 family, 
lysozyme-like 
domain 
putative endolysin 
gp45 of P. aeruginosa phage 
KPP12 (YP_007238200.1, 
e-value 6e-163 
PA5oct gp214 
putative 
VAPGH 
 
 
 
 
P. aeruginosa 
PA5oct phage 
(novel giant) 
1434 447 
(51.08 kDa) 
5.94 
 
52495 
 
globular tail associated 
lysozyme 
 
baseplate hub subunit and 
tail lysozyme gp234  
of Cronobacter phage 
GAP32 (YP_006987339.1, 
e-value 7e-48) 
PA5oct gp250 
putative 
endolysin 
 
516 
 
172 
(18.54 kDa) 
9.26 
 
11710 
 
globular glycoside hydrolase 
19 family, lysozyme-
like domain 
- 
KTN4 gp48 
(ANM44806.1) 
putative 
endolysin 
P. aeruginosa 
KTN4 phage 
(Phikzvirus) 
807 271 
(29.70 kDa) 
3.82 
 
18450 
 
globular N-acetylmuramoyl-L-
alanine amidase 
gp35 of P. aeruginosa phage 
φKZ (NP_803601.1, 
 e-value 0.0) 
Abbreviations: (pI) a isoelectric point, (Ext. coeff.) a extinction coefficient parameter. The protein size in kDa was calculated with ExPASy ProtParam, putative catalytic 
specificity is established based on homology analysis performed with the use of BLAST P, HMMER, HHPRED a PHYRE2.  
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Based on sequence homology four phage proteins, KT28 gp49, KTN6 gp46, 
PA5oct gp250 and KTN4 gp48, are predicted to be globular endolysins. KT28 gp41 and 
PA5oct gp214 are homologues to virion- associated lytic proteins, thus they are potential 
VAPGHs. 
KT28 gp49  
Pfam analysis revealed, that gp49 of Pbunavirus KT28 (chapter 4) consist  
a glycoside hydrolase family 19 chitinase class I domain [locus in full length protein:  
103 - 217 amino acids (aa)]. Prediction by the InterPro Scan showed presence of two 
potential locus of lysozyme-like domains (13 - 76 aa and 108 - 216 aa) and one  
of glycoside hydrolase family 19 (122 - 177 aa). The glycoside hydrolases are enzymes, 
that the β-1,4 linkages between the GluNAc and MurNAc sugars of PG (Wolhlkonig  
et al., 2010). It is very broad group of enzymes, consisting >100 different families 
(http://www.cazy.org/GH1.html; http://enzyme.expasy.org/ EC/3.2.1.-). The glycoside 
hydrolase family 19 comprises enzymes with chitinase activity, that catalyse  
the hydrolysis of the β-1,4-N-acetyl-D-glucosamine linkages in chitin polymers.  
KTN6 gp46 
 Gp46 is a protein of Pbunavirus KTN6 (chapter 4). It presents 98.18% of amino 
acid sequence identity to KT28 gp49 (Clustal Omega) with 4 point amino acids alterations 
(Fig. 8.1). 
KTN6_gp46   MKITKDILITGTGCTTDRAIKWLDDVQAAMDKFHIESPRAIAAYLANIGVESGGLVSLVE 
KT28_gp49    MKITKDVLITGTGCTTDRAIKWLDDVQTAMDKFHIESPRAIAAYLANIGVESGGLVSLVE 
 
KTN6_gp46   NLNYSAQGLANTWPRRYAVDPRVRPYVPNALANRLARNPVAIANNVYADRMGNGCEQDGD 
KT28_gp49    NLNYSAQGLANTWPRRYAVDPRVRPYAPNALANRLARNPVAIANNVYADRMGNGCEQDGD 
 
KTN6_gp46   GWKYRGRGLIQLTGKSNYSLFAEDSGMDVLEKPELLETPAGASMSSAWFFWRNRCIPMAE 
KT28_gp49    GWKYRGRGLIQLTGKSNYSLFAEDSGMDVLEKPELLETPAGASMSSAWFFWRNRCIPMAE 
 
KTN6_gp46   SNNFSMVVKTINGAAPNDANHGQLRINRYMKTIAAINQGS 
KT28_gp49    SNNFSMVVKTINGAAPNDANHGQLRINRYLKTIAAINQGS 
 
Figure 8.1: The amino acid sequence comparison between KT28 gp49 and KTN6 gp46 (Clustal 
Omega v. 1.2.1). Sequence point alterations are marked gray. 
 
Amino acid substitution in position 7 [isoleucine (I, Ile) changed to valine  
(V, Val)] and 210 [methionine (M, Met) changed to leucine (L, Leu)] seems to be neutral. 
The former pair have 1.67 and 1.87 preference to β-strands, respectively, while the latter 
have 1.30 and 1.34 preference to α-helix, respectively (according the Chou-Fasman 
method, 1974). A different situation exists in a) position 28, where alanine (A, Ala)  
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is changed to threonine (T, Thr). First is a strong former of a helix and a weak former  
of a strand with 1.41 preference to α-helix, second is a former of a strand and indifferent 
towards helix with 1.45 preference to β-strands; b) position 87, where valine (V, Val)  
is change to alanine (A, Ala). Val is a strong former of strand and a former of helix, with 
1.87 preference to β-strands, while Ala is strong helix former and a weak former of strand, 
with 1.41 preference to α-helix. Clearly substituted amino acids have different properties, 
however, without protein crystal structure it is difficult to assess the impact on protein 
structure and folding, that could lead to differences in antibacterial activity, substrate 
specificity or stability. Nevertheless, as it will be shown later, enzymes had different 
bacteriolytic activity.  
The HMMER analysis also elucidated presence of glycoside hydrolase family 19 
domain (96 - 219 aa). The InterPro Scan showed three possible domains with almost 
identical locus as it was presented in case of KT28 gp49: lysozyme-like domains  
(12 - 76 aa and 108 - 216 aa) and glycoside hydrolase family 19 (121 - 177 aa). 
PA5oct gp250 
 Gp250 is a protein of a novel giant phage PA5oct (chapter 6). It comprise  
a lysozyme-like domain [pfam (42 - 161 aa) and InterPro Scan (11 - 170 aa) prediction]. 
Lysozyme has activity of muramidase (N-acetylmuramide glycanhydrolase) and catalyze 
hydrolysis of 1,4-β-linkages between N-acetylmuramic acid and N-acetyl-D-glucosamine 
residues in a bacterial peptidoglycan. It also belongs to group of glycoside hydrolases 
(Yoshimura et al., 1988). 
KTN4 gp48 
Gp48 is a protein of Phikzvirus KTN4 (chapter 5). The Pfam analysis showed, that 
its amino acid sequence is homologues to a peptidase and glycoside hydrolase family 18, 
however it was not possible to predict domain locus. According to prediction this protein 
can exhibit N-acetylmuramoyl-L-alanine amidase activity and hydrolyse the amid bond 
that anchors the L-alanine moiety of the pentapeptide chain to the D- lactyl group  
of the MurNAc sugar in the glycan backbone (Cheng et al., 1994).  
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KT28 gp41 
Gp41 is potential VAPGH of Pbunavirus KT28. The pfam and InterPro Scan 
analysis revealed the presence of a transglycosylase SLT (soluble) domain (pfam  
489 - 593 aa; InterPro Scan 480 - 594 aa) (Fig. 8.4). The lytic transglycosylases degrade 
murein via cleavage of the β-1,4-glycosidic bond between GluNAc and MurNAc  
in bacterial PG, followed by the formation of a 1,6-anhydromuramic acid terminal residue 
(Bienkowska-Szewczyk et al., 1980). This protein was very difficult to handle during 
cloning and expression process, as it will be further discuss in section 8.2.2. That is why 
we decided to focus on its active domain (Fig. 8.2). Additional margin of amino acids 
was added on C- and N-termini of predicted domain, to avoid cuts in secondary structure 
elements, i.e. helices and strands, that could have influence on protein folding and 
function. Finally, domain was defined between 463 and 605 amino acid residue of full 
length protein. 
A 
 
 
B 
 
 
 
Figure 8.2: The protein homology analysis of KT28 gp41 with prediction of functional domains.  
(A) analysis performed by HMMER, prediction of transglycosylase SLT domain (489 - 593 aa locus).  
(B) analysis performed by InterPro Scan, elucidation of lysozyme- like domain or transglycoslylase SLT 
domain 1, located between 480 and 595 amino acid.  
PA5oct gp214 
 The potential VAPGH gp214 of the giant phage PA5oct consist of a phage tail 
associated lysozyme-like domain [(42 - 161 aa) pfam, (11 - 170 aa) InterPro Scan].  
All protein activity was assigned only based on available homology in databases. 
For proper catalytic specificity elucidation a detail biochemical analysis has to be 
introduced.  
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Further potential protein secondary and tertiary structure was predicted and 
analyzed for all proteins with the use of Phyre2 (Kelley et al., 2015), PyMol Molecular 
Graphics System v. 1.8 Schrödinger (Fig. 8.3, Table 8.2.). This analysis was also essential 
for KT28 gp41 domain definition. 
Table 8.2: Prediction of the protein secondary structure composition with elucidation of ligand 
binding site.  
Protein Secondary 
structure 
composition 
The closest protein structure 
homologue 
Amino acid 
composition  
of ligand binding side 
KT28 gp49 12 α-helices,  
1 β-strand,  
8% disordered 
structure  
endolysin spn1a from S. 
Typhimurium with glycosidase 
activity through the catalytic dyad 
(96% and 97% coverage, 
respectively; PDB code 4OK7, Park 
et al., 2014) 
130 ILE, 131 GLN, 
132 LEU, 169 PHE, 
172 ARG 191 ILE 
KTN6 gp46 130 ILE, 131 GLN, 
169 PHE, 191 ILE 192 
ASN 
KT28 gp41 41 α-helices,  
2 β-strand,  
31% disordered 
structure 
complex of the 70 kDa soluble lytic 
transglycosylase with bulgecin A, an  
O-sulfonated glycopeptide with  
N-acetyl-D-glucosamine binding 
side (71% and 94% coverage, 
respectively; PDB code 1SLY, 
Thunnissen et al., 1995) 
- 
KT28 gp41 
domain 
8 α-helices,  
11% disordered 
structure 
69 GLN, 70 LEU, 71 
MET, 74 ILE, 96 LEU, 
114 TYR, 115 TYR, 
116 HIS, 117 GLY, 
118 GLY, 119 LEU, 
120 ASP, 123 ASN 
PA5oct gp214 3 α-helices,  
41 β-strand,  
52% disordered 
structure 
pa0091 vgrg1 protein, the central 
spike of the type vi2 secretion 
system (84% coverage, PDB code 
4MTK, Sycheva et al., to be 
published) as well as T4 
bacteriophage needle proteins gp27 
and gp5 (25% coverage, PDB code 
2P5Z, Leiman et al., 2009) * 
- 
PA5oct gp250 7 α-helices,  
3 β-strand,  
17% disordered 
structure 
R21 endolysin from coliphage 21 
with N-terminal signal-anchor-
release (SAR) domain (98% 
coverage, PDB code 3HDE, Sun  
et al., 2009) 
30 GLY, 48 GLY, 101 
TYR, 102 ASN, 105 
PRO 
KTN4 gp48 5 α-helices,  
3 β-strand,  
65% disordered 
structure 
rfnbpa in compex with fibrinogen  
2 gamma chain c-terminal peptide 
(22% coverage, PDB code 4B60, 
Stemberk et al., 2014) * 
 
- 
 
(-) no prediction due to low homology score. Bolded amino acids represent the difference in composition  
of predicted binding side between highly similar enzymes, KT28 gp49 and KTN6 gp46. All secondary 
structure components are left- handed. 
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Figure 8.3: Prediction of tertiary protein structure based on a structure homology. (A) protein structure represented by left handed α-helices, β-strands, loops and turns  
as a cartoon, (B) protein structure presented as a surface. Protein structures are not presented in a scale. 
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Furthermore, proteins ligand binding site was predicted based on structure 
homology with the use of 3DLigandSite –Ligand binding site prediction server (Wass  
et al., 2010) (Fig. 8.4). In the case of KT28 gp41, PA5oct gp214 and KTN4 gp48 ligand 
binding side identification was not possible due to low homology. Selected amino acids 
were located in the center of protein structure and could serve in the future as a target for 
side-directed mutagenesis experiments in order to modify enzyme specificity.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 8.4: The predicted ligand binding sides of (A) KT28 gp49, (B) KTN6 gp46, (C) KT28 gp41 
domain and (D) PA5oct gp250. Crucial amino acids from Table 8.2 are represented as colorful sticks.  
The rest of protein structure is shown as lines. Structures were modelled by PyMol v. 1.8 Schrödinger. 
Structures are not presented in scale.  
 
 All above analysis can serve as a basis for potential future protein engineering 
experiments or understanding mode of action and enzyme kinetics. However, more  
in depth analysis should be performed, preferably based on protein crystallography, due 
to low homology score and coverage in case of some proteins. 
 
 
B A 
C D 
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8.3. Cloning, recombinant expression and purification 
 The full-length ORFs encoding six chosen PG degrading enzymes (Table 8.1) 
were isolated and amplified by Phusion® High-Fidelity DNA polymerase with low error 
rate. Next, all PCR products were introduced into pEXP5-CT/TOPO® vector. Produced 
proteins carried a 6x His-tag on C-termini, important for further protein purification steps. 
Cloning was successful for KT28 gp49, KTN6 gp46, PA5oct gp214 and KTN4 gp48. 
However, in the case of PA5oct gp250 and KT28 gp41 constructs had several point 
mutations, especially on C-termini. Despite several repetitions of gene amplification and 
cloning, no correct constructs could be obtained. That is why PCR products were further 
successfully introduced into another vector, the pEXP5-NT/TOPO® with 6x His-tag  
on N-termini.  
 Next, protein expression optimization was conducted in 100 ml cultures with  
the use of different E. coli chemicompetent strains, medium, expression temperature and 
inducer concentration (Table 8.3) in order to achieve the most abundant protein 
expression in soluble fraction. First different conditions were tested with KT28 gp49 and 
KTN6 gp46, to reduce the number of variables for the rest of proteins. Unfortunately,  
in the case of full length KT28 gp41 expression failed and protein was continuously 
present in insoluble fraction or expression did not occurred, regardless of a variety  
of expression conditions. To overcome this obstacle KT28 gp41 domain was identified 
and successfully cloned into pEXP5-NT/TOPO® vector (Table 8.3). The solubility  
of proteins was checked with the use of SDS-PAGE and Western Blot methods  
(S Fig. 8.1).  
 Based on a broad range expression optimization, for this particular set of proteins 
it can be concluded, that :1) the most suitable E. coli expression strains were Lemo21 
(DE3) and BL21 (DE3) pLysS, both under control of T7 promoter; 2) the most universal 
for protein expression was 2xTY medium, 3) expression at 16°C allowed bacteria  
to produce proteins slower with higher abundance in soluble fraction, 4) the protein yield 
was the same regardless of inducer concentration used. 
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Table. 8.3: Protein expression optimization process for all chosen PG degrading enzymes.  
Type Name KT28 gp49 KTN6 gp46 KT28 gp41 KT28 gp41 
domain 
PA5oct gp214 PA5oct gp250 KTN4 gp48 
vector pEXP5-CT/TOPO √ √   √  √ 
pEXP5-NT/TOPO   √ √  √  
expression 
strain 
Lemo21 (DE3) √ √ √ √ √ √ √ 
BL21 CodonPlus (DE3)   √ √ √ √ √ 
BL21 (DE3) pLysS    √   √ √ 
BL21 AI    √   √  
Arctic Express (DE3)   √   √  
medium LB √ √ √ √ √ √ √ 
2xTY √ √ √ √ √ √ √ 
Modified LB √ √ √ √ √   
TB √ √ √ √    
Autoinduction √ √ √ √    
temperature 
post 
induction 
37°C (4.5 h) √ √  √ √   
16°C (overnight) √ √ √ √ √ √ √ 
L-rhamnose 2 mM √ √      
1 mM √ √      
0.5 mM √ √ √ √ √ √ √ 
0.1 mM √ √      
IPTG 0.1 mM √ √ √  √  √ 
0.4 mM √ √ √ √  √  
final conditions Lemo21 (DE3) 
LB medium 
0.4 mM IPTG 
0.5 mM  
L-rhamnose 
16°C (overnight 
expression) 
Lemo21 (DE3) 
2xTY medium 
0.4 mM IPTG 
0.5 mM  
L-rhamnose 
16°C (overnight 
expression) 
Lack  
of suitable 
conditions 
Lemo21 (DE3) 
2xTY medium 
0.4 mM IPTG 
0.5 mM  
L-rhamnose 
16°C (overnight 
expression) 
CodonPlusTM 
2xTY medium 
0.1 mM IPTG 
16°C (overnight 
expression) 
Lemo21 (DE3) 
2xTY medium 
0.4 mM IPTG 
0.5 mM  
L-rhamnose 
16°C (overnight 
expression) 
BL21 pLysS 
2xTY medium 
0.1 mM IPTG 
16°C (overnight 
expression) 
Gray color marks conditions were expression was successful and protein appeared in soluble fraction. 
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 The next step was a large scale purification performed with the use of ÄKTA 
FPLC system in combination with HisTrapTM HP 1 ml columns or gravity-flow 
chromatography at 4°C with a Ni2+-NTA resin (Fig. 8.5). Purity of all proteins was further 
increased by filtration through 10 K filter units. For KTN6 gp46 and PA5oct gp214 it was 
necessary to apply additional purification step, the size exclusion chromatography with 
the use of the HiLoad 16/600 Superdex 200 Prep grade gel filtration column and  
the HiLoad 16/600 Superdex 75 Prep grade gel filtration column, respectively  
(S Fig. 8.1). Highly pure proteins were kept in elution buffer at 4°C with precipitation 
inspections. In case of KT28 gp49 and KTN6 gp46 precipitation occurred after few days. 
To improve the stability, all proteins were kept further in 5mM HEPES buffer with 30% 
glycerol, proven in several studies to be a suitable buffer for endolysins as well as proteins  
in a broader sense (Briers et al., 2014a, 2011; Oliveira et al., 2016).  
Based on size exclusion chromatography, the native state of PA5oct gp214 and 
KTN6 gp46 was estimated (52.1 kDa and 20.98 kDa, repectively). This suggest, that both 
proteins occur as a monomeric structures, however further analysis should be conducted, 
e.g. crystallography.  
 Table 8.4 presents the protein yields of different PG degrading enzymes with 
 the use of three different protein purification techniques. The highest yield was achieved 
for KTN6 gp46 (3.37 g/750 ml culture). The lowest yields and the most complicated 
expression and purification were in case of KT28 gp41 and KTN4 gp48. Preferably other 
expression systems should be introduced, such as expression in yeast system, to which 
proteins should not be toxic. For PA5oct gp250 and gp214 protein purity increased with 
the use of 10 K filter units, however further purification steps and optimization should  
be introduced.  
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Table 8.4. The average yields of purified proteins. Measurements were performed on a Nanodrop  
at wavelength of 280nm with specific parameters of molecular weight and extinction coefficient (Expasy 
Protparam).  
(*) in 0.5 ml fractions, (FPLC) Fast Protein Liquid Chromatography 
 
8.4. Assessment of PG degradation activity 
To demonstrate the ability of six purified phage enzymes to degrade the PG layer, 
several techniques were applied. 
Zymography with crude peptidoglycan 
This technique was used to identify the hydrolytic activity of pure proteins 
towards crude PG, isolated from P. aeruginosa PAO1 Krylov. The positive activity was 
visualized by appearance of transparent bands on 12% SDS-PAGE gel containing crude 
PG. Results for six phage PG hydrolases were positive (Fig. 8.5). However, it has  
to be stressed, that PA5oct gp214 presented very weak band, which was hard to capture 
on a photo. In order to assess if phage PG hydrolases were associated with viral structural 
proteins, whole phage proteomes were also loaded on zymograms. Only in the case  
of PA5oct gp214 a very small transparent band appeared, corresponding to the band from 
PA5oct proteome (Fig. 8.5).  
 
  
Protein Average protein yield 
(mg) after gravity 
affinity purification 
Total protein yield (mg) 
after FPLC affinity 
purification* 
Total protein yield (mg) 
after size exclusion 
purification* 
750 ml culture 750 ml culture 750 ml culture 
KT28 gp49 4.84  3375 N/A 
KTN6 gp46 5.77 2578 1100 
KT28 gp41 
domain 
1.0  3.50 N/A 
PA5oct gp214 1.54 N/A 0.50 
PA5oct gp250 1.62 0.67 N/A 
KTN4 gp48 0.50 N/A N/A 
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Figure 8.5: Zymograms of six purified phage PG hydrolases. A 10 µl/well of KT28 gp49 (6.88 mg/ml, 24.14 kDa), KT28 gp41d (0.41 mg/ml, 16.22 kDa), KTN6 gp46  
(6.08 mg/ml, 24.14 kDa), PA5oct gp214 (1.43 mg/ml, 51.08 kDa), PA5oct gp250 (0.86 mg/ml, 18.54 kDa) or KTN4 gp48 (0.44 mg/ml, 29.70 kDa) in 5 mM HEPES/NaOH 
buffer (pH 7.4) was loaded on a 12% acrylamide SDS-PAGE gels containing crude PG of P. aeruginosa PAO1 Krylov strain. To assess the size of bands indicating  
PG degradation (light blue bands), identical standard 12% SDS-PAGE gels were performed in the same conditions and stained with GelCode™ Blue Safe Protein Stain (Thermo 
Scientific). As a positive control served a hen egg-white lysozyme (HEWL) in 10 μg/ml, 5 μg/ml concentrations. (LMW) Low Molecular Weight marker (GE Healthcare),  
(M) PageRuler Prestained Protein Ladder (Thermo Scientific). [edited images]  
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Antibacterial assay 
Degradation of PG ultimately leads to a killing effect. To demonstrate  
the bactericidal activity of the phage enzymes, an antibacterial assay was performed  
in triplicate with the use of P. aeruginosa PAO1 Pirnay cells and freshly purified proteins 
(final concentration of 2.5 μM) kept in 5 mM HEPES/NaOH buffer (pH 7.4) (Fig. 8.6).  
 
 
 
 
 
 
 
 
 
 
 
Figure 8.6: Assessment of antibacterial activity of 6 phage PG hydrolases on P. aeruginosa PAO1 
Prinay strain. (Blue) KT28 gp41 domain, (orange) KT28 gp49, (gray) KTN6 gp46, (yellow) PA5oct 
gp214, (dark blue) Pa5oct gp250, (green) KTN4 gp48. (Control) P. aeruginosa PAO1 Prinay strain mixed 
with 5 mM HEPES/NaOH buffer; (Control + EDTA) P. aeruginosa PAO1 Prinay strain mixed with 5 mM 
HEPES/NaOH buffer 0.5 mM EDTA; (PG hydrolase) P. aeruginosa PAO1 Prinay strain mixed with PG 
hydrolase in 5 mM HEPES/NaOH buffer (2.5 μM final concentration); (PG hydrolase + EDTA)  
P. aeruginosa PAO1 Prinay strain mixed with PG hydrolase in 5 mM HEPES/NaOH buffer (2.5 μM final 
concentration) and 0.5 mM EDTA. Columns represent average log10 (CFU/mL) from three independent 
experiments with error bars indicating the standard deviation. (*) significant log reduction. 
 Population of P. aeruginosa PAO1 Prinay strain was significantly reduced  
(p < 0.05) in the presence of 0.5 mM EDTA in combination with 2.5 μM of KT28 gp41 
domain (2.5 ± 0.2 log reduction), KT28 gp49 (1.8 ± 0.23 log reduction), KTN6 gp46  
(3.0 ± 0.3 log reduction), PA5oct gp214 (1.9 ± 0.48 log reduction), PA5oct gp250  
(1.6 log ± 0.23 reduction), and KTN4 gp48 (1.0 ± 0.5 log reduction). KTN6 gp46 
exhibited the strongest bactericidal activity, while KTN4 gp48 the weakest influence. 
Enzyme concentration used in the study was chosen in order to compare the presented 
results with the activity of other endolysisns, belonging to the collection of the Laboratory 
of Gene Technology (KU Leuven) and previously described by Prof. Y. Briers and  
Dr. L. Rodrigues-Rubio. Preliminary tests with undiluted concentrations of KT28gp49 
(14.5 μM) and KTN6 gp46 (20.9 μM) in the presence of 0.5 mM EDTA resulted  
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in 5.99 log reduction and no survival of P. aeruginosa PA01 Pirnay cells, respectively. 
In the absence of EDTA, no significant antibacterial activity was observed. This justifies 
the need for an OM permeabilizing agents to promote the access of the protein  
to the PG substrate. EDTA binds the stabilizing divalent cations in the LPS layer, thereby 
destabilizing the OM. Application of EDTA alone had no influence on CFUs numbers. 
Host range 
To verify whether PG hydrolases also demonstrate antibacterial activity towards 
E. coli APEC Ch2 strain and S. Enteritidis ATCC13076 strain, an antibacterial assay was 
performed with freshly purified proteins in 5 mM HEPES/NaOH buffer (pH 7.4) (final 
concentration 2.5 μM). However, no significant log reduction was observed  
in the treatment of 0.5 mM EDTA in combination with 2.5 µM of all tested proteins. This 
can be explained by the lower degree of phosphorylation of the LPS molecules and thus 
a lower amount of stabilizing divalent cations in the OM of E. coli and Salmonella, which 
makes their OM less prone to the action of EDTA. This phenomenon was also observed 
by other researches (Oliveira et al., 2014 and 2016, Walmagh et al., 2013). Based  
on Oliveira et al. (2014) study other two OM permeabilizers were introduced, 2 mM citric 
acid or 5 mM malic acid, however results remain the same.  
Since KTN6 gp46 exhibited the highest activity, further analysis was focused only 
on this protein. 
Quantitative assessment of enzymatic activity 
 To quantified the hydrolytic activity of KTN6 gp46, the drop in turbidity  
of an OM-permeabilized P. aeruginosa Pirnay suspension was measured with small 
intervals after addition of the purified recombinant enzyme (Fig. 8.7). The general 
formula to express enzymatic activity (activity units/mg) was previously defined  
by Prof. Y. Briers (Briers et al., 2007).  
 
Activity (units mg )⁄ = 
𝛥OD 655nm
(min.mg)⁄
0.001
×
reaction volume (µl)
1000 µ𝑙
 
 
First different linear regressions for an increasing data (n = number  
of measurements in time, starting from n = 5, 6, 7…) were calculated. Next,  
the corresponding determination coefficient (R2) indicated the degree of linear relation 
between optical density and time and it is a measure of how well the linear regression 
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represents the selected data set. The R2 will maximize, as more data of the linear 
regression are included, however it will decrease beyond the linear region. When R2 was 
maximized, the slope of the linear regression was calculated and presented as a drop  
in OD655 nm per minute. The reliability of the slope will rise with increasing number  
of measurements with the linear region. Enzyme activity is expressed in units/mg. Excel 
spreadsheet created by Prof. Y. Briers allowed to increase efficiency in a data statistically 
processing (Briers et al., 2007). Endolysin KZ144 (0.95 mg/ml) was used as a positive 
control and 5 mM HEPES/NaOH (pH 7.4) as a negative control.  
Figure. 8.7: Enzymatic activity of different concentrations of KTN6 gp46 towards P. aeruginosa 
PAO1 Pirnay substrate. Recombinant protein KTN6 gp46 and P. aeruginosa substrate were suspended 
in 5 mM HEPES/NaOH (pH 7.4). As a negative control served 5 mM HEPES/NaOH buffer (pH 7.4) alone 
and as a positive control endolysin KZ144 (0.95 mg/ml), also in 5 mM HEPES/NaOH buffer (pH 7.4). 
 
Figure 8.8 shows the saturation curve obtained from three independent replicates. 
Each data point is an average with its standard deviation. For the lower concentrations  
a linear trend line with a R2 of 97.3% could be obtained leading to the calculation  
of muralytic activity in units/μM. The ΔOD655nm/min value increased proportionally  
to the amount of enzyme added. From 11129 units/μM of enzyme the curve was saturated, 
which indicates the maximum activity. 
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Figure 8.8: The saturation curve of KTN6 gp46. 
Muralytic activity was quantified against OM 
permeabilized P. aeruginosa PAO1 cells according  
to Briers et al. method (2007). The X- and Y-axes 
display the amount of gp46 (in μM) added and the 
corresponding activity (OD655nm/min) measured, 
respectively. Each data point shows the average and 
error bars of three independent experiments. R2=0.973. 
 
Visualizing individual cell lysis using time-lapse microscopy 
To visualize the mode of action of KTN6 gp46 a time-lapse microscopy was 
applied with the use of a phase-contrast microscope (Prof. A. Aertsen, Department  
of Microbial and Molecular Systems, KU Leuven). With the highest concentrations  
of KTN6 gp46 (82–144.8 µM), lysis could not be recorded due to its rapid action. That  
is why low concentration (44 μM) was applied to enable recordings. An equal amounts 
of KTN6 gp46 in 5 mM HEPES/NaOH (pH 7.4) and P. aeruginosa PAO1 Pirnay cells 
were mixed and fixed on a PBS - 0.2% agar pad for observation under the microscope. 
KTN6 cause complete lysis of the bacterial cells after 16 min (Fig. 8.9). 
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Figure 8.9: Recordings of P. aeruginosa Prinay strain lysis caused by KTN6 gp46. White arrow indicates bacterial cell, that was lysed after around 15 min after application 
of 44 μM of phage enzyme. Scale bare represents 3µm. 
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8.5. Evaluation of enzyme stability  
Some statements and observations were made after recombinant protein preparation: 
1) the elution buffer used for purification caused protein precipitation within three 
days in case of all proteins. 
2) 5 mM HEPES pH 7.4 with 30% glycerol prevented precipitation and kept  
the protein stable at 4°C. Importantly, glycerol is a broadly used stabilizer  
of proteins at low temperatures since it has cryoprotectant properties.  
3) The highest enzymatic activity was achieved, when protein was purified  
by gravity-flow chromatography at 4°C using a Ni2+-NTA resin. Possibly due  
to different imidazole concentrations, temperature, as well as higher pressure 
applied during purification with FPLC.  
pH stability of KTN6 gp46 
Using OM permeabilized P. aeruginosa PAO1 cells suspensions adjusted  
to a different pH, it was determined that KTN6 gp46 (0.125 µM) is active at pH values 
ranging from 5 to 9, maintaining between 26.6 ± 10% and 100% of its maximal activity 
at pH 7 (Fig. 8.10). The highest activity is observed at pH range 6 - 8 with a sharp decrease 
below pH 6 and above pH 8. At pH 8 the relative activity remains 77.2 ± 3.74% and  
at pH 6 remains 73.9 ± 25.6%, although for this condition the standard deviation was very 
high.  
 
Figure 8.10: The KTN6 gp46 enzymatic activity dependence on pH dependence. Activity is expressed 
relative to the maximal muralytic activity at the optimal pH (pH 7). Each bar represents the mean of three 
independent experiments, error bars indicate the standard deviation. 
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8.6. Discussion  
 The increasing frequency of multi-drug-resistant pathogens becomes a serious 
public-health problem, due to limited treatment options (Breidenbach Stein et al., 2011; 
Poole, 2011). The need for new therapeutics is high. Bacteriophages offer an alternative 
to current antibacterial treatments, however they present also few disadvantages, such  
as possible DNA transduction or mutation tendency. In 1991 Gasson introduced  
the concept of endolysins, phage-borne enzymes with bacteriolytic activity towards 
Gram-positive microbes. In 2001 Nelson et al. (2001) proved for the first time their 
bactericidal effect against Streptococcus using a mouse model of infection in the upper 
respiratory tract. Since that time many endolysins against Gram-positive pathogens have 
been studied. In the case of Gram-negative pathogens situation remained for a long time 
unsolved and neglected (Nelson et al., 2012). Only in recent years, new ideas and 
strategies to overcome OM barrier were presented, allowing successful administration  
of endolysin (Briers et al. 2007, 2008, 2012, 2014, 2016; Oliveira et al., 2014). 
 In this chapter, we described six PG hydrolases encoded by P. aeruginosa phages. 
Among which two are VAPGHs associated with phage tail structure (KT28 gp41 and 
PA5oct gp214) and four are endolysins, expressed in the end of lytic cycle (KT28 gp49, 
KTN6 gp46, PA5oct gp250 and KTN4 gp48). In silico analysis indicated that all tested 
proteins have globular structure, which is a common feature of PG degrading enzymes 
isolated from phages infecting Gram-negative bacteria (Briers et al., 2007; Walmagh  
et al., 2013). The prediction of secondary structure elements and tertiary conformation 
allowed for prediction of KT28 gp41 domain, which was implemented in analysis due  
to difficulties in full length protein expression. Moreover, this analysis in combination 
with a ligand binding sites prediction provided suitable targets for proteins engineering 
with the use of e.g. side-directed mutagenesis in order to alter protein specificity  
or influence protein stability, that could be of interest in food technology, where 
processing at high temperatures occurs (e.g. pasteurization). In the case of PA5oct gp214 
and KTN4 gp48 coverage score was below 30%, and achieved structures cannot  
be trusted. In depth protein structure analysis with the use of e.g. crystallography, would 
also improve understanding of enzyme function and evaluate the presented analysis.  
 Protein expression of KT28 gp41 and KTN4 gp48 was difficult with occurrence  
of inclusion bodies. Possibly introduction of an alternative expression system, such  
as yeast system, could solve protein toxicity problem. Further, protein purification 
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required implementation of different chromatography steps. An suitable alternative could 
be the use of e.g. Dynabeads® coated in a cobalt-based Immobilized Metal Affinity 
Chromatography (IMAC) chemistry (Life Technologies), which binds histidine-tagged 
proteins with higher selectivity. Another possibility is an alternation of His-tag  
to e.g. Strep-tag.  
The antibacterial activity of phage recombinant proteins was analyzed  
by use of several techniques. The PG degradation ability of all enzymes was first 
confirmed by zymography, that also excluded the potential influence on PG of other  
co-purified proteins. The muralytic activity with the use of zymograms was also reported 
in the case of e.g. LysK and endolysin 555 from RcGTA phage (Westbye et al., 2014; 
Becker et al., 2009; Westbye et al., 2013). According to antimicrobial assay the most 
potent enzyme proven to be KTN6 gp46. This protein had only 4 amino acid residues 
difference in compare to KT28 gp49 amino acid sequence, however its bactericidal 
activity was almost two times stronger. Further investigation is required to establish  
if amino acid sequence alterations caused changes of protein tertiary structure 
conformation and enzyme activity or observed differences are result of recombinant 
protein preparations. Importantly, a similar observation was made by Walmagh et al. 
(2013), who reported different results for highly similar (94%) PsP3 gp10 and P2 gp09 
enzymes. In presented study antibacterial activity of all six proteins was in a range  
of 1.0 ± 0.5 to 3.0 ± 0.3 log reduction of bacterial CFUs. Walmagh et al. (2013) and 
Oliveira et al. (2014) presented also similar bactericidal effect of other endolysins derived 
from Gram-negative infecting phages, where reduction in log-units ranged from a 1.89  
to a 3.08. However, modular endolysins showed a greater antibacterial activity against  
P. aeruginosa PAO1 ranging from a 4.36 to a 2.74 log reduction (Walmagh et al., 2013 
and Rodriguez-Rubio et al., 2016). This presents a high potential of modular endolysins. 
With the power of protein engineering such enzymes could be manufactured by fusion  
of different PG degrading enzymes domains.  
If we compare enzymatic activity of KTN6 gp46 with other endolysins analyzed 
using the same method under optimal conditions, its specific activity (11,129 units/μM) 
is the second best activity from all of the globular endolysins tested and the fifth best 
activity if modular endolysins are also taken into account (Table 8.5). However, the assay 
was conducted in 1:10 dilutions, which gave the rough indication of activity. The slope 
should be calculated with more narrow dilutions, like a 1:2 dilution, as it was performed 
by Briers et al. (2007) and Rodriguez-Rubio et al. (2016). It also has to be stressed, that 
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antibacterial and enzymatic assays do not correlate with each other. This was also 
observed by Rodriguez-Rubio et al. (2014) in the case of gp110 from Salmonella phage 
10, that presented the highest specific activity (34,240 units/μM) for OM permeabilized 
P. aeruginosa PAO1, but a moderate antibacterial activity (2.74 ± 0.11) to PAO1.  
A plausible explanation could be the difference in permeability of the outer membrane 
after chloroform and EDTA treatment. Chloroform disrupts the outer membrane more 
severely than EDTA does, making the peptidoglycan more accessible for the endolysin 
(Lazaroaie et al. 2010; Briers et al., 2008).  
Table 8.5: List of modular and globular endolysins ranked in decreasing activity (units/μM) 
(Rodriguez-Rubio et al., 2016). 
Endolysin Activity (units/ μM) Structure 
Gp110 34240 Modular 
OBPgp279 19979 Modular 
LysEC8 17103 Globular 
PVP-SE1gp146 13614 Modular 
EL188 4735 Modular 
201φ2-1gp229 4469 Modular 
KZ144 2058 Modular 
PsP3gp10 1380 Globular 
P2gp09 829 Globular 
BcepC6Bgp22 786 Globular 
Lys68 400 Globular 
CR8gp3.5 315 Globular 
K11gp3.5 134 Globular 
KP32gp15 1117 Globular 
LysAci7 94 Globular 
 
Further, the host range was tested on E. coli and S. Enteritids strains, however  
no effect was observed. Although the peptidoglycan layer of all Gram-negative pathogens  
is chemically the same (A1γ-chemotype), the permeabilization effect of EDTA  
on the outer membrane is different. EDTA binds the stabilizing divalent cations  
in the LPS layer, thereby destabilizing the OM. Due to the lower degree of LPS 
phosphorylation and thus a lower amount of stabilizing divalent cations of the OM  
of E. coli and Salmonella in compare to P. aeruginosa, their OM is less prone to the action 
of EDTA (Schleifer et al., 1972; Loessner, 2005). Similar results were also observed with 
other previously characterized endolysins (Walmagh et al., 2012; Rodríguez-Rubio et al., 
2016; Oliveira et al., 2014; Lim et al., 2014). Oliveira et al. (2014) suggested new  
OM permeabilizers, a citric acid or malic acid, however in case of our PG hydrolases this 
did not improve the results. Alakomi et al. (2003) reported also different response  
of S. Typhimurium to EDTA treatment along the logarithmic growth. Bacteria in early-
exponential phase were more sensitive in compare to mid- and late-exponential phase. 
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Moreover, the increase of cross-linked bonds in the peptidoglycan layer of bacteria  
in stationary phase can interfere with the antibacterial activity of endolysins. 
 The optimal pH for KTN6 gp46 is pH 7. This neutral pH for KTN6 gp46 activity  
is consistent with other previously characterized Gram-negative endolysins (Loessner  
et al., 2005; Walmagh et al., 2012; Oliveira et al., 2014 and Briers et al., 2007), such  
as a globular endolysin Lys68 isolated from phage lytic towards S. Enteritidis (Oliveira 
et al. 2014). The drop in activity at pH below pH 6 and above pH 8 is also comparable  
to the observations recently made for endolysin gp110 from Salmonella phage 10 
(Rodriguez-Rubio et al. 2016).  
 The presented study is only the initial analysis PG degrading enzymes activity, 
further experiments elucidating e.g. its cytotoxicity, bactericidal effect in combination 
with other antimicrobials, the resistance occurrence, as well as detailed biochemistry 
analysis would be essential. Nevertheless, the features of KTN6 gp46 makes it a good 
candidate for future engineering with antibacterial peptides (‘Artilysation’). This 
approach has the possibility to further improve its lytic activity and expand the host 
spectrum. It has already been demonstrated that fusion with a CBD improve  
the antimicrobial activity of PG hydrolases (Rodriguez-Rubio et al.. 2012). In Rodríguez-
Rubio et al. (2012) study, a 4.8 - fold increase of the HydH5 lytic activity was observed 
when one of the catalytic domains was fused to a lysostaphin SH3b CBD.  
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“The more you know, the more you know you don't know.” 
Aristotle 
9.1. Bacteriophage research 
 The discovery of the first antibiotics, Salvarsan, Prontosil and penicillin  
at the beginning of 20th century gave hope to the world to end the bacterial infectious 
diseases (Almov, 2010). However, only a few years later the presence of the first bacterial 
resistance was reported. In years 1950-1970 there was a “golden era” for identification 
and development of new antibiotics, however inappropriate therapy and drug overuse led 
to a selection of multidrug resistance bacteria. Currently, antibiotics still save many lives, 
but there are many hurdles in the new antibiotic development, especially against resistant 
Gram-negative pathogens. Thus there is an urgent demand for novel and effective 
strategies to combat bacterial infections. The vast bacteriophage diversity, low cost 
production and their high efficacy against the target bacteria, make phages and their 
derived products very attractive alternative/complementary antibacterial therapies. 
 The therapeutic features of bacteriophages were already noticed at the beginning 
of 20th century. Unfortunately, due to antibiotic era most of studies and phage therapy 
were continued only in Georgia, Russia and Poland. Recently “old-new” therapy is again 
intensively studied, yet most of the research focus on in vitro evaluation. There is only  
a small number of in vivo studies, especially focused on phage interaction with immune 
system, phage safety and bacterial resistance analysis. For this reason bacteriophages 
currently are not allowed in Europe for therapy. Thus it is important to further explore 
phage biology, genetics and their safeness.  
9.1.1. Microbiological assessment of P. aeruginosa phages for 
therapeutic purposes 
The first goal of the present study was to isolate and characterize four  
P. aeruginosa specific phages and evaluate their lytic activity. Phages KT28, KTN6 and 
KTN4 have a broad host range against several P. aeruginosa clinical strains, in contrast 
to novel giant PA5oct which exhibited a narrow lytic spectrum. Furthermore, testing  
of their efficacy against biofilm and Pseudomonas infection of healthy and CF lung 
epithelia cell lines revealed a potent phage activity. This feature could be a good indicator 
for therapeutic purposes. Further tests with human lung epithelia cells would be required, 
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especially with the use of primary cell cultures, isolated from healthy individuals and CF 
patients without extensive passages, to retain as much as possible their natural properties. 
Additionally, the ability of the lung mucus penetration by bacteria and phage should  
be tackled it detail, by introducing e.g. fluorescent tag, that could be visualized using 
microscopy. Furthermore, the experimental animal lung infection model could be applied 
to study influence of phage therapy in vivo.  
The biggest hurdle remain the biofilm degradation experiments, due to lack  
of highly sensitive and reproducible techniques with low standard deviations. The Drulis-
Kawa group and collaborators address this problem by applying new alternative assays 
including interferometry, goniometry and profilometry (Danis-Wlodarczyk et al., 2015 
and 2016). Biofilm research should be also further extended by analysis of phage 
cocktails efficacy and study of mixed biofilms, that would mimic more natural 
multispecies biofilms. 
9.1.2. Phage genome analysis  
The functional annotation of phage genomes is a crucial step to assess phage 
safety and to reveal and explain basic phage biology properties. In our study, we focused 
on four phage genomes. A first set of ORFs was identified and gene features were 
assigned based on genome sequence homology. No unwanted genetic elements  
(e.g. associated with lysogeny or virulence) were identified. However, for more than half 
of predicted genes possible function could not be assigned. These proteins could have  
an impact on phage biology and different aspects of bacterial physiology. Unraveling 
biological functions of these unknown proteins is a major importance and it could  
be elucidated by e.g. screening the libraries of unknown genes toward e.g. inhibitory, 
antibiofilm or metabolism modulation functions. Unfortunately, this research  
is complex and time consuming. Nevertheless, it could increase availability of new phage-
born therapeutics and allow to design the high-throughput screens with targeted host 
process to improve the selection of desirable phage proteins (Van den Bossche et al., 
2014; Wagemans et al., 2014).  
Moreover, elucidation of protein structure by NMR, crystallography or CryoEM 
analysis, would provide important new information about the interaction site and allow 
protein docking studies. Recently more studies address this problem, but still detailed 
analysis are required and a systematic approach is lacking (Van den Bossche et al., 2014; 
De Smet et al., 2016).  
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Suitable tools to address the identification of genes and gene products include  
ESI-MS/MS and RNA seq, which drastically impact genome annotations by providing 
experimental confirmation. Mass spectrometry provides an identification of individual 
proteins, but no functional insights can be gathered. RNA seq was performed on the novel 
giant phage PA5oct, which confirmed the presence and expression of a vast number  
of ‘ORFan’ genes (without sequence homology). This technique can also lead  
to the elucidation of regulatory elements and gene expression pattern, as well as evaluate 
the impact of phage infection on transcription regulation of host genes. Particularly early 
gene features could be assigned, involved in the shutdown of host metabolism through 
various mechanisms, e.g. redirection of host RNA polymerase to phage middle and late 
promoters (Calendar, 2006; Rothman-Denes, 2015; Chevallereau et al., 2016).  
The P. aeruginosa transcription apparatus was rapidly overwhelmed with viral protein 
transcription. This has been previously reported also in case of e.g. phage T4 and PAK_P3 
(Ueno et al., 2004; Uzan, 2009; Chevallereau et al., 2016). The big challenge of RNA seq 
remains the cost as well as the manual curation needed to process the data. The correct 
storage and visualization of this information also remains a challenge. 
9.1.3. Phage evolution 
Comparative genomics allowed for the implementation of a genome-based 
mathematical model for reticulate phylogenomic networks based on ortholog clustering 
(Lima-Mendez et al., 2008; Leplae et al., 2010; Jang et al., 2013). Subsequent elucidation 
of a common ancestors of phage families, phage evolution and diversity at the genomic 
and amino acid sequence level is possible. The pool of shared proteins/genes was 
reconstructed from the pattern of protein families included in a pool of homologous 
proteins identified in different phages (Jang et al., 2013). In presented dissertation, phages 
KT28 and KTN6 had the highest similarity to Pbunavirus, particularly with Pseudomonas 
phage LMA2, whereas KTN4 forms an in-group relationship with φKZ, φPA3, and 
201φ2-1 phages. However, novel giant phage PA5oct showed only small pool of protein 
homology to T4virus and proved that the diversity of phages is not yet „saturated”.  
The question is how many phage genera remain to be discovered? Well, with global 
amount of phages estimated at 1031 particles any estimation is purely speculative, 
although closely related phage can be found on distinct geographical locations (Savalia 
et al., 2008). However, the standard phage identification and propagation procedures 
appears be insufficient for isolation and identification of all bacteriophage species. Chen 
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et al. (2001) estimated, that less than 1% of the phage species residing in river samples 
could be detected by standard plaque assay. The viral metagenomics present a new 
approach of phage diversity assessment. This method allows for sequencing of total viral 
components present in a particular environment sample. Moreover, the most dominant 
viral particles can be elucidated in particular location, without phage propagation step  
as well as presence of phages, that are not amenable for propagation or simply do not 
have a host in culture (Clokie et al., 2011).  
In my opinion, the biggest hurdle of genome analysis today is the lack of general 
rules or guidelines for annotation, especially for the gene feature naming, that leads  
to accumulation of homologues genes with different names. Unfortunately, efforts  
of e.g. ICTV (Kropinski et al., 2009) to systematize annotation, classification and phage 
naming are sometimes ignored, which complicates data information available  
in databases. Moreover, number of NCBI submitted genomes are sometimes annotated 
inaccurately, which is misleading and masks promising data. 
9.1.4. The future of bacteriophage therapy  
Phages exhibit several advantages for therapeutic purposes, such as high diversity 
and abundance, and bacteriolytic activity. In addition, they show a high specificity to one 
genus or species, synergy with other phages with different lysis mechanisms and/or 
bacterial surface receptors in cocktail preparations, as well as with antibiotics. Moreover, 
phage therapy is self-dosing and phage preparations are not expensive (Drulis-Kawa  
et al., 2012 and 2015; Hyman et al., 2012; Bikard et al., 2014; Brown-Jaque et al., 2015; 
Roach et al, 2015). To date, bacteriophages have proven to be useful in the food 
processing and show encouraging results in animal models. Also, many years of phage 
therapy conducted on humans in Tbilisi (Georgia) and Wrocław (Poland) presented high 
success rate of this alternative therapy. In Europe, Pherecydes Pharma launched 
randomized controlled single-blind clinical study in I/II trial phase of two phage cocktails 
tested on serious burn victims in 2013. This is the first international clinical phage therapy 
study, that introduce international standards of clinical assessment (www.pherecydes-
pharma.com). These efforts indicate that it is possible to move phage therapy forward 
under the current legislative requirements. However, it is of a crucial importance for  
the competent public authorities to formulate a tailored legislative framework that 
encourages companies to invest in bacteriophage therapy and formulate appropriate 
solutions in a classical pharmaceutical context (clinical trials, production requirements 
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etc.). Hopefully, a rational bacteriophage therapy concept will be developed, to avoid 
historical mistakes that occurred in case of antibiotic therapy (Kegan, 1988, Miller, 1996). 
9.2. Harvesting of antibacterial enzymes 
Phage therapy also has distinct disadvantages, including the vast pool of unknown 
and potentially unwanted proteins, such as toxins or integrases, that could lead  
to lysogeny state and horizontal gene transfer between phages and its host (e.g. transfer 
of virulence genes) via specialized or generalized transduction. Moreover, bacterial 
resistance to phages was also noticed previously (Labrie et al., 2010; Danis-Wlodarczyk 
et al., 2015). The Drulis-Kawa group in their biofilm eradication assays observed  
the rapid appearance of phage-resistant variants (Danis-Wlodarczyk et al., 2015).  
We have presented our preliminary results during the 21st Biennial Evergreen 
International Phage Meeting (2015) (Drulis-Kawa et al., unpublished results), regarding 
the emergence of phage-resistant P. aeruginosa PAO1 mutants obtained from biofilms 
treated with KT28 and KTN6 (LPS-dependent) phages, as well as for KTN4 and φKZ 
(pili-dependent) phages, which exhibited the lost or truncation in LPS O-antigen structure 
and reduction in twitching motility, respectively. The receptor modification is the first 
line defense mechanism of P. aeruginosa in response to phage presence (Labrie et al., 
2010). Moreover, bacterial resistance occurred faster in bacteria embedded in biofilms, 
compared to their planktonic counterparts.  
To circumvent phage therapy hurdles, phage-borne enzymes with antibacterial 
properties could be introduced as antimicrobials. This seems to be an alternative solution 
in compare to phage formulations. In this study we presented two types of proteins,  
PG degrading enzymes and polysaccharide depolymerases. 
9.2.1. Peptidoglycan degrading enzymes 
PG degrading enzymes, including virion-associated PG hydrolases and 
endolysins, have muralytic activity and are responsible for host cell wall degradation 
during infection and phage progeny release at the end of infection cycle, respectively. 
Several studies have already proven their antibacterial potential against Gram-positive 
and Gram-negative bacteria in vitro and in vivo. Despite conserved biological function, 
PG degrading enzymes are heterogeneous in structure. This divergence is directly related 
to the Gram-positive and Gram-negative bacteria cell wall structure. They can be globular 
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or modular enzymes. The first type, mainly correlated with Gram-negative infecting 
phages, consist a single EAD, that cleaves specific bonds within PG (Briers et al., 2007). 
Second type, often related to Gram-positive infecting phages, have an N-terminal EAD 
and C-terminal cell wall-binding domain (CBD) (Fischetti, 2010; Nelson et al., 2012) 
with few exceptions.  
The antibacterial tests with P. aeruginosa and equal concentrations  
of both types of endolysins revealed that modular structures can have up to five-fold 
greater activity in compare to their globular counterparts (Walmagh et al., 2013). Also 
fusion of the CBD to a virion-associated endolysin can triple the activity (Briers et al., 
2015). The superior efficiency of modular endolysins with a CBD can be explained  
by its ability to cleave and increase insoluble substrate proximity, positioning it into 
enzyme active site, as well as improvement of enzyme kinetics (Alberghina, 2005).  
Gram-negative bacteria have an OM which is a highly effective permeability 
barrier. To overcome this obstacle, PG degrading enzymes must be delivered  
in combination with a high hydrostatic pressure (150 - 200 MPa) or OM permeabilizers, 
such as EDTA, citric acid or malic acid (Briers et al., 2011; Oliveira et al., 2014), which 
not always work sufficiently. Briers et al. (2014a) presented another approach focusing 
on engineered endolysins named ‘Artilysin®s’, that consists of a recombinant modular 
endolysin and an antimicrobial peptide, enabling transport through the OM. This peptide 
can either be polycationic, to disrupt the stabilizing ionic bonds between divalent cations 
and the negatively charged phosphate groups, or hydrophobic, to interfere with  
the hydrophobic moieties present in the lipid A part of LPS (Briers et al., 2014). 
Moreover, recombinant PG degrading enzymes isolated from phages targeting Gram-
negative bacteria as globular proteins have an theoretically similar enzymatic activity 
towards the peptidoglycan of most Gram-negative bacteria, due to a highly conserved 
A1γ peptidoglycan structure (Schleifer et al., 1972). In contrary, the proteins derived from 
Gram-positive targeting phages, are more bacterial strain/species specific, due  
to the presence of cell wall binding domains presented in most of those enzymes, which 
condition a highly specific recognition of particular targets in the cell wall.  
Importantly, to date there are no reports describing bacterial resistance 
mechanisms or lost sensitivity to ‘lysis from without’ (Roach et al., 2015). Several studies 
failed in resistance generation in vitro by repeated pathogen exposure to sub-lethal 
concentrations of endolysins or endolysin-sensitive strains mutagenesis (Schuch et al., 
2002). No resistance occurred or resistant mutants were not promoted, while in control 
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groups, treated with only antibiotics, resistance increased 10 - 100,000 fold. Also several 
studies on animal models confirmed this in vitro observations (e.g. Nelson et al., 2001; 
Schuch et al., 2002; Cheng et al., 2005; Yiin et al., 2006). For example no resistance 
occurred after treatment of MDR S. aureus by MV-L lysin derived from phage φMR11 
with the use of mouse infection model and pathogen was efficiently eradicated (Rashel  
et al., 2007).  
Identification of genes encoding these proteins in phage genomes is not 
complicated due to the relatively strong conserved protein domains. Furthermore,  
in many cases of PG degrading enzymes of Gram-negative origin, protein expression and 
purification is relatively straightforward, with the exception of Signal-Arrest-Release 
(SAR) endolysins, where protein expression is more complicated (Briers et al., 2011). 
The PG degrading phage enzymes act very rapidly with the microbes being lysed in few 
seconds after exogenous application of even a small amount of purified endolysins (Briers 
et al., 2014).  
In our study we analyzed six enzymes, including four endolysins (KT28 gp49, 
KTN6 gp46, PA5oct gp250, KTN4 gp48) and two VAPGHs (KT28 gp41, PA5oct 
gp214). All presented globular structure. The most active was endolysin KTN6 gp46, that 
showed high efficiency in combination with EDTA. Further efforts should be focused  
on structural studies to gain insight into e.g. substrate binding site, thermostability, that 
could be improved with use of side-directed mutagenesis. Also, as mentioned before, 
protein could be fused with antimicrobial peptide to avoid EDTA/enzyme mixture. 
Moreover, it would be interesting to test susceptibility of the range of Gram-negative 
pathogens to engineered enzyme with or without EDTA. 
Predatory PG degrading enzymes are currently of high interest as alternative 
microbials (Briers et al., 2014). They could be use e.g. externally on wounds in the form  
of ointments or supplementary compounds in bandages or other types of dressings as well 
as biocontrol of animal/plants diseases and food preparation (Kim et al., 2014; 
Schmelcher et al., 2014). There is still little know about their immunogenicity, which 
potentially could limit their internal application. The CBDs are also consider for rapid 
detection of pathogens to prevent food-borne outbreaks. Importantly, with the capabilities 
of modern synthetic biology and molecular engineering, these enzymes could be designed 
and adjusted to specific purposes. The ability to produce them as recombinant proteins 
allows to optimize manufacturing and purification processes, that could be adapted from 
currently existing methods (e.g. those used to produce insulin).  
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9.2.2. EPS degrading enzymes 
P. aeruginosa produces EPS in the form of capsules or a thick biofilm layer 
(Campodonico et al., 2008). EPS serve as molecular patterns for recognition by the innate 
immune system, and also provide shields to antibiotic entry and host defence mechanisms 
(e.g. complement system and phagocytosis). Specific bacteriophages contain EPS 
depolymerases as virion-associated proteins which serve to degrade EPS to enable 
infection. Such phages can be identified by the appearance of a halo zone around  
the phage plaques, which results from the enzymatic degradation of bacterial EPS without 
phage infection (Azeredo et al., 2008). However, the knowledge of EPS depolymerases 
is currently very limited and mainly derived from E. coli phages (e.g., Leiman et al., 
2007). Not much is known of their complicate structure, including a substrate binding  
or cleaving domains. The PDB database contains only few structures of EPS 
depolymerases. It is also unknown to what extent the depolymerase activity is required 
for the infection process and how possible variations in the amount and density  
of the polysaccharide influence this process (Pelkonen et al., 1992). There is also lack  
of biochemical studies, which would revealed protein mode of action and specificity.  
In our research we presented the process of EPS depolymerase identification and 
recombinant protein preparation. The first obstacle was the limited protein sequence 
similarity of these enzymes in the public databases and their limited, general or even 
incorrect annotation. Further, these proteins are relatively large, ranging to >1000 amino 
acids, hampering efficient cloning, expression and proper folding. To achieve a successful 
expression, different expression systems and conditions needed to be evaluated and 
further analyses beyond what’s been evaluated here can be assessed.  
In our study we decided to focus only on enzyme domains, that had shorter amino 
acid sequence and their handling was much easier. The decision how to define those 
domains was not easy, due to lack of EPS depolymerase structural studies. The efforts  
by Cornelissen and Leiman to elucidate LKA1 gp49 structure allowed us to more 
precisely define position of a LKA1 gp49 domain. The stability tests suggested that, 
possibly the C-terminal part of LKA1 gp49 domain should be extended, that proved  
to be responsible for protein folding and trimerization processes, as was described 
elsewhere (Schwarzer et al., 2007; Walter et al., 2008; Xiang et al., 2009).  
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The activity range of these phage enzymes should be studied in details against 
different isolates and species. Cornelissen et al. (2011) presented that an EPS 
depolymerase has a high specificity, limited to the EPS produced by the specific bacterial 
strain used for phage propagation.  
Future perspectives  
The applications of phage-borne EPS degrading enzymes is an innovative 
approach that exploits the weapons of the bacteriophage. Such enzymes could offer  
a novel stand-alone strategy to control biofilm growth, which will be also complementary 
to existing strategies. Unfortunately, extensive fundamental and technology-development 
research remains to be done to allow a proper assessment of the potential of these 
enzymes, including the biochemical analysis of the EPS diversity and the development  
of sensitive, quantitative and reproducible biofilm assays.  
Furthermore, the narrow spectrum of EPS depolymerases could be overcome  
by protein subjection to in vitro direct evolution, in order to tailor them as optimized 
agents that prevent biofilm formation or/and eradicate existing biofilms. Directed 
evolution can broaden the substrate specificity of the enzymes and proteins can be tailored 
to degrade the greatest possible number of biofilm of clinical P. aeruginosa isolates, 
including those of cystic fibrosis infection. The power of in vitro evolution can be used 
to ‘relax’ a natural specificity and to create broad-spectrum EPS depolymerases. 
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Supplementary data 
Table 4.1: The lytic activity of KT28, KTN6, KTN4, PA5oct towards P. aeruginosa Pirnay’s panel. The comparisement with host range of representatives of Luz7virus 
(LUZ7), Lit1virus (LIT1), LUZ24virus (LUZ24), Phikmvvirus (LUZ19, LKD16, LKA1, φKMV), Pbunavirus (LBL3, LMA2, LSL4, KT28, KTN6), Phikzvirus (KTN4, φKZ) 
(Pirnay et al., 2002). Grey box –active, white box – no activity. 
 Strain \ Phage φKZ KTN4 PA5oct KTN6 KT28 φKMV LKD16 LUZ19 LKA1 LIT1 LUZ7 LUZ24 LSL4 LMA2 LBL3 
US449                
LMG14083                
Bu007                
PAO23                
Aa249                
US448                
PAO1Krylov                
Lo050                
US450                
Li004                
Be128                
Lo053                
ATCC27853                
Br906                
PhDW6                
So099                
Aa245                
LMG5031                
C17                
C19                
Lo049                
Br642                
Li012                
Is579                
C                
Lw1047                
Br257                
Br667                
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 Strain \ Phage φKZ KTN4 PA5oct KTN6 KT28 φKMV LKD16 LUZ19 LKA1 LIT1 LUZ7 LUZ24 LSL4 LMA2 LBL3 
C18                
LMG2107                
Bu004                
C1                
PAO29                
C13                
C2                
Aa246                
LMG14084                
Br735                
Mi162                
SG17M                
Pr335                
Is580                
Li009                
Be136                
Is573                
Br908                
TuD199                
So095                
So092                
Br229                
SG50M                
PT31M                
Mi151                
US447                
Bo548                
Br680                
PA6                
Summary 21 20 15 24 16 21 22 23 3 10 18 16 10 12 26 
% 37% 35% 26% 42% 28% 37% 39% 40% 5% 17% 32% 28% 17% 21% 46% 
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Table S 4.2: The Pseudomonas phage KT28 genome annotation. 
Protein 
no. Function Start Stop Strand 
Start 
codon 
Stop 
codon 
Lenght 
(nt) 
Lenght 
(aa) The closest homolog (BLAST P) E-value 
gp001 Uncharacterized protein 1 303 - ATG TAA 303 100 Pseudomonas phage NH-4 4.7e-58 
gp002 Uncharacterized protein 315 461 - ATG TAA 147 48 Pseudomonas phage NH-4 8.0e-23 
gp003 Uncharacterized protein 520 819 - ATG TGA 300 100 KT28 unique protein  
gp004 Uncharacterized protein 865 1059 - ATG TAA 195 64 Pseudomonas phage NH-4 8.1e-36 
gp005 Terminase large subunit 1227 2609 + ATG TAA 1383 460 Pseudomonas phage NH-4 2.3e-314 
gp006 Uncharacterized protein 2646 3029 - ATG TAA 384 127 Pseudomonas phage KPP12 5.3e-75 
gp007 Uncharacterized protein 3029 3244 - ATG TAA 216 71 Pseudomonas phage SN 2.1e-41 
gp008 Uncharacterized protein 3244 3594 - ATG TGA 351 116 Pseudomonas phage PB1 1.9e-69 
gp009 Uncharacterized protein 3639 4073 - ATG TGA 435 144 Pseudomonas phage PB1 7.6e-78 
gp010 Uncharacterized protein 4076 4855 - ATG TAA 780 259 Pseudomonas phage LBL3 4.6e-167 
gp011 Uncharacterized protein 4941 5378 - ATG TAA 438 145 Pseudomonas phage LBL3 2.0e-91 
gp012 Uncharacterized protein 5395 5982 - ATG TAA 588 195 Pseudomonas phage LBL3 4.8e-136 
gp013 Uncharacterized protein 5992 6087 - ATG TGA 96 31 Pseudomonas phage NH-4 1.6e-14 
gp014 Uncharacterized protein 6084 7016 - ATG TGA 933 310 Pseudomonas phage LMA2 7.4e-196 
gp015 Uncharacterized protein 7120 7467 - ATG TGA 348 115 Pseudomonas phage PB1 2.6e-68 
gp016 Uncharacterized protein 7716 8027 - ATG TAA 312 103 Pseudomonas phage PB1 5.8e-61 
gp017 Uncharacterized protein 8033 8236 - ATG TAG 204 67 Pseudomonas phage NH-4 1.7e-37 
gp018 Uncharacterized protein 8233 8556 - ATG TGA 324 107 Pseudomonas phage 14-1 2.7e-71 
gp019 Uncharacterized protein 8588 8989 - ATG TAG 402 133 Pseudomonas phage 14-1 3.3e-85 
gp020 Minor head protein 9170 11467 + ATG TGA 2298 765 Pseudomonas phage JG024 0.0e+00 
gp021 Minor head protein 11467 12303 + ATG TGA 837 278 Pseudomonas phage SN 2.3e-182 
gp022 Uncharacterized protein 12322 12528 + ATG TGA 207 68 Pseudomonas phage LBL3 1.9e-36 
gp023 Uncharacterized protein 12525 12665 + ATG TAA 141 46 Pseudomonas phage LMA2 8.2e-24 
gp024 Structural protein 13217 14611 + ATG TAA 1395 464 Pseudomonas phage NH-4 1.6e-304 
gp025 Structural protein 14615 15250 + ATG TAA 636 211 Pseudomonas phage NH-4 2.2e-133 
gp026 Structural protein 15260 16408 + ATG TAA 1149 382 Pseudomonas phage NH-4 7.3e-254 
gp027 Uncharacterized protein 16510 16947 + ATG TAA 438 145 Pseudomonas phage NH-4 3.4e-91 
gp028 Structural protein 16962 17429 + ATG TGA 468 155 Pseudomonas phage LMA2 3.0e-103 
gp029 Structural protein 17426 17824 + GTG TAG 399 132 Pseudomonas phage SN 8.9e-86 
gp030 Uncharacterized protein 17832 18383 + ATG TGA 552 183 Pseudomonas phage JG024 2.0e-119 
gp031 Uncharacterized protein 18380 18961 + ATG TAA 582 193 Pseudomonas phage LMA2 6.2e-124 
gp032 Structural protein 18977 20491 + GTG TAA 1515 504 Pseudomonas phage KPP12 0.0e+00 
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Protein 
no. Function Start Stop Strand 
Start 
codon 
Stop 
codon 
Lenght 
(nt) 
Lenght 
(aa) The closest homolog (BLAST P) E-value 
gp033 Structural protein 20550 21002 + ATG TGA 453 150 Pseudomonas phage SN 7.4e-94 
gp034 Structural protein 21002 21325 + ATG TGA 324 107 Pseudomonas phage SN 6.7e-71 
gp035 Structural protein 21322 21672 + ATG TGA 351 116 Pseudomonas phage SN 1.0e-70 
gp036 Uncharacterized protein 21674 22105 + ATG TAA 432 143 Pseudomonas phage SN 1.0e-82 
gp037 Structural protein 22115 22618 + ATG TGA 504 167 Pseudomonas phage SN 4.4e-103 
gp038 Structural protein 22753 23157 + ATG TGA 405 134 Pseudomonas phage SN 2.9e-82 
gp039 Structural protein 23166 23759 + TTG TGA 594 197 Pseudomonas phage SN 2.3e-121 
gp040 Uncharacterized protein 23769 24197 + ATG TGA 429 142 Pseudomonas phage SN 8.7e-92 
gp041 Transglycosylase 24201 26777 + ATG TGA 2577 858 Pseudomonas phage SN 0.0e+00 
gp042 Structural protein 26777 27640 + ATG TAA 864 287 Pseudomonas phage SN 1.7e-189 
gp043 Uncharacterized protein 27640 28173 + ATG TAA 534 177 Pseudomonas phage 14-1 8.0e-112 
gp044 Baseplate protein 28229 28894 + ATG TAA 666 237 Pseudomonas phage SN 5.7e-133 
gp045 Baseplate protein 28951 30204 + ATG TGA 1254 417 Pseudomonas phage KPP12 3.0e-268 
gp046 Structural protein 30201 31715 + ATG TAA 1515 504 Pseudomonas phage SN 0.0e+00 
gp047 Tail protein 31720 34608 + GTG TAA 2889 962 Pseudomonas phage SN 0.0e+00 
gp048 Uncharacterized protein 34610 35038 + ATG TGA 429 142 Pseudomonas phage SN 2.2e-93 
gp049 Endolysin 35038 35700 + ATG TGA 663 220 Pseudomonas phage SN 1.5e-147 
gp050 Uncharacterized protein 35724 35975 - ATG TAA 252 83 Pseudomonas phage JG024 6.7e-45 
gp051 DNA ligase 36255 37166 - ATG TGA 912 317 Pseudomonas phage SN 9.6e-201 
gp052 Uncharacterized protein 37221 37775 - ATG TGA 555 184 Pseudomonas phage SN 2.1e-115 
gp053 Uncharacterized protein 37772 38377 - ATG TGA 606 201 Pseudomonas phage LBL3 3.4e-119 
gp054 Uncharacterized protein 38431 39330 - ATG TAA 900 299 Pseudomonas phage LMA2 1.7e-194 
gp055 Uncharacterized protein 30419 40051 - TTG TGA 633 210 Pseudomonas phage NH-4 3.3e-130 
gp056 Helicase 40134 41693 - ATG TAA 1560 519 Pseudomonas phage LMA2 0.0e+00 
gp057 DNA helicase 41690 42106 - ATG TGA 417 138 Pseudomonas phage NH-4 7.0e-88 
gp058 
DNA polymerase III 
alpha subunit  42093 45203 - 
ATG TGA 
3111 1080 Pseudomonas phage NH-4 0.0e+00 
gp059 
DNA polymerase III 
epsilon subunit 45200 45754 - 
ATG TGA 
555 184 Pseudomonas phage LMA2 1.8e-123 
gp060 Polynucleotide kinase 45830 46846 - ATG TAA 1017 338 Pseudomonas phage KPP12 1.1e-223 
gp061 Uncharacterized protein 46849 47040 - ATG TGA 192 63 Pseudomonas phage LMA2 1.7e-32 
gp062 Thymidylate synthase 47042 47959 - ATG TAA 918 305 Pseudomonas phage KPP12 1.1e-205 
gp063 Uncharacterized protein 47959 48165 - ATG TGA 207 68 Pseudomonas phage KPP12 5.1e-37 
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Protein 
no. Function Start Stop Strand 
Start 
codon 
Stop 
codon 
Lenght 
(nt) 
Lenght 
(aa) The closest homolog (BLAST P) E-value 
gp064 Uncharacterized protein 48173 48439 - ATG TGA 267 88 Pseudomonas phage PB1  3.7e-53 
gp065 Uncharacterized protein 48439 48657 - ATG TGA 219 72 Pseudomonas phage KPP12 6.7e-42 
gp066 Uncharacterized protein 48641 48859 - ATG TAA 219 72 Pseudomonas phage KPP12 1.3e-40 
gp067 Uncharacterized protein 48859 49089 - ATG TAA 231 76 Pseudomonas phage NH-4 2.3e-46 
gp068 Uncharacterized protein 49177 50178 - ATG TAA 1002 333 Pseudomonas phage LMA2 1.5e-224 
gp069 Structural protein 50282 51175 - ATG TAA 894 297 Pseudomonas phage NH-4 1.8e-158 
gp070 
ATP-dependent 
exonuclease V 51334 52521 - 
ATG TGA 
1188 395 Pseudomonas phage JG024 8.8e-271 
gp071 Uncharacterized protein 52508 52930 - ATG TAA 423 140 Pseudomonas phage LMA2 1.2e-89 
gp072 Uncharacterized protein 53099 53884 + ATG TGA 786 261 Pseudomonas phage 14-1 1.2e-174 
gp073 Uncharacterized protein 53894 54865 + ATG TAA 972 323 Pseudomonas phage SN 3.4e-176 
gp074 Uncharacterized protein 54889 55347 + ATG TGA 459 152 Pseudomonas phage LMA2 5.4e-96 
gp075 Uncharacterized protein 55344 56420 + ATG TAG 1077 358 Pseudomonas phage LBL3 4.3e-254 
gp076 Uncharacterized protein 56426 56611 + ATG TAA 186 61 Pseudomonas phage PB1 5.5e-32 
gp077 Primase 56759 58498 + ATG TGA 1740 579 Pseudomonas phage KPP12 0.0e+00 
gp078 Uncharacterized protein 59462 60031 + ATG TAG 570 189 Pseudomonas phage LMA2 4.7e-123 
gp079 Uncharacterized protein 60199 60813 - ATG TAA 615 204 Pseudomonas phage LMA2 5.6e-124 
gp080 Uncharacterized protein 61003 61707 - ATG TGA 705 234 Pseudomonas phage NH-4 3.4e-152 
gp081 Uncharacterized protein 61718 62029 - ATG TGA 312 103 Pseudomonas phage SN 2.3e-63 
gp082 Uncharacterized protein 62082 62303 - ATG TAA 222 73 Pseudomonas phage 14-1 1.9e-43 
gp083 Uncharacterized protein 62313 62570 - ATG TAG 258 85 Pseudomonas phage LBL3 3.6e-43 
gp084 Uncharacterized protein 62624 62848 - ATG TAA 225 74 Pseudomonas phage LMA2 9.2e-44 
gp085 Uncharacterized protein 62910 63239 - ATG TGA 330 119 Pseudomonas phage LMA2 6.8e-67 
gp086 Uncharacterized protein 63240 63890 - ATG TAA 651 216 Pseudomonas phage NH-4 5.0e-134 
gp087 Uncharacterized protein 63922 64134 - ATG TAA 213 70 Pseudomonas phage LBL3 2.8e-43 
gp088 Uncharacterized protein 64131 64331 - ATG TGA 201 74 Pseudomonas phage SN 4.9e-37 
gp089 Uncharacterized protein 64328 64543 - ATG TGA 216 71 Pseudomonas phage LMA2 3.6e-41 
gp090 Uncharacterized protein 64540 64740 - GTG TGA 201 66 Pseudomonas phage JG024 2.0e-38 
gp091 Uncharacterized protein 64737 64988 - ATG TGA 252 84 Pseudomonas phage NH-4 3.1e-51 
gp092 Uncharacterized protein 65117 65302 - ATG TGA 186 61 Pseudomonas phage LMA2 3.7e-34 
gp093 Uncharacterized protein 65387 65575 - ATG TAA 189 62 Pseudomonas phage LMA2 3.3e-35 
gp094 Uncharacterized protein 65578 66327 - ATG TGA 750 249 Pseudomonas phage NH-4 8.7e-148 
(gp) gene product, (nt) nucleotides (aa) amino acids 
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Table S 4.3: The Pseudomonas phage KTN6 genome annotation. 
Protein no. Predicted function Start Stop Strand 
Start 
codon 
Stop 
codon 
Lenght 
(nt) 
Lenght 
(aa) The closest homolog (BLAST P) E-value 
1 Uncharacterized protein 1 303 - ATG TAA 303 100 Pseudomonas phage NH-4 9.7e-60 
2 Uncharacterized protein 315 461 - ATG TAA 147 48 Pseudomonas phage LMA2 8.7e-23 
3 Terminase large subunit 638 2020 + ATG TAA 1383 460 Pseudomonas phage NH-4 2.4e-314 
4 Uncharacterized protein 2057 2440 - ATG TAA 384 127 Pseudomonas phage KPP12 5.7e-75 
5 Uncharacterized protein 2440 2655 - ATG TAA 216 71 Pseudomonas phage SN 2.4e-41 
6 Uncharacterized protein 2655 3005 - ATG TGA 351 116 Pseudomonas phage PB1 2.1e-69 
7 Uncharacterized protein 3050 3481 - ATG TGA 432 143 Pseudomonas phage PB1 1.5e-76 
8 Uncharacterized protein 3484 4263 - ATG TAA 780 259 Pseudomonas phage LBL3 5.3e-167 
9 Uncharacterized protein 4349 4786 - ATG TAA 438 145 Pseudomonas phage LBL3 1.8e-89 
10 Uncharacterized protein 4803 5390 - ATG TAA 588 195 Pseudomonas phage SN 3.7e-134 
11 Uncharacterized protein 5492 6424 - ATG TGA 933 310 Pseudomonas phage LMA2 8.5e-196 
12 Uncharacterized protein 6528 6875 - ATG TGA 348 115 Pseudomonas phage PB1 3.0e-68 
13 Uncharacterized protein 7124 7435 - ATG TAA 312 103 Pseudomonas phage PB1 1.2e-59 
14 Uncharacterized protein 7441 7644 - ATG TTG 204 67 Pseudomonas phage NH-4 2.0e-37 
15 Uncharacterized protein 7641 7964 - ATG TGA 324 107 Pseudomonas phage 14-1 3.1e-71 
16 Uncharacterized protein 7996 8397 - ATG TTG 402 133 Pseudomonas phage 14-1 3.8e-85 
17 Minor head protein 8686 10875 + ATG TGA 2190 766 Pseudomonas phage NH-4 0.0e+00 
18 Minor head protein 10875 11711 + ATG TGA 837 278 Pseudomonas phage SN 3.5e-182 
19 Uncharacterized protein 11730 11936 + ATG TGA 207 68 Pseudomonas phage 14-1 2.2e-36 
20 Uncharacterized protein 11933 12073 + ATG TAA 141 46 Pseudomonas phage NH-4 9.5e-24 
21 Structural protein 12586 14019 + ATG TAA 1395 464 Pseudomonas phage NH-4 1.8e-304 
22 Structural protein 14023 14658 + ATG TAA 636 211 Pseudomonas phage LMA2 2.5e-133 
23 Major structural protein 14668 15816 + ATG TAA 1149 382 Pseudomonas phage NH-4 1.1e-253 
24 Uncharacterized protein 15918 16355 + ATG TAA 438 145 Pseudomonas phage 14-1 5.4e-91 
25 Structural protein 16370 16837 + ATG TGA 468 155 Pseudomonas phage KPP12 4.9e-103 
26 Structural protein 16834 17232 + GTG TGA 399 132 Pseudomonas phage KPP12 8.6e-85 
27 Structural protein 17240 17791 + ATG TAA 552 183 Pseudomonas phage SN 1.0e-117 
28 Uncharacterized protein 17788 18369 + GTG TAA 582 193 Pseudomonas phage SN 7.1e-124 
30 Structural protein 19958 20410 + ATG TGA 453 150 Pseudomonas phage KPP12 5.9e-95 
31 Structural protein 20410 20733 + ATG TGA 324 107 Pseudomonas phage NH-4 7.7e-71 
32 Structural protein 20730 21080 + ATG TGA 351 116 Pseudomonas phage NH-4 1.2e-70 
33 Uncharacterized protein 21082 21513 + ATG TAA 432 143 Pseudomonas phage SN 2.2e-83 
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Protein no. Predicted function Start Stop Strand 
Start 
codon 
Stop 
codon 
Lenght 
(nt) 
Lenght 
(aa) The closest homolog (BLAST P) E-value 
34 Structural protein 21523 22026 + ATG TGA 504 167 Pseudomonas phage SN 5.1e-103 
35 Structural protein 22161 22565 + ATG TGA 540 180 Pseudomonas phage LMA2 8.8e-112 
36 Structural protein 22574 23167 + TTG TGA 594 197 Pseudomonas phage KPP12 8.6e-121 
37 Uncharacterized protein 23177 23605 + ATG TGA 429 142 Pseudomonas phage LBL3 2.6e-91 
38 Transglycosydase 23621 26179 + TTG TGA 2571 857 Pseudomonas phage JG024 0.0e+00 
39 Structural protein 26179 27042 + ATG TAA 864 287 Pseudomonas phage LMA2 7.3e-190 
40 Uncharacterized protein 27042 27575 + ATG TAA 534 177 Pseudomonas phage KPP12 1.1e-110 
41 Baseplate 27733 28296 + ATG TAA 666 222 Pseudomonas phage KPP12 2.4e-143 
42 Baseplate 28353 29606 + ATG TGA 1254 417 Pseudomonas phage KPP12 3.4e-268 
43 Structural protein 29603 31117 + ATG TAA 1515 504 Pseudomonas phage KPP12 0.0e+00 
44 Tail fibers protein 31122 34016 + GTG TAA 2895 964 Pseudomonas phage SPM-1 0.0e+00 
45 Tail fiber component 34018 34446 + ATG TGA 429 142 Pseudomonas phage KPP12 5.8e-90 
46 Endolysin 34446 35108 + ATG TGA 663 220 Pseudomonas phage KPP12 1.5e-147 
47 Uncharacterized protein 35133 35384 - ATG TAA 252 83 Pseudomonas phage JG024 7.7e-45 
48 DNA ligase 35664 36566 - ATG TGA 912 304 Pseudomonas phage LMA2 8.4e-212 
49 Uncharacterized protein 36630 37184 - ATG TGA 555 184 Pseudomonas phage NH-4 1.1e-118 
50 Uncharacterized protein 37181 37786 - ATG TGA 606 201 Pseudomonas phage PB1 3.9e-119 
51 Uncharacterized protein 37840 38739 - ATG TAA 900 299 Pseudomonas phage 14-1 1.9e-194 
52 Uncharacterized protein 38828 39448 - ATG TGA 621 206 Pseudomonas phage KPP12 2.0e-128 
53 Helicase 39543 41102 - ATG TAA 1560 519 Pseudomonas phage LMA2 0.0e+00 
54 DNA helicase 41099 41509 - ATG TGA 411 136 Pseudomonas phage SN 1.3e-88 
55 
DNA Polymerase III 
alpha subunit 41502 44609 - 
ATG TGA 
3111 1037 
Pseudomonas phage SN 0.0e+00 
56 
DNA polymerase III 
epsilon subunit 44609 45163 - 
ATG TGA 
555 184 
Pseudomonas phage KPP12 
7.7e-124 
57 Polynucleotide kinase 45239 46258 - ATG TAA 1020 339 Pseudomonas phage KPP12 7.9e-222 
58 Uncharacterized protein 46261 46452 - ATG TGA 192 63 Pseudomonas phage SN 2.6e-33 
59 Thymidylate synthase 46454 47371 - ATG TAA 918 305 Pseudomonas phage LMA2 1.6e-206 
60 Uncharacterized protein 47371 47577 - ATG TGA 207 68 Pseudomonas phage LMA2 1.9e-38 
61 Uncharacterized protein 47585 47842 - ATG TGA 258 86 Pseudomonas phage NH-4 5.8e-46 
62 Tail assembly protein 47842 48060 - ATG TAA 219 72 Pseudomonas phage SPM-1 1.4e-37 
63 Uncharacterized protein 48044 48262 - ATG TAA 219 72 Pseudomonas phage NH-4 1.4e-40 
64 Uncharacterized protein 48262 48492 - ATG TAA 231 76 Pseudomonas phage NH-4 3.4e-46 
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Lenght 
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65 Uncharacterized protein 48580 49581 - ATG TAA 1002 333 Pseudomonas phage KPP12 3.6e-224 
66 Structural protein 49686 50579 - ATG TAA 894 297 Pseudomonas phage NH-4 4.0e-154 
67 
ATP-dependent 
exonuclease V 50740 51927 - 
ATG TGA 
1188 395 
Pseudomonas phage JG024 
7.2e-270 
68 Uncharacterized protein 51914 52336 - ATG TAA 423 140 Pseudomonas phage LMA2 9.1e-92 
69 Uncharacterized protein 52505 53290 + ATG TGA 786 261 Pseudomonas phage 14-1 9.6e-175 
70 Uncharacterized protein 53292 54485 + GTG TAA 1185 395 Pseudomonas phage LMA2 2.2e-263 
71 Uncharacterized protein 54509 54967 + ATG TGA 459 152 Pseudomonas phage SPM-1 5.5e-97 
72 Uncharacterized protein 54964 56040 + ATG TAG 1077 358 Pseudomonas phage KPP12 5.3e-254 
73 Uncharacterized protein 56046 56231 + ATG TAG 186 61 Pseudomonas phage LBL3 2.6e-30 
74 Primase 56379 58118 + ATG TGA 1740 579 Pseudomonas phage NH-4 0.0e+00 
75 Uncharacterized protein 59099 59668 + ATG TAG 570 189 Pseudomonas phage LMA2 1.1e-123 
76 Uncharacterized protein 59835 60449 - ATG TAA 615 204 Pseudomonas phage LMA2 6.4e-124 
77 Uncharacterized protein 60680 61339 - ATG TAA 660 219 Pseudomonas phage NH-4 4.8e-136 
78 Uncharacterized protein 61350 61661 - ATG TGA 312 103 Pseudomonas phage SN 5.4e-65 
79 Uncharacterized protein 61714 61935 - ATG TAA 222 73 Pseudomonas phage LBL3 5.4e-43 
80 Uncharacterized protein 61945 62202 - ATG TTG 258 85 Pseudomonas phage NH-4 2.6e-47 
81 Uncharacterized protein 62256 62480 - ATG TAA 225 74 Pseudomonas phage LMA2 1.1e-43 
82 Uncharacterized protein 62542 62865 - ATG TGA 324 108 Pseudomonas phage LMA2 2.2e-66 
83 Uncharacterized protein 62868 63515 - ATG TGA 648 215 Pseudomonas phage PB1 3.7e-145 
84 Uncharacterized protein 63547 63759 - ATG TAA 213 70 Pseudomonas phage KPP12 1.7e-43 
85 Uncharacterized protein 63756 63944 - ATG TGA 189 62 Pseudomonas phage LBL3 3.0e-38 
86 Uncharacterized protein 63941 64156 - ATG TGA 216 71 Pseudomonas phage LBL3 1.8e-41 
87 Uncharacterized protein 64153 64353 - GTG TGA 201 66 Pseudomonas phage LBL3 2.8e-38 
88 Uncharacterized protein 64350 64601 - ATG TGA 252 83 Pseudomonas phage NH-4 3.6e-51 
89 Uncharacterized protein 64730 64915 - ATG TGA 186 61 Pseudomonas phage LMA2 4.2e-34 
90 Uncharacterized protein 65000 65188 - ATG TAA 189 62 Pseudomonas phage LMA2 3.8e-35 
91 
Tail length tape-measure 
protein 65191 65976 - 
ATG TGA 
750 250 
Pseudomonas phage SPM-1 2.9e-65 
(gp) gene product, (nt) nucleotides (aa) amino acids 
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Table S 5.1: The KTN4 genome annotation. 
Protein 
no. Predicted function Start Stop Strand 
Start 
codon 
Stop 
codon 
Lenght 
(nt) 
Length 
(aa) Homolog protein Homolog bacteria E-value 
gp001 Virion associated protein 1 390 + ATG TAA 389 129 PHIKZ001 Pseudomonas phage φKZ  9.6e-84 
gp002 Uncharacterized protein 354 938 + ATG TAA 584 194 PHIKZ002 Pseudomonas phage φKZ  1.5e-127 
gp003 Uncharacterized protein 913 1419 + ATG TAA 506 168 PHIKZ003 Pseudomonas phage φKZ  8.4e-107 
gp004 Uncharacterized protein 1419 1940 + ATG TAA 521 173 PHIKZ004 Pseudomonas phage φKZ  2.1e-114 
gp005 Uncharacterized protein 2057 2461 + ATG TAA 404 134 PHIKZ005 Pseudomonas phage φKZ  6.2e-86 
gp006 Uncharacterized protein 2556 3071 + ATG TAA 515 171 PHIKZ006 Pseudomonas phage φKZ  2.6e-120 
gp007 Uncharacterized protein 3089 3325 + ATG TAA 236 78 PHIKZ007 Pseudomonas phage φKZ  1.0e-47 
gp008 Uncharacterized protein 3328 3540 + ATG TAA 212 70 PHIKZ008 Pseudomonas phage φKZ  7.6e-41 
gp009 Uncharacterized protein 3642 3974 + ATG TGA 332 110 PHIKZ009 Pseudomonas phage φKZ  5.2e-36 
gp010 Uncharacterized protein 4056 4316 + ATG TAA 260 86 PHIKZ010 Pseudomonas phage φKZ  8.1e-53 
gp011 Uncharacterized protein 4407 4556 + ATG TAG 149 49 PHIKZ010.1 Pseudomonas phage φKZ  1.3e-25 
gp012 Uncharacterized protein 4567 4908 + ATG TAA 341 113 PHIKZ011 Pseudomonas phage φKZ  2.9e-70 
gp013 Uncharacterized protein 4914 5312 + ATG TGA 398 132 PHIKZ012 Pseudomonas phage φKZ  3.7e-76 
gp014 Uncharacterized protein 5309 5482 + 
 
GTG 
 
TAA 173 57 
Glycophorin binding 
protein family, Gbph 
Plasmodium falciparum 
3D7  1.9e-06 
gp015 Uncharacterized protein 5486 5893 + ATG TGA 407 135 PHIKZ013 Pseudomonas phage φKZ  1.7e-83 
gp016 Uncharacterized protein 6043 7155 + ATG TAG 1112 370 PHIKZ014 Pseudomonas phage φKZ  3.6e-252 
gp017 Uncharacterized protein 7260 8261 + ATG TGA 1001 333 PHIKZ015 Pseudomonas phage φKZ  2.5e-211 
gp018 Uncharacterized protein 8274 8753 + ATG TAA 479 159 PHIKZ016 Pseudomonas phage φKZ  2.6e-99 
gp019 Uncharacterized protein 8810 8953 + ATG TAA 143 47 PHIKZ016.1 Pseudomonas phage φKZ  2.0e-25 
gp020 Uncharacterized protein 8982 9374 + ATG TAA 392 130 PHIKZ017 Pseudomonas phage φKZ  3.7e-78 
gp021 Uncharacterized protein 9437 9766 + ATG TAA 329 109 PHIKZ018 Pseudomonas phage φKZ  2.1e-69 
gp022 Uncharacterized protein 9796 10005 + ATG TAA 209 69 PHIKZ019 Pseudomonas phage φKZ  1.7e-40 
gp023 Uncharacterized protein 10063 10350 + ATG TAA 287 95 Uncharacterized protein Pseudomonas phage PA7  7.1e-61 
gp024 Uncharacterized protein 10416 10706 + 
 
GTG 
 
TAG 290 96 Uncharacterized protein 
Pseudomonas phage 
201phi2-1  5.3e-09 
gp025 Uncharacterized protein 10718 11056 + ATG TAG 338 112 Uncharacterized protein Pseudomonas phage PA7  1.8e-70 
gp026 Uncharacterized protein 11046 11186 + ATG TGA 140 46    
gp027 Uncharacterized protein 11186 11443 + ATG TAA 257 85 PHIKZ020 Pseudomonas phage φKZ  7.5e-53 
gp028 Uncharacterized protein 11590 11925 + ATG TGA 335 111 PHIKZ021 Pseudomonas phage φKZ  1.1e-68 
gp029 Uncharacterized protein 11933 12487 + ATG TGA 554 184 PHIKZ022 Pseudomonas phage φKZ  4.7e-114 
gp030 Uncharacterized protein 12484 12693 + ATG TGA 209 69 PHIKZ019 Pseudomonas phage φKZ 2.9e-23 
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codon 
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(nt) 
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(aa) Homolog protein Homolog bacteria E-value 
gp031 Uncharacterized protein 12690 12932 + ATG TAA 242 80    
gp032 Uncharacterized protein 12932 13198 + ATG TAA 266 88    
gp033 Uncharacterized protein 13204 13641 + ATG TAA 437 145 PHIKZ023 Pseudomonas phage φKZ 3.0e-81 
gp034 Uncharacterized protein 13895 14161 + ATG TAA 266 88 Uncharacterized protein Pseudomonas phage PA7  5.3e-47 
gp035 Terminase large subunit 14215 16368 - ATG TAA 2153 717 PHIKZ025 Pseudomonas phage φKZ  0.0e+00 
gp036 Structural head protein 16508 18166 - ATG TAA 1658 552 PHIKZ026 Pseudomonas phage φKZ  0.0e+00 
gp037 Structural head protein 18163 20859 - ATG TGA 2696 898 PHIKZ027 Pseudomonas phage φKZ  0.0e+00 
gp038 Structural head protein 20876 21838 - ATG TAA 962 320 PHIKZ028 Pseudomonas phage φKZ  3.1e-215 
gp039 Tail sheath protein 21967 24054 + ATG TGA 2087 695 PHIKZ029 Pseudomonas phage φKZ  0.0e+00 
gp040 Structural protein 24086 24967 + ATG TAA 881 293 PHIKZ030 Pseudomonas phage φKZ  2.7e-201 
gp041 Uncharacterized protein 24967 25149 + ATG TAA 182 60 PHIKZ030.1 Pseudomonas phage φKZ  3.7e-34 
gp042 Uncharacterized protein 25277 26473 + ATG TGA 1196 398 PHIKZ031 Pseudomonas phage φKZ  1.4e-271 
gp043 Uncharacterized protein 26470 26826 + ATG TAA 356 118 PHIKZ031.1 Pseudomonas phage φKZ  4.4e-74 
gp044 Structural head protein 26873 28111 - ATG TAA 1238 412 PHIKZ032 Pseudomonas phage φKZ  7.3e-275 
gp045 Uncharacterized protein 28202 29071 + ATG TAG 869 289 PHIKZ033 Pseudomonas phage φKZ  4.9e-175 
gp046 Uncharacterized protein 29079 29282 + ATG TAA 203 67 PHIKZ033.1 Pseudomonas phage φKZ  1.3e-39 
gp047 Structural protein 29378 30148 + ATG TAA 770 256 PHIKZ034 Pseudomonas phage φKZ  3.5e-174 
gp048 Structural head protein 30158 30973 + ATG TGA 815 271 PHIKZ035 Pseudomonas phage φKZ  2.5e-166 
gp049 Uncharacterized protein 31077 31889 + ATG TAA 812 270 PHIKZ036 Pseudomonas phage φKZ  3.3e-180 
gp050 Uncharacterized protein 31926 32747 + ATG TGA 821 273 PHIKZ037 Pseudomonas phage φKZ  6.3e-172 
gp051 Uncharacterized protein 32987 33499 + ATG TAA 512 170 PHIKZ038 Pseudomonas phage φKZ  9.7e-106 
gp052 
Chain A, monomeric 
subunit of Tubz 33553 34533 + 
ATG TAA 
980 326 PHIKZ039 
Pseudomonas phage φKZ  
4.5e-215 
gp053 Uncharacterized protein 34588 35070 + ATG TAA 482 160 PHIKZ040 Pseudomonas phage φKZ  5.1e-104 
gp054 Uncharacterized protein 35110 35583 + ATG TGA 473 157 PHIKZ041 Pseudomonas phage φKZ  3.0e-104 
gp055 Uncharacterized protein 35595 35912 + ATG TAA 317 105 PHIKZ041.1 Pseudomonas phage φKZ  2.5e-63 
gp056 Uncharacterized protein 35891 36178 + ATG TAA 287 95 PHIKZ041.2 Pseudomonas phage φKZ  6.9e-55 
gp057 Uncharacterized protein 36246 36473 + ATG TGA 227 101 PHIKZ041.3 Pseudomonas phage φKZ  1.5e-45 
gp058 Virion associated protein 36578 37378 - ATG TAA 800 266 PHIKZ042 Pseudomonas phage φKZ 1.2e-176 
gp059 Uncharacterized protein 37515 37943 + ATG TAA 428 142    
gp060 Uncharacterized protein 37957 39030 + ATG TAA 1073 357 PHIKZ043 Pseudomonas phage φKZ  4.0e-232 
gp061 Uncharacterized protein 39080 39469 + ATG TAA 389 129 PHIKZ044 Pseudomonas phage φKZ  4.2e-73 
gp062 Uncharacterized protein 39393 39845 + ATG TAA 452 150 PHIKZ044.1 Pseudomonas phage φKZ  1.4e-53 
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gp063 Uncharacterized protein 39718 39972 + ATG TAG 254 84 PHIKZ045 Pseudomonas phage φKZ  3.4e-47 
gp064 Uncharacterized protein 40118 40552 + ATG TGA 434 144 PHIKZ046 Pseudomonas phage φKZ  3.3e-94 
gp065 Uncharacterized protein 40549 41085 + ATG TAA 536 178 PHIKZ047 Pseudomonas phage φKZ  5.5e-116 
gp066 Uncharacterized protein 41158 41541 + ATG TAA 383 127 PHIKZ048 Pseudomonas phage φKZ  3.8e-82 
gp067 Virion associated protein 41576 41992 + ATG TAA 416 138 PHIKZ049 Pseudomonas phage φKZ  3.3e-86 
gp068 Uncharacterized protein 42193 44388 + ATG TAA 2195 731 PHIKZ050 Pseudomonas phage φKZ  0.0e+00 
gp069 Uncharacterized protein 44487 44663 + ATG TAA 176 58 PHIKZ050.1 Pseudomonas phage φKZ  9.2e-33 
gp070 Uncharacterized protein 44650 45369 + ATG TAA 719 239 PHIKZ051 Pseudomonas phage φKZ  3.3e-154 
gp071 Structural head protein 45413 46504 - ATG TGA 1091 363 PHIKZ052 Pseudomonas phage φKZ  8.8e-235 
gp072 Uncharacterized protein 46586 46951 + ATG TGA 365 121 PHIKZ053 Pseudomonas phage φKZ  8.4e-75 
gp073 Virion associated protein 47263 49143 + ATG TAA 1880 626 PHIKZ054 Pseudomonas phage φKZ  0.0e+00 
gp074 
Non-virion DNA- 
dependent RNA 
polymerase subunit 49538 50677 + 
 
 
ATG 
 
 
TAA 1139 379 PHIKZ055 Pseudomonas phage φKZ  2.6e-259 
gp075 Uncharacterized protein 50740 51561 + ATG TAA 821 273    
gp076 Uncharacterized protein 52060 53064 + ATG TAA 1004 334 PHIKZ056 Pseudomonas phage φKZ  3.7e-226 
gp077 Uncharacterized protein 53435 53620 + ATG TAA 185 61 PHIKZ056.1 Pseudomonas phage φKZ  2.0e-36 
gp078 Uncharacterized protein 53669 54052 + ATG TAA 383 127 PHIKZ057 Pseudomonas phage φKZ  4.2e-84 
gp079 Uncharacterized protein 54065 54490 + ATG TGA 425 141 PHIKZ058 Pseudomonas phage φKZ  1.4e-93 
gp080 Uncharacterized protein 54613 54795 + ATG TAA 182 60 PHIKZ058.1 Pseudomonas phage φKZ  3.7e-29 
gp081 Uncharacterized protein 54865 55476 + ATG TAA 611 203 PHIKZ059 Pseudomonas phage φKZ  2.5e-133 
gp082 Uncharacterized protein 55528 55863 + ATG TAA 335 111 PHIKZ060 Pseudomonas phage φKZ  1.6e-70 
gp083 Uncharacterized protein 55850 56302 + ATG TAG 452 150 PHIKZ061 Pseudomonas phage φKZ  1.5e-87 
gp084 Virion associated protein 56408 56818 + ATG TAA 410 136 PHIKZ062 Pseudomonas phage φKZ  5.3e-83 
gp085 Virion associated protein 56819 57376 + ATG TAG 557 185 PHIKZ063 Pseudomonas phage φKZ  6.5e-111 
gp086 Virion associated protein 57396 57959 + ATG TGA 563 187 PHIKZ064 Pseudomonas phage φKZ  4.9e-117 
gp087 
Nuclease SbcCD, D 
subunit 57949 59088 + 
 
ATG 
 
TAA 1139 379 PHIKZ065 Pseudomonas phage φKZ  1.6e-258 
gp088 Uncharacterized protein 59101 59931 + ATG TAG 830 276 PHIKZ066 Pseudomonas phage φKZ  2.8e-183 
gp089 Virion associated protein 60018 60758 + ATG TAA 740 246 PHIKZ067 Pseudomonas phage φKZ  6.9e-168 
gp090 
Non-virion DNA- 
dependent RNA 
polymerase subunit 60884 62449 + 
ATG TAA 
1565 521 PHIKZ068 Pseudomonas phage φKZ  0.0e+00 
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gp091 Uncharacterized protein 62466 64139 + ATG TAG 1673 557 PHIKZ069 Pseudomonas phage φKZ  0.0e+00 
gp092 Uncharacterized protein 64186 65487 + ATG TAA 1301 459 PHIKZ070 Pseudomonas phage φKZ  1.4e-285 
gp093 Virion associated protein 65529 65891 - ATG TAA 362 120 Uncharacterized protein Pseudomonas phage PA7  1.3e-78 
gp094 Uncharacterized protein 65956 66075 + ATG TGA 119 36 Uncharacterized protein Pseudomonas phage PA7  2.00E-18 
gp095 
Non-virion DNA- 
dependent RNA 
polymerase subunit 66068 67252 + 
ATG TAA 
1184 399 PHIKZ071 Pseudomonas phage φKZ  1.1e-270 
gp096 
Non-virion DNA- 
dependent RNA 
polymerase subunit 67575 68477 + 
ATG TGA 
902 300 PHIKZ073 
Pseudomonas phage φKZ  
1.8e-201 
gp097 
Non-virion DNA- 
dependent RNA 
polymerase subunit 68508 70541 + 
ATG TAG 
2033 677 PHIKZ074 Pseudomonas phage φKZ  0.0e+00 
gp098 
Putative RAD2/SF2 
helicase 70600 72138 + 
ATG TAG 
1538 512 PHIKZ075 Pseudomonas phage φKZ  0.0e+00 
gp099 Uncharacterized protein 72321 72578 + ATG TGA 257 85 PHIKZ076 Pseudomonas phage φKZ  8.9e-47 
gp100 Uncharacterized protein 72591 72782 + ATG TAG 191 63 PHIKZ076.1 Pseudomonas phage φKZ  7.9e-31 
gp101 Uncharacterized protein 73128 73271 + ATG TAA 143 47 PHIKZ076.3 Pseudomonas phage φKZ  9.7e-22 
gp102 Uncharacterized protein 73322 73564 - ATG TAA 242 80 PHIKZ076.4 Pseudomonas phage φKZ  2.3e-48 
gp103 Uncharacterized protein 73783 75384 - ATG TAG 1601 533 PHIKZ077 Pseudomonas phage φKZ  0.0e+00 
gp104 Virion associated protein 75396 75890 - ATG TAA 494 164 PHIKZ078 Pseudomonas phage φKZ  4.3e-100 
gp105 Structural head protein 76062 76919 + ATG TGA 857 285 PHIKZ079 Pseudomonas phage φKZ  6.1e-172 
gp106 
β/β′-like virion-associated 
proteins 76906 78255 + 
ATG TAA 
1349 449 PHIKZ080 Pseudomonas phage φKZ  1.7e-311 
gp107 Structural protein 78318 79739 + ATG TAA 1421 473 PHIKZ081 Pseudomonas phage φKZ  6.2e-311 
gp108 Uncharacterized protein 79841 81757 + ATG TAA 1916 638 PHIKZ082 Pseudomonas phage φKZ  0.0e+00 
gp109 Uncharacterized protein 82009 82125 + ATG TAA 116 38 PHIKZ082.1 Pseudomonas phage φKZ  2.7e-18 
gp110 Structural head protein 82229 83743 - ATG TAA 1514 504 PHIKZ083 Pseudomonas phage φKZ  0.0e+00 
gp111 Structural head protein 83845 85086 + ATG TAG 1241 413 PHIKZ084 Pseudomonas phage φKZ  1.0e-271 
gp112 Structural head protein 85098 85547 + ATG TGA 449 149 PHIKZ085 Pseudomonas phage φKZ  8.7e-89 
gp113 Structural head protein 85558 86826 + ATG TAA 1268 422 PHIKZ086 Pseudomonas phage φKZ  6.6e-278 
gp114 Structural protein 86868 89783 - ATG TAA 2915 971 PHIKZ087 Pseudomonas phage φKZ  0.0e+00 
gp115 Structural protein 89787 90836 - ATG TAA 1049 349 PHIKZ088 Pseudomonas phage φKZ  3.5e-239 
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gp116 Stuctural head protein 90876 92039 + ATG TAA 1163 387 PHIKZ089 Pseudomonas phage φKZ  2.1e-252 
gp117 Structural head protein 92050 92979 + ATG TAA 929 309 PHIKZ090 Pseudomonas phage φKZ  1.6e-195 
gp118 Structural head protein 92994 93524 + ATG TGA 530 176 PHIKZ091 Pseudomonas phage φKZ  4.4e-117 
gp119 Structural head protein 93534 94856 + ATG TAA 1322 440 PHIKZ092 Pseudomonas phage φKZ  1.7e-288 
gp120 Structural head protein 94862 96169 + ATG TAA 1307 435 PHIKZ093 Pseudomonas phage φKZ  1.3e-270 
gp121 Structural head protein 96239 97756 + ATG TAA 1517 505 PHIKZ094 Pseudomonas phage φKZ  0.0e+00 
gp122 Structural head protein 97844 99487 + ATG TAA 1643 547 PHIKZ095 Pseudomonas phage φKZ  0.0e+00 
gp123 Structural head protein 99549 100664 + ATG TAA 1115 371 PHIKZ096 Pseudomonas phage φKZ  5.0e-240 
gp124 Structural head protein 100764 103214 + ATG TAA 2450 816 PHIKZ097 Pseudomonas phage φKZ  0.0e+00 
gp125 Virion associated protein 103298 104926 + ATG TAA 1628 542 PHIKZ098 Pseudomonas phage φKZ  0.0e+00 
gp126 Structural head protein 104926 106335 + ATG TAA 1409 469 PHIKZ099 Pseudomonas phage φKZ  0.0e+00 
gp127 Virion associated protein 106340 106921 + ATG TGA 581 193 PHIKZ100 Pseudomonas phage φKZ  8.4e-128 
gp128 Structural protein 106923 108305 + ATG TAA 1382 460 PHIKZ101 Pseudomonas phage φKZ  9.7e-311 
gp129 Uncharacterized protein 108330 108752 + ATG TAA 422 140 PHIKZ102 Pseudomonas phage φKZ 1.4e-93 
gp130 Uncharacterized protein 108792 108917 + ATG TAG 125 41 PHIKZ102.1 Pseudomonas phage φKZ  3.9e-21 
gp131 Uncharacterized protein 108926 109318 + ATG TAA 392 130 PHIKZ103 Pseudomonas phage φKZ  1.5e-83 
gp132 Virion associated protein 109399 109887 + ATG TAA 488 162 PHIKZ104 Pseudomonas phage φKZ  1.9e-109 
gp133 Uncharacterized protein 110010 110348 + ATG TAA 338 112 PHIKZ106 Pseudomonas phage φKZ  6.6e-65 
gp134 Uncharacterized protein 110457 110618 + ATG TAA 161 53 PHIKZ106.1 Pseudomonas phage φKZ  1.7e-26 
gp135 Uncharacterized protein 110664 110981 + ATG TAA 317 105 PHIKZ107 Pseudomonas phage φKZ  1.1e-58 
gp136 Uncharacterized protein 110971 111411 + ATG TAA 440 146 PHIKZ107.1 Pseudomonas phage φKZ  4.6e-57 
gp137 Uncharacterized protein 111499 111855 + ATG TAA 356 118 PHIKZ108 Pseudomonas phage φKZ  4.2e-73 
gp138 Uncharacterized protein 111866 112288 + ATG TGA 422 140 PHIKZ109 Pseudomonas phage φKZ  3.1e-89 
gp139 Uncharacterized protein 112360 112611 + ATG TAG 251 83 PHIKZ109.1 Pseudomonas phage φKZ  4.8e-51 
gp140 Uncharacterized protein 112647 113030 + ATG TGA 383 127 PHIKZ110 Pseudomonas phage φKZ  1.7e-82 
gp141 Uncharacterized protein 113066 113563 + ATG TAA 497 165 PHIKZ111 Pseudomonas phage φKZ  5.8e-110 
gp142 Uncharacterized protein 113605 113880 + ATG TAG 275 91 PHIKZ112 Pseudomonas phage φKZ  8.3e-59 
gp143 Uncharacterized protein 113927 114190 + ATG TAA 263 87 PHIKZ113 Pseudomonas phage φKZ  2.4e-56 
gp144 Uncharacterized protein 114198 114482 + ATG TAA 284 94 PHIKZ114 Pseudomonas phage φKZ  8.0e-56 
gp145 Uncharacterized protein 114546 114773 + ATG TGA 227 75 PHIKZ115 Pseudomonas phage φKZ  2.5e-47 
gp146 Uncharacterized protein 114776 114931 + ATG TGA 155 51 PHIKZ115.1 Pseudomonas phage φKZ  6.0e-27 
gp147 Uncharacterized protein 114928 115140 + GTG TAA 212 70 PHIKZ115.2 Pseudomonas phage φKZ  1.1e-42 
gp148 Uncharacterized protein 115180 115323 + ATG TAA 143 47 PHIKZ115.3 Pseudomonas phage φKZ  7.7e-28 
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gp149 Uncharacterized protein 115325 115480 + ATG TGA 155 51 PHIKZ116 Pseudomonas phage φKZ  4.2e-29 
gp150 Uncharacterized protein 115765 116070 + ATG TGA 305 101    
gp151 Uncharacterized protein 116714 116950 - ATG TAA 236 78 PHIKZ117.3 Pseudomonas phage φKZ  3.2e-45 
gp152 Uncharacterized protein 116952 117320 - ATG TAA 368 122 PHIKZ117.4 Pseudomonas phage φKZ  3.3e-79 
gp153 DnaB helicase 117375 118922 - ATG TAA 1547 515 PHIKZ118 Pseudomonas phage φKZ  0.0e+00 
gp154 Structural head protein 119062 119595 + ATG TAG 533 177 PHIKZ119 Pseudomonas phage φKZ  8.7e-113 
gp155 Major head protein 119668 121911 + ATG TGA 2243 747 PHIKZ120 Pseudomonas phage φKZ  0.0e+00 
gp156 Uncharacterized protein 122108 122560 + ATG TAA 452 150 PHIKZ121 Pseudomonas phage φKZ  4.7e-95 
gp157 Uncharacterized protein 122517 123599 + ATG TAG 1082 360 PHIKZ122 Pseudomonas phage φKZ  1.4e-244 
gp158 
non-virion DNA- 
dependent RNA 
polymerase subunit 123609 125240 + 
ATG TAA 
1631 543 PHIKZ123 
Pseudomonas phage φKZ  
0.0e+00 
gp159 Virion associated protein 125276 127441 + ATG TAA 2165 721 PHIKZ124 Pseudomonas phage φKZ  0.0e+00 
gp160 Uncharacterized protein 127522 128154 + ATG TAA 632 210 PHIKZ125 Pseudomonas phage φKZ  7.3e-142 
gp161 Structural protein 128219 128662 - ATG TAA 443 147 PHIKZ126 Pseudomonas phage φKZ  5.7e-94 
gp162 Structural protein 128671 129543 - ATG TGA 872 290 PHIKZ127 Pseudomonas phage φKZ  6.1e-194 
gp163 Structural head protein 129554 131728 - ATG TAA 2174 724 PHIKZ128 Pseudomonas phage φKZ  0.0e+00 
gp164 Structural protein 131764 134445 + ATG TGA 2681 893 PHIKZ129 Pseudomonas phage φKZ  0.0e+00 
gp165 Structural protein 134495 135778 - ATG TAA 1283 427 PHIKZ130 Pseudomonas phage φKZ  4.3e-296 
gp166 Tail tip protein 135876 138191 + ATG TAA 2315 771 PHIKZ131 Pseudomonas phage φKZ  0.0e+00 
gp167 Structural protein 138204 138536 + ATG TAA 332 110 PHIKZ132 Pseudomonas phage φKZ  3.6e-68 
gp168 Structural protein 138611 139999 + ATG TAA 1388 462 PHIKZ133 Pseudomonas phage φKZ  0.0e+00 
gp169 Structural protein 140011 141384 + ATG TAA 1373 457 PHIKZ134 Pseudomonas phage φKZ  0.0e+00 
gp170 Structural protein 141384 142775 + ATG TAA 1391 463 PHIKZ135 Pseudomonas phage φKZ  0.0e+00 
gp171 Virion associated protein 142775 143377 + ATG TGA 602 200 PHIKZ136 Pseudomonas phage φKZ  1.8e-127 
gp172 Uncharacterized protein 143364 143810 + GTG TAG 446 148 PHIKZ137 Pseudomonas phage φKZ 1.8e-99 
gp173 Virion associated protein 143819 144307 + ATG TAA 488 162 PHIKZ138 Pseudomonas phage φKZ  9.5e-108 
gp174 Structural protein 144403 145299 + ATG TAA 896 298 PHIKZ139 Pseudomonas phage φKZ  1.4e-197 
gp175 Uncharacterized protein 145302 145865 + ATG TAA 563 187 PHIKZ140 Pseudomonas phage φKZ  3.4e-122 
gp176 Structural protein 145881 146387 + ATG TAG 506 168 PHIKZ141 Pseudomonas phage φKZ  2.5e-105 
gp177 Uncharacterized protein 146407 146634 + GTG TGA 227 75 PHIKZ141.1 Pseudomonas phage φKZ  2.0e-45 
gp178 Uncharacterized protein 146609 147004 + ATG TAA 395 131 PHIKZ142 Pseudomonas phage φKZ  2.4e-74 
gp179 Structural protein 147086 147619 + ATG TAA 533 177 PHIKZ143 Pseudomonas phage φKZ  1.0e-113 
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gp180 Endolysin 147681 148463 + ATG TAA 782 260 PHIKZ144 Pseudomonas phage φKZ  1.5e-175 
gp181 Putative tail sheath protein 148669 151038 + ATG TAA 2369 789 PHIKZ145 Pseudomonas phage φKZ  0.0e+00 
gp182 Putative tail fiber protein 151038 154319 + ATG TAA 3281 1093 PHIKZ146 Pseudomonas phage φKZ  0.0e+00 
gp183 Uncharacterized protein 154453 155169 - ATG TGA 716 238 PHIKZ147 Pseudomonas phage φKZ  2.8e-158 
gp184 Virion associated protein 155159 155665 - ATG TAA 506 168 PHIKZ148 Pseudomonas phage φKZ  1.5e-106 
gp185 
β/β′-like virion-associated 
protein 155668 156342 - 
 
ATG 
 
TAA 674 224 PHIKZ149 
Pseudomonas phage φKZ  
3.2e-145 
gp186 Uncharacterized protein 156375 156695 - ATG TAA 320 106 PHIKZ150 Pseudomonas phage φKZ  1.4e-66 
gp187 Uncharacterized protein 156719 157069 - ATG TAA 350 116 PHIKZ151 Pseudomonas phage φKZ  2.0e-75 
gp188 Virion associated protein 157146 158585 - ATG TAA 1439 479 PHIKZ152 Pseudomonas phage φKZ  0.0e+00 
gp189 Structural head protein 158683 159597 + ATG TAA 914 304 PHIKZ153 Pseudomonas phage φKZ  2.4e-196 
gp190 Uncharacterized protein 159643 160062 - ATG TGA 419 139 PHIKZ154 Pseudomonas phage φKZ  4.8e-92 
gp191 Ribonuclease H  160073 161521 - ATG TAG 1448 482 PHIKZ155 Pseudomonas phage φKZ  0.0e+00 
gp192 Uncharacterized protein 161577 161978 - ATG TAA 401 133 PHIKZ156 Pseudomonas phage φKZ  3.7e-84 
gp193 Uncharacterized protein 161999 162289 - ATG TAA 290 96 PHIKZ156.1 Pseudomonas phage φKZ  5.1e-54 
gp194 Structural head protein 162468 163805 + ATG TAA 1337 445 PHIKZ157 Pseudomonas phage φKZ  4.9e-304 
gp195 Virion associated protein 163861 164811 + ATG TGA 950 316 PHIKZ158 Pseudomonas phage φKZ  6.8e-219 
gp196 Virion associated protein 164808 165212 + ATG TAA 404 134 PHIKZ159 Pseudomonas phage φKZ  3.2e-87 
gp197 Structural protein 165216 165689 + ATG TAA 473 157 PHIKZ160 Pseudomonas phage φKZ  1.8e-105 
gp198 Virion associated protein 165788 166423 + ATG TAA 635 211 PHIKZ161 Pseudomonas phage φKZ  6.4e-128 
gp199 Structural head protein 166459 168027 + ATG TAG 1568 522 PHIKZ162 Pseudomonas phage φKZ  0.0e+00 
gp200 Structural head protein 168037 169224 + ATG TAA 1187 395 PHIKZ163 Pseudomonas phage φKZ  9.0e-253 
gp201 Uncharacterized protein 169264 169530 - ATG TAA 266 88 PHIKZ163.1 Pseudomonas phage φKZ  1.6e-54 
gp202 Uncharacterized protein 169540 170421 - ATG TAA 881 293 PHIKZ164 Pseudomonas phage φKZ  1.0e-195 
gp203 SbcC protein 170486 172978 + ATG TAA 2492 830 PHIKZ165 Pseudomonas phage φKZ  0.0e+00 
gp204 Uncharacterized protein 173021 173197 - ATG TAA 176 58 PHIKZ165.1 Pseudomonas phage φKZ  7.8e-31 
gp205 Uncharacterized protein 173289 173684 + ATG TGA 395 131 PHIKZ166 Pseudomonas phage φKZ  8.3e-86 
gp206 Uncharacterized protein 173826 174032 + ATG TAA 206 68 PHIKZ166.1 Pseudomonas phage φKZ  2.3e-31 
gp207 Uncharacterized protein 174051 174479 + ATG TAA 428 142 PHIKZ167 Pseudomonas phage φKZ  4.5e-90 
gp208 Uncharacterized protein 174529 175185 + ATG TAA 656 218 PHIKZ168 Pseudomonas phage φKZ  1.0e-136 
gp209 Virion associated protein 175231 175746 - ATG TGA 515 171 PHIKZ169 Pseudomonas phage φKZ  1.1e-104 
gp210 Uncharacterized protein 175826 176350 + ATG TGA 524 174 PHIKZ170 Pseudomonas phage φKZ  8.2e-110 
gp211 Uncharacterized protein 176421 177182 + ATG TAA 761 253 PHIKZ171 Pseudomonas phage φKZ  2.3e-174 
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gp212 Uncharacterized protein 177175 177615 + ATG TAA 440 146 PHIKZ172 Pseudomonas phage φKZ  3.4e-95 
gp213 Uncharacterized protein 177620 178546 + ATG TAG 926 308 PHIKZ173 Pseudomonas phage φKZ  3.0e-204 
gp214 Structural protein 178630 179694 + ATG TGA 1064 354 PHIKZ174 Pseudomonas phage φKZ  4.0e-235 
gp215 Head protease 179743 180555 - ATG TAA 812 270 PHIKZ175 Pseudomonas phage φKZ  2.8e-186 
gp216 Structural head protein 180567 181289 - ATG TAA 722 270 PHIKZ176 Pseudomonas phage φKZ  1.6e-160 
gp217 Structural head protein 181443 183002 - ATG TAA 1559 519 PHIKZ177 Pseudomonas phage φKZ  0.0e+00 
gp218 Uncharacterized protein 183014 183211 - ATG TAA 197 65 PHIKZ177.1 Pseudomonas phage φKZ 3.1e-34 
gp219 
β/β′-like virion-associated 
protein 183195 187550 - 
 
ATG 
 
TAA 4355 1451 PHIKZ178 Pseudomonas phage φKZ  0.0e+00 
gp220 
β/β′-like virion-associated 
protein 187553 189205 - 
 
ATG 
 
TAA 1652 550 PHIKZ180 
Pseudomonas phage φKZ 
0.0e+00 
gp221 
Structural peptidoglycan 
hydrolase 189281 195994 + 
 
ATG 
 
TAA 6713 2237 PHIKZ181 
Pseudomonas phage φKZ  
0.0e+00 
gp222 Structural protein 196050 198044 + ATG TAA 1994 664 PHIKZ182 Pseudomonas phage φKZ  0.0e+00 
gp223 Uncharacterized protein 198103 198408 + ATG TGA 305 101 PHIKZ183 Pseudomonas phage φKZ  1.5e-56 
gp224 Uncharacterized protein 198416 199108 + ATG TGA 692 230 PHIKZ184 Pseudomonas phage φKZ  4.5e-153 
gp225 Uncharacterized protein 199217 199771 + ATG TAG 554 184 PHIKZ185 Pseudomonas phage φKZ  2.0e-116 
gp226 Uncharacterized protein 199773 200015 + ATG TAA 242 80 PHIKZ185.1 Pseudomonas phage φKZ  9.8e-42 
gp227 Uncharacterized protein 200046 200450 + ATG TAA 404 134 PHIKZ186 Pseudomonas phage φKZ  1.3e-79 
gp228 Virion associated protein 200571 200900 + ATG TAG 329 109 PHIKZ187 Pseudomonas phage φKZ 2.0e-62 
gp229 Thymidylate kinase 200903 201961 + ATG TAA 1058 352 PHIKZ188 Pseudomonas phage φKZ  1.0e-234 
gp230 Uncharacterized protein 201999 202250 + ATG TAA 251 83 PHIKZ189 Pseudomonas phage φKZ  2.3e-49 
gp231 Uncharacterized protein 202319 202759 + ATG TAG 440 146 PHIKZ190 Pseudomonas phage φKZ  1.1e-89 
gp232 Virion associated protein 202787 203578 + ATG TAA 791 263 PHIKZ191 Pseudomonas phage φKZ  4.1e-175 
gp233 Uncharacterized protein 203571 204296 + ATG TAA 725 241 PHIKZ192 Pseudomonas phage φKZ  5.7e-168 
gp234 Uncharacterized protein 204296 204658 + ATG TAA 362 120 PHIKZ193 Pseudomonas phage φKZ  6.3e-77 
gp235 Uncharacterized protein 204671 205027 + ATG TAA 356 118 PHIKZ194 Pseudomonas phage φKZ  1.4e-71 
gp236 Uncharacterized protein 205177 205551 + ATG TAA 374 124 PHIKZ195 Pseudomonas phage φKZ 2.5e-78 
gp237 Uncharacterized protein 205553 205915 + ATG TAG 362 120 PHIKZ196 Pseudomonas phage φKZ  1.9e-76 
gp238 Uncharacterized protein 205927 206289 + ATG TAA 362 120 PHIKZ197 Pseudomonas phage φKZ  2.0e-76 
gp239 Virion associated protein 206431 206919 + ATG TAA 488 162 PHIKZ198 Pseudomonas phage φKZ  3.3e-104 
gp240 Structural protein 207010 207441 + ATG TAA 431 143 PHIKZ199 Pseudomonas phage φKZ  4.2e-93 
gp241 Virion associated protein 207461 208120 + ATG TAA 659 219 PHIKZ200 Pseudomonas phage φKZ  1.0e-139 
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gp242 Structural protein 208161 210110 - ATG TAA 1949 649 PHIKZ201 Pseudomonas phage φKZ  0.0e+00 
gp243 Structural protein 210121 210591 - ATG TAA 470 156 PHIKZ202 Pseudomonas phage φKZ  1.9e-96 
gp244 Structural protein 210603 212714 - ATG TAA 2111 703 PHIKZ203 Pseudomonas phage φKZ  0.0e+00 
gp245 Uncharacterized protein 213065 213460 + ATG TAA 395 131 PHIKZ204 Pseudomonas phage φKZ  1.3e-82 
gp246 Uncharacterized protein 213432 213608 + ATG TAA 176 58 PHIKZ204.1 Pseudomonas phage φKZ  1.2e-31 
gp247 Uncharacterized protein 213625 214026 + ATG TGA 401 133 PHIKZ205 Pseudomonas phage φKZ  3.2e-82 
gp248 Virion associated protein 214269 214979 + ATG TAA 710 236 PHIKZ206 Pseudomonas phage φKZ  2.3e-162 
gp249 Uncharacterized protein 214979 215632 + ATG TAA 653 217 PHIKZ207 Pseudomonas phage φKZ  2.5e-147 
gp250 Uncharacterized protein 215736 216836 + ATG TAA 1100 366 PHIKZ208 Pseudomonas phage φKZ  1.3e-238 
gp251 Uncharacterized protein 216944 217546 + ATG TGA 602 200 PHIKZ209 Pseudomonas phage φKZ  3.4e-132 
gp252 Uncharacterized protein 217674 218006 + ATG TAG 332 110 PHIKZ210 Pseudomonas phage φKZ  2.1e-74 
gp253 Uncharacterized protein 218018 218143 + ATG TAG 125 41 PHIKZ210.1 Pseudomonas phage φKZ  4.1e-22 
gp254 Uncharacterized protein 218269 218526 + ATG TAA 257 85 PHIKZ210.2 Pseudomonas phage φKZ  1.3e-51 
gp255 Uncharacterized protein 218539 218958 + ATG TGA 419 139 PHIKZ211 Pseudomonas phage φKZ  4.8e-88 
gp256 Uncharacterized protein 218955 219299 + ATG TAA 344 114 PHIKZ212 Pseudomonas phage φKZ  9.9e-75 
gp257 Uncharacterized protein 219313 219852 + ATG TGA 539 179 PHIKZ213 Pseudomonas phage φKZ 7.4e-125 
gp258 Uncharacterized protein 219876 220445 + ATG TAA 569 189 PHIKZ214 Pseudomonas phage φKZ  3.8e-125 
gp259 Uncharacterized protein 220448 220684 + ATG TGA 236 78 PHIKZ215 Pseudomonas phage φKZ  5.1e-47 
gp260 Uncharacterized protein 220775 221251 + ATG TAA 476 158 PHIKZ216 Pseudomonas phage φKZ  5.2e-100 
gp261 Uncharacterized protein 221309 221500 + ATG TAA 191 63 PHIKZ217 Pseudomonas phage φKZ  8.9e-28 
gp262 Virion associated protein 221520 221735 + ATG TAA 215 71 PHIKZ218 Pseudomonas phage φKZ  4.1e-38 
gp263 Uncharacterized protein 221846 222145 + GTG TAA 299 99 PHIKZ218.1 Pseudomonas phage φKZ  4.1e-64 
gp264 Uncharacterized protein 222195 223328 + ATG TGA 1133 377 PHIKZ219 Pseudomonas phage φKZ  2.3e-249 
gp265 Uncharacterized protein 223325 223795 + ATG TAA 470 156 PHIKZ220 Pseudomonas phage φKZ 2.5e-96 
gp266 Uncharacterized protein 223898 224245 + ATG TGA 347 115 PHIKZ221 Pseudomonas phage φKZ  6.8e-69 
gp267 Uncharacterized protein 224314 224646 + ATG TAA 332 110 PHIKZ222 Pseudomonas phage φKZ  5.6e-70 
gp268 Uncharacterized protein 224835 225233 + ATG TAG 398 132 PHIKZ223 Pseudomonas phage φKZ  5.3e-88 
gp269 Structural protein 225241 225654 + ATG TAA 413 137 PHIKZ224 Pseudomonas phage φKZ  1.2e-89 
gp270 Uncharacterized protein 225777 225968 + ATG TGA 191 63 PHIKZ225 Pseudomonas phage φKZ  1.0e-26 
gp271 Uncharacterized protein 225955 226284 + ATG TGA 329 109 PHIKZ226 Pseudomonas phage φKZ  4.8e-67 
gp272 Uncharacterized protein 226294 226809 + ATG TAA 515 171 PHIKZ227 Pseudomonas phage φKZ  2.4e-113 
gp273 Structural protein 226822 227421 + ATG TGA 599 199 PHIKZ228 Pseudomonas phage φKZ 5.5e-126 
gp274 Uncharacterized protein 227478 227843 + ATG TAA 365 121 PHIKZ229 Pseudomonas phage φKZ  1.9e-75 
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gp275 Uncharacterized protein 227900 228196 + ATG TGA 296 98 PHIKZ230 Pseudomonas phage φKZ  8.5e-60 
gp276 Uncharacterized protein 228189 228479 + ATG TAA 290 96 PHIKZ230.1 Pseudomonas phage φKZ  9.4e-57 
gp277 Uncharacterized protein 228581 228754 + ATG TAA 173 57 PHIKZ230.2 Pseudomonas phage φKZ  6.7e-30 
gp278 Uncharacterized protein 228754 229221 + ATG TAA 467 155 PHIKZ231 Pseudomonas phage φKZ  1.3e-99 
gp279 Virion associated protein 229244 230152 + ATG TGA 908 302 PHIKZ232 Pseudomonas phage φKZ  1.5e-196 
gp280 Uncharacterized protein 230149 230406 + ATG TAG 257 85 PHIKZ232.2 Pseudomonas phage φKZ  7.2e-27 
gp281 Uncharacterized protein 230415 231122 + ATG TAA 707 235 PHIKZ233 Pseudomonas phage φKZ  2.2e-155 
gp282 Uncharacterized protein 231228 231521 + ATG TGA 293 97 PHIKZ234 Pseudomonas phage φKZ  7.3e-60 
gp283 Uncharacterized protein 231549 231749 + ATG TAA 200 66 PHIKZ234.1 Pseudomonas phage φKZ  7.1e-39 
gp284 Thymidylate synthase 231749 233215 + ATG TAA 1466 488 PHIKZ235 Pseudomonas phage φKZ  0.0e+00 
gp285 Uncharacterized protein 233318 233659 + ATG TAA 341 113 PHIKZ236 Pseudomonas phage φKZ  1.3e-43 
gp286 Uncharacterized protein 233671 234183 + 
 
ATG 
 
TAA 512 170 Uncharacterized protein 
Pseudomonas phage 
PhiPA3  2.4e-05 
gp287 Uncharacterized protein 234339 234620 + ATG TGA 281 93    
gp288 Uncharacterized protein 234617 234787 + ATG TAG 170 56 PHIKZ237 Pseudomonas phage φKZ  2.2e-25 
gp289 Uncharacterized protein 235025 235519 + ATG TAA 494 164 PHIKZ238 Pseudomonas phage φKZ  1.5e-46 
gp290 Uncharacterized protein 235609 235902 + ATG TGA 293 97 PHIKZ238.1 Pseudomonas phage φKZ  2.0e-51 
gp291 Uncharacterized protein 235974 236096 + ATG TAA 122 40 PHIKZ238.2 Pseudomonas phage φKZ  2.3e-18 
gp292 Uncharacterized protein 236262 236747 + ATG TAA 485 161 PHIKZ240 Pseudomonas phage φKZ  4.3e-87 
gp293 Uncharacterized protein 236877 237206 + ATG TAA 329 109 PHIKZ241 Pseudomonas phage φKZ  8.3e-51 
gp294 Uncharacterized protein 237318 237755 + ATG TAA 437 145 PHIKZ242 Pseudomonas phage φKZ  1.7e-95 
gp295 Uncharacterized protein 237776 238672 + ATG TAA 896 298 PHIKZ243 Pseudomonas phage φKZ 1.6e-183 
gp296 Structural protein 238730 239086 + ATG TAA 356 118 PHIKZ244 Pseudomonas phage φKZ  3.5e-73 
gp297 Uncharacterized protein 239137 239571 + ATG TAG 434 144 PHIKZ245 Pseudomonas phage φKZ  3.0e-95 
gp298 Virion associated protein 239602 240258 + ATG TAA 656 218 PHIKZ246 Pseudomonas phage φKZ  2.3e-142 
gp299 Uncharacterized protein 240378 240641 + ATG TAA 263 87 PHIKZ246.1 Pseudomonas phage φKZ  1.0e-54 
gp300 Uncharacterized protein 240668 241075 + ATG TAA 407 135 PHIKZ247 Pseudomonas phage φKZ  1.1e-83 
gp301 Uncharacterized protein 241088 241447 + ATG TAG 359 119 PHIKZ248 Pseudomonas phage φKZ  1.2e-73 
gp302 Uncharacterized protein 241451 242245 + ATG TAA 794 264 PHIKZ249 Pseudomonas phage φKZ  3.2e-179 
gp303 Uncharacterized protein 242259 242642 + ATG TAA 383 127 PHIKZ250 Pseudomonas phage φKZ 7.1e-76 
gp304 Uncharacterized protein 242660 243115 + ATG TAA 455 151 PHIKZ251 Pseudomonas phage φKZ  6.5e-95 
gp305 Uncharacterized protein 243148 243525 + ATG TAG 377 125 PHIKZ252 Pseudomonas phage φKZ  1.6e-75 
gp306 Uncharacterized protein 243515 243754 + ATG TAA 239 79 PHIKZ253 Pseudomonas phage φKZ  7.1e-49 
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gp307 Uncharacterized protein 243837 243944 + ATG TAA 107 35 PHIKZ253.1 Pseudomonas phage φKZ  4.9e-17 
gp308 Uncharacterized protein 244048 244422 + ATG TAA 374 124 PHIKZ254 Pseudomonas phage φKZ  6.3e-77 
gp309 Uncharacterized protein 244409 244870 + ATG TAG 461 153 PHIKZ255 Pseudomonas phage φKZ  5.1e-98 
gp310 Uncharacterized protein 244843 245073 + ATG TGA 230 76 PHIKZ256 Pseudomonas phage φKZ  8.6e-49 
gp311 Uncharacterized protein 245070 245756 + ATG TAA 686 228 PHIKZ257 Pseudomonas phage φKZ  5.0e-152 
gp312 Uncharacterized protein 245801 246175 + ATG TAG 374 124 PHIKZ258 Pseudomonas phage φKZ  1.7e-78 
gp313 Uncharacterized protein 246178 246612 + ATG TAA 434 144 PHIKZ259 Pseudomonas phage φKZ  6.2e-81 
gp314 Uncharacterized protein 246737 247096 + ATG TAA 359 119 PHIKZ260 Pseudomonas phage φKZ 8.1e-75 
gp315 Uncharacterized protein 247142 247672 + ATG TAG 530 176 Uncharacterized protein Pseudomonas phage PA7  1.0e-99 
gp316 Uncharacterized protein 247693 248115 + ATG TAA 422 140 PHIKZ261 Pseudomonas phage φKZ  1.2e-84 
gp317 Uncharacterized protein 248169 248402 + ATG TGA 233 77 PHIKZ262 Pseudomonas phage φKZ  4.8e-44 
gp318 Uncharacterized protein 248430 248708 + ATG TAA 278 92 PHIKZ263 Pseudomonas phage φKZ  2.4e-52 
gp319 Uncharacterized protein 248733 249152 + ATG TAA 419 139 PHIKZ264 Pseudomonas phage φKZ  1.2e-84 
gp320 Uncharacterized protein 249231 249527 + ATG TGA 296 98 PHIKZ265 Pseudomonas phage φKZ  6.2e-65 
gp321 Uncharacterized protein 249520 249957 + GTG TAA 437 145 Uncharacterized protein Pseudomonas phage PA7  1.5e-88 
gp322 Uncharacterized protein 249994 250425 + ATG TAA 431 143 PHIKZ266 Pseudomonas phage φKZ  3.3e-93 
gp323 Uncharacterized protein 250488 250790 + ATG TAA 302 100 PHIKZ267 Pseudomonas phage φKZ  5.5e-63 
gp324 Uncharacterized protein 250874 251026 + ATG TAG 152 50 PHIKZ267.1 Pseudomonas phage φKZ  2.8e-25 
gp325 Uncharacterized protein 251083 251385 + ATG TGA 302 100 PHIKZ268 Pseudomonas phage φKZ  2.4e-63 
gp326 Uncharacterized protein 251394 251606 + ATG TGA 212 70 PHIKZ269 Pseudomonas phage φKZ  5.9e-42 
gp327 Uncharacterized protein 251603 251980 + ATG TGA 377 125 PHIKZ270 Pseudomonas phage φKZ  7.8e-78 
gp328 Uncharacterized protein 251982 252347 + ATG TAA 365 121 PHIKZ271 Pseudomonas phage φKZ  3.6e-70 
gp329 Uncharacterized protein 252391 252726 + ATG TAG 335 111 PHIKZ272 Pseudomonas phage φKZ 4.1e-68 
gp330 Uncharacterized protein 252772 253458 + ATG TAA 686 228 PHIKZ273 Pseudomonas phage φKZ  2.4e-153 
gp331 Uncharacterized protein 253471 253710 + ATG TGA 239 79 PHIKZ274 Pseudomonas phage φKZ  7.4e-49 
gp332 Uncharacterized protein 253707 254066 + ATG TAA 359 119 PHIKZ275 Pseudomonas phage φKZ  2.5e-78 
gp333 Uncharacterized protein 254081 254602 + ATG TAA 521 173 PHIKZ276 Pseudomonas phage φKZ  2.7e-111 
gp334 Uncharacterized protein 254614 254913 + ATG TAA 299 99 PHIKZ277 Pseudomonas phage φKZ  6.3e-61 
gp335 Uncharacterized protein 254972 255412 + ATG TAA 440 146 PHIKZ278 Pseudomonas phage φKZ  4.0e-95 
gp336 Uncharacterized protein 255405 255917 + ATG TGA 512 170 PHIKZ279 Pseudomonas phage φKZ  3.1e-116 
gp337 Uncharacterized protein 255931 256263 + ATG TAG 332 110 PHIKZ280 Pseudomonas phage φKZ  3.8e-70 
gp338 Uncharacterized protein 256330 256686 + ATG TGA 356 118 PHIKZ281 Pseudomonas phage φKZ  1.7e-74 
gp339 Virion associated protein 256733 257248 + ATG TAA 515 171 PHIKZ282 Pseudomonas phage φKZ  2.1e-99 
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gp340 Uncharacterized protein 257264 257728 + ATG TAG 464 154 PHIKZ283 Pseudomonas phage φKZ  7.9e-98 
gp341 Uncharacterized protein 257793 258146 + GTG TAA 353 117 PHIKZ283.1 Pseudomonas phage φKZ  4.7e-66 
gp342 Virion associated protein 258188 259060 + ATG TAA 872 290 PHIKZ284 Pseudomonas phage φKZ  2.0e-172 
gp343 Uncharacterized protein 259117 259902 + ATG TGA 785 261 PHIKZ285 Pseudomonas phage φKZ 1.0e-175 
gp344 Uncharacterized protein 259899 261425 + ATG TAA 1526 508 PHIKZ286 Pseudomonas phage φKZ  0.0e+00 
gp345 Uncharacterized protein 261449 261847 + ATG TAA 398 132 PHIKZ286.1 Pseudomonas phage φKZ  6.5e-22 
gp346 Virion associated protein 261939 262592 + ATG TAA 653 217 PHIKZ287 Pseudomonas phage φKZ  8.7e-144 
gp347 Uncharacterized protein 262594 263007 + ATG TAA 413 137 PHIKZ287.1 Pseudomonas phage φKZ  5.6e-28 
gp348 Uncharacterized protein 263149 263529 + ATG TAA 380 126 PHIKZ288 Pseudomonas phage φKZ  7.9e-80 
gp349 Uncharacterized protein 263696 264427 + ATG TGA 731 243 PHIKZ289 Pseudomonas phage φKZ  5.8e-161 
gp350 Uncharacterized protein 264433 264948 + ATG TAA 515 171 PHIKZ290 Pseudomonas phage φKZ  1.6e-114 
gp351 Uncharacterized protein 265117 265797 + ATG TAA 680 226 PHIKZ291 Pseudomonas phage φKZ 5.4e-139 
gp352 Virion associated protein 265858 266247 - ATG TGA 389 129 PHIKZ292 Pseudomonas phage φKZ  1.0e-67 
gp353 Uncharacterized protein 266328 266738 - ATG TAA 410 136 PHIKZ293 Pseudomonas phage φKZ  1.1e-78 
gp354 Virion associated protein 266781 266957 - ATG TAA 176 58 PHIKZ293.1 Pseudomonas phage φKZ  5.2e-32 
gp355 Uncharacterized protein 267307 267444 + ATG TAA 137 45 PHIKZ293.2 Pseudomonas phage φKZ  2.0e-19 
gp356 Uncharacterized protein 267503 268129 - ATG TAA 626 208 PHIKZ294 Pseudomonas phage φKZ  5.5e-95 
gp357 Uncharacterized protein 268294 268752 - 
 
GTG 
 
TAA 458 152 Virion structural protein 
Pseudomonas phage 
201phi2-1  5.0e-10 
gp358 Virion associated protein 268974 269498 - ATG TAA 524 174 PHIKZ297 Pseudomonas phage φKZ  2.7e-66 
gp359 Structural protein 269790 270797 - ATG TAA 1007 335 PHIKZ298 Pseudomonas phage φKZ  9.6e-225 
gp360 Uncharacterized protein 271093 271440 - ATG TAA 347 115 PHIKZ299 Pseudomonas phage φKZ  4.9e-74 
gp361 Uncharacterized protein 271443 271730 - ATG TAA 287 95 PHIKZ299.1 Pseudomonas phage φKZ  9.7e-60 
gp362 Uncharacterized protein 271739 271960 - ATG TAG 221 73 PHIKZ300 Pseudomonas phage φKZ  1.1e-41 
gp363 Uncharacterized protein 272097 272390 - ATG TAA 293 97 PHIKZ301 Pseudomonas phage φKZ  3.5e-63 
gp364 Uncharacterized protein 272640 273092 - ATG TGA 452 150 PHIKZ302 Pseudomonas phage φKZ  1.4e-95 
gp365 Structural protein 273318 275201 - ATG TAA 1883 627 PHIKZ303 Pseudomonas phage φKZ  1.7e-242 
gp366 Uncharacterized protein 275287 275700 - ATG TAG 413 137 PHIKZ304 Pseudomonas phage φKZ  4.7e-81 
gp367 Ribonucleoside reductase 275697 276860 - ATG TGA 1163 387 PHIKZ305 Pseudomonas phage φKZ  2.2e-258 
gp368 
Putative ribonucleotide-
diphosphate reductase 
subunit alpha, NrdA 276961 279249 - 
 
 
ATG 
 
 
TAA 2288 762 PHIKZ306 
Pseudomonas phage φKZ  
0.0e+00 
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Table S 6.2: The genome annotations of giant phage PA5oct. 
Protein no. 
 
Function 
 
Start 
 
Stop 
 
Strand 
 
Start  
codon 
Stop  
codon 
Lenght 
(nt) 
Lenght 
(aa) The closest homolog (BLAST P) E-value 
gp001 Uncharacterized protein 65 307 + ATG TAG 243 80 
   
gp002 Uncharacterized protein 424 1509 + ATG TAA 1086 361 
gp003 Uncharacterized protein 1551 1772 + ATG TAG 222 73 
gp004 Uncharacterized protein 1952 2275 + ATG TAA 324 107 
gp005 Uncharacterized protein 2278 2604 + ATG TAA 327 108 
gp006 Uncharacterized protein 2614 2871 + ATG TGA 258 85 
gp007 Uncharacterized protein 2868 3176 + ATG TGA 309 102 
gp008 Uncharacterized protein 3184 3669 + ATG TAA 486 161 
gp009 Uncharacterized protein 3673 3867 + ATG TGA 195 64 
tRNA   4169 4242 MET (CAT) 74 24 
tRNA   4268 4349 LEU (TAA) 82 27 
tRNA   4403 4475 ASN (GTT) 73 24 
tRNA   4650 4723 MET (CAT) 74 24 
tRNA   4777 4858 LEU (TAA) 82 27 
gp010 Uncharacterized protein 4890 5078 + ATG TGA 189 62 
gp011 Uncharacterized protein 5057 5251 + ATG TAA 195 64 
gp012 Uncharacterized protein 5374 5523 + ATG TGA 150 49 
gp013 Uncharacterized protein 5520 5714 + ATG TAG 195 64 
tRNA   5817 5890 ARG (TCT) 74 24 
gp014 Uncharacterized protein 5860 6144 + ATG TAA 285 94 
gp015 Uncharacterized protein 6162 6404 + ATG TAA 243 80 
gp016 Uncharacterized protein 6433 6765 + ATG TAA 333 110 Putative uncharacterized protein gp70 Pseudomonas phage PAJU2  8,00E-47 
tRNA   6875 6948 PRO (TGG) 74 24 
   
tRNA   6961 7033 GLY (TCC) 73 24 
gp017 Uncharacterized protein 7070 7237 + ATG TAG 168 55 
gp018 Uncharacterized protein 7279 7467 + ATG TAG 189 62 
gp019 Uncharacterized protein 7582 7749 + ATG TGA 168 55 
gp020 Structural protein 7839 8198 + ATG TAG 360 119 
tRNA   8213 8299 SER (TGA) 87 28 
tRNA   8308 8394 SER (GCT) 87 28 
gp021 Uncharacterized protein 8724 8939 + ATG TAA 216 71 
gp022 Uncharacterized protein 8944 9162 + ATG TAA 219 72 
gp023 Uncharacterized protein 9153 9425 + ATG TGA 273 90 
gp024 Uncharacterized protein 9584 9934 + ATG TAA 351 116 
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gp025 Uncharacterized protein 9935 10114 + ATG TGA 180 59 
gp026 Uncharacterized protein 10111 10329 + ATG TGA 219 72 
gp027 Uncharacterized protein 10326 10844 + ATG TAA 519 173 Alteromonas phage vB_AmaP_AD45-P2 hypothetical protein 
AD45P2_00305 
8,00E-38 
gp028 Uncharacterized protein 10906 11544 + ATG TAA 639 212 
   
gp029 Uncharacterized protein 11651 11881 + ATG TGA 231 76 
gp030 Uncharacterized protein 11878 12123 + ATG TAG 246 81 
gp031 Uncharacterized protein 12245 12433 + ATG TAA 189 62 
gp032 Uncharacterized protein 12519 12632 + ATG TAG 114 37 
gp033 Uncharacterized protein 12964 13185 + ATG TAA 222 73 
gp034 Uncharacterized protein 13196 13372 + ATG TAA 177 58 
gp035 Uncharacterized protein 13360 13656 + ATG TAA 297 98 
gp036 Uncharacterized protein 13660 13959 + ATG TAG 300 99 
gp037 Uncharacterized protein 13962 14573 + TTG TAA 612 203 
gp038 Uncharacterized protein 14566 14685 + ATG TGA 120 39 
gp039 Uncharacterized protein 14682 15032 + ATG TAA 351 116 
gp040 Uncharacterized protein 15244 15576 + ATG TAA 333 110 
gp041 Uncharacterized protein 15625 15966 + ATG TAG 342 113 
gp042 Uncharacterized protein 15951 16298 + ATG TAG 348 115 
gp043 Uncharacterized protein 16288 16473 + ATG TAG 186 61 
gp044 Uncharacterized protein 16448 16771 + ATG TGA 324 99 
gp045 Murein hydrolase, 
peptidase 
16768 17262 + ATG TAA 495 164 
gp046 P ti s  M23 17255 17596 + ATG TAA 342 113 
gp047 Uncharacterized protein 17634 17921 + ATG TGA 288 95 
gp048 Uncharacterized protein 18034 18327 + ATG TAA 294 97 
gp049 Uncharacterized protein 18356 18649 + ATG TGA 294 97 
gp050 Uncharacterized protein 18732 18878 + ATG TAA 147 48 
gp051 Uncharacterized protein 18871 19131 + ATG TGA 261 86 
gp052 Uncharacterized protein 19163 19456 + ATG TGA 294 97 
gp053 Uncharacterized protein 19453 19734 + ATG TAA 282 93 
gp054 Uncharacterized protein 19804 20109 + ATG TAA 306 101 
gp055 Uncharacterized protein 20097 20378 + ATG TAA 282 93 
gp056 Uncharacterized protein 20394 20702 + ATG TAG 309 102 
gp057 Uncharacterized protein 20723 20974 + ATG TAA 252 83 
gp058 Uncharacterized protein 20987 21376 + ATG TGA 390 129 
gp059 Uncharacterized protein 21360 21644 + ATG TGA 285 94 
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gp060 Uncharacterized protein 21641 21895 + ATG TAA 255 84 
gp061 Uncharacterized protein 21898 22179 + ATG TAA 282 93 
gp062 Uncharacterized protein 22166 22450 + ATG TGA 285 94 
gp063 Uncharacterized protein 22447 22731 + ATG TGA 285 94 
gp064 Uncharacterized protein 22728 23009 + ATG TAA 282 93 
gp065 Uncharacterized protein 23550 23819 + ATG TAA 270 89 
gp066 Uncharacterized protein 23823 24131 + ATG TAG 309 102 
gp067 Uncharacterized protein 24145 24429 + ATG TAG 285 94 
gp068 Uncharacterized protein 24552 24707 + ATG TAG 156 51 
gp069 Uncharacterized protein 24735 24983 + ATG TGA 249 82 
gp070 Uncharacterized protein 24989 25279 + ATG TAA 291 96 
gp071 Uncharacterized protein 25272 25394 + ATG TAA 123 40 
gp072 Uncharacterized protein 25397 25510 + ATG TAA 114 37 
gp073 Uncharacterized protein 25524 25814 + ATG TAA 291 96 
gp074 Uncharacterized protein 25814 26110 + ATG TAA 297 98 
gp075 Uncharacterized protein 26110 26265 + ATG TGA 156 51 
gp076 Uncharacterized protein 26250 26369 + ATG TAG 120 39 
gp077 Uncharacterized protein 26518 26649 + ATG TAA 132 43 
gp078 Uncharacterized protein 26728 26853 + ATG TAA 126 41 
gp079 Uncharacterized protein 26903 27037 + ATG TAA 135 44 
gp080 Uncharacterized protein 27012 27176 + ATG TAA 165 54 
gp081 Uncharacterized protein 27157 27306 + ATG TAA 150 49 
gp082 Uncharacterized protein 27312 27446 + ATG TAA 135 44 
gp083 Uncharacterized protein 27433 27588 + ATG TGA 156 51 
gp084 Uncharacterized protein 27585 27743 + ATG TGA 159 52 
gp085 Uncharacterized protein 27740 27877 + ATG TAA 138 45 
gp086 Uncharacterized protein 27915 28049 + ATG TAA 135 44 
gp087 Uncharacterized protein 28158 28304 + ATG TAA 147 48 
gp088 Uncharacterized protein 28304 28444 + ATG TAG 141 46 
gp089 Uncharacterized protein 28438 28611 + ATG TAA 174 57 
gp090 Uncharacterized protein 28729 28881 + ATG TAA 153 50 
gp091 Uncharacterized protein 29029 29178 + ATG TAA 150 49 
gp092 Uncharacterized protein 29217 29360 + ATG TGA 144 47 
gp093 Uncharacterized protein 29362 29532 + ATG TAA 171 56 
gp094 Uncharacterized protein 29507 29698 + ATG TGA 192 63 
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gp095 Uncharacterized protein 29695 29883 + ATG TGA 189 62 
gp096 Uncharacterized protein 29880 30191 + ATG TAA 312 103 
gp097 Uncharacterized protein 30313 30420 + ATG TAG 108 35 
gp098 Uncharacterized protein 30672 31079 + ATG TAA 408 135 
gp099 Uncharacterized protein 31616 31795 + ATG TAA 180 59 
gp100 Structural protein 32238 32942 + ATG TAA 705 234 
gp101 Uncharacterized protein 33070 33237 + ATG TGA 168 55 
gp102 Uncharacterized protein 33197 33370 + ATG TAA 174 57 
gp103 Uncharacterized protein 33372 33521 + ATG TAA 150 49 
gp104 Uncharacterized protein 33708 33911 + ATG TAA 204 67 
gp105 Uncharacterized protein 33892 34158 + ATG TAG 267 88 
gp106 Uncharacterized protein 34162 34296 + ATG TGA 135 44 
gp107 Uncharacterized protein 34293 34424 + ATG TAA 132 43 
gp108 Uncharacterized protein 34417 34629 + ATG TAA 213 70 
gp109 Uncharacterized protein 34645 34986 + ATG TAA 342 113 
gp110 Uncharacterized protein 34988 35197 + ATG TAA 210 69 
gp111 Uncharacterized protein 35218 35394 + ATG TAA 177 58 
gp112 Structural protein 35408 35605 + ATG TAA 198 65 
gp113 Uncharacterized protein 35607 35864 + ATG TAA 258 85 
gp114 Uncharacterized protein 36781 37368 + ATG TAA 588 195 
gp115 Structural protein 37372 37920 + ATG TAA 549 182 
gp116 Uncharacterized protein 38079 38636 + ATG TAA 558 185 Pseudomonas phage NP3 hypothetical protein  5,00E-08 
gp117 Uncharacterized protein 38726 38977 + ATG TGA 252 83 Pseudomonas phage PAJU2 hypothetical protein PAJU2_gp39  2,00E-05 
gp118 Uncharacterized protein 38974 39240 + ATG TGA 267 88 Pseudomonas phage YMC11/02/R656 hypothetical protein 
BPPAER656_00320 
4,00E-29 
gp119 Uncharacterized protein 39237 39533 + ATG TAG 297 98    
gp120 Uncharacterized protein 39681 40082 + ATG TGA 402 133 Ralstonia phage RSP15 hypothetical protein  7,00E-10 
gp121 Uncharacterized protein 40086 40352 + ATG TGA 267 88 
   
gp122 Uncharacterized protein 40443 40544 + ATG TGA 102 33 
gp123 Uncharacterized protein 40541 40855 + ATG TAA 315 104 
gp124 Uncharacterized protein 40880 41107 + ATG TAA 228 75 Pseudomonas phage PAK_P5 hypothetical protein PAK_P500131  2,00E-42 
gp125 Uncharacterized protein 41191 41421 + ATG TAA 231 76 
   
gp126 Uncharacterized protein 41634 41810 + ATG TAA 177 58 
gp127 Uncharacterized protein 42052 42393 + ATG TAG 342 113 
gp128 Uncharacterized protein 42421 42741 + ATG TAA 321 106 
gp129 Uncharacterized protein 42871 43095 + ATG TAA 225 74 Pseudomonas phage VCM hypothetical protein VCM_00001 1,00E-11 
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gp130 Uncharacterized protein 43103 43408 + ATG TAA 306 101 
   
gp131 Uncharacterized protein 43410 43703 + ATG TGA 294 97 
gp132 Uncharacterized protein 43939 44229 + ATG TGA 291 96 
gp133 Uncharacterized protein 44226 44414 + ATG TGA 189 62 
gp134 Uncharacterized protein 44415 44612 + ATG TAG 198 65 
gp135 Uncharacterized protein 44999 45142 + ATG TAG 144 47 
gp136 Uncharacterized protein 45272 45439 + ATG TGA 168 55 
gp137 Uncharacterized protein 45436 45711 + ATG TGA 276 91 
gp138 Uncharacterized protein 45708 45926 + ATG TAA 219 72 
gp139 Uncharacterized protein 45937 46143 + ATG TAA 207 68 
gp140 Uncharacterized protein 46159 46362 + ATG TAA 204 67 
gp141 Uncharacterized protein 46373 46567 + ATG TAG 195 64 
gp142 Uncharacterized protein 46593 46892 + ATG TAA 300 99 
gp143 Uncharacterized protein 46914 47018 + ATG TAG 105 34 
gp144 Uncharacterized protein 47035 47178 + ATG TGA 144 47 
gp145 Uncharacterized protein 47175 47390 + ATG TAA 216 71 
gp146 Uncharacterized protein 47464 47661 + ATG TGA 198 65 
gp147 Uncharacterized protein 47840 48292 + ATG TAA 453 150 
gp148 Uncharacterized protein 48385 49032 + ATG TAA 648 215 
gp149 Uncharacterized protein 49034 49261 + ATG TAG 228 75 
gp150 Uncharacterized protein 49304 49453 + ATG TGA 150 49 
gp151 Uncharacterized protein 49610 49720 + ATG TAA 111 36 
gp152 Uncharacterized protein 49696 50040 + ATG TAA 345 114 
gp153 Uncharacterized protein 50597 51064 + ATG TAA 468 155 
gp154 Uncharacterized protein 51219 51356 + ATG TAG 138 45 
gp155 Uncharacterized protein 51371 51661 + ATG TAA 291 96 
gp156 Uncharacterized protein 51817 52065 + ATG TAA 249 82 
gp157 Uncharacterized protein 52077 52379 + ATG TAA 303 100 
gp158 Uncharacterized protein 52593 52913 + ATG TAG 321 106 
gp159 Uncharacterized protein 53310 53615 + ATG TAA 306 101 
gp160 Uncharacterized protein 53752 54039 + ATG TAA 288 95 
gp161 Uncharacterized protein 54221 54592 + ATG TAA 372 123 
gp162 Uncharacterized protein 54599 54886 + ATG TGA 288 95 
gp163 Uncharacterized protein 55037 55219 + ATG TAA 183 60 
gp164 Uncharacterized protein 55263 55502 - ATG TAA 240 79 
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gp165 Uncharacterized protein 55696 55866 - ATG TAA 171 56 
gp166 Uncharacterized protein 55856 56236 + ATG TAA 381 126 
gp167 Uncharacterized protein 56265 56432 + ATG TGA 168 55 
gp168 Uncharacterized protein 56511 56882 + ATG TAA 372 123 
gp169 Uncharacterized protein 56863 57189 + TTG TGA 327 108 
gp170 Uncharacterized protein 57182 57307 + ATG TAA 126 41 
gp171 Uncharacterized protein 57522 57983 + ATG TAA 462 153 Vibrio phage CHOED hypothetical protein 
CHOED_074 
2,00E-20 
gp172 Uncharacterized protein 58212 58628 + ATG TGA 417 138 
   
gp173 Uncharacterized protein 58701 58934 + ATG TAG 234 77 
gp174 Uncharacterized protein 58985 59086 + ATG TGA 102 33 
gp175 Uncharacterized protein 59201 59524 + ATG TAG 324 107 
gp176 Uncharacterized protein 59553 59744 + ATG TAA 192 63 
gp177 Uncharacterized protein 59831 59947 + ATG TAA 117 38 Pseudomonas phage KPP23 hypothetical protein KPP23_055  1,00E-04 
gp178 Uncharacterized protein 60019 60324 + ATG TAA 306 101 
   
gp179 Uncharacterized protein 60266 60472 + ATG TAG 207 68 
gp180 Uncharacterized protein 60426 60557 + ATG TAA 132 43 
gp181 Uncharacterized protein 60607 60816 + ATG TAA 210 69 
gp182 Uncharacterized protein 60850 61341 + ATG TAA 492 163 Pseudomonas phage PMG1 unnamed protein product  7,00E-85 
gp183 Uncharacterized protein 61419 61667 + ATG TAA 249 82 
   gp184 Uncharacterized protein 61808 62008 + ATG TAA 201 66 
gp185 Uncharacterized protein 62039 62203 + ATG TAA 165 54 Pseudomonas phage PAK_P2 hypothetical protein PAK_P200121  3,00E-17 
gp186 Uncharacterized protein 62324 62620 + ATG TAA 297 98 
   
gp187 Uncharacterized protein 63281 63445 + ATG TAA 165 54 
gp188 Uncharacterized protein 63452 63661 + ATG TAG 210 69 
gp189 Uncharacterized protein 63639 63806 + ATG TAA 168 55 
gp190 Uncharacterized protein 63799 64014 + ATG TGA 216 71 
gp191 Uncharacterized protein 64001 64192 + ATG TGA 192 63 
gp192 Uncharacterized protein 64189 64380 + ATG TAG 192 63 
gp193 Uncharacterized protein 64373 64600 + ATG TAA 228 75 
gp194 Uncharacterized protein 64924 65298 + ATG TGA 375 124 Escherichia phage vB_EcoP_PhAPEC7 hypothetical protein 
PhAPEC7_13 
4,00E-45 
gp195 Uncharacterized protein 65295 65510 + ATG TAG 216 71 
   
gp196 Uncharacterized protein 65510 65725 + ATG TAG 216 71 
gp197 Uncharacterized protein 65716 65910 + ATG TAA 195 64 
gp198 Uncharacterized protein 65901 66158 + ATG TAA 258 85 
gp199 Uncharacterized protein 66151 66372 + ATG TGA 222 73 
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gp200 Uncharacterized protein 66369 66608 + ATG TAA 240 79 
gp201 Uncharacterized protein 66748 66933 + ATG TAA 186 61 
gp202 Uncharacterized protein 67035 67220 + ATG TAA 186 61 
gp203 Uncharacterized protein 67224 68201 + ATG TAA 978 325 
gp204 Structural protein 68215 69435 - ATG TAA 1221 406 
gp205 Structural protein 69435 70871 - ATG TAA 1437 478 Campylobacter phage CP21 hypothetical protein 3,00E-12 
gp206 Structural protein 70874 72619 - ATG TAA 1746 581 Salmonella phage 7-11 putative structural protein 2,00E-13 
gp207 Structural protein 72623 73228 - ATG TAA 606 201 Cronobacter phage vB_CsaM_GAP32 hypothetical protein 
GAP32_224 
3,00E-25 
gp208 Uncharacterized protein 73230 73355 - ATG TAA 126 41    
gp209 Structural protein 73380 84956 - ATG TAG 11577 3858 Cronobacter phage vB_CsaM_GAP32 hypothetical protein 
GAP32_230 
9,00E-85 
gp210 Baseplate wedge 84963 88922 - ATG TAA 3960 1319 Klebsiella phage K64-1 hypothetical protein 1,00E-
152 gp211 Baseplate protein 88937 89329 - ATG TAA 393 130 Cronobacter phage vB_CsaM_GAP32 base plate protein  2,00E-12 
gp212 Uncharacterized protein 89466 89708 + ATG TAA 243 80 
   gp213 Uncharacterized protein 89753 90037 + ATG TAA 285 94 
gp214 Baseplate hub subunit and 
tail lysozyme 
90045 91478 - ATG TAA 1434 477 Cronobacter phage vB_CsaM_GAP32 baseplate hub subunit and 
tail lysozyme  
1,00E-48 
gp215 Structural protein 91478 93502 - ATG TAA 2025 674 Klebsiella phage K64-1 hypothetical protein  2,00E-08 
gp216 Uncharacterized protein 93502 93801 - ATG TGA 300 99 Cronobacter phage vB_CsaM_GAP32 hypothetical protein 
GAP32_236 
3,00E-10 
gp217 Structural protein 93801 94436 - ATG TAA 636 211 Cronobacter phage vB_CsaM_GAP32 hypothetical protein 
GAP32_236 
Cronobacter phage vB_CsaM_GAP32 hypothetical protein 
GAP32_237 
 
6,00E-26 
gp218 RNA polymerase Sigma 
factor 
94539 95381 + ATG TAA 843 280 Escherichia phage PBECO 4 RNA polymerase sigma factor 5,00E-47 
gp219 Endonuclease subunit 95393 96406 + ATG TAA 1014 337 Enterobacteria phage vB_KleM-RaK2 endonuclease subunit 2,00E-
104 gp220 Recombination 
endonuclease subunit 
96406 98160 + ATG TAA 1755 584 Cronobacter phage vB_CsaM_GAP32 recombination 
endonuclease subunit 
2,0 E-
117 gp221 Structural protein 98173 98922 - ATG TAA 750 249 Pseudomonas phage EL hypothetical protein PPEV_gp075  2,00E-12 
gp222 Uncharacterized protein 98925 99422 - ATG TAA 498 165 
   
gp223 Uncharacterized protein 99855 100007 + ATG TAA 153 50 
gp224 Uncharacterized protein 100153 100272 + ATG TAA 120 39 
gp225 Uncharacterized protein 100936 101388 + ATG TAA 453 150 
gp226 Uncharacterized protein 101612 102466 - ATG TAG 855 284 Escherichia phage 121Q baseplate hub subunit  8,00E-32 
gp227 Structural protein 102536 104932 + ATG TAA 2397 798    
gp228 Portal vertex protein of 
head 
104962 106677 + ATG TAA 1716 571 Cronobacter phage vB_CsaM_GAP32 portal vertex protein of 
head  
5,00E-
155 gp229 Structural protein 106677 106898 + ATG TAA 222 73 
   gp230 Structural protein 107004 107816 + ATG TAA 813 270 
gp231 Prohead core scaffolding 
protein and protease 
107835 108467 + ATG TAG 633 210 Escherichia phage 121Q capsid maturation protease  2,00E-59 
gp232 Uncharacterized protein 108480 109586 + ATG TAA 1107 368 Enterobacteria phage vB_KleM-RaK2 hypothetical protein 
RaK2_00093 
7,00E-45 
gp233 Precursor of major head 
subunit 
109606 110793 + ATG TAA 1188 395 Cronobacter phage vB_CsaM_GAP32 precursor of major head 
subunit 
0.0 
gp234 Uncharacterized protein 110912 112489 + ATG TAA 1578 525 Klebsiella phage K64-1 hypothetical protein 1,00E-53 
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gp235 Uncharacterized protein 112541 113005 + ATG TAA 465 154 
   gp236 Uncharacterized protein 113007 113705 + ATG TAA 699 232 
gp237 Uncharacterized protein 113714 114019 + ATG TAA 306 101 Pseudomonas phage VCM hypothetical protein VCM_00075  9,00E-30 
gp238 Phage tail fiber protein H 114080 117106 + ATG TAA 3027 1008 Escherichia ABU 83972 putative phage tail fiber protein H 2,00E-35 
gp239  MutT/NUDIX hydrolase 
family protein 
117714 118031 - ATG TAA 318 105 Escherichia phage 121Q MutT-like protein 2,00E-28 
gp240 Tail sheath stabilizer and 
completion protein 
118141 119511 - ATG TAA 1371 456 Cronobacter phage vB_CsaM_GAP32 tail sheath stabilizer and 
completion protein 
6,00E-41 
gp241 Structural protein 119511 120602 - ATG TAA 1092 363 Escherichia phage PBECO 4 hypothetical protein  7,00E-31 
gp242 Uncharacterized protein 120669 121166 - ATG TAA 498 165    
gp243 Tail fiber protein 121180 122715 - ATG TAA 1536 511 Vibrio phage CHOED tail fiber repeat family protein  2,00E-04 
gp244 Structural protein 122717 124315 - ATG TAA 1599 532 
   
gp245 Structural protein 124315 126678 - ATG TAA 2364 787 
gp246 Uncharacterized protein 127262 127429 + ATG TAA 168 55 
gp247 Structural protein 127467 127877 + ATG TAA 411 136 
gp248 Structural protein 127807 128124 + ATG TAA 318 105 
gp249 Uncharacterized protein 128121 128384 - ATG TAA 264 87 
gp250 Glycosyl hydrolase, 
lysozyme-like protein 
128363 128878 - ATG TAA 516 171 
gp251 Uncharacterized protein 129000 129431 + ATG TAG 432 143 
gp252 Structural protein 129433 129645 + ATG TAA 213 70 
gp253 Uncharacterized protein 129645 130115 + ATG TGA 471 156 
gp254 Uncharacterized protein 130112 130357 + ATG TAA 246 81 Vibrio phage nt-1 putative permease  7,00E-08 
gp255 Uncharacterized protein 130350 130619 + ATG TAA 270 89 
   
gp256 Uncharacterized protein 130620 131174 + ATG TAA 555 184 
gp257 Structural protein 131190 131753 + ATG TAA 564 187 
gp258 Uncharacterized protein 131825 132076 + ATG TAA 252 83 
gp259 Uncharacterized protein 132227 132757 + ATG TGA 531 176 
gp260 Uncharacterized protein 132741 132920 + ATG TGA 180 59 
gp261 Uncharacterized protein 132917 133204 + ATG TAA 288 95 
gp262 Uncharacterized protein 133255 133419 + ATG TAA 165 54 
gp263 Uncharacterized protein 133747 135930 + ATG TAA 2184 727 Cronobacter phage S13 putative rIIA protector from prophage-
induced early lysis  
6,00E-54 
gp264 RIIB protector from 
prophage-induced early 
lysis 
135923 136666 + ATG TAA 744 247 Enterobacter phage PG7 protector from prophage-induced early 
lysis  
2,00E-56 
gp265 Uncharacterized protein 136750 138771 + ATG TAA 2022 673 
   
gp266 Uncharacterized protein 138919 139215 + ATG TAG 297 98 
gp267 Uncharacterized protein 139352 139543 + ATG TGA 192 63 
gp268 Uncharacterized protein 139540 139692 + ATG TGA 153 50 
gp269 Uncharacterized protein 139741 140859 + ATG TAA 1119 372 Stenotrophomonas phage vB_SmaS-DLP_6 hypothetical protein 3,00E-23 
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gp270 Neck protein 140895 141647 + ATG TAA 753 250 Cronobacter phage vB_CsaM_GAP32 neck protein  1,00E-49 
gp271 Structural protein 141652 142293 + ATG TAA 642 213 Enterobacteria phage vB_KleM-RaK2 putative deoxynucleoside 
monophosphate kinase 
5,00E-42 
gp272 Tail sheath monomer 142411 145050 + ATG TAA 2640 879 Escherichia phage 121Q tail sheath protein  2,00E-
105 gp273 Homing endonuclease 145152 146768 + ATG TAA 1617 538 Yersinia phage phiR1-37 g171 7,00E-52 
gp274 Structural protein 146857 147477 + ATG TAA 621 206 Cronobacter phage vB_CsaM_GAP32 hypothetical protein 
GAP32_199 
7,00E-38 
gp275 Structural protein 147537 149015 + ATG TAA 1479 492 Cronobacter phage vB_CsaM_GAP32 hypothetical protein 
GAP32_201 
3,00E-10 
gp276 Structural protein 149015 149470 + ATG TAA 456 151    
gp277 Head completion protein 149470 149898 + ATG TAA 429 142 Enterobacteria phage vB_KleM-RaK2 head completion protein 1,00E-32 
gp278 Uncharacterized protein 149900 150406 + ATG TAA 507 168 
   
gp279 Structural protein 150431 151033 + ATG TAA 603 200 
gp280 Structural protein 151063 152568 + ATG TAA 1506 501 
gp281 DNA terminase packaging 
enzyme large subunit 
152597 154192 + ATG TAA 1596 531 Cronobacter phage vB_CsaM_GAP32 DNA terminase packaging 
enzyme large subunit 
1,00E-
142 gp282 Structural protein 154224 155714 + ATG TAA 1491 496    
gp283 Structural protein 155743 157233 + TTG TAA 1491 496 Enterobacteria phage vB_KleM-RaK2 hypothetical protein 
RaK2_00112 
4,00E-28 
gp284 Structural protein 157432 158418 + ATG TAA 987 328 Enterobacteria phage vB_KleM-RaK2 hypothetical protein 
RaK2_00113 
1,00E-69 
gp285 RecA-like protein 158525 158770 + ATG TAA 246 81 Cronobacter phage vB_CsaM_GAP32 RecA-like protein 2,00E-15 
gp286 Uncharacterized protein 158823 160256 + ATG TAA 1434 477 Vibrio phage vB_VmeM-32 hypothetical protein VmeM32_00088  3,00E-04 
gp287 RecA-like protein 160260 161531 + ATG TAA 1272 423 Cronobacter phage vB_CsaM_GAP32 RecA-like protein 6,00E-
122 gp288 Uncharacterized protein 161524 163359 + ATG TGA 1836 611 Campylobacter phage NCTC12673 Hef59  2,00E-46 
gp289 Uncharacterized protein 163356 163556 + ATG TAA 201 66 
   gp290 Uncharacterized protein 163546 163872 + ATG TAA 327 108 
gp291 Uncharacterized protein 163856 164320 + ATG TAA 465 154 Enterobacteria phage vB_KleM-RaK2 hypothetical protein 
RaK2_00116 
2,00E-36 
gp292 RNA-DNA + DNA-DNA 
helicase 
164333 165784 + ATG TAA 1452 483 Cronobacter phage vB_CsaM_GAP32 RNA-DNA + DNA-DNA 
helicase  
2,00E-
151 gp293 Uncharacterized protein 165786 166037 + ATG TAA 252 83    
gp294 Uncharacterized protein 166048 166551 + TTG TAA 504 167 Cronobacter phage vB_CsaM_GAP32 hypothetical protein 
GAP32_278 
2,00E-24 
gp295 Uncharacterized protein 166551 167018 + ATG TAA 468 155    
gp296 Uncharacterized protein 167068 167739 + ATG TAA 672 223 Escherichia phage 121Q hypothetical protein PBI_121Q_14  7,00E-30 
gp297 Uncharacterized protein 167741 168343 + ATG TGA 603 200 Escherichia phage PBECO 4 hypothetical protein 1,00E-37 
gp298 Structural protein 168788 169657 + ATG TAA 870 289 Enterobacteria phage vB_KleM-RaK2 hypothetical protein 
RaK2_00126 
3,00E-06 
gp299 DNA primase 169693 170715 + ATG TAG 1023 340 Cronobacter phage vB_CsaM_GAP32 putative DNA primase  3,00E-43 
gp300 DNA primase-helicase 
subunit 
170717 172156 + ATG TAA 1440 479 Klebsiella phage K64-1 DNA primase-helicase subunit  2,00E-76 
gp301 Uncharacterized protein 172197 172436 + ATG TAA 240 79 Enterobacteria phage vB_KleM-RaK2 hypothetical protein 
RaK2_00129 
4,00E-06 
gp302 Structural protein 172439 173050 + ATG TAA 612 203 
   
gp303 Structural protein 173043 174242 + ATG TAA 1200 399 
gp304 Uncharacterized protein 174327 175667 + ATG TAG 1341 446 
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gp305 Uncharacterized protein 175668 176687 + ATG TAG 1020 339 
gp306 Structural protein 176678 176923 + ATG TAA 246 81 
gp307 Structural protein 176923 177636 + ATG TAG 714 237 
gp308 Structural protein 177644 178075 + ATG TAG 432 143 
gp309 Structural protein 178142 178444 + ATG TAA 303 100 
gp310 Structural protein 178563 179027 + ATG TGA 465 154 
gp311 Structural protein 179024 179650 + ATG TAA 627 208 
gp312 Uncharacterized protein 179652 180107 + ATG TAA 456 151 
gp313 Structural protein 180144 181331 + ATG TAA 1188 395 
gp314 Structural protein 181332 181646 + ATG TAA 315 104 
gp315 Structural protein 181646 181981 + ATG TAA 336 111 
gp316 Exonuclease 182045 182710 + ATG TAA 666 221 Escherichia phage 121Q exonuclease  5,00E-50 
gp317 Structural protein 182742 183941 + ATG TAA 1200 399 
   
gp318 Uncharacterized protein 183958 184392 + ATG TAA 435 144 
gp319 Structural protein 184401 186686 + ATG TAA 2286 761 
gp320 Structural protein 186740 187879 + ATG TAA 1140 379 Caulobacter phage Cr30 baseplate hub subunit and tail lysozyme  6,00E-27 
gp321 Baseplate hub sub and tail 
lysozyme, muramoyl-
pentapeptidase 
187904 188926 + ATG TAA 1023 340 
   
gp322 Uncharacterized protein 188969 189193 + ATG TAA 225 74 
gp323 Uncharacterized protein 189186 189401 + ATG TGA 216 71 
gp324 Uncharacterized protein 189495 190220 + ATG TGA 726 241 
gp325 Uncharacterized protein 190217 190585 + ATG TGA 369 122 
gp326 Uncharacterized protein 190578 190898 + ATG TAA 321 106 
gp327 Structural protein 190898 191794 + ATG TAA 897 298 
gp328 Uncharacterized protein 191794 192105 + ATG TAA 312 103 
gp329 GTP cyclohydrolase 192254 192943 + ATG TAA 690 229 Vibrio phage KVP40 GTP cyclohydrolase I  3,00E-83 
gp330 Structural protein 193011 193529 + TTG TAA 519 172 
   
gp331 Uncharacterized protein 193547 194773 + ATG TAA 1227 408 
gp332 Uncharacterized protein 194760 194966 + ATG TAA 207 68 
gp333 Uncharacterized protein 195050 195304 + TTG TAA 255 84 
gp334 Uncharacterized protein 195306 195776 + ATG TAA 471 156 
gp335 Heat shock protein 195859 196290 + ATG TAA 432 143 Synechococcus phage S-SM1 heat shock protein 4,00E-17 
gp336 Uncharacterized protein 196405 196707 + ATG TAA 303 100 
   
gp337 Structural protein 196782 197330 + ATG TAA 549 182 
gp338 Uncharacterized protein 197350 197634 + ATG TAA 285 94 
gp339 Uncharacterized protein 197644 197937 + ATG TGA 294 97 
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gp340 Uncharacterized protein 198005 198232 + ATG TAA 228 75 
gp341 Uncharacterized protein 198278 198922 + TTG TAA 645 214 
gp342 Structural protein 198963 200693 + ATG TAA 1731 576 
gp343 DNA ligase 200721 202091 + ATG TAA 1371 456 Vibrio phage ValKK3 DNA ligase  8,00E-58 
gp344 Uncharacterized protein 202101 202262 + ATG TAA 162 53 
   gp345 Structural protein 202282 202791 + ATG TAA 510 169 
gp346 DNA polymerase III 
epsilon subunit 
202888 203661 + ATG TAA 774 257 Escherichia phage 121Q DNA polymerase III  2,00E-29 
gp347 Uncharacterized protein 203840 203962 + ATG TAA 123 40 
   
gp348 Uncharacterized protein 203985 204092 + ATG TAG 108 35 
gp349 Structural protein 204152 204823 + ATG TAA 672 223 
gp350 Uncharacterized protein 205033 205263 - ATG TAG 231 76 
gp351 Uncharacterized protein 205351 205608 + ATG TAA 258 85 
gp352 Uncharacterized protein 205733 205990 + ATG TGA 258 85 
gp353 Uncharacterized protein 205987 206601 + ATG TAG 615 204 Pseudomonas phage phiPsa374 hypothetical protein  4,00E-13 
gp354 Uncharacterized protein 206763 207020 + ATG TAA 258 85 
   gp355 Uncharacterized protein 207020 207496 + ATG TAA 477 158 
gp356 MazG pyrophosphatase 207480 207881 + ATG TAA 402 133 Synechococcus phage ACG-2014f pyrophosphatase  1,00E-40 
gp357 Uncharacterized protein 207841 208278 + ATG TAA 438 145 
   
gp358 Uncharacterized protein 208326 208595 + ATG TAA 270 89 
gp359 Uncharacterized protein 208610 208870 + ATG TAG 261 86 
gp360 Uncharacterized protein 208891 209103 + ATG TGA 213 70 
gp361 Uncharacterized protein 209100 209435 + ATG TAA 336 111 
gp362 Uncharacterized protein 209428 209730 + ATG TAA 303 100 
gp363 Structural protein 209753 210253 + ATG TAA 501 166 
gp364 Uncharacterized protein 210329 210625 + ATG TAA 297 98 
gp365 Uncharacterized protein 210626 211333 + ATG TAA 708 235 
gp366 DNA polymerase III alpha 
subunit 
211317 211826 + ATG TAA 510 169 Cronobacter phage vB_CsaM_GAP32 DNA polymerase III alpha 
subunit 
6,00E-28 
gp367 Uncharacterized protein 211839 212180 + ATG TAA 342 113 Escherichia phage 121Q hypothetical protein PBI_121Q_57  1,00E-08 
gp368 Uncharacterized protein 212182 212508 + ATG TAA 327 108 Escherichia phage 121Q chaperonin  2,00E-15 
gp369 Clamp loader subunit DNA 
polymerase accessory 
protein 
212522 213451 + ATG TAA 930 309 uncultured Mediterranean phage uvMED clamp loader subunit  5,00E-63 
gp370 Structural protein 213453 213815 + ATG TAA 363 120    
gp371 Uncharacterized protein 213805 214401 + ATG TAA 597 198 Stenotrophomonas phage vB_SmaS-DLP_6 hypothetical protein 1,00E-23 
gp372 Uncharacterized protein 214484 215257 - TTG TAA 774 257    
gp373 Structural protein 215434 215955 + ATG TAA 522 173 Escherichia phage 121Q structural protein  5,00E-16 
gp374 Uncharacterized protein 215985 216686 + ATG TAA 702 233 Escherichia phage 121Q structural protein  7,00E-17 
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gp375 Uncharacterized protein 216725 217414 + ATG TAA 690 229 
   gp376 Uncharacterized protein 217424 219643 + ATG TAA 2220 739 
gp377 Structural protein 219761 220195 + ATG TAA 435 144 Cronobacter phage vB_CsaM_GAP32 hypothetical protein 
GAP32_223 
7,00E-09 
gp378 Structural protein 220209 226919 + ATG TAA 6711 2236 Ralstonia phage RSL1 unnamed protein product  1,00E-21 
gp379 Uncharacterized protein 226921 227307 + ATG TAA 387 128 
   
gp380 Structural protein 227423 230443 + ATG TAA 3021 1006 
gp381 Structural protein 230447 232420 + ATG TAA 1974 657 
gp382 Structural protein 232463 233098 + ATG TAA 636 211 
gp383 Structural protein 233165 235849 + ATG TAA 2685 894 uncultured Mediterranean phage uvMED phage-related tail fiber 
protein 
4,00E-08 
gp384 Structural protein 236022 236348 + ATG TAA 327 108    
gp385 Uncharacterized protein 236556 237128 + ATG TAA 573 190 uncultured Mediterranean phage uvMED hypothetical protein  1,00E-21 
gp386 Structural protein 237131 238078 + ATG TAA 948 315    
gp387 Structural protein 238081 239991 + ATG TAA 1911 636 Pseudomonas phage PaBG putative adhesin  1,00E-24 
gp388 Structural protein 240072 240347 + ATG TAA 276 91    
gp389 DNA polymerase 240401 242812 + ATG TAA 2412 803 Cronobacter phage vB_CsaM_GAP32 DNA polymerase  1,00E-
154 gp390 Hef-like homing 
endonuclease 
242805 244487 + ATG TAA 1683 560 Yersinia phage vB_YenM_TG1 hypothetical protein 
YenMTG1_176 
8,00E-77 
gp391 DNA polymerase 244488 245627 + ATG TAA 1140 379 Cronobacter phage vB_CsaM_GAP32 DNA polymerase  7,00E-53 
gp392 Structural protein 245708 246454 + ATG TAA 747 248 
   
gp393 Uncharacterized protein 246458 246718 + ATG TAA 261 86 
gp394 Uncharacterized protein 246791 248413 + ATG TAA 1623 540 
gp395 Uncharacterized protein 248413 249474 + ATG TAA 1062 353 
gp396 Uncharacterized protein 249559 249936 + ATG TAA 378 125 
gp397 Uncharacterized protein 249951 250211 + ATG TAA 261 86 
gp398 Uncharacterized protein 250212 250730 + ATG TAA 519 172 
gp399 Uncharacterized protein 250742 251176 + ATG TAA 435 144 
gp400 Radical SAM domain-
containing protein 
251247 252119 + ATG TAA 873 290 Vibrio phage ValKK3 radical SAM domain-containing protein 2,00E-52 
gp401 Uncharacterized protein 252124 252543 + ATG TGA 420 139    
gp402 Uncharacterized protein 252540 253151 + ATG TAA 612 203 Escherichia phage PBECO 4 hypothetical protein  7,00E-19 
gp403 RNaseH ribonuclease 253151 254137 + ATG TAA 987 328 Cronobacter phage vB_CsaM_GAP32 RNaseH ribonuclease  1,00E-96 
gp404 Uncharacterized protein 254140 254598 + ATG TAA 459 152 
   
gp405 Uncharacterized protein 254610 254900 + ATG TAA 291 96 
gp406 Uncharacterized protein 254903 255448 + ATG TAA 546 181 
gp407 Uncharacterized protein 255451 255651 + ATG TAG 201 66 
gp408 Uncharacterized protein 255728 256021 + ATG TAA 294 97 
gp409 Uncharacterized protein 256008 256358 + ATG TGA 351 116 
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gp410 Uncharacterized protein 256413 256787 + ATG TAA 375 124 
gp411 Uncharacterized protein 256798 257106 + ATG TAA 309 102 
gp412 Uncharacterized protein 257172 257681 + ATG TAA 510 169 
gp413 Structural protein 257884 258999 + ATG TAA 1116 371 
gp414 Uncharacterized protein 259069 259524 + ATG TAG 456 151 
gp415 Uncharacterized protein 259526 259984 + ATG TGA 459 152 
gp416 Uncharacterized protein 259981 260334 + ATG TAA 354 117 
gp417 Homing endonuclease 260334 261830 + ATG TAG 1497 498 Enterobacteria phage vB_KleM-RaK2 putative homing 
endonuclease 
3,00E-76 
gp418 HNH endonuclease 261886 263070 + ATG TAA 1185 394 Escheri hi  phage 121Q Zn-dependent hydrolase 2,00E-86 
gp419 Uncharacterized protein 263352 263594 + ATG TGA 243 80    
gp420 Uncharacterized protein 263687 264007 - ATG TAA 321 106 
gp421 Uncharacterized protein 264174 264413 - ATG TAA 240 79 
gp422 Uncharacterized protein 264415 265155 - ATG TAA 741 246 Escherichia phage 121Q hypothetical protein PBI_121Q_566  1,00E-20 
gp423 Uncharacterized protein 265173 265445 - ATG TAA 273 90 
   
gp424 Uncharacterized protein 265438 266040 - ATG TAA 603 200 
gp425 Uncharacterized protein 266068 266310 - ATG TAA 243 80 
gp426 Structural protein 266297 266545 - ATG TAA 249 82 
gp427 Structural protein 266666 267091 - ATG TAA 426 141 Vibrio phage nt-1 hypothetical protein VPFG_00035  8,00E-07 
gp428 Uncharacterized protein 267163 267909 - ATG TAA 747 248 
   
gp429 Structural protein 267902 268861 - ATG TAA 960 319 
gp430 Uncharacterized protein 268861 269100 - ATG TAA 240 79 
gp431 Uncharacterized protein 269237 269755 - ATG TAG 519 172 
gp432 Uncharacterized protein 270165 270266 + ATG TAG 102 33 
gp433 Uncharacterized protein 271373 271570 + ATG TAA 198 65 
gp434 Uncharacterized protein 271564 271785 + ATG TGA 222 73 
gp435 Uncharacterized protein 271782 272000 + ATG TGA 219 72 
gp436 Uncharacterized protein 271997 272206 + ATG TAA 210 69 
gp437 Uncharacterized protein 272209 272406 + ATG TAA 198 65 Vibrio phage henriette 12B8 hypothetical protein VPDG_00063  1,00E-05 
gp438 Uncharacterized protein 272510 273664 + ATG TAA 1155 384 Cronobacter phage S13 hypothetical protein S13_001  1,00E-50 
gp439 Uncharacterized protein 273708 274265 + ATG TAA 558 185 
   
gp440 Uncharacterized protein 274234 274641 + ATG TAA 408 135 
gp441 Uncharacterized protein 274644 275510 + ATG TAA 867 288 
gp442 Uncharacterized protein 275510 276412 + ATG TAA 903 300 
gp443 Uncharacterized protein 276415 276927 + ATG TAA 513 170 
gp444 Uncharacterized protein 276911 277216 + TTG TAA 306 101 
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gp445 Uncharacterized protein 277286 277756 + ATG TAA 471 156 
gp446 Uncharacterized protein 277716 277955 + ATG TAG 240 79 
gp447 Cell wall hydrolase domain 
protein, SleB 
277966 278532 + ATG TAA 567 188 Pseudomonas phage vB_PaeM_PAO1_Ab03 putative cell wall 
hydrolase  
5,00E-55 
gp448 Uncharacterized protein 278546 278776 + ATG TAA 231 76 
   
gp449 Uncharacterized protein 278757 279056 + ATG TAA 300 99 
gp450 Uncharacterized protein 279131 279490 + ATG TAA 360 119 
gp451 Uncharacterized protein 279677 280288 + ATG TAA 612 203 
gp452 Uncharacterized protein 280282 280890 + ATG TGA 609 202 
gp453 Uncharacterized protein 280883 281362 + ATG TAA 480 159 
gp454 Uncharacterized protein 281397 281774 + ATG TGA 378 125 
gp455 Uncharacterized protein 281771 282397 + ATG TAG 627 208 
gp456 Uncharacterized protein 282408 282737 + ATG TAA 330 109 
gp457 Uncharacterized protein 282727 284154 + ATG TAA 1428 475 
gp458 Uncharacterized protein 284160 284423 + ATG TAA 264 87 
gp459 Structural protein 284454 285206 - ATG TAA 753 250 
gp460 Structural protein 285187 285876 - ATG TAA 690 229 
gp461 Uncharacterized protein 285883 286077 - ATG TAG 195 64 
gp462 Structural protein 286163 287143 + ATG TAA 981 326 
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Table S 6.3: The ESI-MS/MS analysis of denaturated phage PA5oct particles after fractionation on SDSPAGE gel. 
Protein 
no. 
Identified function 
Band 
no.  
Molecular weight (Da) Number of 
identified 
peptides 
Sequence 
coverage 
Identity with other pahges (BLASTP) 
MS  SDS-PAGE GAP32 
PBECO 
4 121Q 
KleM-
RaK2 K64-1 
gp20 Structural protein 15 14 003,90 13090 4 44,53% 
 
gp100 Structural protein 11 26 989,70 25740 5 28,20% 
gp112 Structural protein 15 8 566,50 7150 2 35,38% 
gp115 Structural protein 13 22 088,90 20020 2 29,12% 
gp204 Structural protein 7 44 484,70 44660 3 21,67% 
gp205 Structural protein 6 50 631,60 52580 12 62,34% 
gp206 Structural protein 5 62 159,40 63910 21 65,58% 
gp207 Structural protein 12 22 521,10 22110 10 69,65% 
gp209 Structural protein 1 437 680,80 424380 107 43,65% 
gp210 Baseplate wedge 2 150 682,40 145090 52 63,76% 28% 27% 27% 32% 32% 
gp211 Baseplate protein 15 16 540,30 14300 5 49,23% 37% - 33% 33% - 
gp214 Baseplate hub subunit and tail lysozyme 6 51 283,90 52470 17 57,65% 31% 30% 30% 32% 32% 
gp215 Structural protein 4 79 369,90 74140 8 19,88% 21% - 21% 22% 22% 
gp217 Structural protein 11 24 530,10 23210 8 77,25% 31% - 29% 31% - 
gp220 Recombination endonuclease subunit* 5 68 787,50 64240 10 25,00% 35% 34% 34% 33% - 
gp221 Structural protein 11 28 585,50 27390 10 44,98% 
 gp227 Structural protein 4 86 353,30 87780 27 49,87% 
gp228 Portal vertex protein of head 5 65 729,50 62810 17 48,69% 44% 43% 42% 43% - 
gp229 Structural protein 15 10 165,00 8030 4 67,12% 48% - 38% 41% - 
gp230 Structural protein 10 30 221,10 29700 8 44,07%  
gp231 Prohead core scaffolding protein and protease 12 23 825,40 23100 6 40,00% 48% - 53% 44% - 
gp233 Precursor of major head subunit 7 43 001,30 43450 18 97,47% 68% - 66% 66% - 
gp238 Phage tail fiber protein H 3 106 898,80 110880 23 50,20%  
gp240 Tail sheath stabilizer and completion protein 6 52 038,00 50160 13 38,60% 28% - 32% 36% 36% 
gp241 Structural protein 8 41 824,70 39930 2 6,34% 34% 30% 30% 32% 32% 
gp243 Tail fiber protein 6 57 453,40 56210 19 48,34% 
 
gp244 Structural protein 5 60 641,20 58520 20 64,47% 
gp245 Structural protein 4 86 840,50 86570 18 35,07% 
gp247 Structural protein 15 16 690,10 14960 4 43,38% 
gp248 Structural protein 15 12 844,40 11550 2 42,86% 
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RaK2 K64-1 
gp250 Glycosyl hydrolase, lysozyme-like protein 14 18 902,50 18810 5 45,03% 
gp252 Structural protein 15 9 114,50 7700 2 25,71% 
gp257 Structural protein 13 21 738,70 20570 5 39,57% 
gp264 
RIIB protector from prophage-induced early 
lysis* 
10 
29 135,10 27170 10 53,04% 
 
gp270 Neck protein 10 29 133,00 27500 9 62,40% 42% 40% 40% 40% - 
gp271 Structural protein 11 26 823,60 23430 5 32,86% 45% 42% 41% 43% - 
gp272 Tail sheath monomer 3 95 769,60 96690 37 80,55% 52% - 51% 50% 50% 
gp274 Structural protein 10 29 474,00 22660 9 82,04% 44% 36% 44% 40% - 
gp275 Structural protein 5 59 138,80 54120 16 52,24% 
 
gp276 Structural protein 15 17 211,80 16610 4 50,33% 
gp279 Structural protein 12 22 977,90 22000 13 98,00% 
gp280 Structural protein 6 55 894,10 55110 10 25,95% 
gp282 Structural protein 5 59 957,40 54560 20 55,04% 
gp283 Structural protein 6 57 679,30 54560 11 28,02% 52% - 38% 40% 40% 
gp284 Structural protein 9 37 579,30 36080 8 40,55% 42% - 45% 43% - 
gp287 RecA-like protein 6 47 297,00 46530 2 7,56% 59% - 58% 56% - 
gp298 Structural protein 9 35 821,40 31790 4 23,18% 
 
gp302 Structural protein 12 23 295,90 22330 7 48,77% 
gp303 Structural protein 7 45 019,60 43890 13 47,37% 
gp306 Structural protein 15 9 395,90 8910 3 35,80% 
gp307 Structural protein 11 28 071,10 26070 6 56,96% 
gp308 Structural protein 14 18 165,80 15730 6 55,94% 
gp309 Structural protein 15 11 193,40 11000 4 87,00% 
gp310 Structural protein 15 17 023,00 16940 4 48,70% 
gp311 Structural protein 11 28 225,90 20240 2 11,41% 
gp313 Structural protein 7 44 353,50 43450 9 27,34% 
gp314 Structural protein 15 11 322,20 11440 2 22,12% 
gp315 Structural protein 15 13 692,40 12210 2 32% 
gp317 Structural protein 7 45 172,10 43890 11 44,86% 
gp319 Structural protein 4 88 245,70 83710 3 8,54% 
295 
 
Protein 
no. 
Identified function 
Band 
no.  
Molecular weight (Da) Number of 
identified 
peptides 
Sequence 
coverage 
Identity with other pahges (BLASTP) 
MS  SDS-PAGE GAP32 
PBECO 
4 121Q 
KleM-
RaK2 K64-1 
gp320 Structural protein 7 45 858,00 41690 7 20,84% 
gp321 
Putative baseplate hub sub and tail lysozyme, 
muramoyl-pentapeptidase 8 37 776,60 37400 4 15,88% 
gp327 Structural protein 9 34 524,70 32780 9 37,25% 
gp329 GTP cyclohydrolase* 11 26 338,70 25190 13 79,91% 
gp330 Structural protein 13 21 589,60 18920 3 26,16% 
gp337 Structural protein 12 23 119,90 20020 3 31,32% 
gp342 Structural protein 5 63 016,60 63360 2 2,95% 
gp343 DNA ligase* 6 52 246,10 50160 2 7,02% 34% 33% 33% - - 
gp345 Structural protein 13 19 181,60 18590 4 39% 
 
gp349 Structural protein 11 26 446,00 24530 5 33,18% 
gp356 MazG pyrophosphatese* 15 15 569,30 14630 1 18,04% 
gp363 Structural protein 13 21 637,60 18260 7 57,23% 
gp370 Structural protein 15 14 739,40 13200 3 30,00% 
gp373 Structural protein 13 20 812,50 19030 9 60,69% 29% 34% 34% 30% - 
gp377 Structural protein 14 18 313,30 15840 5 59,72% 38% - 33% 31% - 
gp378 Structural protein 1 237 196,80 245960 31 29,20% 
 
gp380 Structural protein 3 106 920,50 110660 8 16,89% 
gp381 Structural protein 4 71 076,70 72270 8 17,20% 
gp382 Structural protein 12 22 605,90 23210 4 29,38% 
gp383 Structural protein 4 91 998,00 98340 16 40,60% 
gp384 Structural protein 15 13 740,70 11880 2 39,81% 
gp386 Structural protein 9 34 454,70 34650 8 43,49% 
gp387 Structural protein 4 70 630,00 69960 15 37,58% 
gp388 Structural protein 15 11 452,20 10010 4 65,93% 
gp392 Structural protein 11 27 239,60 27280 5 39,64% 
gp403 RNaseH ribonuclease* 8 37 919,60 36080 5 24,39% 46% 44% 45% 45% - 
gp413 Structural protein 7 42 181,70 40810 7 22,64% 
 
gp426 Structural protein 15 10 749,90 9020 3 39,02% 
gp427 Structural protein 15 16 830,80 15510 8 81,56% 
gp429 Structural protein 8 37 720,50 35090 8 36,05% 
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MS  SDS-PAGE GAP32 
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4 121Q 
KleM-
RaK2 K64-1 
gp459 Structural protein 10 29 986,60 27500 13 77,20% 
gp460 Structural protein 11 27 328,40 25190 12 68,56% 
gp462 Structural protein 9 36 516,80 35860 11 50,92% 
(*) proteins non-associated with phage particles 
  
297 
 
Table S 6.4: List of jumbo phages and relevant phages that belong to the viral vlusters (VCs). 
VC_77  VC_150 
Accession No.  Name Taxonomy  Accession No.  Name Taxonomy 
NC_019526.1 Enterobacteria phage vB_KleM-RaK2  unclassified Myoviridae  NC_027402.1 Salmonella phage SPN3US  unclassified Myoviridae 
NC_025447.1 Escherichia phage 121Q  unclassified Myoviridae  NC_021531.1 Cronobacter phage CR5  unclassified Myoviridae 
NC_027399.1 Klebsiella phage K64-1  unclassified Myoviridae  NC_019929.1 Erwinia phage phiEaH2  unclassified Siphoviridae 
NC_027364.1 Escherichia phage PBECO 4  unclassified Myoviridae   VC_43  
PA5oct     Accession No.  Name Taxonomy 
NC_019401.1 Cronobacter phage vB_CsaM_GAP32  unclassified Myoviridae  NC_023007.1 Bacillus phage vB_BanS-Tsamsa  unclassified Siphoviridae 
 VC_87   NC_007581.1 Clostridium phage c-st  unclassified Myoviridae 
Accession No.  Name Taxonomy  NC_029073.1 Geobacillus virus E3  unclassified Siphoviridae 
NC_019410.1 Caulobacter phage karma  Phicbkvirus  NC_023574.1 Lactococcus phage phiL47  unclassified Siphoviridae 
NC_019411.1 Caulobacter phage swift  Phicbkvirus  NC_001884.1 Bacillus phage SPbeta  Spbetavirus 
NC_019405.1 Caulobacter phage phiCbK  Phicbkvirus  NC_027341.1 Lactococcus phage WRP3  unclassified Siphoviridae 
NC_019407.1 Caulobacter phage magneto  Phicbkvirus  NC_029048.1 Clostridium phage phiCD211  unclassified Myoviridae 
NC_019406.1 Caulobacter phage CcrColossus  unclassified Siphoviridae  NC_028749.1 Brevibacillus phage Sundance  unclassified Siphoviridae 
NC_019408.1 Caulobacter phage rogue  Phicbkvirus  NC_015263.1 Lactococcus phage 949  unclassified Siphoviridae 
 VC_172   NC_029119.1 Staphylococcus phage SPbeta-like  Spbetavirus 
Accession No.  Name Taxonomy  NC_023719.1 Bacillus phage G  unclassified Myoviridae 
NC_022096.1 Pseudomonas phage PaBG  unclassified Myoviridae   VC_184  
NC_017972.1 Pseudomonas phage Lu11  unclassified Myoviridae  Accession No.  Name Taxonomy 
NC_010811.2 Ralstonia phage RSL1  unclassified Myoviridae  NC_028805.1 Brevibacillus phage Jenst  unclassified Siphoviridae 
 VC_44   NC_009760.1 Bacillus phage 0305φ8-36   unclassified Myoviridae 
Accession No.  Name Taxonomy     
NC_028899.1 Ralstonia phage RSF1  unclassified Myoviridae     
NC_004629.1 Pseudomonas phage φKZ  Phikzvirus     
NC_028999.1 Pseudomonas phage PhiPA3  Phikzvirus     
NC_007623.1 Pseudomonas phage EL  Phikzvirus     
NC_016571.1 Pseudomonas phage OBP  unclassified Myoviridae     
NC_010821.1 Pseudomonas phage 201phi2-1  Phikzvirus     
NC_017975.1 Vibrio phage JM-2012  unclassified Myoviridae     
NC_023610.1 Erwinia phage PhiEaH1  unclassified Myoviridae     
NC_023557.1 Erwinia phage Ea35-70  unclassified Myoviridae     
NC_016163.1 Yersinia phage phiR1-37  unclassified Myoviridae     
NC_028950.1 Ralstonia phage RSL2  unclassified Myoviridae     
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Table S 6.5: List of jumbo phages and relevant phages that belong to the viral vlusters (VCs). 
VC_2  VC_8 
Accession No.  Name Taxonomy  Accession No.  Name Taxonomy 
NC_015251.1 Aeromonas phage 65 T4virus  NC_006820.1 Synechococcus phage S-PM2  T4virus 
NC_005260.1 Aeromonas phage Aeh1  T4virus  NC_006884.2 Prochlorococcus phage P-SSM4  T4virus 
NC_019538.1 Aeromonas phage CC2  T4virus  NC_008296.2 Synechococcus phage syn9  T4virus 
NC_014636.1 Aeromonas phage phiAS5  T4virus  NC_013085.1 Synechococcus phage S-RSM4  T4virus 
NC_023688.1 Aeromonas phage PX29  T4virus  NC_015279.1 Synechococcus phage S-SM2 unclassified myoviridae 
NC_000866.4 Enterobacteria phage T4  T4virus  NC_015280.1 Prochlorococcus phage P-HM1 unclassified myoviridae 
NC_004928.1 Enterobacteria phage RB69  T4virus  NC_015281.1 Synechococcus phage S-ShM2 unclassified myoviridae 
NC_005066.1 Enterobacteria phage RB49  T4virus  NC_015282.1 Synechococcus phage S-SM1 unclassified myoviridae 
NC_005135.1 Aeromonas phage 44RR2.8t  T4virus  NC_015283.1 Prochlorococcus phage P-RSM4 unclassified myoviridae 
NC_007022.1 Aeromonas phage 31  T4virus  NC_015284.1 Prochlorococcus phage P-HM2 unclassified myoviridae 
NC_007023.1 Enterobacteria phage RB43  T4virus  NC_015285.1 Prochlorococcus phage Syn33 unclassified myoviridae 
NC_008208.1 Aeromonas phage 25  T4virus  NC_015286.1 Synechococcus phage Syn19 unclassified myoviridae 
NC_008515.1 Enterobacteria phage RB32  T4virus  NC_015288.1 Prochlorococcus phage Syn1 unclassified myoviridae 
NC_009821.1 Enterobacteria phage Phi1  T4virus  NC_015289.1 Synechococcus phage S-SSM5 unclassified myoviridae 
NC_010105.1 Enterobacteria phage JS98  T4virus  NC_015290.1 Prochlorococcus phage P-SSM7 unclassified myoviridae 
NC_012635.1 Enterobacteria phage RB51  T4virus  NC_015569.1 Synechococcus phage S-CRM01 unclassified myoviridae 
NC_012638.1 Enterobacteria phage RB14  T4virus  NC_019443.1 Synechococcus phage metaG-MbCM1  T4virus 
NC_012740.1 Enterobacteria phage JSE  T4virus  NC_019444.1 Synechococcus phage ACG-2014c  T4virus 
NC_012741.1 Enterobacteria phage JS10  T4virus  NC_020484.1 Pelagibacter phage HTVC008M  unclassified Myoviridae 
NC_014036.1 Klebsiella phage KP15  T4virus  NC_020486.1 Synechococcus phage S-RIM8  unclassified Myoviridae 
NC_014260.1 Enterobacteria phage IME08  T4virus  NC_020837.1 Synechococcus phage S-CAM1  unclassified Myoviridae 
NC_014467.1 Enterobacteria phage RB16  T4virus  NC_020845.1 Prochlorococcus phage MED4-213  unclassified Myoviridae 
NC_014595.1 Shigella phage SP18  T4virus  NC_020855.1 Cyanophage P-RSM6  unclassified Myoviridae 
NC_014635.1 Aeromonas phage phiAS4  T4virus  NC_020859.1 Synechococcus phage S-RIM2  unclassified Myoviridae 
NC_014660.1 Acinetobacter phage Ac42  T4virus  NC_020875.1 Synechococcus phage S-SSM4  unclassified Myoviridae 
NC_014661.1 Acinetobacter phage Acj61  T4virus  NC_021071.1 Cyanophage P-RSM1  unclassified Myoviridae 
NC_014662.1 Enterobacteria phage CC31  T4virus  NC_021072.1 Cyanophage Syn30  unclassified dsDNA phages 
NC_014663.1 Acinetobacter phage Acj9  T4virus  NC_021530.1 Synechococcus phage S-CAM8  unclassified Myoviridae 
NC_014792.1 Enterobacteria phage vB_EcoM-VR7  T4virus  NC_021536.1 Synechococcus phage S-IOM18  unclassified Myoviridae 
NC_015250.1 Acinetobacter phage 133  T4virus  NC_021559.1 Prochlorococcus phage P-SSM3  unclassified Myoviridae 
NC_015457.1 Shigella phage Shfl2  T4virus  NC_023584.1 Synechococcus phage S-MbCM100  T4virus 
NC_015464.1 Campylobacter phage NCTC12673  Cp8unavirus  NC_023587.1 Synechococcus phage ACG-2014h  T4virus 
NC_016562.1 Campylobacter phage CPX  Cp8unavirus  NC_025422.1 Caulobacter phage Cr30  unclassified Myoviridae 
NC_018087.3 Acinetobacter phage ZZ1  T4virus  NC_026923.1 Synechococcus phage ACG-2014d  T4virus 
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NC_018855.1 Enterobacteria phage HX01  T4virus  NC_026924.1 Synechococcus phage ACG-2014g  T4virus 
NC_018861.1 Campylobacter phage CP30A  unclassified Myoviridae  NC_026926.1 Synechococcus phage ACG-2014j  T4virus 
VC_2  VC_8 
NC_019398.1 Cronobacter phage vB_CsaM_GAP161  T4virus  NC_026928.1 Synechococcus phage ACG-2014e  T4virus 
NC_019399.1 Enterobacteria phage vB_EcoM_ACG-C40  T4virus  NC_027130.1 Synechococcus phage ACG-2014b  T4virus 
NC_019500.1 Enterobacteria phage Bp7  T4virus  NC_027132.1 Synechococcus phage ACG-2014i  T4virus 
NC_019503.1 Enterobacteria phage ime09  T4virus  NC_028663.1 Cyanophage P-TIM40  unclassified Myoviridae 
NC_019505.1 Escherichia phage wV7  T4virus  NC_028955.1 Prochlorococcus phage P-TIM68  unclassified Myoviridae 
NC_019543.1 Aeromonas phage Aes508  T4virus  VC_18 
NC_019909.1 Yersinia phage phiR1-RT  unclassified Myoviridae  Accession No.  Name Taxonomy 
NC_020080.1 Klebsiella phage KP27  T4virus  NC_013693.1 Shigella phage Ag3  Viunavirus 
NC_020416.1 Salmonella phage S16  T4virus  NC_013697.1 Deftia phage phiW-14 unclassified myoviridae 
NC_020879.1 Aeromonas phage Aes012  T4virus  NC_015296.1 Salmonella phage ViI unclassified myoviridae 
NC_021073.1 Vibrio phage henriette 12B8 
 unclassified dsDNA 
phages 
 NC_016073.1 Salmonella phage SFP10  Viunavirus 
NC_021344.2 Escherichia phage Lw1  T4virus  NC_016570.1 Escherichia phage Cba120  Viunavirus 
NC_023561.1 Enterobacter phage PG7  unclassified Myoviridae  NC_019452.1 Escherichia phage PhaxI  Viunavirus 
NC_024121.1 Serratia phage PS2  T4virus  NC_019530.1 Salmonella phage PhiSH19  Viunavirus 
NC_024124.2 Escherichia phage vB_EcoM_JS09  T4virus  NC_019910.1 Salmonella phage SKML-39  unclassified Myoviridae 
NC_024125.2 Escherichia phage e11/2  T4virus  NC_019925.1 Dickeya phage Limestone  Viunavirus 
NC_024794.1 Escherichia phage vB_EcoM_PhAPEC2  T4virus  NC_020083.1 Serratia phage phiMAM1  unclassified Myoviridae 
NC_025414.1 Citrobacter phage Miller  T4virus  NC_022343.1 Klebsiella phage 0507-KN2-1  unclassified Myoviridae 
NC_025419.1 Escherichia phage T4  T4virus  NC_022768.1 Salmonella phage Maynard  unclassified Myoviridae 
NC_025425.1 Enterobacteria phage GEC-3S  T4virus  NC_022772.1 Salmonella phage Marshall  unclassified Myoviridae 
NC_025429.1 Rhizobium phage vB_RleM_P10VF  unclassified Myoviridae  NC_023856.1 Salmonella phage vB_SalM_SJ2  unclassified Myoviridae 
NC_025437.1 Shigella phage Shf125875  unclassified Myoviridae  NC_024122.1 Salmonella phage vB_SalM_SJ3  unclassified Myoviridae 
NC_025448.1 Escherichia phage T4  T4virus  NC_025446.1 Escherichia phage ECML-4  Viunavirus 
NC_025449.1 Escherichia phage ECML-134  T4virus  NC_025452.1 Dickeya phage RC-2014  unclassified Myoviridae 
NC_025829.1 Shigella phage pSs-1  unclassified Myoviridae  NC_027119.1 Salmonella phage Det7  unclassified Myoviridae 
NC_026607.2 Salmonella phage STP4-a  T4virus  NC_027340.1 Erwinia phage phiEa2809  unclassified Myoviridae 
NC_027204.1 Sinorhizobium phage phiM19  T4virus  NC_029042.1 Salmonella phage 38  unclassified Myoviridae 
NC_027331.1 Citrobacter phage Moon  unclassified Myoviridae   VC_111  
NC_027344.1 Salmonella phage STML-198  unclassified Myoviridae  Accession No.  Name Taxonomy 
NC_027349.1 Escherichia phage HY01  unclassified Myoviridae  NC_019507.1 Campylobacter phage CP21 Cp220virus 
NC_027353.1 Yersinia phage phiD1  unclassified Myoviridae  NC_027996.1 Campylobacter phage CPt10 Cp220virus 
NC_027404.1 Yersinia phage PST  T4virus  NC_027997.1 Campylobacter phage CP220 Cp220virus 
NC_027979.1 Escherichia phage T4  T4virus   VC_150  
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NC_027983.1 Enterobacteria phage AR1  T4virus  Accession No.  Name Taxonomy 
NC_028448.1 Escherichia phage slur08  T4virus  NC_027402.1 Salmonella phage SPN3US  unclassified Myoviridae 
NC_028676.1 Sinorhizobium phage phiM9  unclassified Myoviridae  NC_021531.1 Cronobacter phage CR5  unclassified Myoviridae 
NC_028683.1 Edwardsiella phage PEi20  unclassified Myoviridae  NC_019929.1 Erwinia phage phiEaH2  unclassified Siphoviridae 
VC_2  VC_43 
NC_028686.1 Klebsiella phage JD18  unclassified Myoviridae  Accession No.  Name Taxonomy 
NC_028762.1 Proteus phage vB_PmiM_Pm5461  T4virus  NC_023007.1 Bacillus phage vB_BanS-Tsamsa  unclassified Siphoviridae 
NC_028773.1 Cronobacter phage S13  unclassified Myoviridae  NC_007581.1 Clostridium phage c-st  unclassified Myoviridae 
NC_028780.1 Escherichia phage slur07  T4virus  NC_029073.1 Geobacillus virus E3  unclassified Siphoviridae 
NC_028820.1 Yersinia phage vB_YenM_TG1  unclassified Myoviridae  NC_023574.1 Lactococcus phage phiL47  unclassified Siphoviridae 
NC_028829.1 Vibrio phage ValKK3 
 unclassified 
Caudovirales 
 NC_001884.1 Bacillus phage SPbeta  Spbetavirus 
NC_028847.1 Enterobacteria phage QL01  T4virus  NC_027341.1 Lactococcus phage WRP3  unclassified Siphoviridae 
NC_028881.1 Enterobacteria phage vB_EcoM_VR5  T4virus  NC_029048.1 Clostridium phage phiCD211  unclassified Myoviridae 
NC_028894.1 Enterobacteria phage vB_EcoM_VR20  T4virus  NC_028749.1 Brevibacillus phage Sundance  unclassified Siphoviridae 
NC_028925.1 Enterobacteria phage vB_EcoM_VR25  T4virus  NC_015263.1 Lactococcus phage 949  unclassified Siphoviridae 
NC_028927.1 Escherichia phage slur02  T4virus  NC_029119.1 Staphylococcus phage SPbeta-like  Spbetavirus 
NC_028940.1 Pectobacterium bacteriophage PM2  unclassified Myoviridae  NC_023719.1 Bacillus phage G  unclassified Myoviridae 
NC_028957.1 Enterobacteria phage vB_EcoM_VR26  T4virus  VC_184 
NC_029000.1 Stenotrophomonas phage IME13  T4virus  Accession No.  Name Taxonomy 
  
NC_029013.1 Citrobacter phage IME-CF2  T4virus  NC_028805.1 Brevibacillus phage Jenst  unclassified Siphoviridae 
NC_029091.1 Escherichia phage APCEc01  unclassified Myoviridae  NC_009760.1 Bacillus phage 0305φ8-36   unclassified Myoviridae 
NC_006883.2 Prochlorococcus phage P-SSM2  T4virus     
NC_028945.1 Sinorhizobium phage phiN3  T4virus   VC_77 
NC_019521.1 Sphingomonas phage PAU  unclassified Myoviridae  Accession No.  Name Taxonomy 
NC_026927.1 Synechococcus phage ACG-2014f  T4virus  NC_019526.1 Enterobacteria phage vB_KleM-RaK2  unclassified Myoviridae 
NC_020851.1 Synechococcus phage S-SKS1 
 unclassified 
Siphoviridae 
 NC_025447.1 Escherichia phage 121Q  unclassified Myoviridae 
NC_015287.1 Synechococcus phage S-SSM7  unclassified Myoviridae  NC_027399.1 Klebsiella phage K64-1  unclassified Myoviridae 
NC_021529.2 Vibio phage nt-1  SchizoT4virus  NC_027364.1 Escherichia phage PBECO 4  unclassified Myoviridae 
NC_005083.2 Vibrio phage KVP40  SchizoT4virus    Pseudomonas PA5oct   
NC_023568.1 Vibrio phage VH7D  SchizoT4virus  NC_019401.1 Cronobacter phage vB_CsaM_GAP32  unclassified Myoviridae 
  VC_44     VC_87  
Accession No.  Name Taxonomy  Accession No.  Name Taxonomy 
NC_028899.1 Ralstonia phage RSF1  unclassified Myoviridae  NC_019410.1 Caulobacter phage karma  Phicbkvirus 
NC_004629.1 Pseudomonas phage φKZ  Phikzvirus  NC_019411.1 Caulobacter phage swift  Phicbkvirus 
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NC_028999.1 Pseudomonas phage PhiPA3  Phikzvirus  NC_019405.1 Caulobacter phage phiCbK  Phicbkvirus 
NC_007623.1 Pseudomonas phage EL  Phikzvirus  NC_019407.1 Caulobacter phage magneto  Phicbkvirus 
NC_016571.1 Pseudomonas phage OBP  unclassified Myoviridae  NC_019406.1 Caulobacter phage CcrColossus  unclassified Siphoviridae 
NC_010821.1 Pseudomonas phage 201phi2-1  Phikzvirus  NC_019408.1 Caulobacter phage rogue  Phicbkvirus 
NC_017975.1 Vibrio phage JM-2012  unclassified Myoviridae  VC_172 
NC_023610.1 Erwinia phage PhiEaH1  unclassified Myoviridae  Accession No.  Name Taxonomy 
NC_023557.1 Erwinia phage Ea35-70  unclassified Myoviridae  NC_022096.1 Pseudomonas phage PaBG  unclassified Myoviridae 
VC_44  VC_172 
NC_016163.1 Yersinia phage phiR1-37  unclassified Myoviridae  NC_017972.1 Pseudomonas phage Lu11  unclassified Myoviridae 
NC_028950.1 Ralstonia phage RSL2  unclassified Myoviridae  NC_010811.2 Ralstonia phage RSL1  unclassified Myoviridae 
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Figure. S 7.1: Expression and purification analysis in optimal conditions of LKA1 gp49.  
(A) 12% acrylamide SDS-PAGE gel with: 1) (M) PageRuler™ Prestained Marker; 2) recombinant protein 
expression in (NI) not induced, (T) total, (S) soluble and (IS) insoluble fractions processed from 10 ml 
sample (10µl/well); 3) affinity chromatography fractions from FPLC purification, fractions A5 - A9 
(10µl/well). Under T, S, IS fractions corresponding bands from Western Blot are presented. Expected 
protein size (80.34 kDa) is marked on the left side of the gel with a red band. (B) 12% acrylamide  
SDS-PAGE gel with: 1) (M) PageRuler™ Prestained Marker; 2) size exclusion chromatography fractions 
B2 - B8 (10µl/well). The SDS-PAGE gels are stained with GelCode™ Blue Safe Protein Stain (Thermo 
Scientific). 
 
LKA1 gp49 domain  
 
 
 
 
 
 
 
 
 
 
 
 
Figure. S 7.17: Expression and purification analysis in optimal conditions of LKA1 gp49 domain.  
(A) 12% acrylamide SDS-PAGE gel with: 1) (M) PageRuler™ Prestained Marker; 2) recombinant protein 
expression in (NI) not induced, (T) total, (S) soluble and (IS) insoluble fractions processed from 10 ml 
sample (10µl/well); 3) affinity chromatography fractions from FPLC purification, fractions A5 - A10 
A B  
A B 
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(10µl/well). Under T, S, IS fractions corresponding bands from Western Blot are presented. Expected 
protein size (20.81 kDa) is marked on the left side of the gel with a red band. (B) 12% acrylamide SDS-
PAGE gel with: 1) (M) PageRuler™ Plus Prestained Marker; 2) size exclusion chromatography fractions 
E1-E2 from protein peak no. 5 (10µl/well). The SDS-PAGE gels are stained with GelCode™ Blue Safe 
Protein Stain (Thermo Scientific). 
LUZ7 gp56 domain 
 
 
 
 
 
 
 
 
Figure. S 7.18: Expression and purification analysis in optimal conditions of LUZ7 gp56 domain.  
(A) On the left site is a 12% acrylamide SDS-PAGE gel with: 1) (M) PageRuler™ Prestained Marker;  
2) recombinant protein expression in (NI) not induced, (T) total, (S) soluble and (IS) insoluble fractions 
processed from 10 ml sample (10µl/well); 3) affinity chromatography fractions from FPLC purification, 
fractions A6 - A9 (10µl/well). Under T, S, IS fractions corresponding bands from Western Blot are 
presented. Expected protein size (29.00 kDa) is marked on the left side of the gel with a red band. On the 
right side is a 12% acrylamide SDS-PAGE gel with: 1) (M) PageRuler™ Plus Prestained Marker; 2) size 
exclusion chromatography fractions B7-B10 from protein peak no. 1 (10µl/well). The SDS-PAGE gels are 
stained with GelCode™ Blue Safe Protein Stain (Thermo Scientific). 
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Figure S 8.1: Expression and purification analysis of PG degrading enzymes. (A) KT28 gp49 (B) 
KTN4 gp48 (C) KT28 gp41, (D) PA5oct gp250, (E) KTN6 gp46, (F) PA5octgp214. Abbreviations: (NI) 
not induced, (T) total, (S) soluble, (IS) insoluble fractions processed from 10 ml sample;(M) PageRuler™ 
Prestained Marker; (G) protein purification fractions collected from gravity Ni2+-NTA affinity 
chromatography; (FPLC) protein purification fractions collected from affinity chromatography with the use 
of HisTrapTM HP 1 ml columns and Akta FPLC-system; (size exclusion) protein purified with the use  
of size exclusion chromatography. Each fraction is loaded on a gel in volume of 10µl/well. Under T, S, IS 
fractions corresponding bands from Western Blot are presented. Expected protein size is marked on the left 
side of the gel with red band.  
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